0001628280-24-005397.txt : 20240216 0001628280-24-005397.hdr.sgml : 20240216 20240216172627 ACCESSION NUMBER: 0001628280-24-005397 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 134 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BALCHEM CORP CENTRAL INDEX KEY: 0000009326 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 132578432 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13648 FILM NUMBER: 24649691 BUSINESS ADDRESS: STREET 1: 5 PARAGON DRIVE CITY: MONTVALE STATE: NJ ZIP: 07645 BUSINESS PHONE: (845) 326-5600 MAIL ADDRESS: STREET 1: 5 PARAGON DRIVE CITY: MONTVALE STATE: NJ ZIP: 07645 10-K 1 bcpc-20231231.htm 10-K bcpc-20231231
2023FYfalse0000009326P3Y0.66660.6666http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParenthttp://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParenthttp://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParenthttp://fasb.org/us-gaap/2023#OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTaxhttp://fasb.org/us-gaap/2023#OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTaxhttp://fasb.org/us-gaap/2023#OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax00000093262023-01-012023-12-3100000093262023-06-30iso4217:USD00000093262024-02-02xbrli:shares00000093262023-12-3100000093262022-12-31iso4217:USDxbrli:shares00000093262022-01-012022-12-3100000093262021-01-012021-12-3100000093262020-12-310000009326us-gaap:RetainedEarningsMember2020-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000009326us-gaap:CommonStockMember2020-12-310000009326us-gaap:AdditionalPaidInCapitalMember2020-12-310000009326us-gaap:RetainedEarningsMember2021-01-012021-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-3100000093262021-12-310000009326us-gaap:CommonStockMember2021-01-012021-12-310000009326us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000009326us-gaap:RetainedEarningsMember2021-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000009326us-gaap:CommonStockMember2021-12-310000009326us-gaap:AdditionalPaidInCapitalMember2021-12-310000009326us-gaap:RetainedEarningsMember2022-01-012022-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000009326us-gaap:CommonStockMember2022-01-012022-12-310000009326us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000009326us-gaap:RetainedEarningsMember2022-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000009326us-gaap:CommonStockMember2022-12-310000009326us-gaap:AdditionalPaidInCapitalMember2022-12-310000009326us-gaap:RetainedEarningsMember2023-01-012023-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000009326us-gaap:CommonStockMember2023-01-012023-12-310000009326us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000009326us-gaap:RetainedEarningsMember2023-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000009326us-gaap:CommonStockMember2023-12-310000009326us-gaap:AdditionalPaidInCapitalMember2023-12-310000009326us-gaap:BuildingMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberus-gaap:BuildingMember2023-12-310000009326us-gaap:EquipmentMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberus-gaap:EquipmentMember2023-12-310000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-01-012022-12-310000009326bcpc:CardinalAssociatesIncBergstromMember2022-01-012022-12-310000009326bcpc:CardinalAssociatesIncBergstromMember2023-01-012023-12-310000009326bcpc:HumanNutritionAndHealthMember2023-12-310000009326bcpc:HumanNutritionAndHealthMember2022-12-310000009326bcpc:AnimalNutritionAndHealthMember2023-12-310000009326bcpc:AnimalNutritionAndHealthMember2022-12-310000009326bcpc:SpecialtyProductsMember2023-12-310000009326bcpc:SpecialtyProductsMember2022-12-310000009326bcpc:IndustrialProductsMember2023-12-310000009326bcpc:IndustrialProductsMember2022-12-310000009326us-gaap:CustomerListsMembersrt:MinimumMember2023-12-310000009326us-gaap:CustomerListsMembersrt:MaximumMember2023-12-310000009326us-gaap:TrademarksAndTradeNamesMembersrt:MinimumMember2023-12-310000009326us-gaap:TrademarksAndTradeNamesMembersrt:MaximumMember2023-12-310000009326us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2023-12-310000009326us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2023-12-310000009326bcpc:RegulatoryRegistrationCostsMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberbcpc:RegulatoryRegistrationCostsMember2023-12-310000009326bcpc:PatentsTradeSecretsMembersrt:MinimumMember2023-12-310000009326bcpc:PatentsTradeSecretsMembersrt:MaximumMember2023-12-310000009326bcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMembersrt:MinimumMember2023-12-310000009326bcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMembersrt:MaximumMember2023-12-310000009326bcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326bcpc:CardinalAssociatesIncBergstromMemberbcpc:FormerShareholdersMember2022-08-302022-08-300000009326bcpc:FormerBankMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326bcpc:CardinalAssociatesIncBergstromMember2023-12-310000009326bcpc:CardinalAssociatesIncBergstromMember2023-07-012023-09-300000009326bcpc:CardinalAssociatesIncBergstromMember2022-08-300000009326bcpc:HumanNutritionAndHealthMember2022-08-302022-08-30xbrli:pure0000009326bcpc:AnimalNutritionAndHealthMember2022-08-302022-08-300000009326us-gaap:CustomerRelationshipsMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-300000009326us-gaap:DevelopedTechnologyRightsMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-300000009326bcpc:CardinalAssociatesIncBergstromMemberus-gaap:TrademarksMember2022-08-300000009326us-gaap:CustomerRelationshipsMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326bcpc:CorporateTrademarkMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326bcpc:ProductTrademarksMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326us-gaap:DevelopedTechnologyRightsMemberbcpc:CardinalAssociatesIncBergstromMember2022-08-302022-08-300000009326bcpc:CardinalAssociatesIncBergstromMember2021-01-012021-12-310000009326bcpc:CardinalAssociatesIncBergstromMember2023-10-012023-12-310000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-21iso4217:NOK0000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMemberbcpc:FormerShareholdersMember2022-06-212022-06-210000009326bcpc:FormerShareholdersLendersAndCreditorsMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-210000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-12-310000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-210000009326us-gaap:CustomerRelationshipsMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-210000009326us-gaap:DevelopedTechnologyRightsMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-210000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMemberus-gaap:TrademarksMember2022-06-210000009326us-gaap:CustomerRelationshipsMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-210000009326bcpc:CorporateTrademarkMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-210000009326bcpc:ProductTrademarksMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-210000009326us-gaap:DevelopedTechnologyRightsMemberbcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2022-06-212022-06-210000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2023-01-012023-12-310000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2021-01-012021-12-310000009326bcpc:KechuBidCoASAndItsSubsidiaryCompaniesKappaMember2023-10-012023-12-310000009326us-gaap:CostOfSalesMember2023-01-012023-12-310000009326us-gaap:CostOfSalesMember2022-01-012022-12-310000009326us-gaap:CostOfSalesMember2021-01-012021-12-310000009326us-gaap:OperatingExpenseMember2023-01-012023-12-310000009326us-gaap:OperatingExpenseMember2022-01-012022-12-310000009326us-gaap:OperatingExpenseMember2021-01-012021-12-31bcpc:plan0000009326bcpc:OmnibusIncentivePlan2017Member2023-12-310000009326bcpc:OmnibusIncentivePlan2017Member2023-06-222023-06-220000009326bcpc:OmnibusIncentivePlan2017Member2023-01-012023-12-310000009326bcpc:OmnibusIncentivePlan2017Memberus-gaap:EmployeeStockOptionMember2023-12-310000009326us-gaap:ShareBasedPaymentArrangementNonemployeeMemberbcpc:OmnibusIncentivePlan2017Member2023-01-012023-12-310000009326us-gaap:PerformanceSharesMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-012023-12-310000009326us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000009326us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000009326us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000009326us-gaap:PerformanceSharesMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-01-012022-12-310000009326us-gaap:PerformanceSharesMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2021-01-012021-12-310000009326srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310000009326srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310000009326us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RestrictedStockMember2023-01-012023-12-310000009326us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:RestrictedStockMember2023-01-012023-12-310000009326bcpc:ExercisePriceRange1Member2023-01-012023-12-310000009326bcpc:ExercisePriceRange1Member2023-12-310000009326bcpc:ExercisePriceRange2Member2023-01-012023-12-310000009326bcpc:ExercisePriceRange2Member2023-12-310000009326bcpc:ExercisePriceRange3Member2023-01-012023-12-310000009326bcpc:ExercisePriceRange3Member2023-12-310000009326us-gaap:RestrictedStockMember2022-12-310000009326us-gaap:RestrictedStockMember2021-12-310000009326us-gaap:RestrictedStockMember2020-12-310000009326us-gaap:RestrictedStockMember2023-01-012023-12-310000009326us-gaap:RestrictedStockMember2022-01-012022-12-310000009326us-gaap:RestrictedStockMember2021-01-012021-12-310000009326us-gaap:RestrictedStockMember2023-12-310000009326us-gaap:PerformanceSharesMember2022-12-310000009326us-gaap:PerformanceSharesMember2021-12-310000009326us-gaap:PerformanceSharesMember2020-12-310000009326us-gaap:PerformanceSharesMember2023-01-012023-12-310000009326us-gaap:PerformanceSharesMember2022-01-012022-12-310000009326us-gaap:PerformanceSharesMember2021-01-012021-12-310000009326us-gaap:PerformanceSharesMember2023-12-310000009326us-gaap:LandMember2023-12-310000009326us-gaap:LandMember2022-12-310000009326us-gaap:BuildingMember2023-12-310000009326us-gaap:BuildingMember2022-12-310000009326us-gaap:EquipmentMember2023-12-310000009326us-gaap:EquipmentMember2022-12-310000009326us-gaap:ConstructionInProgressMember2023-12-310000009326us-gaap:ConstructionInProgressMember2022-12-310000009326srt:NorthAmericaMember2023-12-310000009326srt:NorthAmericaMember2022-12-310000009326srt:EuropeMember2023-12-310000009326srt:EuropeMember2022-12-310000009326us-gaap:CustomerListsMember2023-12-310000009326us-gaap:CustomerListsMember2022-12-310000009326us-gaap:TrademarksAndTradeNamesMember2023-12-310000009326us-gaap:TrademarksAndTradeNamesMember2022-12-310000009326us-gaap:DevelopedTechnologyRightsMember2023-12-310000009326us-gaap:DevelopedTechnologyRightsMember2022-12-310000009326us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember2023-12-310000009326us-gaap:OtherIntangibleAssetsMember2023-12-310000009326us-gaap:OtherIntangibleAssetsMember2022-12-310000009326bcpc:StGabrielCCCompanyLLCMember2013-12-310000009326bcpc:EastmanChemicalCompanyMemberbcpc:StGabrielCCCompanyLLCMember2013-12-31bcpc:vote0000009326bcpc:StGabrielCCCompanyLLCMember2023-01-012023-12-310000009326bcpc:StGabrielCCCompanyLLCMember2022-01-012022-12-310000009326bcpc:StGabrielCCCompanyLLCMember2021-01-012021-12-310000009326bcpc:StGabrielCCCompanyLLCMember2023-12-310000009326bcpc:StGabrielCCCompanyLLCMember2022-12-310000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2018-06-270000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2022-04-012022-06-300000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2022-07-270000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2022-07-272022-07-270000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2022-07-012022-09-300000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2023-12-310000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2022-12-310000009326us-gaap:RevolvingCreditFacilityMemberbcpc:A2018CreditAgreementMember2023-01-012023-12-310000009326bcpc:RevolvingCreditAgreementMember2023-12-310000009326srt:MinimumMemberbcpc:RevolvingCreditAgreementMember2023-01-012023-12-310000009326srt:MaximumMemberbcpc:RevolvingCreditAgreementMember2023-01-012023-12-310000009326bcpc:RevolvingCreditAgreementMember2023-01-012023-12-310000009326us-gaap:StateAndLocalJurisdictionMember2023-12-31bcpc:segment0000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2022-12-310000009326us-gaap:CorporateNonSegmentMember2023-12-310000009326us-gaap:CorporateNonSegmentMember2022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2023-01-012023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2022-01-012022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2021-01-012021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2023-01-012023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2022-01-012022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2021-01-012021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2023-01-012023-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2022-01-012022-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2021-01-012021-12-310000009326us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000009326us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000009326us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000009326us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-310000009326us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310000009326us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000009326bcpc:ProductSalesMember2023-01-012023-12-310000009326bcpc:ProductSalesMember2022-01-012022-12-310000009326bcpc:ProductSalesMember2021-01-012021-12-310000009326us-gaap:RoyaltyMember2023-01-012023-12-310000009326us-gaap:RoyaltyMember2022-01-012022-12-310000009326us-gaap:RoyaltyMember2021-01-012021-12-310000009326country:US2023-01-012023-12-310000009326country:US2022-01-012022-12-310000009326country:US2021-01-012021-12-310000009326us-gaap:NonUsMember2023-01-012023-12-310000009326us-gaap:NonUsMember2022-01-012022-12-310000009326us-gaap:NonUsMember2021-01-012021-12-310000009326us-gaap:CurrencySwapMember2023-01-012023-12-310000009326us-gaap:CurrencySwapMember2022-01-012022-12-310000009326us-gaap:CurrencySwapMember2021-01-012021-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-3100000093262021-01-012021-01-010000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2022-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2021-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-01-012023-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2022-01-012022-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2021-01-012021-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2023-01-012023-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2022-01-012022-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2021-01-012021-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000009326us-gaap:PensionPlansDefinedBenefitMember2023-12-310000009326us-gaap:PensionPlansDefinedBenefitMember2022-12-310000009326bcpc:ChemogasDefinedPensionPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000009326us-gaap:FairValueInputsLevel1Member2023-12-310000009326us-gaap:FairValueInputsLevel1Member2022-12-31bcpc:financial_instrument0000009326us-gaap:MoneyMarketFundsMember2023-12-310000009326us-gaap:MoneyMarketFundsMember2022-12-310000009326us-gaap:CurrencySwapMember2022-12-310000009326us-gaap:InterestRateSwapMember2022-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:ServicesProvidedMember2023-01-012023-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:ServicesProvidedMember2022-01-012022-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:ServicesProvidedMember2021-01-012021-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:RawMaterialsSoldMember2023-01-012023-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:RawMaterialsSoldMember2022-01-012022-12-310000009326us-gaap:CorporateJointVentureMemberbcpc:RawMaterialsSoldMember2021-01-012021-12-310000009326us-gaap:CorporateJointVentureMember2023-01-012023-12-310000009326us-gaap:CorporateJointVentureMember2022-01-012022-12-310000009326us-gaap:CorporateJointVentureMember2021-01-012021-12-310000009326us-gaap:CorporateJointVentureMember2023-12-310000009326us-gaap:CorporateJointVentureMember2022-12-310000009326bcpc:NonContractualMoniesOwedMemberus-gaap:CorporateJointVentureMember2023-12-310000009326bcpc:NonContractualMoniesOwedMemberus-gaap:CorporateJointVentureMember2022-12-31bcpc:tranche0000009326bcpc:LesseeOperatingLeaseTrancheOneMembersrt:MinimumMember2023-12-310000009326bcpc:LesseeOperatingLeaseTrancheOneMembersrt:MaximumMember2023-12-310000009326srt:MinimumMemberbcpc:LesseeOperatingLeaseTrancheTwoMember2023-12-310000009326srt:MaximumMemberbcpc:LesseeOperatingLeaseTrancheTwoMember2023-12-310000009326bcpc:LesseeOperatingLeaseTrancheThreeMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberbcpc:LesseeOperatingLeaseTrancheThreeMember2023-12-310000009326bcpc:LesseeOperatingLeaseTrancheFourMember2023-12-310000009326bcpc:LesseeOperatingLeaseTrancheFourMembersrt:MinimumMember2023-12-310000009326srt:MaximumMemberbcpc:LesseeOperatingLeaseTrancheFourMember2023-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberbcpc:PayFixedInterestRateMember2019-05-280000009326us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-05-280000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberbcpc:PayFixedInterestRateMemberus-gaap:CurrencySwapMember2019-05-280000009326bcpc:ReceiveFixedInterestRateMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2019-05-280000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2019-05-280000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000009326us-gaap:InterestRateSwapMember2023-01-012023-12-310000009326us-gaap:InterestRateSwapMember2022-01-012022-12-310000009326us-gaap:InterestRateSwapMember2021-01-012021-12-310000009326us-gaap:ForwardContractsMember2022-06-21bcpc:derivative0000009326us-gaap:ForwardContractsMember2023-01-012023-12-310000009326us-gaap:ForwardContractsMember2023-12-310000009326us-gaap:ForwardContractsMember2022-12-3100000093262023-01-012023-03-3100000093262023-04-012023-06-3000000093262023-07-012023-09-3000000093262023-10-012023-12-3100000093262022-01-012022-03-3100000093262022-04-012022-06-3000000093262022-07-012022-09-3000000093262022-10-012022-12-310000009326us-gaap:AllowanceForCreditLossMember2020-12-310000009326us-gaap:InventoryValuationReserveMember2020-12-310000009326us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310000009326us-gaap:InventoryValuationReserveMember2021-01-012021-12-310000009326us-gaap:AllowanceForCreditLossMember2021-12-310000009326us-gaap:InventoryValuationReserveMember2021-12-310000009326us-gaap:AllowanceForCreditLossMember2022-01-012022-12-310000009326us-gaap:InventoryValuationReserveMember2022-01-012022-12-310000009326us-gaap:AllowanceForCreditLossMember2022-12-310000009326us-gaap:InventoryValuationReserveMember2022-12-310000009326us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310000009326us-gaap:InventoryValuationReserveMember2023-01-012023-12-310000009326us-gaap:AllowanceForCreditLossMember2023-12-310000009326us-gaap:InventoryValuationReserveMember2023-12-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number: 1-13648
_______________________________________________________________________________________________________________
Balchem Corporation
(Exact name of Registrant as specified in its charter)
Maryland 13-2578432
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number)
5 Paragon Drive, Montvale, NJ 07645
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (845) 326-5600
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $.06-2/3 per shareBCPCThe Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes No

Indicate by check mark whether the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes No
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes   No





Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer
Accelerated filer
 
 
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No
The aggregate market value of the common stock, par value $.06-2/3 per share (the “Common Stock”), issued and outstanding and held by non-affiliates of the Registrant, based upon the closing price for the Common Stock on the NASDAQ Stock Market LLC on June 30, 2023 was approximately $4,321,000,000. For purposes of this calculation, shares of the Registrant held by directors and officers of the Registrant and under the Registrant’s 401(k)/profit sharing plan have been excluded.
The number of shares outstanding of Common Stock was 32,266,941 as of February 2, 2024.
DOCUMENTS INCORPORATED BY REFERENCE
Selected portions of the Registrant’s proxy statement for its 2024 Annual Meeting of Shareholders (the “2024 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2023 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein.


Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this Annual Report on Form 10-K, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations or beliefs concerning future events and results. We generally use the words “believe,” “expect,” “intend,” “plan,” “anticipate,” “likely,” “will,” “would,” “will be,” “will continue,” “will likely result,” “estimate,” “project,” “forecast,” “outlook,” “strategy,” “future,” “opportunity,” “may,” “should,” or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and factors that could cause our results to differ materially from our expectations and beliefs include, but are not limited to, those factors set forth in this Annual Report on Form 10-K under “Item 1A. - Risk Factors.” You should read that information in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of this report and our Consolidated Financial Statements and related notes in Item 8 of this report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


BALCHEM CORPORATION
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Page Numbers



PART I
Item 1.    Business (All amounts in thousands, except share and per share data)
General
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
We sell our products through our own sales force, independent distributors and sales agents. Financial information concerning our business, business segments and geographic information appears in Management’s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 below and in the Notes to our Consolidated Financial Statements included under Item 8 below, which information is incorporated herein by reference.
Human Nutrition and Health
The Human Nutrition and Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products; proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity, and methylsulfonylmethane ("MSM"), which is a widely used nutritional ingredient that helps provide benefits for joint health, sports nutrition, skin and beauty, and healthy aging. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.
Animal Nutrition and Health

The Company’s Animal Nutrition and Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. This segment also manufactures MSM, which is a widely used nutritional ingredient that provides benefits for pet health.


1


Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.

Specialty Products
The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. Ethylene oxide is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Contract sterilizers and medical device manufacturers are principal customers for this product. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage, to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes, and for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to.
The Company’s performance gases and chemicals are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. The Company also sells single use canisters for use in sterilizing re-usable devices typically processed in autoclave units in hospitals.
The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.
Acquisitions
On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc. ("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc. ("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom"). Bergstrom is a leading science-based manufacturer of MSM, based in Vancouver, Washington. Details related to the Bergstrom acquisition are disclosed in Note 2, Significant Acquisitions. The addition of OptiMSM®, Bergstrom Nutrition's MSM brand, to the Company's portfolio within the Human Nutrition and Health and Animal Nutrition and Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products.
On June 21, 2022, the Company and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as “Kappa”). Details related to the Kappa acquisition are disclosed in Note 2, Significant Acquisitions. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition and Health segment.

Raw Materials

The raw materials utilized by us in the manufacture of our products are sourced from suppliers both domestically and internationally. Such raw materials include materials derived from petrochemicals, minerals, metals, agricultural commodities and other readily available commodities and are subject to price fluctuations due to market conditions. In 2023, supply reliability improved due to a weaker macroeconomic (demand) environment though we experienced some difficulties in procuring certain materials due to the challenging geopolitical environment impacting some supply lanes. In a year of mixed inflationary and
2

deflationary trends across key categories we source, we were able to secure most necessary materials from our suppliers and continued to strive to ensure a sustainable supply chain to support our growing business operations.

Intellectual Property

We currently hold over 130 patents and over 400 trademarks in the United States and overseas. We also use know-how, trade secrets, formulae, and manufacturing techniques that assist in maintaining competitive positions of certain of our products. Formulae and know-how are of particular importance in the manufacture of a number of our proprietary products. We believe that our patents, in the aggregate, are advantageous to our business. However, we do not believe we are materially dependent on any particular patent or any particular group of patents. We believe that our sales and competitive position are dependent primarily upon the quality of our products, technical sales efforts and market conditions, rather than on patent protection.
Seasonality
While in general, the businesses of our segments are not seasonal to any material extent, the plant nutrition business within Specialty Products is a seasonal business with the vast majority of sales occurring in the first half of the year, based on the planting season in the northern hemisphere.
Backlog
At December 31, 2023, we had a total backlog of $42,957 (comprised of $32,418 for the HNH segment; $7,639 for the ANH segment; $2,678 for the Specialty Products segment, and $222 for other), as compared to a total backlog of $47,022 at December 31, 2022 (comprised of $31,550 for the HNH segment; $11,983 for the ANH segment; $2,980 for the Specialty Products segment and $509 for other). It has generally been our policy and practice to maintain an inventory of finished products and/or component materials for our segments to enable us to ship products within two months after receipt of a product order. All orders in the current backlog are expected to be filled in the 2024 fiscal year.
Competition
Our competitors include many large and small companies, some of which have greater financial, research and development, production and other resources than us. Competition in the supplement, food and beverage markets we serve are based primarily on product performance, customer support, quality, service and price. The development of new and improved products is important to our success. This competitive environment requires substantial investments in product and manufacturing process research and development. In addition, the winning and retention of customer acceptance of our food and nutrition products involve substantial expenditures for application testing, either internally or at customer/prospect sites, and sales efforts. Our competition in this market includes a variety of ingredient and nutritional supplement companies, many of which are privately-held. Therefore, it is difficult to assess the size of all of our segment competitors or where we rank in comparison to such privately-held competitors.
Competition in the animal feed and industrial markets we serve is based primarily on product performance, customer support, quality, service and price. The markets for our products are subject to competitive risks because these markets are highly price competitive. Our competition in this market includes a variety of animal nutrition and health ingredient companies, along with certain industrial companies, many of which are privately-held. Therefore, we are unable to assess the size of all of our competitors or where we rank in comparison to such privately-held competitors.
In the Specialty Products segment, competition within Performance Gases is based primarily on service, reliability, quality, and price. Our competitors in this market vary globally, many of which are regional privately-held companies. We also face competition from alternate technologies or substitute products. In our plant nutrition business, competition is based primarily on product performance, customer support, quality, and price. The development of new and improved products is also important to our ability to compete. Our competition in this market is primarily regional privately-held companies.
Research and Development
During the years ended December 31, 2023, 2022 and 2021, we incurred research and development expenses of approximately $15,049, $12,191, and $13,524, respectively, on Company-sponsored research and development for new products, improvements to existing products, and manufacturing processes. We have historically funded our research and development programs with
3

funds available from current operations with the intent of recovering those costs from profits derived from future sales of products resulting from, or enhanced by, the research and development effort.
We prioritize our product development activities in an effort to allocate resources to those product candidates that, we believe, have the greatest commercial potential. Factors we consider in determining the products to pursue include projected markets and needs, status of our proprietary rights, technical feasibility, expected and known product attributes, and estimated costs to bring the product to market.
Capital Projects
We continue to invest in projects across all production facilities and capital expenditures were approximately $37,274, $49,086, and $36,142 for 2023, 2022 and 2021, respectively. In 2023, we invested $20,720 on projects expected to provide favorable returns on investment, including expanded capacity in key product lines in the HNH segment. In addition, we invested $6,900 for environmental, health, safety, and security upgrades to our facilities. In 2022, we invested $29,759 on projects expected to provide favorable returns on investment, including expanded capacity in key product lines in the HNH segment. In addition, we invested $6,020 for environmental, health, safety, and security upgrades to our facilities and $3,024 in automation projects that improved quality and efficiency of our operations. In 2021, we invested $20,544 on projects expected to provide favorable returns on investment, including expanded capacity in key product lines in the HNH segment. In addition, we invested $3,138 for environmental, health, safety, and security upgrades to our facilities, $2,330 in automation projects that improved quality and efficiency of our operations, and $2,222 in research and development projects. Capital expenditures are projected to range from $35,000 to $40,000 for 2024, including our continued efforts to invest in energy and water saving projects, while exploring additional renewable energy opportunities in support of the company's sustainability efforts.
Environmental and Regulatory Matters
The Federal Insecticide, Fungicide and Rodenticide Act (“FIFRA”), a health and safety statute, requires that certain products within our Specialty Products segment must be registered with the U.S. Environmental Protection Agency ("EPA") because they are considered pesticides. As part of the registration review process, the EPA assesses a wide variety of studies to determine the likelihood of risk to human health and the environment from exposure associated with use of the product. We hold EPA registrations permitting us to sell ethylene oxide as a medical device sterilant and spice fumigant and propylene oxide as a fumigant of nuts and spices.
In April 2008, the EPA issued a RED (“Re-registration Eligibility Decision”) for ethylene oxide which permitted the continued use of ethylene oxide “to sterilize medical or laboratory equipment, pharmaceuticals, and aseptic packaging, or to reduce microbial load on musical instruments, cosmetics, whole and ground spices and other seasoning materials and artifacts, archival material or library objects”. In 2013, the EPA initiated a new registration review of ethylene oxide, in line with and as part of the registration review scheduled for a large number of other pesticides. When the Final Work Plan was issued in March 2014, the EPA anticipated that this registration review process would take approximately seven years. In December 2016, the EPA issued its Integrated Risk Information System (“IRIS”) assessment of ethylene oxide (the "IRIS Assessment"), another aspect of the EPA’s safety review of ethylene oxide. In November 2020, the EPA issued a Draft Human Health Risk Assessment for Ethylene Oxide (“Draft HHRA”). In this Draft HHRA, the EPA presented multiple perspectives on risk extrapolation, including the IRIS Assessment. While acknowledging the necessity of maintaining the critical uses of ethylene oxide, based on the range of unit risk provided in this qualitative assessment, the EPA stated that there should be further mitigation measures implemented. In April 2023, the EPA released a Proposed Interim Decision and Draft Human Health Risk Assessment addendum which included certain proposed mitigation measures. We believe that the EPA intends to reregister ethylene oxide for the sterilization of medical or laboratory equipment, pharmaceuticals, aseptic packaging, and the reduction of microbes on spices/seasonings, with the proposed mitigation measures potentially impacting such users, including our customers. The product, when used as a sterilant for certain medical devices, has no known equally effective substitute. In October 2019, the U.S. Food and Drug Administration in a public statement said, "Although medical devices can be sterilized by several methods, ethylene oxide is the most common method of sterilization of medical devices in the U.S. and is a well-established and scientifically-proven method of preventing harmful microorganisms from reproducing and causing infections." Management believes the lack of availability of this product could not be reasonably tolerated by various medical device manufacturers or the health care industry due to the resultant infection potential.
Similarly, the EPA issued a RED for propylene oxide in August 2006. At that time, the EPA “determined that products containing the active ingredient propylene oxide ("PPO") are eligible for re-registration provided that…risk mitigation measures…are adopted.” In 2013, the EPA initiated a new registration review of propylene oxide, in line with and as part of the registration review scheduled for a large number of other pesticides. A Final Work Plan was issued in March 2014, and the EPA anticipated that this review process would take approximately seven years. In October 2020, the EPA issued both the Proposed Interim
4

Decision and Draft Risk Assessment for propylene oxide. In July 2021, the EPA issued the Interim Decision. Based on these documents, the use of propylene oxide to treat nuts and spices will continue to be permitted with minimal changes to the current approved usage. We submitted those changes and expect the EPA to review and approve them in the coming months during 2024.
Our facility in Verona, Missouri facility, while held by a prior owner, Syntex Agribusiness, Inc. (“Syntex”), was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by Syntex under the oversight of the EPA and the Missouri Department of Natural Resources. We are indemnified by the sellers under our May 2001 asset purchase agreement covering our acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site, and one of the sellers, in turn, has the benefit of certain contractual indemnification by Syntex in relation to the implementation of the above-described Superfund remedy. In June 2023, in response to a Special Notice Letter received from the EPA in 2022, BCP Ingredients, Inc. ("BCP"), the Company's subsidiary that operates the site, Syntex, EPA, and the State of Missouri entered into an Administrative Settlement Agreement and Order on Consent (“ASAOC”) for a focused remedial investigation/feasibility study ("RI/FS") under which (a) BCP will conduct a source investigation of potential source(s) of releases of 1,4-dioxane and chlorobenzene at a portion of the site and (b) BCP and Syntex will complete a RI/FS to determine a potential remedy, if any is required. Activities under the ASAOC are underway and are expected to continue for some period of time.
In connection with normal operations at our plant facilities, we are required to maintain environmental and other permits, including those relating to the use of ethylene oxide. From time to time, our manufacturing sites may be subject to inspections by the EPA and other agencies. To the extent any consent orders or other agreements are entered into as a result of findings from such inspections, the Company is committed to ensuring compliance with such orders or agreements. For a further discussion of our potential environmental liabilities, see Note 16, Commitments and Contingencies, to our Consolidated Financial Statements.
We believe we are in compliance in all material respects with applicable laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. Such compliance includes the maintenance of required permits under air pollution regulations and compliance with requirements of the Occupational Safety and Health Administration. The cost of such compliance has not had a material effect upon the results of our operations or our financial condition.
We produce products which are required to be manufactured in conformity with current Good Manufacturing Practice (“cGMP”) regulations as interpreted and enforced by the FDA, through third party contract arrangement. Modifications, enhancements or changes in contracted manufacturing facilities or procedures relating to our pharmaceutical products are, in many circumstances, subject to FDA approval, which may be subject to a lengthy application process or which we may be unable to obtain. Any contracted manufacturing facilities that manufacture our pharmaceutical products are periodically subject to inspection by the FDA and other governmental agencies, and operations at these facilities could be interrupted or halted if the results of these inspections are unsatisfactory.
Human Capital
Our employees are our most valued asset and fundamental to our success. As of December 31, 2023, we employed approximately 1,302 full-time employees worldwide, with approximately 18% covered by collective bargaining agreements. We are seeing some modest improvement in most relevant labor markets and we believe that we have been successful in attracting skilled and experienced personnel in a competitive environment and that our human capital resources are adequate to perform all business functions. In addition, we continue to enhance technology to further optimize productivity and performance.
Health and Safety
Protecting the workplace environment and the health and safety of our employees, contractors, visitors, and neighbors is our top priority. Our recordable injury rate, which is defined as recordable injuries per 200,000 hours worked, was 1.39 and 1.17 in 2023 and 2022, respectively. The injuries were primarily the result of manual material handling and cultural/behavioral factors that influence outcome. We are adjusting our 2024 environmental, health, safety, and security management system to include an even greater emphasis on hazard identification/correction and cultural/behavioral aspects of personal safety. In addition, we continually upgrade our facilities to reduce health and safety risks and establish procedures with appropriate personnel protection for the safety of our employees.
Diversity and Inclusion
We recognize that our best performance is achieved when our teams are diverse, and accordingly, diversity and inclusion are important elements of Balchem's Human Resources strategy. We strive to promote inclusion through the implementation of inclusive leadership training across the Company and are committed to increasing representation of minorities throughout the organization. In 2023, our total workforce consisted of 74% male and 26% female among all employees and 47% male and 53%
5

female when excluding supply chain and operations functions. In 2022, our total workforce consisted of 75% male and 25% female among all employees and 50% male and 50% female when excluding supply chain and operations functions. With the support of our Board of Directors, we continue to explore additional diversity and inclusion initiatives.
Training and Well-Being Programs
We strive to develop employee skills and knowledge, which includes training for job-specific technical knowledge, regulatory requirements, and company policies, through our internal learning and development platform. The topics of trainings include the Company's Code of Conduct, anti-harassment and discrimination, foreign corrupt practices, antitrust, cyber security, and various other compliance subjects. Our sponsored employee continuing learning program offers a broad base of assistance for employees, including learning and development courses. We also deployed unconscious bias and inclusive leadership training to our management team. Employees have access to healthy lifestyle discounts through our Wellness Center, as well as debt, legal, and financial counseling. Leadership programs, peak performance training and multiple online services and courses enable our employees to choose their own learning paths and work towards achieving their goals for education, finances, and overall well-being.
Performance Review, Compensation and Benefits
Our annual performance review process is an important, objective-based dialogue to foster continuous growth and development by providing an opportunity to establish goals and deliver feedback relative to each employee's performance. Balchem's annual review process is closely aligned with a formal succession planning and talent review process designed to identify and develop the next generation of leaders.
We are dedicated to providing full-time employees with a competitive compensation package that includes medical, dental, vision, and prescription benefits in addition to a 401(k) matching program. Balchem also provides financial support for health and wellness programs such as online financial wellness content, sponsored weight loss programs and subsidized gym memberships. We also provide generous time off and leave benefits, which are important to help ensure employees can enjoy a healthy balance between work and family time.
For the years ended December 31, 2023 and 2022, our turnover rate was 11% and 15%, respectively, for salaried employees with an average length of service of over 9 years for both years. For the years ended December 31, 2023 and 2022, our turnover rate was 29% and 36%, respectively, for hourly employees with an average length of service of about 7 years for both years. We are continuing to improve employee retention with effective employment engagement efforts, a productive performance review process, and competitive compensation.
Sustainability
We operate as strong stewards of our shareholders, customers, suppliers, employees, and the communities in which we operate. We are working to make our workforce more inclusive, our business more sustainable, and our communities more engaged by maintaining strong environmental, social and governance practices.
In 2023, we published our 2022 Sustainability Report. This report provides detailed information regarding our Corporate Responsibility strategy, focus areas and governance structure. We are committed to reducing our greenhouse gas emissions by implementing new technologies, improving operational efficiencies, and expanding green energy usages. In addition, we are committed to reducing our global water use by reducing and recycling water usage and investing new technologies to improve water efficiency. For more information on our approach to sustainability management, refer to our 2022 Sustainability Report, which is available on our website at https://balchem.com/our-company/corporate-social-responsibility/sustainability. The information contained on, or that may be accessed through, the Company’s website is not incorporated by reference into, and is not part of, this Annual Report on Form 10-K.
In December 2023, Balchem was named on Newsweek's 2024 list of America's Most Responsible Companies and has earned a ranking amongst this prestigious list of companies for the fourth consecutive year. This prestigious list, compiled by Newsweek in partnership with Statista Inc., recognizes the most responsible companies in the U.S. across a variety of industries, and is based on their assessment of publicly available corporate responsibility data. We are pleased to be recognized by Newsweek and Statista for our leadership in corporate responsibility.
Available Information
Our headquarters is located at 5 Paragon Drive, Montvale, NJ 07645. Our telephone number is (845) 326-5600 and our Internet website address is www.balchem.com. We make available through our website, free of charge, our Annual Reports on Form 10-
6

K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to such reports, as soon as reasonably practicable after they have been electronically filed with the Securities and Exchange Commission (the "SEC"). Such reports are available via a link from the Investor Relations page on our website to a list of our reports on the SEC’s EDGAR website. The address of the SEC's website is www.sec.gov.

Item 1A.    Risk Factors
We discuss our expectations regarding future performance, events and outcomes in this Form 10-K, quarterly and annual reports, press releases and other written and oral communications. All statements except for historical and present factual information are “forward-looking statements” and are based on financial data and business plans available only as of the time the statements are made, which may become outdated or incomplete. Forward-looking statements are inherently uncertain, and investors must recognize that events could significantly differ from our expectations. You should carefully consider the risk factors discussed below, together with all the other information included in this Form 10-K, in evaluating us and our ordinary shares. If any of the risks below actually occurs, our business, financial condition, results of operations and cash flows could be materially and adversely affected. Any such adverse effect may cause the trading price of our ordinary shares to decline, and as a result, you could lose all or part of your investment in us. Our business may also be adversely affected by risks and uncertainties not known to us or risks that we currently believe to be immaterial. We assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Operational Risks

We face risks associated with our sales to customers and manufacturing operations outside the United States.
Our net sales consist of sales both within and outside the United States. In addition, we conduct a portion of our manufacturing outside the United States. The majority of our foreign sales occur through our foreign subsidiaries and the remainder of our foreign sales result from exports to foreign distributors, resellers and customers. Our foreign sales and operations are subject to a number of risks, including: longer accounts receivable collection periods; the impact of recessions and other economic conditions in economies outside the United States; export duties and quotas; imposition of, or changes in, tariffs, sanctions, trade restrictions, and trade relations including but not limited to those associated with the United States-Mexico-Canada Agreement ("USMCA") which replaced the North American Free Trade Agreement ("NAFTA"), other free trade agreements, and the exit of the United Kingdom from the European Union; unexpected changes in regulatory requirements; certification requirements; environmental regulations; reduced protection for intellectual property rights in some countries; potentially adverse tax consequences; political and economic instability; and preference for locally produced products. These factors could have a material adverse impact on our ability to increase or maintain our international sales.

Our sales and operations may be adversely affected by supply chain disruptions due to political unrest, terrorist acts, and national and international conflicts.
Our sales and operations are subject to a number of risks, including political and economic instability, which could have a material adverse impact on our ability to increase or maintain our international sales and operations. National and international conflicts such as war, border closures, civil disturbances and terrorist acts, including Russia's invasion of Ukraine and the ongoing conflict between Israel and Hamas, may increase the likelihood of already strained supply interruptions and further hinder our ability to access the materials and energy we need to manufacture our products. Additional supply chain disruptions will make it harder for us to find favorable pricing and reliable sources for the materials we need. As a result, such disruptions will put upward pressure on our costs and increase the risk that we may be unable to acquire the materials and services we need to continue to make certain products, in particular at our manufacturing facilities in Europe.

Our financial success depends in part on the reliability and sufficiency of our manufacturing facilities.
Our revenues depend on the effective operation of our manufacturing, packaging, and processing facilities. The operation of our facilities involves risks, including the breakdown, failure, or substandard performance of equipment, power outages, the improper installation or operation of equipment, explosions, fires, natural disasters, failure to achieve or maintain safety or quality standards, work stoppages, supply or logistical outages, and the need to comply with environmental and other directives of governmental agencies. The occurrence of material operational problems, including, but not limited to, the above events, could adversely affect our profitability during the period of such operational difficulties.
Our ability to successfully grow and expand our business depends on our ability to recruit and retain a highly qualified and diverse workforce.
7

Our ability to successfully grow and expand our business is dependent upon our ability to recruit and retain a workforce with the skills necessary to develop, manufacture and deliver the products and services desired by our customers. We need highly skilled and qualified personnel in multiple areas, including research and development, engineering, sales, manufacturing, information technology, cybersecurity, accounting, regulatory, and management. We must therefore continue to effectively recruit, retain and motivate highly qualified, skilled and diverse personnel to maintain our current business and support our projected growth. A shortage of these employees for various reasons, including intense competition for skilled employees, labor shortages, increased labor costs, candidates’ preference to work remotely, changes in laws and policies regarding immigration and work authorizations in jurisdictions where we have operations, or any government mandates that may result in workforce attrition and difficulty with recruiting, may jeopardize our ability to grow and expand our business.

We may, from time to time, experience problems in our labor relations.
A portion of our North American workforce is represented by a union under a single collective bargaining agreement. In Europe, employees at our Marano, Ticino, Italy facility and Bertinoro, Italy facility are covered by a national collective bargaining agreement, respectively. We believe that our present labor relations with all our union employees are satisfactory, however, our failure to renew these agreements on reasonable terms could result in labor disruptions and increased labor costs, which could adversely affect our financial performance. Similarly, if our relations with the union portion of our workforce do not remain positive, such employees could initiate a strike, work stoppage or slowdown in the future. In the event of such an action, we may not be able to adequately meet the needs of our customers using our remaining workforce and our operations and financial condition could be adversely affected. Additionally, other portions of our workforce could become subject to union campaigns.

The effects of global climate change or other unexpected events, including global health crises, may disrupt our operations and have a negative impact on our business.
The effects of global climate change, such as extreme weather conditions and natural disasters occurring more frequently or with more intense effects, or the occurrence of unexpected events including wildfires, tornadoes, hurricanes, earthquakes, floods, tsunamis and other severe hazards or global health crises, such as the outbreak of Ebola or the global COVID-19 pandemic, or other actual or threatened epidemic, pandemic, outbreak and spread of a communicable disease or virus, in the countries where we operate or sell products and provide services, could adversely affect our operations and financial performance. Extreme weather, natural disasters, power outages, global health crises or other unexpected events could disrupt our operations by impacting the availability and cost of materials needed for manufacturing, causing physical damage and partial or complete closure of our manufacturing sites or distribution centers, loss of human capital, temporary or long-term disruption in the manufacturing and supply of products and services and disruption in our ability to deliver products and services to customers. These events and disruptions could also adversely affect our customers’ and suppliers’ financial condition or ability to operate, resulting in reduced customer demand, delays in payments received or supply chain disruptions. Further, these events and disruptions could increase insurance and other operating costs, including impacting our decisions regarding construction of new facilities to select areas less prone to climate change risks and natural disasters, which could result in indirect financial risks passed through the supply chain or other price modifications to our products and services.

We may be subject to risks relating to our information technology and operational technology systems.
We rely extensively on information technology and operational technology systems, networks and services including hardware, software, firmware and technological applications and platforms (collectively, "IT Systems") to manage and operate our business from end-to-end, including ordering and managing materials from suppliers, design and development, manufacturing, marketing, selling and shipping to customers, invoicing and billing, managing our banking and cash liquidity systems, managing our enterprise resource planning and other accounting and financial systems and complying with regulatory, legal and tax requirements. We have invested and will continue to invest in improving our IT Systems. Some of these investments are significant and impact many important operational processes and procedures. There is no assurance that newly implemented IT Systems will improve our current systems, improve our operations or yield the expected returns on the investments. In addition, the implementation of new IT Systems may be more difficult, costly or time consuming than expected and cause disruptions in our operations and, if not properly implemented and maintained, negatively impact our business. If our IT Systems cease to function properly or if these systems do not provide the anticipated benefits, our ability to manage our operations could be impaired.

We currently rely on third-party service providers for many of the critical elements of our global information and operational technology infrastructure and their failure to provide effective support for such infrastructure could negatively impact our business and financial results.
We have outsourced many of the critical elements of our global information and operational technology infrastructure to third-party service providers in order to achieve efficiencies. If such service providers do not perform or do not perform effectively, we may not be able to achieve the expected efficiencies and may have to incur additional costs to address failures in providing service
8

by the service providers. Depending on the function involved, such non-performance, ineffective performance or failures of service may lead to business disruptions, processing inefficiencies or security breaches.

Disruptions or breaches of our information systems could adversely affect us.
Despite our implementation of cybersecurity measures which have focused on prevention (including a robust cybersecurity employee education program to train our employees on email and password security, recognizing phishing and related topics on a regular basis), mitigation, resilience and recovery, our network and products, including access solutions, may be vulnerable to cybersecurity attacks, computer viruses, malicious codes, malware, ransomware, phishing, social engineering, denial of service, hacking, break-ins and similar disruptions, including through use of new artificial intelligence tools or methods. Cybersecurity attacks and intrusion efforts are continuous and evolving, and in certain cases they have been successful at the most robust institutions. The scope and severity of risks that cyber threats present have increased dramatically and include, but are not limited to, malicious software, attempts to gain unauthorized access to data or premises, exploiting weaknesses related to vendors or other third parties that could be exploited to attack our systems, denials of service and other electronic security breaches that could lead to disruptions in systems, unauthorized release of confidential or otherwise protected information and corruption of data. Any such event could have a material adverse effect on our business, operating results and financial condition, as we face regulatory, reputational and litigation risks resulting from potential cyber incidents, as well as the potential of incurring significant remediation costs. Further, while we maintain insurance coverage that may, subject to policy terms and exclusions, cover certain aspects of our cyber risks, such insurance coverage may be insufficient to cover our losses or all types of claims that may arise in the continually evolving area of cyber risk.
We also face increasing and evolving disclosure obligations related to cybersecurity events. Despite rigorous processes, we may not adequately meet all our existing or future disclosure obligations and/or having our disclosures misinterpreted. Determining whether a cybersecurity incident is notifiable or reportable may not be straightforward and any such mandatory disclosures could lead to negative publicity, loss of customer confidence in the effectiveness of our security measures, diversion of management's attention and governmental investigations.
Our daily business operations also require us to collect and/or retain sensitive data such as intellectual property, proprietary business information and data related to customers, employees, suppliers and business partners within our networking infrastructure including data from individuals subject to the European Union's General Data Protection Regulation, that is subject to privacy and security laws, regulations and/or customer-imposed controls. Despite our efforts to protect such data, the loss or breach of such data due to various causes including material security breaches, catastrophic events, extreme weather, natural disasters, power outages, system failures, computer viruses, improper data handling, programming errors, unauthorized access and employee error or malfeasance could result in wide reaching negative impacts to our business, and as such, the ongoing maintenance and security of this information is pertinent to the success of our business operations and our strategic goals.
Our networking infrastructure and related assets may be subject to unauthorized access by hackers, employee error or malfeasance or other unforeseen activities. Such issues could result in the disruption of business processes, network degradation and system downtime, along with the potential that a third party will exploit our critical assets such as intellectual property, proprietary business information and data related to our customers, suppliers and business partners. To the extent that such disruptions occur and our business continuity plans do not effectively address these disruptions in a timely manner, they may cause delays in the manufacture or shipment of our products and the cancellation of customer orders and, as a result, our business, operating results and financial condition could be materially and adversely affected, resulting in a possible loss of business or brand reputation.

Business and Financial Risks

Increased competition could adversely affect our business and financial results.
We face competition in our markets from a number of large and small companies, some of which have greater financial, research and development, production and other resources than we do. Our competitive position is based principally on performance, quality, customer support, service, breadth of product line, manufacturing or packaging technology and the selling prices of our products. We may be unable to effectively compete on all these bases. Further, our competitors may improve the design and performance of their products and introduce new products with competitive price and performance characteristics. While we expect to do the same to maintain our current competitive position and market share, if we are unable to anticipate evolving trends in the market or the timing and scale of our competitors’ activities and initiatives, the demand for our products and services could be negatively impacted.

Global economic conditions may adversely affect our business, operating results and financial condition.
Unfavorable changes in economic conditions, including inflation, recession, changes in tariffs and trade relations amongst international trading partners, or other changes in economic conditions, may adversely impact the markets in which we operate.
9

These conditions may make it extremely difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could cause U.S. and foreign businesses to slow spending on our products which would reduce our revenues and profitability. If inflation in costs such as raw materials, packaging, freight, labor and energy prices increase beyond our ability to control for them through measures such as implementing operating efficiencies, we may not be able to increase prices to sufficiently offset the effect of various costs increases without negatively impacting customer demand, thereby negatively impacting our margin performance and results of operations.
Furthermore, during challenging economic times our customers may face issues gaining timely access to sufficient credit, which could result in an impairment of their ability to make timely payments to us. If that were to occur, we may be required to increase our allowance for doubtful accounts and cash flow would be negatively impacted. We cannot predict the timing, depth or duration of any economic slowdown or subsequent economic recovery, worldwide, or in the markets in which we operate. Also, at any point in time we have funds in our cash accounts that are with third party financial institutions. These balances in the U.S. and other countries could exceed the Federal Deposit Insurance Corporation (“FDIC”) and other relevant insurance limits, respectively. While we monitor the cash balances in our accounts, these balances could be impacted if the underlying financial institutions fail or could be subject to other adverse conditions in the financial markets. Additionally, our future results of operations could be adversely affected by changes in the effective tax rate as a result of a change in the mix of earnings in jurisdictions with differing statutory tax rates, changes in tax laws, regulations and judicial rulings or changes in the interpretation thereof.

Raw material shortages or price increases could adversely affect our business and financial results.
The principal raw materials that we use in the manufacture of our products can be subject to price fluctuations due to market conditions and factors beyond our control, including the COVID-19 pandemic and inflationary pressures, both of which have impacted our business over the past several years and are likely to continue for some time. Such raw materials include materials derived from petrochemicals, minerals, metals, agricultural commodities and other commodities. While the selling prices of our products tend to increase or decrease over time with the cost of raw materials, these changes may not occur simultaneously or to the same degree. At times, including during periods of rapidly increasing raw material prices, we may be unable to pass increases in raw material costs through to our customers due to certain contractual obligations. Such increases in the price of raw materials, if not offset by product price increases, or substitute raw materials, would have an adverse impact on our profitability. We believe we have reliable sources of supply for our raw materials under normal market conditions. We cannot, however, predict the likelihood or impact of any future raw material shortages. Any shortages or unforeseen price increases could have a material adverse impact on our results of operations.

Our international operations subject us to currency translation risk and currency transaction risk which could cause our results to fluctuate from period to period.
The financial condition and results of operations of our foreign subsidiaries are reported in local currencies and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Exchange rates between these currencies in recent years have fluctuated and may do so in the future. Furthermore, we incur currency transaction risk whenever we enter into either a purchase or a sales transaction using a currency different than the functional currency. Given the volatility of exchange rates, we may not be able to effectively manage our currency transactions and/or translation risks. Volatility in currency exchange rates could impact our business and financial results.
Although we utilize risk management tools, such as derivative instruments, to mitigate market fluctuations in foreign currencies, any changes in strategy in regard to risk management tools can also affect revenue, expenses and results of operations and there can be no assurance that such measures will result in cost savings or that all market fluctuation exposure will be eliminated.

Our debt instruments are subject to interest rate risks and impose operating and financial restrictions which could have an adverse impact on our business and results of operations.
Our incurrence of indebtedness could have negative consequences to us, including limiting our ability to borrow additional monies for our working capital, capital expenditures, acquisitions, debt service requirements or other general corporate purposes; limiting our flexibility in planning for, or reacting to, changes in our operations, our business or the industries in which we compete; our leverage may place us at a competitive disadvantage by limiting our ability to invest in the business or in further research and development; making us more vulnerable to downturns in our business or the economy; and there would be a material adverse effect on our business and financial condition if we were unable to service our indebtedness or obtain additional financing, as needed.
Our ability to make payments on our indebtedness depends on our ability to generate cash in the future. If we do not generate sufficient cash flow to meet our debt service and working capital requirements, we may need to seek additional financing or sell assets. This may make it more difficult for us to obtain financing on terms that are acceptable to us, or at all. Without any such
10

financing, we could be forced to sell assets to make up for any shortfall in our payment obligations under unfavorable circumstances.
Interest payable in accordance with our five-year senior secured revolving credit agreement (the "Credit Agreement") is based on a fluctuating rate. In light of potential fluctuations, including interest rate increases which may continue, we are exposed to risk resulting from adverse changes in interest rates.
Further, due to the cessation of the London Interbank Offered Rate (“LIBOR”), we have entered into financial transactions such as credit agreements that use the Secured Overnight Financing Rate (“SOFR”) as interest rate benchmarks. SOFR is calculated differently from LIBOR and has inherent differences which could give rise to uncertainties, including the limited historical data and volatility in the benchmark rates. The full effects of the transition to SOFR or other rates remain uncertain.

We may not be able to successfully consummate and manage acquisition, joint venture and divestiture activities which could have an impact on our results.
From time to time, we may acquire other businesses, enter into joint ventures and, based on an evaluation of our business portfolio, divest existing businesses. These acquisitions, joint ventures and divestitures may present financial, managerial and operational challenges, including diversion of management attention from existing businesses, difficulty with integrating or separating personnel and financial and other systems, increased expenses, difficulties in realizing synergies expected to result from acquisitions, potential loss of key employees, key contractual relationships or key customers of acquired companies or of us, difficulties in integrating financial reporting systems and implementing controls, procedures and policies, including disclosure controls and procedures and internal control over financial reporting, appropriate for public companies of our size at companies that, prior to the acquisition, had lacked such controls, procedures and policies, assumption of unknown liabilities and indemnities, and potential disputes with the buyers or sellers. In addition, we may be required to incur asset impairment charges (including charges related to tangible assets, goodwill and other intangible assets) in connection with acquired businesses which may reduce our profitability. If we are unable to consummate such transactions, or successfully integrate and grow acquisitions and achieve contemplated revenue synergies and cost savings, our financial results could be adversely affected. Additionally, joint ventures inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks.

We may not be able to effectively manage and implement restructuring initiatives or other organizational changes.
We may, from time to time, restructure or make other adjustments to our workforce and manufacturing footprint in response to market or product changes, performance issues, changes in strategy, acquisitions and/or other internal and external considerations. These restructuring activities and other organizational changes may result in increased restructuring costs, diversion of management’s time and attention from daily operations and temporarily reduced productivity. If we are unable to successfully manage and implement restructuring and other organizational changes, we may not achieve or sustain the expected growth or cost savings benefits of these activities or do so within the expected timeframe. These effects could recur in connection with future acquisitions and other organizational changes and our results of operations could be negatively affected.

Changes in our relationships with our vendors, changes in tax or trade policy, interruptions in our operations or supply chain or increased commodity or supply chain costs could adversely affect our results of operations.
We are dependent on our vendors, including common carriers, to supply raw materials to our manufacturing facilities. As we continue to add capabilities to quickly move the appropriate amount of inventory at optimal operational costs through our entire supply chain, operating our fulfillment network becomes more complex and challenging. If our fulfillment network does not operate properly, if a vendor fails to deliver on its commitments, or if common carriers have difficulty providing capacity to meet demands for their services, we could experience inventory shortages, delivery delays or increased delivery costs, which could lead to lost sales and decreased guest confidence, and adversely affect our results of operations.
A large portion of our raw materials are sourced, directly or indirectly, from outside the U.S. Any major changes in tax or trade policy, such as the imposition of additional tariffs or duties on imported products, between the U.S. and countries from which we source raw materials could require us to take certain actions, including for example raising prices on products we sell and seeking alternative sources of supply from vendors in other countries with whom we have less familiarity, which could adversely affect our reputation, sales, and our results of operations.
Political or financial instability, currency fluctuations, the outbreak of pandemics or other illnesses (such as the COVID-19 pandemic), labor unrest, transport capacity and costs, port security, weather conditions, natural disasters, or other events that could alter or suspend our operations, slow or disrupt port activities, or affect foreign trade are beyond our control and could materially disrupt our supply of raw materials, increase our costs, and/or adversely affect our results of operations. There have been periodic labor disputes impacting the U.S. ports that have caused us to make alternative arrangements to continue the flow of
11

inventory, and if these types of disputes recur, worsen, or occur in other countries through which we source products, it may have a material impact on our costs or inventory supply. Changes in the costs of procuring commodities used in our products or the costs related to our supply chain, could adversely affect our results of operations.

Adverse publicity or consumer concern regarding the safety or quality of food products containing our products, or health concerns, whether with our products, products in the same general class as our products or for food products containing our products, may result in the loss of sales. Also, consumer preferences for products containing our products may change.
We are dependent upon consumers’ perception of the safety, quality and possible dietary benefits of products containing our food ingredient products. As a result, substantial negative publicity concerning our products or other foods and beverages in which our products are used could lead to a loss of consumer confidence in those products, removal of those products from retailers’ shelves and reduced sales and prices of our products. Product quality issues, actual or perceived, or allegations of product contamination, even when false or unfounded, could hurt the image of our products or of brands of products containing our products, and cause consumers to choose other products. Further, any product recall, whether our own or by a third party, whether due to real or unfounded allegations, could impact demand on food products containing our products or even our products. Any of these events could have a material adverse effect on our business, results of operations and financial condition. Consumer preferences, as well as trends, within the food industries change often and our failure to anticipate, identify or react to changes in these preferences and trends could, among other things, lead to reduced demand and price reductions, and could have an adverse effect on our business, results of operations and financial condition. While we continue to diversify our product offerings, developing new products entails risks and we cannot be certain that demand for our products and products containing our products will continue at current levels or increase in the future.

Legal, Regulatory and Compliance Risks

Material adverse legal judgments, fines, penalties or settlements could adversely affect our business.
We may from time to time become involved in legal proceedings and disputes incidental to the operation of our business. Our business may be adversely affected by the outcome of these proceedings and other contingencies (including, without limitation, product liability, tort, environmental, intellectual property, antitrust, data protection, privacy, and labor and employment matters) that cannot be predicted with certainty. As required by GAAP, if applicable, we establish reserves based on our assessment of contingencies. Subsequent developments in legal proceedings and other contingencies may affect our assessment and estimates of the loss contingency recorded as a reserve, and we may be required to make additional material payments.

Our business exposes us to potential product liability claims and recalls, which could adversely impact our financial condition and performance.
Our development, manufacture and sales of food ingredient, pharmaceutical and nutritional supplement products involve an inherent risk of exposure to product liability claims, product recalls, product seizures and related adverse publicity. A product liability judgment against us could also result in substantial and unexpected expenditures, affect consumer confidence in our products, and divert management’s attention from other responsibilities. Although we maintain product liability insurance coverage in amounts we believe are customary within the industry, there can be no assurance that this level of coverage is adequate or that we will be able to continue to maintain our existing insurance or obtain comparable insurance at a reasonable cost, if at all. A product recall or a partially or completely uninsured judgment against us could have a material adverse effect on results of operations and financial condition.

Our brands are important assets of our businesses, and violation of our trademark rights by imitators could negatively impact revenues and brand reputation.
Our brands and trademarks enjoy a reputation for quality and value and are important to our success and competitive position. Unauthorized use of our trademarks may not only erode sales of our products but may also cause significant damage to our brand name and reputation, interfere with relationships with our customers and increase litigation costs. There can be no assurance that our on-going effort to protect our brand and trademark rights will prevent all violations.

Allegations that we have infringed the intellectual property rights of third parties could negatively affect us.
We may be subject to claims of infringement of intellectual property rights by third parties. In general, if it is determined that one or more of our technologies, products or services infringes the intellectual property rights owned by others, we may be required to cease marketing those products or services, to obtain licenses from the holders of the intellectual property at a material cost or to take other actions to avoid infringing such intellectual property rights. The litigation process is costly and subject to inherent uncertainties, and we may not prevail in litigation matters regardless of the merits of our position. Adverse intellectual property
12

litigation or claims of infringement against us may become extremely disruptive if the plaintiffs succeed in blocking the trade of our products and services and may have a material adverse effect on our business.

We are subject to risks related to corporate social responsibility and reputational matters.
Our reputation and the reputation of our brands, including the perception held by our customers, end-users, business partners, investors, other key stakeholders and the communities in which we do business are influenced by various factors. There is an increased focus from our stakeholders on Environmental, Social and Governance (“ESG”) practices and disclosure – and if we fail, or are perceived to have failed, in any number of ESG matters, such as environmental stewardship, goals regarding our intended reduction of carbon emissions and water usage, inclusion and diversity, workplace conduct and support for local communities, or to effectively respond to changes in, or new, legal or regulatory requirements concerning climate change or other sustainability concerns, our reputation or the reputation of our brands may suffer. Such damage to our reputation and the reputation of our brands may negatively impact our business, financial condition and results of operations. Further, there are an increasing number of anti-ESG legislative initiatives that may conflict with other regulatory requirements or our stakeholders' expectations.
In addition, negative or inaccurate postings or comments on social media or networking websites about the Company or our brands could generate adverse publicity that could damage our reputation or the reputation of our brands. If we are unable to effectively manage real or perceived issues, including concerns about product quality, safety, corporate social responsibility or other matters, sentiments toward the Company or our products could be negatively impacted, and our financial results could suffer.

Our reputation, ability to do business and results of operations could be impaired by adverse publicity or improper conduct by any of our employees, agents or business partners.
We are subject to regulation under a variety of U.S. federal and state and non-U.S. laws, regulations and policies including laws related to anti-corruption, export and import compliance, anti-trust and money laundering due to our global operations. We cannot provide assurance that our internal controls will always protect us from the improper conduct of our employees, agents and business partners. Any improper conduct could damage our reputation and subject us to, among other things, civil and criminal penalties, material fines, equitable remedies (including profit disgorgement and injunctions on future conduct), securities litigation and a general loss of investor confidence.

Our operations are subject to regulatory risks and the loss of governmental permits and approvals would materially and adversely affect some of our businesses.
Our U.S. and non-U.S. operations are subject to a number of laws and regulations, including environmental, health and safety standards. We have incurred, and will be required to continue to incur, significant expenditures to comply with these laws and regulations. Changes to, or changes in interpretations of, current laws and regulations, including climate change legislation or other environmental mandates, could require us to increase our compliance expenditures, cause us to significantly alter or discontinue offering existing products and services or cause us to develop new products and services. Altering current products and services or developing new products and services to comply with changes in the applicable laws and regulations could require significant research and development investments, increase the cost of providing the products and services and adversely affect the demand for our products and services, including shifting demand to competitors in countries where laws and regulations may be less stringent.
In the event a regulatory authority concludes that we are not or have not at all times been in full compliance with these laws or regulations, we could be fined, criminally charged or otherwise sanctioned. Certain environmental laws assess liability on current or previous owners of real property or operators of manufacturing facilities for the costs of investigation, removal or remediation of hazardous substances or materials at such properties or at properties at which parties have disposed of hazardous substances. Liability for investigative, removal and remedial costs under certain U.S. federal and state laws and certain non-U.S. laws are retroactive, strict and joint and several. In addition to cleanup actions brought by governmental authorities, private parties could bring personal injury or other claims due to the presence of, or exposure to, hazardous substances. For more information, see "Item 1. Business – Environmental and Regulatory Matters" of this report.
While we have planned for future capital and operating expenditures to maintain compliance with environmental laws, our costs of compliance may exceed our estimates. We may also be subject to environmental claims for personal injury, liabilities arising from past, present or future releases of, or exposures to, hazardous substances, or cost recovery actions for remediation of facilities in the future based on our past, present or future business activities.
Further, pursuant to applicable environmental and safety laws and regulations, we are required to obtain and maintain certain governmental permits and approvals, including EPA registrations under FIFRA for some of our products. We maintain EPA
13

FIFRA registrations for ethylene oxide as a medical device sterilant and spice fumigant and for propylene oxide as a fumigant of nuts and spices. These products are progressing through a multi-year FIFRA re-registration review process. Recent draft documents indicate that the EPA intends to continue the registrations for both ethylene oxide and propylene oxide with certain additional mitigation measures. The EPA may re-examine the registrations in the future in accordance with the provisions of FIFRA. Any future determination by the EPA to discontinue permitted use of ethylene oxide or propylene oxide would have a material adverse effect on our business and financial results.

Commercial supply of pharmaceutical products that we may develop, subject to cGMP manufacturing regulations, would be performed by third-party cGMP manufacturers. Modifications, enhancements or changes in third-party manufacturing facilities or procedures of our pharmaceutical products are, in many circumstances, subject to FDA approval, which may be subject to a lengthy application process or which we may be unable to obtain. Any third-party cGMP manufacturers that we may use are periodically subject to inspection by the FDA and other governmental agencies, and operations at these facilities could be interrupted or halted if the results of these inspections are unsatisfactory. Failure to comply with the FDA or other governmental regulations can result in fines, unanticipated compliance expenditures, recall or seizure of products, total or partial suspension of production, enforcement actions, injunctions and criminal prosecution, which could have a material adverse effect on our business and financial results.

Permits and approvals may be subject to revocation, modification or denial under certain circumstances. Our operations or activities could result in administrative or private actions, revocation of required permits or licenses, or fines, penalties or damages, which could have an adverse effect on us. In addition, we cannot predict the extent to which any legislation or regulation may affect the market for our products or our cost of doing business.

Concerns about ethylene oxide emissions have resulted in certain state actions against certain of our customers that are currently impacting these customers’ ability to use the ethylene oxide process to sterilize medical devices, which may, in turn, affect sales to these customers.
There is increased focus on the use and emissions of ethylene oxide by the EPA and state environmental agencies. Certain of the Company’s customers who use ethylene oxide in the U.S. for the sterilization of medical devices have received ongoing state and local scrutiny for environmental concerns at their facilities. This scrutiny is associated with the IRIS Assessment described in “Item 1. Business – Environmental and Regulatory Matters” of this report, which deemed exposure to ethylene oxide as unsafe at levels far below those found in the environment. The EPA began using the IRIS Assessment in 2020 to regulate change to existing permissible emissions limits at facilities that produce or use ethylene oxide in non-sterilization processes, and subsequently proposed rules for ethylene oxide sterilization facilities as well. These rules have yet to be finalized. Additionally, some state and local regulators have drawn their own conclusions from the IRIS Assessment, which has resulted in certain state actions against our customers that continue to impact these customers’ ability to use the ethylene oxide process to sterilize medical devices. Due to these regulatory actions, many customers have taken or are expected to take some voluntary downtime to install new abatement equipment. The installation of the new abatement equipment is being done ahead of what is expected to be changes in the EPA regulations. The Company remains confident that the sterilization industry will be able to install abatement equipment to satisfy the new forthcoming EPA requirements. The Company is working with various stakeholders to ensure the EPA considers all available assessments to appropriately quantify ethylene oxide's risks. While the Company believes that EPA will, as it has in the past, ultimately regulate to lower emissions levels based on a combined consideration of the various assessments available and that industry will then adopt practices and procedures to ensure compliance with these new regulations, there is no assurance that this will be the case. Further, additional regulatory requirements associated with the use and emission of ethylene oxide may be imposed in the future, both within and outside of the U.S. Such increased regulation could require our customers and/or the Company to temporarily suspend operations to install additional fugitive emissions control technology, limit the use of ethylene oxide or take other actions which could impact our business, financial condition or results of operations.


Item 1B.    Unresolved Staff Comments

None.

14


Item 1C.    Cybersecurity
Cybersecurity is a critical part of our enterprise risk management. The Board, through its Audit Committee, oversees enterprise risk management, including cybersecurity. To more effectively address cybersecurity threats, we have numerous security layers within our least privilege network approach which is managed by our Information Technology Department. Our cybersecurity programs align with numerous standards and continues to grow and develop as new technologies emerge. Further, we have regular user awareness testing and trainings in place which helps keep all end users and executive leadership up-to-date on the most current threats. The global head of Information Security, possessing credentials in both information technology (“IT”) and cybersecurity, provides regular updates to senior management. Additionally, they provide at least an annual update, or more frequently if necessary, to both the Audit Committee and the full Board regarding the current threat landscape at Balchem, cybersecurity technologies, mitigation strategies, industry trends and best practices that we follow, major cybersecurity incidents (if any), and other areas of importance. The global head of Information Security has responsibility over cybersecurity management globally and reports directly to the Chief Financial Officer. Additional activities to maintain and enhance information security are discussed below.
Reliable, Scalable Systems and Infrastructure
Our information security systems, infrastructure, and processes are built on and follow the U.S. National Institute of Standards and Technology ("NIST") framework for information security, which is a set of guidelines, accepted standards, and best practices for mitigating organization cybersecurity risks published by NIST. We continue to make significant investments in industry-leading and advanced technologies as part of our strategy to strengthen our security posture, business continuity capabilities, and ability to protect and safeguard systems and stakeholder data. Our Information Security Program and systems are tested and assessed annually by an independent third party.
Automation and Artificial Intelligence
We have implemented automated systems to proactively test attack vectors by emulating inside and outside threats resulting in the validation of our ability to detect and defend against a cyber attack. Artificial intelligence is used as part of early warning systems designed to detect, alert, and respond to potential cyber threats.
Training
Recognizing that information security, stakeholder data, and privacy principles involve more than just systems and infrastructure, we provide semi-annual cybersecurity education and training to all users with access to IT systems, devices, or applications. Internal social engineering phishing campaigns are conducted regularly with the goal of building a culture of cybersecurity, as well as raising awareness and reinforcing best practices across the organization.
Third parties also play a role in our cybersecurity. We engage third-party services to conduct evaluations of our security controls, whether through penetration testing, independent audits or consulting on best practices to address new challenges. These evaluations include testing both the design and operational effectiveness of security controls.
We apply a risk-based approach to mitigate cybersecurity risks associated with our use of third-party service providers and cybersecurity considerations affect the selection and oversight of these third-party service providers. We perform due diligence on third parties that have access to our most critical systems, data or facilities that house such systems or data.
While we have experienced cybersecurity threats in the past in the normal course of business and expect to continue to experience such threats from time to time, to date, none have had a material adverse effect on our business, financial condition, results of operations or cash flows. Even with the extensive approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us. See Item 1A. “Risk Factors - Operational Risks - Disruptions or breaches of our information systems could adversely affect us” for a discussion of cybersecurity risks.
In the event of a possible cybersecurity incident, we would immediately implement our crisis management plan, which includes the following steps:
(1) Internal reporting and review of the incident or development
(2) Gathering and assessing information
(3) Developing and implementing a communications strategy
(4) Monitoring and evaluating a response
15

(5) Debrief and recovery
As part of the gathering and assessment of information in step 2, we will consider various factors to make a materiality determination of the incident, including business impact, potential costs, impacted data, scope of the incident, possible litigation or regulatory implications, and reputational damage.

Item 2.    Properties
Our corporate headquarters is located in Montvale, New Jersey. Our operations are conducted at our owned and leased facilities throughout the U.S. and other foreign countries. These facilities house manufacturing and warehousing operations, as well as administrative offices. We have a total of 38 locations across the world and some of these manufacturing and warehousing locations serve multiple segments.
The following is a summary of our principal properties:

SegmentLocationAdministrativeManufacturingWarehousing
Corporate5 U.S. cities5
HNH17 U.S. cities and 6 foreign countries1166
ANH9 U.S. cities and 3 foreign countries102
Specialty Products6 U.S. cities and 6 foreign countries282
Other2 U.S. cities and 1 foreign country3

We believe that our production facilities and related machinery and equipment are well maintained, suitable for their purpose, and     adequate to support our businesses.

Item 3.    Legal Proceedings

In the normal course of business, we are involved in a variety of lawsuits, claims and legal proceedings, from time to time, including commercial and contract disputes, labor and employment matters, product liability claims, environmental liabilities, trade regulation matters, intellectual property disputes and tax-related matters. Further, in connection with normal operations at our plant facilities, our manufacturing sites may, from time to time, be subject to inspections or inquiries by the EPA and other agencies. To the extent any consent orders or other agreements are entered into as a result of findings from such inspections or inquiries, the Company is committed to ensuring compliance with such orders or agreements.

Information with respect to certain legal proceedings is included in Note 16, Commitments and Contingencies, to our Consolidated Financial Statements for the year ended December 31, 2023 contained in this Annual Report on Form 10-K, and is incorporated herein by reference.

In our opinion, we do not expect pending legal matters to have a material adverse effect on our consolidated financial position, results of operations, liquidity or cash flows.

Item 4.    Mine Safety Disclosures
Not applicable.


16

INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The following is a list of executive officers of the Company as of February 16, 2024.
Theodore L. Harris, age 58, has served as our Chairman, President and Chief Executive Officer since 2017.
C. Martin Bengtsson, age 46, has served as our Executive Vice President and Chief Financial Officer since February 2019.
Hatsuki Miyata, age 48, has served as our Executive Vice President, General Counsel and Secretary since July 2022. Ms. Miyata previously served as Deputy General Counsel and Corporate Secretary at Allegion plc, a global manufacturing company in seamless access and security products, from October 2018 to July 2022.
Frederic Boned, age 46, has served as our Senior Vice President and General Manager, Human Nutrition and Health, since November 2022. Prior to that, he served as Regional Vice President, Health Nutrition and Care – North America from January 2022 to November 2022, and Vice President, Human Nutrition and Health – North America from September 2018 to January 2022, each at DSM, a Dutch multinational corporation in the fields of health and nutrition.
Jonathan H. Griffin, age 48, has served as our Senior Vice President and General Manager, Animal Nutrition and Health, since September 2022. Prior to that, he led that business segment as our Vice President and General Manager, Animal Nutrition and Health from 2016 to September 2022.
Martin L. Reid, age 57, has served as our Senior Vice President and Chief Supply Chain Officer since September 2022. Prior to that, he served as Vice President and Chief Supply Chain Officer from January 2021 to September 2022. Mr. Reid served as Chief Supply Chain Officer at Godiva Chocolate from May 2019 to December 2020, and as Vice President, Supply Chain – North America Manufacturing at The Estee Lauder Companies, Inc., a multinational cosmetics company, prior to that.
Michael R. Sestrick, Ph.D., age 60, has served as our Senior Vice President and Chief Technology Officer since September 2022. Prior to that he served as our Vice President and Chief Technology officer from April 2017 to September 2022.
M. Brent Tignor, age 46, has served as our Senior Vice President and Chief Human Resources Officer since September 2022. Prior to that, he led the Human Resources department as our Vice President and Chief Human Resources Officer from February 2022 to September 2022 and as our Vice President, Human Resources from 2016 to February 2022.
Job L. van Gunsteren, age 48, has served as our Senior Vice President and General Manager, Specialty Products, since September 2022. Prior to that, he served as our Vice President and General Manager, Special Products from August 2019 to September 2022 and as our Director for Animal Nutrition and Health – EMEA from 2013 to 2019.
William A. Backus, age 57, has served as our Vice President and Chief Accounting Officer since October 2017. He also served as interim Chief Financial Officer from October 2018 to February 2019.

All above-listed officers except for Ms. Miyata, Mr. Boned, and Mr. Reid have been employed by the Company for more than the past five years. No family relationship exists between any of the above-listed executive officers of the Company. All officers are elected to hold office for one year or until their successors are elected and qualified or their earlier death, resignation or removal from office by the Board of Directors of the Company.
17

PART II
Item 5.    Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
The Common Stock is listed on the Nasdaq Stock Market LLC under the symbol “BCPC.”
On February 2, 2024, the closing price for the Common Stock on the Nasdaq Stock Market LLC was $143.14.
Record Holders
As of February 2, 2024, the approximate number of holders of record of Common Stock was 64. Such number does not include stockholders who hold their stock in street name.

18

Performance Graph
The graph below sets forth the cumulative total stockholder return on the Common Stock (referred to in the table as “BCPC”) for the five years ended December 31, 2023, the overall stock market return during such period for shares comprising the Russell 2000® Index (which we believe includes companies with market capitalization similar to that of us), and the overall stock market return during such period for shares comprising the Dow Jones U.S. Specialty Chemicals Index, in each case assuming a comparable initial investment of $100 on December 31, 2018 and the subsequent reinvestment of dividends. The Russell 2000® Index measures the performance of the shares of the 2000 smallest companies included in the Russell 3000® Index. In light of our industry segments, we do not believe that published industry-specific indices are necessarily representative of stocks comparable to us. Nevertheless, we consider the Dow Jones U.S. Specialty Chemicals Index to be potentially useful as a peer group index with respect to us. The performance of the Common Stock shown on the graph below is historical only and not necessarily indicative of future performance.
1656

19

Issuer Purchase of Equity Securities
The following table summarizes the share repurchase activity for the year ended December 31, 2023:
 
Total Number of Shares
Purchased (1)
Average Price Paid Per Share
Total Number of Shares
Purchased as
Part of Publicly Announced
Programs(2)
Approximate Dollar Value of Shares that May Yet Be
Purchased Under the
Plans or Programs(2)(3)
January 1-31, 20231,343 $130.96 1,343 $90,512,611 
February 1-28, 202326,766 $137.24 26,766 $91,178,224 
March 1-31, 2023— $— — $91,178,224 
     First Quarter28,109 28,109 
April 1-30, 2023— $— — $91,178,224 
May 1-31, 2023504 $132.26 504 $87,807,402 
June 1-30, 202363 $134.81 63 $89,488,765 
     Second Quarter 567 567 
July 1-31, 2023482 $128.54 482 $85,264,695 
August 1-31, 2023— $— — $85,264,695 
September 1-30, 2023293 $134.00 293 $88,847,226 
     Third Quarter775 775 
October 1-31, 2023— $— — $88,847,226 
November 1-30, 2023241 $119.51 241 $79,211,236 
December 1-31, 20232,866 $144.94 2,866 $95,651,484 
     Fourth Quarter3,107  3,107  
Total32,558 32,558 
(1) The Company repurchased (withheld) shares from employees solely in connection with the tax settlement of vested shares and/or exercised stock options under the Company's omnibus incentive plan.
(2) Our Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,103,106 shares have been repurchased. Other than shares withheld for tax purposes, as described in footnote 1 above, no share repurchases were made under the Company's stock repurchase program during the year ended December 31, 2023. There is no expiration for this program.
(3) Dollar amounts in this column equal the number of shares remaining available for repurchase under the stock repurchase program as of the last date of the applicable month multiplied by the monthly average price paid per share.

Item 6.    [Reserved]

20


Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
(All amounts in thousands, except share and per share data)
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and the related notes included in this report. Refer to Part II, Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (filed with the SEC on February 24, 2023) for additional discussion of our financial condition and results of operations for the year ended December 31, 2021. In addition, discussion of year-to-year comparisons between 2022 and 2021 are not included in this Annual Report on Form 10-K, and can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Those statements in the following discussion that are not historical in nature should be considered to be forward-looking statements that are inherently uncertain. See “Cautionary Statement Regarding Forward-Looking Statements.”


Overview
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, as more fully described in Note 11, Segment Information, of the consolidated financial statements. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

Segment Results

We sell products for all three segments through our own sales force, independent distributors, and sales agents.
The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three years ended December 31, 2023, 2022 and 2021 (in thousands):

Business Segment Net Sales
202320222021
Human Nutrition and Health$550,751 $527,131 $442,733 
Animal Nutrition and Health238,326 262,297 226,776 
Specialty Products125,965 131,438 117,020 
Other and Unallocated (1)
7,397 21,492 12,494 
Total$922,439 $942,358 $799,023 
Business Segment Earnings From Operations
202320222021
Human Nutrition and Health$102,419 $82,125 $76,031 
Animal Nutrition and Health27,576 36,056 26,179 
Specialty Products34,579 32,789 30,020 
Other and Unallocated (1)
(5,381)(5,784)(4,728)
Total$159,193 $145,186 $127,502 
(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,617, $3,581 and $1,264 for years ended December 31, 2023, 2022 and 2021, respectively, and (ii) Unallocated amortization expense of $312, $2,951, and $2,510 for years ended December 31, 2023, 2022, and 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.


21

Acquisitions
On August 30, 2022, we completed the acquisition of Bergstrom, a leading science-based manufacturer of MSM, based in Vancouver, Washington, and on June 21, 2022, we completed the acquisition of Kappa, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. Details related to both acquisitions are disclosed in Note 2, Significant Acquisitions, and the "Acquisitions" section in Item 1. Business.

Results of Operations - Fiscal Year 2023 compared to Fiscal Year 2022

Summary of Consolidated Statements of Earnings
(in thousands)20232022Increase
(Decrease)
% Change
Net sales$922,439 $942,358 $(19,919)(2.1)%
Gross margin302,056 280,451 21,605 7.7 %
Operating expenses142,863 135,265 7,598 5.6 %
Earnings from operations159,193 145,186 14,007 9.6 %
Interest and other expenses21,932 11,437 10,495 91.8 %
Income tax expense28,718 28,382 336 1.2 %
Net earnings$108,543 $105,367 $3,176 3.0 %
Management's discussion and analysis of the Consolidated Statements of Earnings is included below:
Net Sales
Increase
(Decrease)
(in thousands)20232022% Change
Human Nutrition and Health$550,751 $527,131 $23,620 4.5 %
Animal Nutrition and Health238,326 262,297 (23,971)(9.1)%
Specialty Products125,965 131,438 (5,473)(4.2)%
Other7,397 21,492 (14,095)(65.6)%
Total$922,439 $942,358 $(19,919)(2.1)%

The increase in net sales within the Human Nutrition and Health segment for 2023 compared to 2022 was primarily driven by the contribution from recent acquisitions, higher sales within the minerals and nutrients business, and a favorable impact related to changes in foreign currency rates, partially offset by lower sales within food and beverage markets. Total sales for this segment grew 4.5%, with average selling prices contributing 2.6%, volume and mix contributing 1.6%, and the change in foreign currency exchange rates contributing 0.3%.

The decrease in net sales within the Animal Nutrition and Health segment for 2023 compared to 2022 was primarily driven by lower sales in both the monogastric and ruminant species markets, partially offset by incremental sales related to the Bergstrom acquisition, and a favorable impact related to changes in foreign currency exchange rates. Total sales for this segment decreased by 9.1%, with volume and mix contributing -6.3%, average selling prices contributing -3.5%, and the change in foreign currency exchange rates contributing 0.7%.

The decrease in Specialty Products segment sales for 2023 compared to 2022 was primarily due to lower sales in both the plant nutrition and performance gases businesses, partially offset by a favorable impact related to changes in foreign currency exchange rates. Total sales for this segment decreased by 4.2%, with volume and mix contributing -9.4%, the change in foreign currency exchange rates contributing 0.7%, and average selling prices contributing 4.5%.

Sales relating to Other decreased from the prior year primarily due to lower demand.

Sales may fluctuate in future periods based on macroeconomic conditions, competitive dynamics, changes in customer preferences, and our ability to successfully introduce new products to the market.

22

Gross Margin
(in thousands)20232022Increase
(Decrease)
% Change
Gross margin$302,056 $280,451 $21,605 7.7 %
% of net sales32.7 %29.8 %
Gross margin dollars increased for 2023 compared to 2022 due to a decrease in cost of goods sold of $41,524. The 6.3% decrease in cost of goods sold was mainly driven by lower sales and certain lower manufacturing input costs.
Operating Expenses
(in thousands)20232022Increase
(Decrease)
% Change
Operating expenses$142,863 $135,265 $7,598 5.6 %
% of net sales15.5 %14.4 %
The increase in operating expenses was primarily due to restructuring-related impairment and asset disposal charges of $7,764, incremental operating expenses related to the Kappa and Bergstrom acquisitions of $7,699, and higher compensation-related expenses of $2,323, partially offset by favorable adjustments to transaction costs of $10,828.
Earnings From Operations
(in thousands)20232022Increase
(Decrease)
% Change
Human Nutrition and Health$102,419 $82,125 $20,294 24.7 %
Animal Nutrition and Health27,576 36,056 (8,480)(23.5)%
Specialty Products34,579 32,789 1,790 5.5 %
Other and unallocated(5,381)(5,784)403 7.0 %
Earnings from operations$159,193 $145,186 $14,007 9.6 %
% of net sales (operating margin)17.3 %15.4 %
Human Nutrition & Health segment earnings from operations increased $20,294 and the gross margin contribution was $30,144. This was partially offset by an increase in operating expenses of $9,850, primarily due to the incremental operating expenses related to the Kappa and Bergstrom acquisitions of $7,502, restructuring-related impairment and asset disposal charges of $6,031, and an increase in amortization of $2,435, partially offset by favorable adjustments to transaction costs of $7,855.

Animal Nutrition & Health segment earnings from operations decreased $8,480. Gross margin decreased $7,547 primarily due to aforementioned lower sales.
Specialty Products segment earnings from operations increased $1,790, which was primarily driven by a 410 basis point increase in gross margin as a percent of sales. The increase in gross margin was due to higher average selling prices and decreases in certain manufacturing input costs. The increase was partially offset by an increase in operating expenses of $897, primarily driven by higher compensation-related expenses of $1,586.

The increase in Other and unallocated was primarily driven by decreases of unallocated corporate expenses, partially offset by the aforementioned lower sales.
23

Other Expenses (Income)
(in thousands)20232022Increase
(Decrease)
% Change
Interest expense, net$22,613 $10,268 $12,345 120.2 %
Other, net(681)1,169 (1,850)(158.3)%
$21,932 $11,437 $10,495 91.8 %
Interest expense for 2023 and 2022 was primarily related to outstanding borrowings under the 2022 Credit Agreement. The increase in interest expense is due to the additional borrowings in connection with the acquisitions and higher interest rates.
Income Tax Expense
(in thousands)20232022Increase
(Decrease)
% Change
Income tax expense$28,718 $28,382 $336 1.2 %
Effective tax rate20.9 %21.2 %
The decrease in the effective tax rate was primarily due to an increase in certain tax credits.
Liquidity and Capital Resources
(All amounts in thousands, except share and per share data)
Contractual Obligations
Our short-term purchase obligations primarily include contractual arrangements in the form of purchase orders with suppliers. As of December 31, 2023, such purchase obligations were $72,958. For debt obligations, see Note 8, Revolving Loan, and for operating and finance lease obligations, see Note 19, Leases.
We know of no current or pending demands on, or commitments for, our liquid assets that will materially affect our liquidity.
There were no material changes during the year ended December 31, 2023 outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2022 other than the reduction of the contingent consideration liabilities to $100.
We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.
Cash

Cash and cash equivalents decreased to $64,447 at December 31, 2023 from $66,560 at December 31, 2022. At December 31, 2023, we had $53,152 of cash and cash equivalents held by our foreign subsidiaries. We presently intend to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds. Due to prevailing economic conditions of increased interest rates and subsequent borrowing costs, we remitted approximately $18,000 from our Belgium subsidiary to pay down U.S. debt, resulting in income tax expense of $20. The remittance was used to pay down U.S. debt. Working capital was $165,751 at December 31, 2023 as compared to $195,761 at December 31, 2022, a decrease of $30,010. Significant cash payments during the year included net payments on the revolving loan of $131,000, capital expenditures and intangible assets acquired of $37,892, and the payment of the 2022 declared dividend in 2023 of $22,872.
24

(in thousands)20232022Increase
(Decrease)
% Change
Cash flows provided by operating activities$183,761 $138,536 $45,225 32.6 %
Cash flows used in investing activities(34,813)(416,014)381,201 91.6 %
Cash flows (used in) provided by financing activities(153,321)246,679 (400,000)(162.2)%
Operating Activities
The increase in cash flows from operating activities was primarily driven by the impact from changes in working capital.
Investing Activities
We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $37,892 and $49,945 for the years ended December 31, 2023 and 2022, respectively. Capital expenditures are projected to be approximately $35,000 to $40,000 for 2024. As mentioned above, we expect that our operations will continue to generate sufficient cash flow to fund the commitments for capital expenditures. These capital expenditures are part of our continuous efforts to support our growing businesses.
In 2022, we completed the acquisitions of Kappa and Bergstrom. Cash paid for these acquisitions, net of cash acquired, amounted to $1,252 and $365,780, for years ended December 31, 2023 and 2022, respectively.
Financing Activities
In 2023, we borrowed $18,000 to fund the payment of the 2022 dividend and made total loan payments of $149,000, resulting in $240,431 available under the 2022 Credit Agreement (see Note 8, Revolving Loan) as of December 31, 2023.
We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,103,106 shares have been repurchased. We intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors. Open market repurchases of common stock could be made pursuant to a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit common stock to be repurchased at a time that we might otherwise be precluded from doing so under insider trading laws or self-imposed trading restrictions. We also purchase (withhold) shares from employees in connection with the tax settlement of vested shares and/or exercised stock options under the Company's omnibus incentive plan. Share repurchases are funded with existing cash on hand.

Proceeds from stock options exercised were $5,242 and $3,212 for the years ended December 31, 2023 and 2022, respectively. Dividend payments were $22,872 and $20,713 during 2023 and 2022, respectively.
Other Matters Impacting Liquidity
We have a liability of $4,650 for uncertain tax positions, including the related interest and penalties, recorded in accordance with ASC 740-10, for which we are unable to reasonably estimate the timing of settlement, if any.
We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 15, Employee Benefit Plans. The liability recorded in other long-term liabilities on the consolidated balance sheets as of December 31, 2023 and December 31, 2022 was $1,395 and $1,465, respectively, and the plans are not funded. Historical cash payments made under these plans have typically been less than $200 per year. We do not anticipate any changes to the payments made in the current year for the plans.
Balchem NV ("Chemogas") has an unfunded defined benefit plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on our balance sheet as of December 31, 2023 and December 31, 2022 was $420 and $393, respectively, and was included in other long-term obligations.
We provide an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are included in "Other non-current assets" on the consolidated balance sheet. They are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2023 and December 31, 2022 was $10,188 and $8,543, respectively, and is included in "Other long-term obligations" on the consolidated balance sheets. The related rabbi trust assets
25

were $10,188 and $8,547 as of December 31, 2023 and December 31, 2022, respectively, and were included in "Other non-current assets" on the consolidated balance sheets.

Related Party Transactions

We were engaged in related party transactions with St. Gabriel CC Company, LLC for the years ended December 31, 2023 and December 31, 2022. Refer to Note 18, Related Party Transactions.

Critical Accounting Estimates

Critical accounting estimates are those estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Our management is required to make these critical accounting estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.

Our critical accounting estimates are those that require application of management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and that may change in subsequent periods. Management considers the following to be critical accounting estimates.

Goodwill and Intangible Assets

The valuation methods and assumptions used in valuing goodwill and identified intangibles and assessing the impairment of goodwill and identified intangibles involves a significant level of estimation uncertainty. In addition, the assumptions used in determining the useful life of an intangible asset involves a significant level of estimation uncertainty. Refer to the Goodwill and Acquired Intangible Assets section in Note 1, Business Description and Summary of Significant Accounting Policies, for details related to the valuation and impairment process of both goodwill and intangible assets. Changes in market conditions, laws and regulations, and key assumptions made in future quantitative assessments, including expected cash flows, competitive factors and discount rates, could result in the recognition of an impairment charge, and in turn could have a material impact on our financial condition or results of operations in subsequent periods.

Contingent Consideration Liabilities

In connection with recent acquisitions (see Note 2, Significant Acquisitions), the sellers of each of the acquired entities had an opportunity to receive an additional payment if certain financial performance targets and other metrics were met, thereby requiring us to record contingent consideration liabilities on our balance sheet. The valuation methods and assumptions used in assessing the contingent consideration liabilities involve a significant level of estimation uncertainty, however, as of December 31, 2023, the earn-out periods concluded and the Company recorded a contingent consideration liability of $100.

Income Taxes

The valuation methods and assumptions used in calculating income taxes, deferred tax assets and liabilities, and valuation allowances involve a significant level of estimation uncertainty. Refer to the Income Taxes in Note 1, Business Description and Summary of Significant Accounting Policies, for details. Changes in the assumptions such as our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies could result in income taxes adjustments, and in turn could have a material impact on our financial condition or results of operations in subsequent periods.


Significant Accounting Policies and Recent Accounting Pronouncements

See Note 1, Business Description and Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements regarding significant accounting policies and recent accounting pronouncements.

26


Item 7A.    Quantitative and Qualitative Disclosures About Market Risk

Our cash and cash equivalents are held primarily in checking accounts, certificates of deposit, and money market investment funds. In 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. These derivatives settled on their maturity date of June 27, 2023. Refer to details noted below (see Note 20, Derivative Instruments and Hedging Activities). Additionally, as of December 31, 2023, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the 2022 Credit Agreement plus an applicable rate (see Note 8, Revolving Loan). The applicable rate is based upon our consolidated net leverage ratio, as defined in the 2022 Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at December 31, 2023, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $3,096. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change.

Interest Rate Risk

We have exposure to market risk for changes in interest rates, including the interest rate relating to the 2022 Credit Agreement. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. These derivatives were utilized for risk management purposes, and were not used for trading or speculative purposes. We hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 20, Derivative Instruments and Hedging Activities). This derivative settled on its maturity date of June 27, 2023.

Foreign Currency Exchange Risk

The financial condition and results of operations of our foreign subsidiaries are reported in local currencies and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Therefore, we are exposed to foreign currency exchange risk related to these currencies. In 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas (see Note 20, Derivative Instruments and Hedging Activities). This derivative settled on its maturity date of June 27, 2023.
27

Item 8.    Financial Statements and Supplementary Data


28

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Balchem Corporation

Opinions on the Financial Statements and Internal Control Over Financial Reporting
We have audited the accompanying consolidated balance sheets of Balchem Corporation and its subsidiaries (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of earnings, comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and schedule listed at Item 8 (collectively, the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

Basis for Opinions
The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's financial statements and an opinion on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

29

Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of Reporting Units for Goodwill Impairment Testing
As described in Notes 1 and 6 to the financial statements, the Company’s goodwill balance was $779 million as of December 31, 2023. The Company performed an annual goodwill impairment test as of October 1, 2023 using a quantitative evaluation for each of its reporting units. The Company determines the fair value of its reporting units using the income approach, based on a discounted cash flow valuation model. To test for goodwill impairment, the Company compares the fair value of each reporting unit to its carrying value. When determining the fair value of each reporting unit, management makes significant estimates and assumptions related to a number of factors. The Company considers the impact of factors that are specific to each of the reporting units such as industry and economic changes as well as projected sales and expense growth rates based upon annual budgets and longer-range strategic plans, which are highly sensitive to changes in domestic and foreign economic conditions, and the selection of appropriate discount rates.

Given the significant estimates and assumptions management makes to determine the fair value of the reporting units and the sensitivity of the operations to changes in U.S. and foreign economic conditions, we identified management’s assumptions related to the sales and expense growth rates, the discount rates, and the terminal value calculation utilized in the valuation of the reporting units within the Company’s goodwill impairment tests as a critical audit matter. Auditing the reasonableness of management’s estimates and assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

Our audit procedures related to sales and expense growth rates, discount rates, and the terminal value calculation utilized in the valuation of the Company’s reporting units included the following, among others:

We obtained an understanding of the relevant controls related to the valuation of the Company’s reporting units and tested such controls for design and operating effectiveness, including management review controls related to sales and expense growth rates and the selection of appropriate discount rates.
We evaluated the reasonableness of management’s forecasts of sales and expense growth rates by comparing the forecasts to (1) the historical results, (2) internal communications to management and the Board of Directors, and (3) external communications made by management to analysts and investors, as applicable.
We evaluated changes in the regulatory environment using industry reports containing analysis of the Company’s markets and assessed whether these changes were reflected in management’s forecasts of sales and expense growth rates.
With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rates and tested the relevance and reliability of source information underlying the determination of the discount rates, tested the mathematical accuracy of the calculation, and developed a range of independent estimates and compared those to the discount rates selected by management.
With the assistance of our fair value specialists, we evaluated the reasonableness and tested the mathematical accuracy of the terminal value calculations.



/s/ RSM US LLP

We have served as the Company's auditor since 2004.

New York, New York
February 16, 2024

30

BALCHEM CORPORATION
Consolidated Balance Sheets
December 31, 2023 and 2022
(Dollars in thousands, except share and per share data)
20232022
Current assets:
Cash and cash equivalents$64,447 $66,560 
Accounts receivable, net of allowance for doubtful accounts of $908 and $1,226 at
December 31, 2023 and 2022, respectively
125,284 131,578 
Inventories, net109,521 119,668 
Prepaid expenses7,798 4,903 
Derivative assets 5,993 
Other current assets7,192 7,101 
Total current assets314,242 335,803 
Property, plant and equipment, net276,039 271,355 
Goodwill778,907 769,509 
Intangible assets with finite lives, net191,212 213,295 
Right of use assets - operating leases17,763 17,094 
Right of use assets - finance lease2,101 2,338 
Other non-current assets16,947 15,118 
Total assets$1,597,211 $1,624,512 
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable$55,503 $57,322 
Accrued expenses40,855 36,745 
Accrued compensation and other benefits17,228 16,544 
Dividends payable25,717 23,129 
Income tax payable4,967 2,280 
Operating lease liabilities - current3,949 3,796 
Finance lease liabilities - current272 226 
Total current liabilities148,491 140,042 
Revolving loan309,569 440,569 
Deferred income taxes52,046 62,784 
Operating lease liabilities - non-current14,601 13,806 
Finance lease liabilities - non-current1,943 2,213 
Other long-term obligations16,577 26,814 
Total liabilities543,227 686,228 
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding
  
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,254,728 shares issued and outstanding at December 31, 2023 and 32,152,787 shares issued and outstanding at December 31, 2022, respectively
2,152 2,145 
Additional paid-in capital145,653 128,806 
Retained earnings897,488 814,487 
Accumulated other comprehensive income (loss)8,691 (7,154)
Total stockholders’ equity1,053,984 938,284 
Total liabilities and stockholders’ equity$1,597,211 $1,624,512 
See accompanying notes to consolidated financial statements.
31

BALCHEM CORPORATION
Consolidated Statements of Earnings
Years Ended December 31, 2023, 2022 and 2021
(In thousands, except per share data)
202320222021
Net sales$922,439 $942,358 $799,023 
Cost of sales620,383 661,907 555,849 
Gross margin302,056 280,451 243,174 
Operating expenses:
Selling expenses74,397 67,409 60,413 
Research and development expenses15,049 12,191 13,524 
General and administrative expenses53,417 55,665 41,735 
142,863 135,265 115,672 
Earnings from operations159,193 145,186 127,502 
Other expenses:
Interest expense, net22,613 10,268 2,456 
Other (income) expense, net(681)1,169 (187)
21,932 11,437 2,269 
Earnings before income tax expense137,261 133,749 125,233 
Income tax expense28,718 28,382 29,129 
Net earnings$108,543 $105,367 $96,104 
Basic net earnings per common share$3.38 $3.29 $2.98 
Diluted net earnings per common share$3.35 $3.25 $2.94 

See accompanying notes to consolidated financial statements.
32

BALCHEM CORPORATION
Consolidated Statements of Comprehensive Income
Years Ended December 31, 2023, 2022 and 2021
(In thousands)
202320222021
Net earnings$108,543 $105,367 $96,104 
Other comprehensive income (loss), net of tax:
Net foreign currency translation adjustment16,809 (4,799)(11,255)
Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively
(1,065)2,696 2,053 
Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively
101 (58)36 
Other comprehensive income (loss), net of tax15,845 (2,161)(9,166)
Comprehensive income$124,388 $103,206 $86,938 

See accompanying notes to consolidated financial statements.
33

BALCHEM CORPORATION
Consolidated Statements of Stockholders’ Equity
Years Ended December 31, 2023, 2022 and 2021
(Dollars in thousands, except share and per share data)
Total
Stockholders'
Equity
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Common StockAdditional
Paid-in
Capital
SharesAmount
Balance - December 31, 2020$828,233 $656,740 $4,173 32,372,621 $2,160 $165,160 
Net earnings96,104 96,104 — — — — 
Other comprehensive loss(9,166)— (9,166)— — — 
Dividends ($.64 per share)
(20,706)(20,706)— — — — 
Repurchases of common stock(35,239)— — (249,848)(17)(35,222)
Shares and options issued under stock plans17,789 — — 164,377 11 17,778 
Balance - December 31, 2021877,015 732,138 (4,993)32,287,150 2,154 147,716 
Net earnings105,367 105,367 — — — — 
Other comprehensive loss(2,161)— (2,161)— — — 
Dividends ($.71 per share)
(23,018)(23,018)— — — — 
Repurchases of common stock(35,423)— — (252,304)(16)(35,407)
Shares and options issued under stock plans16,504 — — 117,941 7 16,497 
Balance - December 31, 2022938,284 814,487 (7,154)32,152,787 2,145 128,806 
Net earnings108,543 108,543 — — — — 
Other comprehensive income15,845 — 15,845 — — — 
Dividends ($.79 per share)
(25,542)(25,542)— — — — 
Repurchases of common stock, including excise tax *(4,514)— — (32,558)(2)(4,512)
Shares and options issued under stock plans21,368 — — 134,499 9 21,359 
Balance - December 31, 2023$1,053,984 $897,488 $8,691 32,254,728 $2,152 $145,653 
 * On August 16, 2022, the U.S. government enacted the Inflation Reduction Act (the "IRA") into law. The IRA imposes a 1% excise tax on share repurchases, which is effective for repurchases completed after December 31, 2022. The excise tax is recorded within equity as part of the repurchase of the common stock.

See accompanying notes to consolidated financial statements.
34


BALCHEM CORPORATION
Consolidated Statements of Cash Flows
Years Ended December 31, 2023, 2022 and 2021
(In thousands)
 202320222021
Cash flows from operating activities:   
Net earnings$108,543 $105,367 $96,104 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization54,935 51,848 48,879 
Stock compensation expense16,052 13,224 10,802 
Deferred income taxes(10,814)(8,362)(5,944)
Provision for doubtful accounts37 401 180 
Unrealized (gain) loss on foreign currency transactions and deferred compensation(733)914 (384)
Asset impairment charge and (gain) loss on disposal of assets7,031 366 (53)
Change in fair value of contingent consideration liability(11,300)  
Changes in assets and liabilities, net of acquired balances
Accounts receivable6,969 (3,618)(20,700)
Inventories10,530 (7,804)(21,023)
Prepaid expenses and other current assets(3,540)1,870 (881)
Accounts payable and accrued expenses3,552 (15,543)47,067 
Income taxes2,194 296 4,787 
Other305 (423)1,680 
Net cash provided by operating activities183,761 138,536 160,514 
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired(1,252)(365,780) 
Capital expenditures and intangible assets acquired(37,892)(49,945)(37,363)
Proceeds from sale of assets1,881 206 318 
Proceeds from settlement of net investment hedge2,740   
Proceeds from insurance  1,831 
Investment in affiliates(290)(495)(86)
Net cash used in investing activities(34,813)(416,014)(35,300)
Cash flows from financing activities:
Proceeds from revolving loan18,000 435,000 5,000 
Principal payments on revolving debt(149,000)(103,000)(60,000)
Principal payment on acquired debt (30,988) 
Cash paid for financing costs (1,232) 
Principal payments on finance lease(222)(177)(159)
Proceeds from stock options exercised5,242 3,212 6,943 
Dividends paid(22,872)(20,713)(18,723)
Repurchases of common stock(4,469)(35,423)(35,239)
Net cash (used in) provided by financing activities(153,321)246,679 (102,178)
Effect of exchange rate changes on cash2,260 (5,880)(4,368)
(Decrease) increase in cash and cash equivalents(2,113)(36,679)18,668 
Cash and cash equivalents beginning of period66,560 103,239 84,571 
Cash and cash equivalents end of period$64,447 $66,560 $103,239 

Supplemental Cash Flow Information - see Note 13
See accompanying notes to consolidated financial statements.
35

BALCHEM CORPORATION
Notes to Consolidated Financial Statements
(All amounts in thousands, except share and per share data)

NOTE 1 - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Description
Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries.
Principles of Consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S. and other countries exceed the insurance limits of the Federal Deposit Insurance Corporation (“FDIC”) and other relevant insurance limits in other countries.
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
36

Inventories
Inventories are valued at the lower of cost (first in, first out) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2023, 2022 and 2021, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired in accordance with ASC 805, "Business Combinations". Goodwill and intangible assets acquired in a business combination that have indefinite useful lives are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the assets might be impaired, in accordance with the provisions of ASC 350, "Intangibles-Goodwill and Other". The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the assets might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. In accordance with this update, a goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.


37

As of October 1, 2023 and 2022, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2023 and 2022. The Company may resume performing the qualitative assessment in subsequent periods.
The Company had goodwill in the amount of $778,907 and $769,509 as of December 31, 2023 and 2022, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2021$523,949 
Goodwill as a result of the Kappa acquisition216,295 
Goodwill as a result of the Bergstrom acquisition31,209 
Impact due to change in foreign exchange rates(1,944)
Goodwill at December 31, 2022769,509 
Goodwill as a result of the Bergstrom acquisition341 
Impact due to change in foreign exchange rates9,057 
Goodwill at December 31, 2023$778,907 

 December 31, 2023December 31, 2022
HNH$673,207 $665,804 
ANH24,469 24,218 
Specialty Products81,175 79,429 
Other and Unallocated56 58 
Total$778,907 $769,509 
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks and trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents and trade secrets
15 - 17
Other
 2 - 18
Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2023, there were no triggering events which required intangible asset impairment reviews.

38

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also had derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which were included in derivative assets and derivative liabilities, in the consolidated balance sheets (see Note 20, Derivative Instruments and Hedging Activities). The fair values of these derivative instruments were determined based on Level 2 inputs, using significant inputs that were observable either directly or indirectly, including interest rate curves and implied volatilities. These derivatives were settled on their maturity date on June 27, 2023 and there were no other derivatives outstanding as of December 31, 2023.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.


39

Research and Development
Research and development costs are associated directly with the Company's efforts to develop, design, and enhance its products, services, technologies, or processes. Such costs are expensed as incurred.
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3, Stockholders' Equity. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the statement of earnings as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets
Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows.

Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments was to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

The derivative instruments were with the above single counterparty and were subject to a contractual agreement that provided for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments were categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet as of December 31, 2022. The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2023.

On a quarterly basis through their maturity, we assessed the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. The hedging relationships were determined to be highly effective. As such, the net change in fair values of the interest rate swap, that qualified as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and subsequently reclassified into interest expense as interest payments were made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remain in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, Derivative Instruments and Hedging Activities, for detailed information about our derivative financial instruments.


40

Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment in this Update should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have to the financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures." The ASU expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning December 15, 2024. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. The adoption of this guidance will not affect the Company's consolidated results of operations, financial position or cash flows. The Company is currently evaluating the effect the guidance will have on its disclosures.
In August 2023, the FASB issued ASU 2023-05, "Business Combinations - Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement." The new guidance applies to the formation of a joint venture and requires a joint venture to initially measure all contributions received upon its formation at fair value. The guidance is intended to reduce diversity in practice and is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. While ASU 2023-05 is not currently applicable to Balchem, the Company will apply this guidance in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", and in December 2022 subsequently issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” These ASU’s provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The Standards Updates provide optional expedients and exceptions for applying accounting principles generally accepted in the United States to contract modifications and hedging relationships that reference LIBOR or another reference rate that are expected to be discontinued. The Standards Updates were effective upon issuance and can generally be applied through December 31, 2024. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its interest rate swap and replaced LIBOR with 1-month CME Term SOFR. The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. The interest rate swap matured on June 27, 2023.

NOTE 2 – SIGNIFICANT ACQUISITIONS
Cardinal Associates Inc. ("Bergstrom")
On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc. ("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc. ("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom"). Bergstrom Nutrition is a leading science-based manufacturer of MSM, based in Vancouver, Washington. MSM is a widely used nutritional ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. The addition of OptiMSM®, Bergstrom Nutrition's MSM brand, to the Company's portfolio within the Human Nutrition and Health and Animal Nutrition and Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products.
The Company made payments of $72,143 for the acquisition, amounting to $71,937 to the former shareholders or on behalf of the former shareholders and $206 to pay off Bergstrom's bank debt. Net of cash acquired of $773, total payments made to the former shareholders or on behalf of the former shareholders of Bergstrom were $71,164. The acquisition was primarily financed through the 2022 Credit Agreement (see Note 8, Revolving Loan). In connection with this transaction, the former shareholders of Bergstrom had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. As of December 31, 2023, the earn-out periods concluded and the Company recorded a contingent consideration liability of $100 which was included in "Accrued expenses" on the consolidated balance sheets. The Company also made an additional post-closing payment of $910 in the third quarter of 2023 that was negotiated as a deduction of the cash consideration at closing. As a result, total payments related to the transaction are expected to be $72,243, comprised of the upfront cash
41

consideration of $70,892, a working capital adjustment of $341, an additional post-closing payment of $910, and the fair value of the earn-out payment of $100.
The goodwill of $31,550 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. 80% of the goodwill is assigned to the Human Nutrition and Health business segment and 20% of the goodwill is assigned to the Animal Nutrition and Health business segment. For tax purposes, a joint election under 338(h)(10) was made to treat the stock acquisition as a deemed asset acquisition, therefore generating tax amortizable goodwill.
The following table summarizes the fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$773 
Accounts receivable4,699 
Inventories3,972 
Property, plant and equipment2,243 
Right of use assets866 
Customer relationships29,900 
Developed technology4,600 
Trademarks2,300 
Other assets197 
Accounts payable(699)
Bank debt(206)
Lease liabilities(871)
Other liabilities(462)
Goodwill31,550 
Total consideration on acquisition date and working capital adjustment78,862 
Net decrease to contingent consideration liability and other post-closing payments(6,825)
Total expected consideration72,037 
To pay off bank debt206 
Total expected payments $72,243 
The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration.
Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.

Transaction and integration costs related to the Bergstrom acquisition are included in general and administrative expenses and were $(10,614) and $4,604 for the years ended December 31, 2023 and 2022, respectively. There were no such amounts related to this acquisition for the year ended December 31, 2021. These amounts included favorable adjustments to transaction costs of $11,300 for the year ended December 31, 2023 and an unfavorable adjustment to transaction costs of $3,565 for the year ended December 31, 2022.



42

Kechu BidCo AS and Its Subsidiary Companies ("Kappa")

On June 21, 2022, Balchem Corporation and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as “Kappa”). Kappa manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition and Health segment.

The Company made payments of approximately kr3,305,653 ("kr" indicates the Norwegian krone), amounting to approximately kr3,001,981 to the former shareholders and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments to the former shareholders were kr2,938,917. Net of gains on foreign currency forward contracts of $512 (see Note 20, Derivative Instruments and Hedging Activities), these payments translated to approximately $333,112, amounting to approximately $302,464 paid to the former shareholders and approximately $30,648 to Kappa's lenders. Net of cash acquired of $6,365, total payments made to the former shareholders of Kappa were approximately $296,099. The acquisition was primarily financed through the 2018 Credit Agreement (see Note 8, Revolving Loan). In connection with this transaction, the former shareholders of Kappa had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. There was no contingent consideration liability recorded as of December 31, 2023.
The goodwill of $216,383 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition and Health business segment and is not deductible for income tax purposes.
The following table summarizes the fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022.
Cash and cash equivalents$6,365 
Accounts receivable8,036 
Inventories17,600 
Property, plant and equipment9,854 
Right of use assets3,349 
Customer relationships88,813 
Developed technology15,643 
Trademarks5,046 
Other assets2,399 
Accounts payable(3,301)
Bank debt(30,648)
Lease liabilities(3,349)
Other liabilities(4,461)
Deferred income taxes, net(24,716)
Goodwill216,383 
Total consideration on acquisition date307,013 
Decrease to contingent consideration liability(4,037)
Net gain on foreign currency exchange forward contracts(512)
Total expected consideration302,464 
Kappa bank debt paid on acquisition date30,648 
Total expected payments$333,112 

43

The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration.
Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
Transaction and integration costs related to the Kappa acquisition are included in general and administrative expenses and were $533 and $(2,306) for the years ended December 31, 2023 and 2022, respectively. There were no such amounts related to this acquisition for the year ended December 31, 2021. The amount included a favorable adjustment to transaction costs of $4,037 for the year ended December 31, 2022.
The following selected unaudited pro forma information presents the consolidated results of operations as if the business combinations in 2022 had occurred as of January 1, 2021.

Twelve Months ended December 31,
Net SalesNet Earnings
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023
$59,532 $5,487 
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2022
$22,158 $(5,359)
2023 Supplemental pro forma combined financial
$922,439 $116,317 
2022 Supplemental pro forma combined financial
$982,021 $110,181 
2021 Supplemental pro forma combined financial
$859,252 $90,672 

The above selected unaudited pro forma information includes the following acquisition-related adjustments: (1) additional amortization of intangible assets and depreciation of fixed assets; (2) adjustments related to the fair value of the acquired inventory, (3) adjustments to interest expense on borrowings at rates in effect during the related period, factoring in estimated payments based on free cash flow, and (4) other one-time adjustments.

The pro forma information presented does not purport to be indicative of the results that actually would have been attained if these acquisitions had occurred at the beginning of the periods presented and is not intended to be a projection of future results.

44


NOTE 3 - STOCKHOLDERS’ EQUITY

Stock-Based Compensation

All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values.

The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest.
The Company’s results for the years ended December 31, 2023, 2022 and 2021 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended December 31,
 202320222021
Cost of sales$1,900 $1,302 $845 
Operating expenses14,152 11,922 9,957 
Net earnings(12,375)(10,214)(8,370)

On December 31, 2023, the Company had one share-based compensation plan under which awards may be granted, which is described below.

In June 2017, the Company’s shareholders approved the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired in April 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. On June 22, 2023, the Company’s shareholders approved an amendment and restatement of the 2017 Plan (the “Amended 2017 Plan”). The Amended 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The Amended 2017 Plan provides as follows: (i) for a termination date of June 22, 2033; (ii) the authorization of 2,400,000 shares for future grants (which represents an increase of 800,000 shares from the amount approved under the 2017 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided by the Compensation Committee or in an employment agreement as in effect on the effective date of the Amended 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vi) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for incentive compensation recovery if the Company is required to prepare an accounting restatement of its financial statements, in accordance with any compensation recovery policy adopted by the Company, applicable law, government regulations or national securities exchange requirements, or in the discretion of the Compensation Committee in the event of a restatement due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant.

The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2023, the Amended 2017 Plan had 1,034,260 shares available for future awards.

The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements.

The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) market condition where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents.

45

The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. For the years ended December 31, 2023, 2022, and 2021, the fair value of each option grant uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202320222021
Expected Volatility28.1 %30.3 %32.9 %
Expected Term (in years)4.87.34.9
Risk-Free Interest Rate3.9 %2.8 %0.5 %
Dividend Yield0.5 %0.5 %0.5 %
The value of the restricted shares is based on the fair value of the award at the date of grant.
Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 4.2%, 1.8%, and 0.2%; dividend yields of 0.5%, 0.5%, and 0.6%; volatilities of 32%, 32%, and 33%; and initial TSR’s of 4.2%, -15.7%, and 11.7% in each case for the years ended December 31, 2023, 2022, and 2021, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.
Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three to five years for stock options, three years for employee restricted stock awards, three years for employee performance share awards, and three years for non-employee director restricted stock awards.
A summary of stock option plan activity for 2023, 2022, and 2021 for all plans is as follows:
202320222021
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
Outstanding at beginning of year1,045 $99.82 867 $88.19 858 $80.58 
Granted109 138.09 239 139.04 129 119.12 
Exercised(64)81.98 (44)73.58 (109)63.42 
Forfeited(11)131.79 (17)124.89 (10)106.93 
Cancelled(1)138.07   (1)74.57 
Outstanding at end of year1,078 $104.38 1,045 $99.82 867 $88.19 
Exercisable at end of year720 $88.49 654 $81.95 538 $75.51 

The aggregate intrinsic value for outstanding stock options was $47,889, $27,221 and $69,711 at December 31, 2023, 2022 and 2021, respectively, with a weighted average remaining contractual term of 5.7 years at December 31, 2023. Exercisable stock options at December 31, 2023 had an aggregate intrinsic value of $43,364 with a weighted average remaining contractual term of 4.4 years.


46

Other information pertaining to option activity during the years ended December 31, 2023, 2022 and 2021 is as follows:

 Years Ended December 31,
 202320222021
Weighted-average fair value of options granted$40.91 $44.77 $33.11 
Total intrinsic value of stock options exercised ($000s)$3,241 $2,713 $7,866 

Additional information related to stock options outstanding under all plans at December 31, 2023 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices
Shares
Outstanding
(000s)
Weighted
Average
Remaining
Contractual
 Term
Weighted
Average
 Exercise
Price
Number
Exercisable
(000s)
Weighted
Average
Exercise
Price
$54.87 - $85.33
387 3.5$72.41 387 $72.41 
$85.40 - $118.60
250 4.9101.84 248 101.71 
$118.96 - $150.85
441 8.1133.93 85 123.47 
 1,078 5.7$104.38 720 $88.49 

Non-vested restricted stock activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:
202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 122 $124.42 166 $99.7 159 $90.71 
Granted40 137.20 46 137.17 42 123.58 
Vested(42)112.30 (82)82.15 (24)85.83 
Forfeited(4)128.06 (8)118.07 (11)90.49 
Non-vested balance at end of year 116 $133.06 122 $124.42 166 $99.7 

Non-vested performance share activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:

202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 70 $127.69 69 $110.72 71 $91.99 
Granted42 139.66 39 114.22 36 108.74 
Vested(36)98.84 (35)53.17 (24)70.64 
Forfeited  (3)84.09 (14)81.03 
Non-vested balance at end of year 76 $135.25 70 $127.69 69 $110.72 

As of December 31, 2023, 2022 and 2021, there was $18,817, $20,791 and $13,980, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2023, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.6 years. We estimate that share-based compensation expense for the year ended December 31, 2024 will be approximately $14,800.
47

Repurchase of Common Stock
The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,103,106 shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. Open market repurchases of common stock could be made pursuant to trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit common stock to be repurchased at a time that the Company might otherwise be precluded from doing so under insider trading laws or self-imposed trading restrictions. The Company also repurchases (withholds) shares from employees in connection with the tax settlement of vested shares and/or exercised stock options under the Company's omnibus incentive plan. Such repurchases of shares from employees are funded with existing cash on hand. During 2023, 2022, and 2021, the Company purchased 32,558, 252,304, and 249,848 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $137.29, $140.40, and $141.04 per share, respectively.

NOTE 4 - INVENTORIES
Inventories, net of reserves at December 31, 2023 and 2022 consisted of the following:
 20232022
Raw materials$39,517 $44,477 
Work in progress3,960 3,143 
Finished goods66,044 72,048 
Total inventories$109,521 $119,668 
On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $2,463 and $2,640 at December 31, 2023 and 2022, respectively.

NOTE 5 - PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at December 31, 2023 and 2022 are summarized as follows:
 20232022
Land$11,787 $11,415 
Building104,363 90,644 
Equipment312,704 278,851 
Construction in progress59,981 79,928 
 488,835 460,838 
Less: Accumulated depreciation212,796 189,483 
Property, plant and equipment, net$276,039 $271,355 

Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20232022
United States$203,692 $211,588 
Foreign Countries72,347 59,767 
Total$276,039 $271,355 
Depreciation expense was $26,373, $24,033 and $23,295 for the years ended December 31, 2023, 2022 and 2021, respectively.

48

In accordance with Topic 360, the Company reviews long-lived assets for impairment on an annual basis and also whenever events indicate that the carrying amount of the assets may not be fully recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. Included in “General and administrative expenses” were restructuring-related impairment and asset disposal charges of $7,764 related to building, equipment, and construction in progress mainly in the Human Nutrition and Health and the Animal Nutrition and Health segments, for the year ended December 31, 2023. Such expenses for the year ended December 31, 2022 were not material.


NOTE 6 - INTANGIBLE ASSETS

The Company had goodwill in the amount of $778,907 and $769,509 as of December 31, 2023 and 2022, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is primarily due to foreign currency translation adjustments.

As of December 31, 2023 and 2022, the Company had identifiable intangible assets as follows:
20232022
 Amortization
Period
(In years)
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount

Accumulated
Amortization
Customer relationships and lists
10-20
$362,032 $209,651 $357,131 $190,576 
Trademarks and trade names
2-17
50,286 37,773 50,058 33,416 
Developed technology
5-12
41,184 17,516 40,473 16,171 
Other
2-18
25,733 23,083 25,041 19,245 
  $479,235 $288,023 $472,703 $259,408 

Amortization of identifiable intangible assets was $28,035, $27,271 and $25,092 for 2023, 2022 and 2021, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $18,971 in 2024, $15,509 in 2025, $15,308 in 2026, $14,784 in 2027, and $14,387 in 2028. At December 31, 2023 and 2022, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2023 and 2022.

The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included as other in the table above.


NOTE 7 – EQUITY-METHOD INVESTMENT
In 2013, the Company and Eastman Chemical Company formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity ("VIE") because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $509, $559, and $557 for the years ended December 31, 2023, 2022, and 2021, respectively, relating to its portion of the joint venture’s expenses in other expense. The Company made capital contributions to the investment totaling $290, $355, and $85 for the years ended December 31, 2023, 2022, and 2021 respectively. The carrying value of the joint venture at December 31, 2023 and 2022 was $4,076 and $4,295, respectively, and is recorded in "Other non-current assets" on the consolidated balance sheets.


49

NOTE 8 – REVOLVING LOAN

On June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "2018 Credit Agreement"), which provided for revolving loans up to $500,000, due on June 27, 2023. During the second quarter of 2022, the Company borrowed $345,000 under the 2018 Credit Agreement to fund the Kappa acquisition (see Note 2, Significant Acquisitions). On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement (the "2022 Credit Agreement") with certain lenders in the form of a senior secured revolving credit facility, due on July 27, 2027. The 2022 Credit Agreement allows for up to $550,000 of borrowing. The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The Company used initial proceeds from the 2022 Credit Agreement to repay the outstanding balance of $433,569 due in June 2023 under the 2018 Credit Agreement. During the third quarter of 2022, the Company borrowed another $70,000 to fund the Bergstrom acquisition (see Note 2, Significant Acquisitions). As of December 31, 2023 and 2022, the total balance outstanding on the 2022 Credit Agreement amounted to $309,569 and $440,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date.

Amounts outstanding under the 2022 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2022 Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2022 Credit Agreement, and the interest rate was 6.580% at December 31, 2023. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2022 Credit Agreement and ranges from 0.150% to 0.225% (0.175% at December 31, 2023). The unused portion of the revolving loan amounted to $240,431 at December 31, 2023. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the 2022 Credit Agreement. Capitalized costs net of accumulated amortization totaled $1,030 and $1,317 at December 31, 2023 and 2022, respectively, and are included in "Other non-current assets" on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $287, $335, and $282 for the years ended December 31, 2023, 2022, and 2021, respectively, and are included in "Interest expense" in the accompanying consolidated statements of earnings.

The 2022 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At December 31, 2023, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements is secured by assets of the Company.


NOTE 9 - NET EARNINGS PER COMMON SHARE
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202320222021
Net Earnings - Basic and Diluted$108,543 $105,367 $96,104 
Share (000s)
Weighted Average Common Shares - Basic32,108 32,019 32,215 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares340 374 457 
Weighted Average Common Shares - Diluted32,448 32,393 32,672 
Net Earnings Per Share - Basic$3.38 $3.29 $2.98 
Net Earnings Per Share - Diluted$3.35 $3.25 $2.94 
The number of anti-dilutive shares were 354,619, 371,513, and 155,294 for 2023, 2022, and 2021. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

50


NOTE 10 - INCOME TAXES

The Company’s effective tax rate for 2023, 2022 and 2021 was 20.9%, 21.2%, and 23.3%, respectively. The decrease from 2022 to 2023 is primarily due to an increase in certain tax credits.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences.
The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs. However, due to prevailing economic conditions of increased interest rates and subsequent borrowing costs, the Company remitted approximately $18,000 from its Belgium subsidiary and has incurred an income tax expense of approximately $20. The remittance was used to pay down U.S. debt. The Company had unremitted foreign earnings of approximately $109,000 and $94,000 for the years ended December 31, 2023 and 2022, respectively. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to change its assertion on its remaining undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion.
Income tax expense consists of the following:
 202320222021
Current:   
Federal$27,306 $26,423 $25,019 
Foreign7,634 7,103 7,553 
State4,403 3,964 3,664 
Deferred:
Federal(7,737)(7,532)(3,709)
Foreign(2,285)(215)(3,038)
State(603)(1,361)(360)
Total income tax provision$28,718 $28,382 $29,129 
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2023, 2022, and 2021 to earnings before income tax expense due to the following:
 202320222021
Income tax at Federal statutory rate$28,825 $28,087 $26,299 
State income taxes, net of Federal income taxes2,513 1,862 2,406 
Stock Options(1,004)(676)(924)
Foreign-derived intangible income (FDII)(1,752)(1,778)(1,540)
Foreign rate differential946 2,066 1,188 
Other(810)(1,179)1,700 
Total income tax provision$28,718 $28,382 $29,129 
51

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022 were as follows:
 20232022
Deferred tax assets:  
Inventories$1,049 $1,038 
Restricted stock and stock options5,565 3,932 
Lease liabilities4,812 5,439 
Research and development12,653 4,134 
Other3,874 3,717 
Total deferred tax assets27,953 18,260 
Deferred tax liabilities:
Amortization$(42,351)$(46,688)
Depreciation(28,937)(25,097)
Prepaid expenses(421)(462)
Foreign currency and interest rate swaps(647)(1,456)
Right of use assets(4,574)(5,324)
Other(3,047)(1,995)
Total deferred tax liabilities(79,977)(81,022)
Valuation allowance(22)(22)
Net deferred tax liability$(52,046)$(62,784)

As of December 31, 2023, the Company has state income tax net operating loss (NOL) carryforwards of $348. The state NOL carryforwards will expire between 2026 and 2035. The Company believes that the benefit from the state NOL carryforwards will not be realized, therefore, a valuation allowance has been established in the amount of $22.
Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202320222021
Balance at beginning of period$5,815 $5,881 $5,335 
Increases for tax positions of prior years1,353 2,194 806 
Decreases for tax positions of prior years(2,518)(2,260)(260)
Balance at end of period$4,650 $5,815 $5,881 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2023 and 2022, these amounts were reduced by $322 and $371, respectively. During the year ended December 31, 2021, this amounted to $262. As of December 31, 2023 and 2022, accrued interest and penalties were $1,413 and $1,735, respectively.
Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2019 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months.
The European Union (“EU”) member states formally adopted the EU’s Pillar Two Directive, which was established by the Organization for Economic Co-operation and Development. Pillar Two generally provides for a 15 percent minimum effective tax rate for the jurisdictions where multinational enterprises operate. While the Company does not anticipate that this will have a
52

material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates.


NOTE 11 - SEGMENT INFORMATION
Balchem Corporation reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated."

Human Nutrition and Health

The Human Nutrition and Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products; proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity, and methylsulfonylmethane ("MSM"), which is a widely used nutritional ingredient that helps provide benefits for joint health, sports nutrition, skin and beauty, and healthy aging. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.

Animal Nutrition and Health

The Company’s Animal Nutrition and Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. This segment also manufactures MSM, which is a widely used nutritional ingredient that provides benefits for pet health.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.

Specialty Products

The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. Ethylene oxide is sold as a sterilant gas, primarily for use in the health
53

care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Contract sterilizers and medical device manufacturers are principal customers for this product. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage, to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes, and for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to.

The Company’s performance gases and chemicals are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. The Company also sells single use canisters for use in sterilizing re-usable devices typically processed in autoclave units in hospitals.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.

The segment information is summarized as follows:

Business Segment Assets
 20232022
Human Nutrition and Health$1,180,527 $1,170,238 
Animal Nutrition and Health166,994 175,972 
Specialty Products168,307 177,187 
Other and Unallocated (1)
81,383 101,115 
Total$1,597,211 $1,624,512 

Business Segment Net Sales
 202320222021
Human Nutrition and Health$550,751 $527,131 $442,733 
Animal Nutrition and Health238,326 262,297 226,776 
Specialty Products125,965 131,438 117,020 
Other and Unallocated (2)
7,397 21,492 12,494 
Total$922,439 $942,358 $799,023 

Business Segment Earnings Before Income Taxes
202320222021
Human Nutrition and Health$102,419 $82,125 $76,031 
Animal Nutrition and Health27,576 36,056 26,179 
Specialty Products34,579 32,789 30,020 
Other and Unallocated (2)
(5,381)(5,784)(4,728)
Interest and other expense(21,932)(11,437)(2,269)
Total$137,261 $133,749 $125,233 


54

Depreciation/Amortization
 202320222021
Human Nutrition and Health$38,568 $33,728 $30,012 
Animal Nutrition and Health7,876 6,685 7,414 
Specialty Products7,278 7,507 8,332 
Other and Unallocated (2)
1,213 3,928 3,121 
Total$54,935 $51,848 $48,879 

Capital Expenditures
 202320222021
Human Nutrition and Health$26,415 $33,668 $23,714 
Animal Nutrition and Health6,993 10,809 8,100 
Specialty Products3,535 4,004 3,804 
Other and Unallocated (2)
331 605 524 
Total$37,274 $49,086 $36,142 

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,617, $3,581 and $1,264 for years ended December 31, 2023, 2022 and 2021, respectively, and (ii) Unallocated amortization expense of $312, $2,951, and $2,510 for years ended December 31, 2023, 2022, and 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.


NOTE 12 - REVENUE
Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

 202320222021
Product Sales Revenue$919,951 $939,166 $794,518 
Royalty Revenue2,488 3,192 4,505 
Total Revenue$922,439 $942,358 $799,023 


The following table presents revenues disaggregated by geography, based on customers' delivery addresses:

 202320222021
United States$689,601 $682,238 $584,661 
Foreign Countries232,838 260,120 214,362 
Total$922,439 $942,358 $799,023 

Product Sales Revenues
55

The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue.
Royalty Revenues
Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities
The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.

The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions
The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

NOTE 13 - SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the year for:
202320222021
Income taxes$35,725 $33,016 $25,355 
Interest$25,933 $11,879 $4,547 
Non-cash financing and investing activities:
202320222021
Dividends payable$25,717 $23,129 $20,886 
Contingent consideration liability$ $11,872 $ 

56

NOTE 14 – ACCUMULATED OTHER COMPREHENSIVE INCOME
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202320222021
Net foreign currency translation adjustment$16,809 $(4,799)$(11,255)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized (loss) gain on cash flow hedge(1,406)3,564 2,707 
Tax341 (868)(654)
Net of tax(1,065)2,696 2,053 
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service loss (gain) arising during the period132 (41)(4)
Amortization of prior service gain 9 74 
Amortization of loss (gain)8 (2)(21)
Total before tax140 (34)49 
Tax(39)(24)(13)
Net of tax101 (58)36 
Total other comprehensive income/(loss)$15,845 $(2,161)$(9,166)
Included in "Net foreign currency translation adjustment" was loss of $1,455 related to a net investment hedge, which was net of tax benefit of $471 for the year ended December 31, 2023, and gains of $3,851, and $4,766, related to a net investment hedge, net of tax expenses of $1,236, and $1,527, for the years ended December 31, 2022 and 2021, respectively. See Note 20, Derivative Instruments and Hedging Activities.

Accumulated other comprehensive loss at December 31, 2023 and 2022 consisted of the following:
 Foreign currency
translation
adjustment
Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2022$(8,401)$1,065 $182 $(7,154)
Other comprehensive income (loss)16,809 (1,065)101 15,845 
Balance December 31, 2023$8,408 $ $283 $8,691 


NOTE 15 - EMPLOYEE BENEFIT PLANS
Defined Contribution Plans
The Company sponsors one 401(k) savings plan for eligible employees, which allows participants to make pretax or after tax contributions and the Company matches certain percentages of those contributions. The plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees. In addition, on August 30, 2022, the Company completed the acquisition of Bergstrom, which sponsored one defined contribution plan for its employees. The Bergstrom plan merged into the Company sponsored 401(k) savings plan on January 1, 2023. The Company provided for matching 401(k) savings plan contributions of $4,381, $4,363, and $4,142 in 2023, 2022 and 2021, respectively. Profit sharing contributions in 2023, 2022, and 2021 were not material.
57

Postretirement Medical Plans
The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for executive officers of the Company who meet eligibility requirements as set forth in the Company's Officer Retiree Program. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,465 $1,293 
Service cost with interest to end of year108 79 
Interest cost62 26 
Participant contributions23 27 
Benefits paid(30)(69)
Actuarial (gain) loss(233)109 
Benefit obligation at end of year$1,395 $1,465 
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$ $ 
Employer contributions7 42 
Participant contributions23 27 
Benefits paid(30)(69)
Fair value of plan assets at end of year$ $ 
Amounts recognized in consolidated balance sheet:
 20232022
Accumulated postretirement benefit obligation$(1,395)$(1,465)
Fair value of plan assets  
Funded status(1,395)(1,465)
Unrecognized prior service cost9 74 
Unrecognized net loss (gain)(2)(24)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations")$(1,395)$(1,465)
Accrued postretirement benefit cost (included in "Other long-term obligations")N/AN/A
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$108 $79 $87 
Interest cost62 26 23 
Amortization of prior service cost 9 74 
Amortization of loss (gain)8 (2)(24)
Total net periodic benefit cost$178 $112 $160 
58

Estimated future employer contributions and benefit payments are as follows:
Year 
2024$131 
2025132 
202699 
2027101 
202885 
Years 2029-2033615 
Assumptions to determine benefit obligations:
 20232022
Discount rate4.15 %4.40 %
Assumptions to determine net cost:
 202320222021
Discount rate4.40 %2.10 %1.75 %
Defined Benefit Pension Plans
The Company contributes to one multi-employer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability.
The Company’s participation in this plan for the annual period ended December 31, 2023 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2023 and 2022 was affected by a 4.0% increase in the 2023 contribution rate. There have been no other significant changes that affect the comparability of 2023 and 2022 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
Pension
Fund
EIN/Pension
Plan
Number
Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented
Contributions of Balchem CorporationSurcharge
Imposed
Expiration Date of Collective-
Bargaining
Agreement
20232022202320222021
Central States,
Southeast and
Southwest Areas
Pension Fund
36-6044243Critical & Declining as of 1/1/23Critical & Declining as of 1/1/22Implemented$1,020$939$816No7/12/2025

The Company provides an unfunded defined benefit pension plan for employees working in Belgium. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees.

59

The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows:
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,589 $1,859 
Service cost with interest to end of year65 44 
Interest cost65 17 
Participant contributions 27 
Benefits paid(188)(60)
Actuarial loss (gain)80 (194)
Exchange rate changes49 (104)
Benefit obligation at end of year$1,660 $1,589 
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$1,196 $1,175 
Actual return on plan assets56 26 
Employer contributions138 94 
Participant contributions 27 
Benefits paid(188)(60)
Exchange rate changes38 (66)
Fair value of plan assets at end of year$1,240 $1,196 

Amounts recognized in consolidated balance sheet:
 20232022
Benefit obligation$(1,660)$(1,589)
Fair value of plan assets1,240 1,196 
Funded status(420)(393)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$(420)$(393)
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$65 $44 $67 
Interest cost65 17 14 
Expected return on plan assets(42)(37)(34)
Amortization of net loss  3 
Total net periodic benefit cost$88 $24 $50 

60

Estimated future benefit payments are as follows:
Year 
2024$1 
202552 
20261 
20271 
20281 
Years 2029-20331,096 
Assumptions to determine benefit obligations:
 20232022
Discount rate3.45 %4.00 %


Assumptions to determine net cost:
 202320222021
Discount rate4.00 %1.00 %0.75 %
Expected return on assets3.25 %3.25 %3.25 %
Deferred Compensation Plan

The Company maintains an unfunded, non-qualified deferred compensation plan for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2023 and 2022 was $10,188 and $8,543, respectively, and was included in "Other long-term obligations" on the Company's balance sheet. The related rabbi trust assets were $10,188 and $8,547 as of December 31, 2023 and 2022, respectively, and were included in "Other non-current assets" on the Company's consolidated balance sheets.



NOTE 16 - COMMITMENTS AND CONTINGENCIES
The Company is obligated to make rental payments under non-cancelable operating and finance leases. Aggregate future minimum rental payments required under these leases at December 31, 2023 are disclosed in Note 19, Leases.
The Company’s Verona, Missouri facility, while held by a prior owner, Syntex Agribusiness, Inc. (“Syntex”), was designated by the U.S. Environmental Protection Agency (the "EPA") as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by Syntex under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. One of the sellers, in turn, has the benefit of certain contractual indemnification by Syntex in relation to the implementation of the above-described Superfund remedy. In June 2023, in response to a Special Notice Letter received from the EPA in 2022, BCP Ingredients, Inc. ("BCP"), the Company's subsidiary that operates the site, Syntex, EPA, and the State of Missouri entered into an Administrative Settlement Agreement and Order on Consent (“ASAOC”) for a focused remedial investigation/feasibility study ("RI/FS") under which (a) BCP will conduct a source investigation of potential source(s) of releases of 1,4-dioxane and chlorobenzene at a portion of the site and (b) BCP and Syntex will complete a RI/FS to determine a potential remedy, if any is required. Activities under the ASAOC are underway and are expected to continue for some period of time.
Separately, in June 2022, the EPA conducted an inspection of BCP’s Verona, Missouri facility (“2022 EPA Inspection”) which was followed by BCP entering into an Administrative Order for Compliance on Consent (“AOC”) with the EPA in relation to its risk management program at the Verona facility. Further, in January 2023, BCP entered into an Amended AOC with the EPA


whereby the parties agreed to the extension of certain timelines. BCP timely completed all requirements under the Amended AOC. In November 2023, BCP received a notice from the Environment and Natural Resources Division of the U.S Department of Justice (“DOJ”) primarily related to the 2022 EPA Inspection, which extended the opportunity to discuss alleged violations of Sections 112(r)(7) of the Clean Air Act and regulations in 40 C.F.R. Part 68, commonly known as the Risk Management Plan Rule (“RMP Rule”). BCP intends to participate in such discussions in 2024. In connection with the 2022 EPA Inspection, the Company believes that a loss contingency in this matter is probable and reasonably estimable and has recorded a loss contingency in an amount that is not material to its financial performance or operations.
In addition to the above, from time to time, the Company is a party to various legal proceedings, litigation, claims and assessments. While it is not possible to predict the ultimate disposition of each of these matters, management believes that the ultimate outcome of such matters will not have a material effect on the Company's consolidated financial position, results of operations, liquidity or cash flows.


NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2023 and 2022 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2023 and 2022 included $959 and $934 in money market funds and other interest-bearing deposit accounts, respectively.
Non-current assets at December 31, 2023 and 2022 included $10,188 and $8,547, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”
The contingent consideration liabilities included on the balance sheet at of December 31, 2023 and 2022 amount to $100 and $11,400, respectively, and were valued using level three inputs, as defined by ASC 820, "Fair Value Measurement".
The Company also had derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which were included in "Derivative assets" in the Company's consolidated balance sheets. The fair values of these derivative instruments were determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The Company settled its cross-currency swap and interest rate swap on June 27, 2023 and had no other derivatives outstanding as of December 31, 2023. The derivative assets related to the cross-currency swap and the interest rate swap were $4,587 and $1,406 at December 31, 2022, respectively.


NOTE 18 – RELATED PARTY TRANSACTIONS
The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties. As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings.
Payments for the services the Company provided amounted to $4,363, $4,213, and $3,637, respectively, for the years ended December 31, 2023, 2022, and 2021. The raw materials purchased and subsequently sold amounted to $34,219, $39,853, and $27,915, respectively, for the years ended December 31, 2023, 2022, and 2021. These services and raw materials are primarily recorded in cost of goods sold, net of the finished goods received from St. Gabriel CC Company, LLC of $28,099, $29,062, and $22,043, respectively, for the years ended December 31, 2023, 2022, and 2021. At December 31, 2023 and 2022, the Company had receivables of $8,314 and $8,820, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. At December 31, 2023 and 2022, the Company had payables of $6,050 and $5,224,
62

respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had payables in the amount of $329 and $296, respectively, related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of December 31, 2023 and 2022.


NOTE 19 – LEASES
The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2023. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2023: (1) 1-2 years, 5.45%-6.72% (2) 3-4 years, 6.04%-7.31% (3) 5-9 years, 6.38%-7.65% and (4) 10+ years, 7.10%-8.37%.

Right of use assets and lease liabilities at December 31, 2023 and 2022 are summarized as follows:

Right of use assets20232022
Operating leases$17,763 $17,094 
Finance lease2,101 2,338 
Total$19,864 $19,432 

Lease liabilities - current20232022
Operating leases$3,949 $3,796 
Finance lease272 226 
Total$4,221 $4,022 
Lease liabilities - non-current20232022
Operating leases$14,601 $13,806 
Finance lease1,943 2,213 
Total$16,544 $16,019 



63

For the years ended December 31, 2023, 2022, and 2021, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:
Year ended December 31,
202320222021
Lease Cost
Operating lease cost$5,307 $4,478 $3,143 
Finance Lease cost
Amortization of ROU asset242 210 210 
Interest on lease liabilities115 125 129 
Total finance lease357 335 339 
Total lease cost$5,664 $4,813 $3,482 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$4,757 $4,269 $3,097 
Operating cash flows from finance leases115 125 129 
Financing cash flows from finance leases222 177 159 
$5,094 $4,571 $3,385 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$6,365 $11,488 $3,804 
Weighted-average remaining lease term - operating leases9.33 years5.63 years4.21 years
Weighted-average remaining lease term - finance leases9.07 years9.95 years11.41 years
Weighted-average discount rate - operating leases7.4 %2.7 %3.5 %
Weighted-average discount rate - finance leases5.0 %5.0 %5.1 %

Rent expense charged to operations under operating lease agreements for 2023, 2022, and 2021 aggregated approximately $5,307, $4,478, and $3,143, respectively.
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2023 are as follows:
Year 
2024$5,407 
20254,219 
20263,638 
20272,736 
20282,219 
Thereafter7,717 
Total minimum lease payments$25,936 



64

NOTE 20 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023, which was designated as cash flow hedge. The net interest income related to the interest rate swap contract were $1,518 and $400 for the years ended December 31, 2023 and 2022, respectively. The net interest expense related to the interest rate swap contract was $2,144 for the year ended December 31, 2021. The net interest income and expense were recorded in the consolidated statements of earnings under "Interest expense, net."
On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas, which was designated as net investment hedge. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $1,119, $2,250, and $2,257 for the years ended December 31, 2023, 2022, and 2021, respectively. The interest income was recorded in the consolidated statements of earnings under "Interest expense, net."

The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2023. The proceeds from the settlement of the cross-currency swap in the amount of $2,740 were classified as investing activities in the Consolidated Statements of Cash Flows.

As of December 31, 2022, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative assetsDecember 31, 2022
Interest rate swap$1,406 
Cross-currency swap4,587 
Derivative assets$5,993 

Gains and losses on our hedging instruments were recognized in accumulated other comprehensive income (loss) and categorized as follows for the years ended December 31, 2023, 2022, and 2021:

Location within Statements of Comprehensive IncomeYear ended December 31,
202320222021
Cash flow hedge (interest rate swap), net of taxUnrealized (loss) gain on cash flow hedge, net$(1,065)$2,696 $2,053 
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment(1,455)3,851 4,766 
$(2,520)$6,547 $6,819 

In connection with the Kappa acquisition (see Note 2, Significant Acquisitions), the Company entered into four short-term foreign currency exchange forward contracts to manage fluctuations in foreign currency exchange rates. The Company did not designate these contracts as hedged transactions under the applicable sections of ASC Topic 815, "Derivatives and Hedging". For the year ended December 31, 2022, the net gains on these forward contracts of $512 were recorded in other income or loss in the consolidated statements of earnings. As of December 31, 2023, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts expired during 2022.


65

NOTE 21 - QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
(In thousands, except per share data)
 20232022
 First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Net sales$232,540 $231,252 $229,948 $228,699 $228,867 $236,693 $244,267 $232,531 
Gross margin73,170 77,349 76,544 74,993 71,506 71,876 68,430 68,639 
Earnings before income taxes29,119 38,400 36,475 33,267 37,630 39,258 31,085 25,776 
Net earnings22,710 30,110 29,075 26,648 28,930 29,782 25,249 21,406 
Basic net earnings per common share$0.71 $0.94 $0.91 $0.83 $0.90 $0.93 $0.79 $0.67 
Diluted net earnings per common share$0.70 $0.93 $0.90 $0.82 $0.89 $0.92 $0.78 $0.66 

66

BALCHEM CORPORATION
Valuation and Qualifying Accounts
Years Ended December 31, 2023, 2022 and 2021
(In thousands)
Allowance
for Doubtful Accounts
Inventory
Reserve
Balance - December 31, 2020$2,092 $2,782 
Additions charged to costs and expenses180 7,312 
Adjustments/deductions (a)
(1,344)(8,669)
Balance - December 31, 2021928 1,425 
Additions charged to costs and expenses401 6,786 
Adjustments/deductions (a)
(103)(5,571)
Balance - December 31, 20221,226 2,640 
Additions charged to costs and expenses37 2,450 
Adjustments/deductions (a)
(355)(2,627)
Balance - December 31, 2023$908 $2,463 
(a) Represents write-offs and other adjustments



67

Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.

Item 9A.    Controls and Procedures
Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2023. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; provide reasonable assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.    

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of controls effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
As of December 31, 2023, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the 2013 Internal Control-Integrated Framework (New Framework) to conduct an assessment of the effectiveness of our internal control over financial reporting. Based on this assessment, management has determined that our internal control over financial reporting was effective as of December 31, 2023.
Attestation Report of Registered Public Accounting Firm
The independent registered public accounting firm of RSM US LLP has issued an attestation report on our internal control over financial reporting, which is included herein.
Changes in Internal Control Over Financial Reporting
There has been no significant change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. As of December 31, 2023, management's assessment of and conclusion of the effectiveness of our internal controls over financial reporting of both Kappa and Bergstrom have been
68

completed. Therefore, management's assessment of and conclusion of the effectiveness of our internal control over financial reporting also includes the internal controls over financial reporting of Kappa and Bergstrom.

Item 9B.    Other Information
No directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement during the fiscal quarter ended December 31, 2023.
69


PART III
Item 10.    Directors, Executive Officers of the Registrant, and Corporate Governance.

The information regarding our executive officers is included in Part I of this report under the heading “Information about our Executive Officers.”

The other information required by this item is incorporated by reference to the information contained under the headings “Proposal 1. Election of Directors”, “Delinquent Section 16(a) Reports,” and “Corporate Governance” in our Proxy Statement for the 2024 Annual Meeting of Shareholders which will be filed no later than 120 days after December 31, 2023 (the “2024 Proxy Statement”).

Item 11.    Executive Compensation.

The information required by this item is incorporated by reference to the information contained under the headings “Executive Compensation,” “Compensation Committee Report,” and “Compensation Committee Interlocks and Insider Participation” in our 2024 Proxy Statement.

Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item is incorporated by reference to the information contained under the headings “Security Ownership of Certain Beneficial Owners and of Management” and Equity Compensation Plan Information” in our 2024 Proxy Statement.

Item 13.    Certain Relationships and Related Transactions and Director Independence.

The information required by this item is incorporated by reference to the information contained under the headings “Related Party Transactions” and “Director Independence” in our 2024 Proxy Statement.

Item 14.    Principal Accountant Fees and Services.

The information required by this item is incorporated by reference to the information contained under the heading “Information Relating to Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm” of our 2024 Proxy Statement.

70

PART IV

Item 15.    Exhibits and Financial Statement Schedules.
The following documents are filed as part of this Form 10-K:
1.Financial StatementsPage Number
 
 
 
 
 
2.Financial Statement Schedules
 
3.Exhibits
2.1
3.1
  
3.2
  
3.3
  
3.4
4.1
10.1
10.2
  
71

10.3
10.4
  
10.5
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
 
21.1
 
23.1
 
31.1
 
31.2
 
32.1
 
32.2
 
97.1
101.INSXBRL Instance Document
 
101.SCHXBRL Taxonomy Extension Schema Document
 
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
 
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
72

 
101.LABXBRL Taxonomy Extension Label Linkbase Document
 
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Each of the Exhibits noted by an asterisk is a management compensatory plan or arrangement.

73

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 16, 2024BALCHEM CORPORATION
 By:/s/ Theodore L. Harris
 Theodore L. Harris, Chairman, President and
 and Chief Executive Officer

74

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
/s/ Theodore L. Harris 
Theodore L. Harris, Chairman, President and
Chief Executive Officer
Date: February 16, 2024
/s/ C. Martin Bengtsson
C. Martin Bengtsson, Executive Vice President and
Chief Financial Officer
Date: February 16, 2024
/s/ William A. Backus 
William A. Backus, Vice President and
Chief Accounting Officer
Date: February 16, 2024
/s/ David B. Fischer 
David B. Fischer, Director
Date: February 16, 2024
/s/ Kathleen B. Fish
Kathleen B. Fish, Director
Date: February 16, 2024
/s/ Daniel E. Knutson 
Daniel E. Knutson, Director
Date: February 16, 2024
/s/ Joyce J. Lee
Joyce J. Lee, Director
Date: February 16, 2024
/s/ Olivier Rigaud
Olivier Rigaud, Director
Date: February 16, 2024
/s/ Monica Vicente
Monica Vicente, Director
Date: February 16, 2024
/s/ Matthew D. Wineinger 
Matthew D. Wineinger, Director
Date: February 16, 2024

75
EX-4.1 2 axex41descriptionofsecurit.htm EX-4.1 Document

Exhibit 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.06-2/3 per share (“common stock”). References herein to “we,” “us,” “our” and the “Company” refer to Balchem Corporation and not to any of its subsidiaries.

The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the applicable provisions of the Maryland General Corporation law (the “MGCL”), the Company’s Composite Articles of Incorporation (our “charter”), and its Amended and Restated Bylaws (our “bylaws”). Each of our charter and our bylaws is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part. We encourage you to read our charter, bylaws, our Corporate Governance Guidelines (which are available on our website), and the applicable provisions of the MGCL for additional information.

General

Under our charter, we may issue up to 122,000,000 shares of stock, comprised of 120,000,000 shares of common stock and 2,000,000 shares of preferred stock, par value $25.00 per share (“preferred stock”).

Our charter authorizes our board of directors (our “Board”) to issue shares of stock of the Company or securities convertible into shares of its stock. As allowed by the MGCL, our charter authorizes our Board, without stockholder approval, to issue preferred stock, in one or more series, each series to be with such preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications and terms and conditions of redemption as our Board shall determine, with the foregoing potentially having the effect of delaying, deferring or preventing a change in control of the Company. We believe that the power to issue additional shares of our stock and to classify unissued shares of our preferred stock and to issue the classified shares provides us with increased flexibility in structuring possible future financings and acquisitions and in meeting other needs which might arise, but our issuance of additional shares of stock could dilute voting and other stockholder rights. See “Certain Provisions of Our Charter and Bylaws and of Maryland Law” below.

Common Stock

All of the outstanding shares of our common stock are duly authorized, fully paid and nonassessable. Our common stockholders are entitled to receive dividends when authorized by our Board and declared by us out of assets legally available for the payment of dividends. They are also: (i) entitled to share ratably in our assets legally available for distribution to our stockholders in the event of our liquidation, dissolution or winding up, after payment of, or adequate provision for, all of our known debts and liabilities, and (ii) generally are not liable for our debts or obligations. These rights may be subject to the preferential rights of any other class or series of our stock, including any preferred stock. All shares of common stock have equal dividend and liquidation rights.

1


Each outstanding share of common stock is entitled to one vote on all matters submitted to a vote of the stockholders and, except for the rights that may be held by the holders of shares of any subsequently issued class or series of preferred stock, the holders of our common stock possess exclusive voting power. There is no cumulative voting in the election of our directors. A majority of votes cast at a meeting of stockholders duly called and at which a quorum is present is sufficient to elect a director, other than in the case of a “contested election,” in which case a plurality of the votes cast is sufficient to elect a director. A “contested election” is any election of directors with respect to which (i) the Company receives notice that a stockholder has nominated an individual for election as a director in compliance with our bylaws and (ii) such nomination has not been withdrawn by the stockholder prior to the date when the Company first mails notice of the meeting to its stockholders and, as a result, the number of nominees for director is greater than the number of directors to be elected at the meeting. The Company’s Corporate Governance Guidelines set forth the procedures that are applicable if an incumbent director in an uncontested election receives a greater number of “withhold” votes for election than “for” votes. For all other matters, unless a different number is required by law, our charter or our bylaws, a majority of votes cast at a meeting of stockholders duly called and at which a quorum is present is sufficient to approve or authorize such other matter.

Our stockholders have no exchange, sinking fund or redemption rights, and have no preemptive rights to subscribe for any future issuance of our securities. Because our stockholders do not have preemptive rights, we may issue additional shares of stock that may reduce their proportionate voting and financial interest in the Company. Rights to receive dividends on our common stock may be limited by the terms of any future classified and issued shares of our preferred stock.

A Maryland corporation generally may not dissolve, amend its charter, merge, convert, consolidate, sell all or substantially all of its assets or engage in a statutory share exchange unless declared advisable by its board of directors and approved by the affirmative vote of stockholders holding at least two-thirds of the shares entitled to vote on the matter.

Transfer Agent and Registrar

The transfer agent and registrar for shares of our common stock is Broadridge Corporate Issuer Solutions, Inc.

Certain Provisions of Our Charter and Bylaws and of Maryland Law

Our Board of Directors

Our Board is divided into three classes, with the term of each class of directors expiring in a different successive year. Directors of each class are elected to serve until the third annual meeting following their election and until their successors are duly elected and qualify. As a general matter, a classified board can render a change in control of the Company or removal of incumbent management more difficult. We believe that the classification of our Board helps to assure the continuity and stability of our strategies and policies as determined by our Board.

Board vacancies may be filled by a majority of the remaining members of our Board even if such majority is less than a quorum. A director elected by our Board to fill a vacancy shall be elected to serve until the next annual meeting of stockholders and until his or her successor is duly elected and qualifies.

2


Under our bylaws, directors may be removed from office by the affirmative vote of a majority of all of the votes of stockholders entitled to be cast for the election of directors and any resulting vacancy for the unexpired term of the removed director shall be filled by action of the stockholders. In addition, the MGCL provides that, for so long as our Board is classified, a director may only be removed for cause.

Business Combinations

Under the MGCL, “business combinations” (as defined therein) between the Company and an “interested stockholder” or any affiliate thereof are prohibited for five years after the most recent date on which the interested stockholder became an interested stockholder. An interested stockholder is defined as:

any person that beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock; or
an affiliate or associate of the corporation and was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding stock of the corporation at any time within the two-year period immediately prior to the date in question.
Our Board may approve in advance the transaction by which such person otherwise would have become an interested stockholder, in which case, that person will not be an interested stockholder.

After the five-year prohibition, any business combination between us and an interested stockholder or any affiliate thereof generally must be recommended by our Board and approved by the affirmative vote of at least:

80% of the votes entitled to be cast by holders of outstanding shares of voting stock; and
two-thirds of the votes entitled to be cast by holders of voting stock other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or shares held by any affiliate or associate of the interested stockholder.

These super-majority vote requirements do not apply if, among other conditions, our stockholders receive a minimum price, as defined under the MGCL, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares. The statute permits various exemptions from its provisions, including, without limitation, business combinations that are exempted by our Board prior to the time that an interested stockholder becomes an interested stockholder.

Control Share Acquisitions

The MGCL provides that a holder of “control shares” of a Maryland corporation acquired in a “control share acquisition” has no voting rights with respect to such shares except to the extent approved by the affirmative vote of two-thirds of all the votes entitled to be cast on the matter, excluding “interested shares,” as defined in MGCL section 3-701(g). A “control share acquisition” means the acquisition of ownership of, or the power to direct the exercise of voting
3


power with respect to, control shares, subject to certain exceptions. Control shares are voting shares of stock that, if aggregated with all other shares of stock owned by the acquiror or in respect of which the acquiror is entitled to exercise or direct the exercise of voting power, except solely by virtue of a revocable proxy, would entitle the acquiror to exercise voting power in electing directors within one of the ranges of voting power specified in the MGCL section 3-701(d)(i) – (iii). Control shares do not include shares the acquiror is entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation.

A person who has made or proposes to make a control share acquisition may compel our Board to call a special meeting of stockholders to consider the voting rights of the shares within 50 days of demand. This right is subject to the satisfaction of certain conditions, including an undertaking to pay the expenses of the meeting and delivering an “acquiring person statement” as described in the MGCL. If no request for a meeting is made, the Company may present the question at any stockholders’ meeting.

If voting rights are not approved at the meeting or if the acquiring person does not deliver an “acquiring person statement,” then we may redeem for “fair value” any or all of the control shares, except those for which voting rights have previously been approved. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the meeting date of the non-approval of the voting rights or, if no meeting is held, as of the date of the last control share acquisition by the acquiror. If voting rights for control shares are approved at a stockholders’ meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights. The fair value of the shares as determined for purposes of appraisal rights may not be less than the highest price per share paid by the acquiror in the control share acquisition.

The control share acquisition statute does not apply to shares acquired in a merger, consolidation, or statutory share exchange if we are a party to the transaction or to acquisitions approved or exempted by the charter or our bylaws.

Our bylaws contain a provision exempting any and all acquisitions by any person of our shares of stock from the Control Share Acquisition Act. This bylaw provision may be amended or eliminated at any time in the future.

Subtitle 8

Title 3, Subtitle 8, of the Corporations and Associations Article of the Annotated Code of Maryland (“Subtitle 8”) permits a Maryland corporation, such as the Company, with at least three directors who are not officers or employees of the corporation or affiliates of, or nominated by, a person seeking to acquire control of the corporation and a class of stock registered under the Exchange Act, to elect to be subject to any or all of the following provisions, by provision in its charter or bylaws or a resolution of its board of directors and notwithstanding any contrary provision in the charter or bylaws and without any action by stockholders:
a classified board;
a two-thirds vote requirement for removing a director;
a requirement that the number of directors be fixed only by the board of directors;
4


a requirement that a vacancy on the board be filled only by the remaining directors and for the remainder of the full term of the class of directors in which the vacancy occurred; or
a majority requirement for the calling by stockholders of a special meeting of stockholders.
We have not elected to be subject to any provisions of Subtitle 8. However, through a provision in our bylaws unrelated to Subtitle 8, we have had a classified board for more than 25 years. In the future, our Board may elect, without stockholder approval, to be subject to one or more of the provisions of Subtitle 8.

Meetings of Stockholders

Under our bylaws, annual meetings of stockholders must be held each year at a date, time and place determined by our Board. Special meetings of stockholders may be called by the chair of our Board, our chief executive officer, our president and our Board. Additionally, subject to the provisions of our bylaws, a special meeting of stockholders to act on any matter that may properly be considered at a meeting of stockholders must be called by our secretary upon the written request of stockholders entitled to cast at least 25% of all of the votes entitled to be cast on the matter at such meeting. Only matters set forth in the notice of a special meeting of stockholders may be considered and acted upon at such a meeting.
Advance Notice of Director Nominations and New Business

Our bylaws provide that, with respect to an annual meeting of stockholders, nominations of individuals for election to our Board and the proposal of business to be considered by stockholders may be made only:
pursuant to our notice of the meeting (or any supplement thereto) by or at the direction of our Board;
otherwise properly brought before the meeting by or at the direction of our Board; or
by a stockholder of record of the Company at the time such notice of meeting is delivered, who is entitled to vote at the meeting, and who complies with the advance notice procedures of our bylaws.
With respect to special meetings of stockholders, only the business specified in the notice of the meeting may be brought before the meeting. Nominations of individuals for election to our Board at a special meeting at which directors are to be elected may only be made:

by or at the direction of our Board; or
provided that our Board has determined that directors will be elected at the meeting, by a stockholder of record at the time of giving notice, who is entitled to vote at the meeting and upon such election, and who complies with the advance notice procedures of our bylaws.
The purpose of requiring stockholders to give advance notice of nominations and other proposals is to afford our Board and our stockholders the opportunity to consider the qualifications of the proposed nominees or the advisability of the other proposals and, to the
5


extent considered necessary by our Board, to inform stockholders and make recommendations regarding the nominations or other proposals.

Limitation of Liability and Indemnification of Directors and Officers

The MGCL permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (i) actual receipt of an improper benefit or profit in money, property or services or (ii) active and deliberate dishonesty that is established by a final judgment and that is material to the cause of action. Our charter contains such a provision that eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law.

Our bylaws obligate us, to the maximum extent permitted by Maryland law, to indemnify any present or former director or officer or any individual who, while a director or officer of the Company and at the request of the Company, serves or has served another corporation, real estate investment trust, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner, trustee, member or manager, is made or threatened to be made a party to, or witness in, a proceeding by reason of his or her service in that capacity, and to pay or reimburse his or her reasonable expenses in advance of final disposition of a proceeding to the maximum extent permitted by law.

6
EX-10.7 3 axex107xrsuformagreementfe.htm EX-10.7 Document
FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Exhibit 10.7

BALCHEM CORPORATION
RESTRICTED STOCK GRANT AGREEMENT

2017 Omnibus Incentive Plan

This RESTRICTED STOCK GRANT AGREEMENT (the “Agreement”), is made as of this __th day of __________, _____, between Balchem Corporation, a Maryland corporation (the “Company”) and ________________ (“Grantee”).

1.    Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the same may be amended from time to time (the “Plan”), the Company hereby grants to Grantee _______________ (______) shares of the common stock par value six and two-thirds cents ($0.06 2/3) per share of the Company (the “Restricted Shares”), on the terms and subject to the conditions and restrictions and other provisions set forth in this Agreement and in the Plan. Any capitalized terms used in this Agreement and not defined herein shall have the meanings set forth in the Plan. This grant of Restricted Shares is subject to Grantee’s execution and delivery to the Company of a copy of this Agreement. Grantee is not required to pay any purchase price for the Restricted Shares.

2.    Vesting of Restricted Shares. Unless they vest on an earlier date as provided in Section 4 hereof, the Restricted Shares will vest on ___________, which is three (3) years from the date first set forth above, provided that Grantee has remained in continuous employment with the Company and/or any member of the Group through such vesting date.

3.    Restrictions on the Restricted Shares. Until the Restricted Shares have vested, Grantee may not sell, transfer, assign, pledge, or otherwise encumber them except as permitted in Section 6 hereof. Stock certificates representing the Restricted Shares will be registered in Grantee’s name (or Grantee will be recorded as the owner of the shares on the Company’s books) as of the date of this Agreement, but such certificates will be held by the Company on Grantee’s behalf until such shares vest. When all or a portion of the Restricted Shares vest, a certificate representing such shares (minus any shares retained to satisfy tax withholding obligations, as described in Section 10 hereof) will be delivered to Grantee (or the vesting of such shares will be duly recorded on the Company’s books) as soon as practicable. To the extent the Restricted Shares have vested, they shall be fully transferable (subject to applicable securities law requirements) and not subject to forfeiture upon termination of employment or otherwise. Except in circumstances where a different treatment is provided in Section 4 hereof, in the event of a termination of Grantee’s employment with the Company and the other members of the Group for any reason, all of the Restricted Shares that have not previously vested will be forfeited and automatically transferred to and reacquired by the Company at no cost to the Company. At the request of the Company, Grantee shall execute and deliver to the Company a stock power, endorsed in blank, relating to the Restricted Shares.

4.    Acceleration of Vesting. Notwithstanding the vesting date set forth in Section 2 hereof, the following vesting rules shall apply upon the following events.

(a)    Death. In the event of Grantee’s death while employed by the Company or a member of the Group, all Restricted Shares shall immediately vest.

(b)    Disability. If the Grantee ceases to be employed by the Company and all other members of the Group by reason of his or her Disability (as such term is defined below), the number of Restricted Shares that shall vest upon such Disability shall be the number of whole shares equal to the product of (A) 1/36th of the total number of Restricted Shares subject to this
1


Grant and (B) the number of full months of Grantee’s continuous employment with the Company and/or the other members of the Group from the date of this Agreement to the date of Grantee’s Disability; and all Restricted Shares not so vested shall be immediately forfeited. For the purposes of this Agreement, the term “Disability” shall mean “permanent and total disability” as defined in Section 22(e)(3) of the Code or successor statute.

(c)    Change in Control. The treatment of the Restricted Shares in the event of a Change in Control (as defined in the Plan), shall be governed by the terms of the Plan.

(d)    Committee Discretion. The Committee shall have absolute discretion to determine the date and circumstances of Grantee’s termination of employment or of the occurrence of Disability or a Change in Control, and its determination shall be final, conclusive and binding. The Committee, in its sole discretion, may accelerate the vesting of Restricted Shares, in whole or in part, based on service, performance, and/or such other factors or criteria as the Committee may determine, subject to the minimum vesting restrictions set forth in the Plan.

5.    Voting and Dividends. Grantee shall have the right to vote the Restricted Shares and to receive dividends with respect to the Restricted Shares equal to the dividends paid on the Stock. If any dividend is declared and paid in cash, such cash dividend will be accrued without interest until, and will be paid within thirty (30) days following the date that, the restrictions applicable to such Restricted Shares lapse, or will be forfeited at such time as such Restricted Shares are forfeited. If any dividend is declared and paid by the Company in a form other than cash, such non-cash dividend shall be subject to the same vesting schedule, forfeiture terms and other restrictions as are applicable to the Restricted Shares with respect to which the dividends were paid. Any dividends received or accrued by Grantee applicable to the Restricted Shares granted hereunder shall be forfeited and, if applicable, returned to the Company in the event the Restricted Shares do not vest in accordance with Section 2 above.

6.    Permitted Transfers. The following transactions shall be exempt from the restrictions on transfer set forth in Section 3 hereof:

(a)    Grantee’s transfer of any or all of the Restricted Shares either during his/her lifetime or on death by will or intestacy to his/her immediate family or to a trust the beneficiaries of which are exclusively one or more of Grantee and a member or members of Grantee’s immediate family, except any such transfers made pursuant to any divorce or separation proceedings or settlement (for purposes hereof, the term “immediate family” shall mean spouse, lineal descendant, father, mother, brother or sister of Grantee making the transfer); or

(b)    a transfer of Restricted Shares to the guardian or conservator of Grantee; provided, however, that in any such case, the transferee or other recipient shall receive and hold such Restricted Shares subject to the provisions of this Agreement and there shall be no further transfer of such Restricted Shares except in accordance with this Agreement.

No transfer pursuant to this Section 6 shall be effective, and the Company shall not be required to recognize any transferee of Restricted Shares hereunder as a stockholder of the Company, unless and until the transferee agrees in writing to be bound by the provisions of this Agreement.

7.    Restrictive Legend. At the discretion of the Company, all certificates (electronic or otherwise) representing Restricted Shares owned by Grantee shall have affixed thereto a legend in substantially the following form, in addition to any other legends that may be required under federal or state securities laws or under any applicable shareholders agreement:

2


THE SHARES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO FORFEITURE AND RESTRICTIONS ON TRANSFER AS SET FORTH IN A CERTAIN RESTRICTED STOCK GRANT AGREEMENT BETWEEN THE CORPORATION AND THE REGISTERED OWNER OF THIS CERTIFICATE (OR HIS/HER PREDECESSOR IN INTEREST), AND SUCH AGREEMENT IS AVAILABLE FOR INSPECTION WITHOUT CHARGE AT THE OFFICE OF THE CORPORATION.

8.    Adjustments for Stock Splits, Stock Dividends, etc. In the event of any stock split-up, stock dividend, stock distribution or other reclassification of the stock of the Company, any and all new, substituted or additional securities to which Grantee is entitled by reason of his or her ownership of the Restricted Shares shall be automatically subject to the same vesting schedule, forfeiture terms and other restrictions in the same manner and to the same extent as the Restricted Shares.

9.    Section 83(b) Election. Grantee understands that under Section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), unless Grantee files an election under Section 83(b) of the Code, Grantee will recognize ordinary compensation income on the date the Restricted Shares are no longer subject to a substantial risk of forfeiture (which is generally the date such shares vest) in an amount equal to the fair market value of the Restricted Shares on that date. Grantee may, however, elect to recognize income with respect to some or all of the Restricted Shares as of the date of grant of such Restricted Shares in an amount equal to the fair market value of the Restricted Shares on that date (without any discount for the transfer and forfeiture restrictions on the Restricted Shares). In order to make this election, Grantee must file an election under Section 83(b) of the Code with the Internal Revenue Service no later than 30 days after the date of grant of the Restricted Shares. Grantee also understands that if he or she makes a Section 83(b) election and subsequently forfeits some or all of the Restricted Shares that were subject to the election, he or she will not be able to claim a deduction or capital loss with respect to the forfeited shares. Grantee also understands that cash dividends accrued on the Restricted Shares (prior to vesting) will be taxable as ordinary compensation income when received if Grantee did not make a Section 83(b) election, and will be taxable as dividend income if Grantee made a Section 83(b) election; and that non-cash dividends on the Restricted Shares generally will be taxable as ordinary compensation income at the same time as the Restricted Shares to which such dividends relate if Grantee did not make a Section 83(b) election, or treated as dividend income when received if Grantee made a Section 83(b) election. Grantee acknowledges that it is Grantee’s sole responsibility, and not the Company’s, to file a timely election under Section 83(b) if he or she chooses to do so. Grantee is relying solely on Grantee’s advisors with respect to the decision as to whether or not to file a Section 83(b) election. Grantee also agrees to provide the Company with a copy of the Section 83(b) election if one is filed.

10.    Withholding. Grantee shall be required to remit to the Company, and the Company shall have the right to deduct from any compensation payable to Grantee, the amount sufficient to satisfy any federal, state or local withholding tax liability in respect of the Restricted Shares and to take all such other action as the Committee deems necessary to satisfy all obligations for payment of such withholding taxes. To the extent permitted by the Committee, and subject to any terms and conditions imposed by the Committee, Grantee may elect to have the Company’s withholding obligation for federal, state and local taxes, including payroll taxes, with respect to the Restricted Shares satisfied (i) by having the Company withhold from the shares otherwise deliverable to Grantee shares of Stock having a value equal to the amount of such withholding obligation with respect to the Stock or (ii) by delivering to the Company shares of unrestricted Stock. Alternatively, the Committee may require that a portion of shares of Stock
3


otherwise deliverable be withheld and applied to satisfy the statutory withholding obligation with respect to the Restricted Shares.

11.    Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.

12.    Amendment. No provision of this Agreement shall be amended, either generally or in any particular instance, except in a writing signed by the Company and Grantee.

13.    Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and Grantee and their respective heirs, executors, administrators, legal representatives, and permitted transferees. No transfer of any of the Restricted Shares shall be effective unless the transferee first agrees in writing to all of the terms hereof.

14.    No Rights to Employment. Nothing contained in this Agreement or the Plan shall be construed as giving Grantee any right to be retained, in any position, as an employee of or consultant or advisor to the Company.

15.    Notices. All notices required or permitted hereunder shall be in writing and deemed effectively given upon personal delivery, delivery by Federal Express or other recognized overnight delivery service or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, return receipt requested, if to the Company at its executive offices and if to Grantee at the address shown beneath his or her signature to this Agreement, or in either case at such other address or addresses as either party shall designate to the other in accordance with this Section.

16.    Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa.

17.    Entire Agreement. This Agreement and the documents and agreements referenced herein constitute the entire agreement between the parties, and supersede all prior agreements and understandings, relating to the subject matter of this Agreement.

18.    Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles. The Company and Grantee hereby (a) agree that any action, suit or other proceeding arising out of or based upon this Agreement shall be brought in the courts of the State of Maryland or any federal court located in such state, and (b) irrevocably consent and submit to the exclusive jurisdiction of such courts for the purpose of any such action, suit or proceeding.

19.    Terms of Plan Control. The Restricted Shares are issued pursuant to the provisions of the Plan, a copy of which has been furnished to Grantee, and are subject to the Plan in all respects. Nothing contained in this Agreement shall in any way be deemed to alter or modify the provisions of the Plan and no act of the Company or its directors, officers or employees shall be deemed to be a waiver or modification of any provision of the Plan. The provisions of the Plan shall in all respects govern this Agreement. The Committee shall have authority in its discretion, but subject to the express provisions of the Plan, to interpret the Plan and this Agreement; to prescribe, amend and rescind rules and regulations relating to the Plan and this Agreement; and to make all other determinations deemed necessary or advisable for the administration of the Plan or this Agreement. The Committee’s determination on the foregoing matters shall be conclusive.
4



20.    Section 409A Compliance. This Agreement is intended to comply with, or be exempt from, the requirements of Section 409A of the Code and the regulations issued thereunder. To the extent of any inconsistencies with the requirements of Section 409A, this Agreement shall be interpreted and amended in order to meet such Section 409A requirements. Notwithstanding anything contained in this Agreement or in any amendments hereto to the contrary, it is the intent of the Company to have the Plan interpreted and construed to comply with, or be exempt from, any and all provisions of Section 409A including any subsequent amendments, rulings or interpretations from appropriate governmental agencies.

21.    Data Privacy.
(a)     Data Collection and Usage. The Company may collect, process and use certain personal information about Grantee, including, but not limited to, Grantee’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all Restricted Shares granted under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Grantee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The Company, with its address at 5 Paragon Drive, Montvale, New Jersey 07645, acts as the data controller in respect of such Data and may be contacted at DataPrivacy@balchem.com.

For Grantees in the European Union / European Economic Area / Switzerland / United Kingdom (“EEA+”), the legal basis for the processing of Data is that it is necessary for the performance of the Company's contractual obligation to deliver shares (if the conditions of the Plan and the Award Agreement are satisfied) and, generally, for the Company’s legitimate interests to manage and administer Grantee's participation in the Plan.

(b)    Data Disclosures. The Company transfers Data to service providers which assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select different service providers and share Data with such other providers serving in a similar manner. Grantee may be asked to acknowledge or (where applicable) agree to separate terms and data processing practices with the service providers, with such agreement (where applicable) being a condition to the ability to participate in the Plan. The Company may also share Data: with its affiliates: with other businesses in connection with a substantial corporate transaction (such as a sale, merger, consolidation, initial public offering, or in the unlikely event of bankruptcy); in response to a subpoena, court order, legal process, law enforcement request, legal claim or government inquiry; to protect and defend the rights, interests, safety, and security of the Company, Grantee, or others; or for any other purposes disclosed to the Grantee at the time the Company collects the Data. The Company does not sell Data or share Data for cross-context behavioral / targeted advertising purposes.

(c)    International Data Transfers. The Company and its service providers are based in the United States, and Data may be transferred to the United States to administer the Plan as a result. Grantee’s country or jurisdiction may have different data privacy laws and protections than the United States, and the Company complies with applicable laws that may place certain restrictions on such transfers.

For Grantees in the EEA+, the Company implements appropriate safeguards in accordance with applicable law to ensure the protection of Data outside of the EEA+, including by implementing standard contractual clauses, for which Grantees based in the EEA+ may request a copy.

5


(d)    Data Retention. The Company will hold and use Data only as long as is necessary to implement, administer and manage Grantee’s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and for archiving, back-up and deletion processes. This may extend beyond Grantee’s period of employment with the Company or the Employer.

(e)    Data Subject Rights. Depending on where Grantee is based, and subject to applicable exceptions or exemptions, Grantee may have rights to access, correct, delete, restrict processing, or port their Data and lodge complaints with competent authorities in Grantee’s jurisdiction. Grantee or Grantee’s authorized agent may contact the Company at DataPrivacy@balchem.com to exercise such rights where applicable.

22.    Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Shares or other equity awards granted by the Company, whether under the Plan or otherwise, or any other Company securities by electronic means. By accepting this grant of Restricted Shares, whether electronically or otherwise, Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company, including but not limited to the use of electronic signatures or click-through acceptance of terms and conditions.
23.    Compensation Recovery. The Restricted Shares shall be subject to the provisions of any applicable compensation recovery policy contained in the Plan or implemented by the Company, including without limitation any compensation recovery policy adopted to comply with the requirements of applicable law, to the extent set forth in such compensation recovery policy.
24.    Parachute Payments.
(a)    Grantee shall bear all expense of, and be solely responsible for, any excise tax imposed by Section 4999 of the Code (the “Excise Tax”); provided, however, that any payment or benefit received or to be received by Grantee (whether payable under the terms of this Agreement or any other plan, arrangement or agreement with the Company or any of its affiliates) (collectively, the “Payments”) that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax but only if, by reason of such reduction, the net after-tax benefit received by Grantee exceeds the net after-tax benefit that would be received by Grantee if no such reduction was made. If a reduction in payments or benefits constituting “parachute payments” is necessary under the preceding sentence, the reduction shall be made in the manner that results in the greatest economic benefit for Grantee.

(b)    The “net after-tax benefit” shall mean (i) the Payments that Grantee receives or is then entitled to receive from the Company that would constitute “parachute payments” within the meaning of Section 280G of the Code, less (ii) the amount of all federal, state and local income and employment taxes payable by Grantee with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to Grantee (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in Section 24(a) above.

(c)    The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such change in control, change of ownership or similar transaction, the Company shall appoint a nationally recognized
6


independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.

(d)    The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Grantee within thirty (30) calendar days after the date on which Grantee’s right to a Payment is triggered (if requested at that time by the Company or Grantee) or such other time as reasonably requested by the Company or Grantee. Any good faith determinations of the independent registered public accounting firm made hereunder shall be final, binding and conclusive upon the Company and Grantee.

25.    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

BALCHEM CORPORATION


By: ________________________________
Theodore L. Harris
Chairman, President and CEO



GRANTEE:

___________________________________        
                        (Signature)

Print Name: ____________________________________

Address:                            

                                    

                        
    

7


Appendix
to

Balchem Corporation
Restricted Stock Grant Agreement

Country-Specific Terms and Conditions


This Appendix includes special terms and conditions applicable to Grantee if Grantee is primarily employed in one of the countries listed below. These terms and conditions supplement or replace (as indicated) the terms and conditions set forth in the Award Agreement. If Grantee is a citizen or resident of a country other than the one in which he or she is currently primarily working, or if Grantee transfers primary employment or residency to another country after the Restricted Shares is granted, the Company, in its discretion but subject to applicable laws, will determine the extent to which the terms and conditions set forth in this Appendix will apply to the Grantee.

This Appendix also includes information relating to exchange control, foreign asset / account reporting requirements and other issues of which Grantee should be aware with respect to his or her participation in the Plan. Such laws are often complex and change frequently. As a result, the Company strongly recommends that Grantee not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time the Restricted Shares vests or the shares acquired under the Plan are sold.

In addition, the information is general in nature and may not apply to Grantee’s particular situation. The Company is not in a position to assure Grantee of any particular result. Accordingly, Grantee should seek appropriate professional advice as to how the relevant laws in his or her country may apply to his or her situation. Finally, if Grantee is a citizen or resident of a country other than the one in which he or she is currently primarily working, or if Grantee transfers employment or residency to another country after the Restricted Shares are granted, the information contained herein may not be applicable to Grantee.

France

Restricted Shares Not Tax-Qualified. The Restricted Shares are not intended to be French tax-qualified.

Language Consent. In accepting the Restricted Shares, Grantee confirms having read and understood the documents relating to the Restricted Shares (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

8


Consentement Relatif à la Langue Utilisée. En acceptant cette Attribution, le Grantee confirme avoir lu et compris les documents relatifs à cette Attribution (le Plan, le Contrat d’Attribution incluant cette Annexe), qui ont été remis en langue anglaise. Le Grantee accepte les termes de ces documents en conséquence.

Foreign Asset/Account Reporting Information. Grantee is required to report any shares and foreign bank accounts, including accounts closed during the tax year, to the French tax authorities when filing his or her annual tax return on form Cerfa number 3916. This also applies to foreign accounts holding the allocated shares.

Germany

Exchange Control Information. Grantee must report any cross-border payments in excess of €12,500 to the German Federal Bank (Bundesbank). The report must be filed electronically by the 5th day of the month following the month in which the payment occurred. The form of report (Allgemeine Meldeportal Statistik) can be accessed via the Bundesbank’s website (www.bundesbank.de). Grantee should consult his or her personal legal advisor to ensure compliance with applicable reporting obligations.

Sole Contractual Relationship. Grantee understands that the Restricted Shares are offered solely by the Company and not by any other member of the Group or entity that may be employing Grantee from time to time. Only the terms and conditions of the Plan and this Agreement shall govern the Agreement as well as the Restricted Shares as a contractual relationship solely between the Company and Grantee.

Language Consent. In accepting the Restricted Shares, Grantee confirms having read and understood the documents relating to the Restricted Shares (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Einwilligung zur Sprache. Mit der Annahme der Restricted Shares bestätigt der Teilnehmer, dass er die mit den Restricted Shares zusammenhängenden Dokumente (den Plan und diese Zuteilungsvereinbarung einschließlich dieses Anhangs), die jeweils in englischer Sprache zur Verfügung gestellt wurden, gelesen und verstanden hat. Der Teilnehmer akzeptiert die Bedingungen dieser Dokumente entsprechend.


Netherlands

Language Consent. In accepting the Restricted Shares, Grantee confirms having read and understood the documents relating to the Restricted Shares (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Instemming taal. Met het accepteren van de voorwaardelijk toegekende aandelen (RSU’s), bevestigt de Deelnemer dat hij/zij de documenten met betrekking tot de voorwaardelijk toegekende aandelen (RSU’s) (het Plan en de toekenningsovereenkomst inclusief deze Bijlage), die in het Engels zijn opgesteld, heeft gelezen en begrepen. De deelnemer aanvaardt de voorwaarden van deze documenten dienovereenkomstig.
9





Norway

Tax information: Norwegian Grantees who acquire shares will be required to report certain information related to their holdings with their annual tax return. Grantee should consult with Grantee’s personal tax or legal advisor, as appropriate, regarding any reporting requirements with respect to any shares acquired upon settlement of their award.

Language Consent: In accepting the Restricted Shares, Grantee confirms having read and understood the documents relating to the Restricted Shares (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Språksamtykke: Ved å akseptere bundne aksjer bekrefter mottakeren å ha lest og forstått dokumentene knyttet til bundne aksjer (planen og tildelingsavtalen, inkludert dette vedlegget), som ble gitt på engelsk. Mottakeren godtar vilkårene i disse dokumentene tilsvarende


10
EX-10.8 4 axex108xpsuformagreementfe.htm EX-10.8 Document
FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Exhibit 10.8

BALCHEM CORPORATION
PERFORMANCE SHARE UNIT
GRANT AGREEMENT

2017 Omnibus Incentive Plan

This PERFORMANCE SHARE UNIT GRANT AGREEMENT (the “Agreement”) made as of this _________th day of _____________, is between Balchem Corporation, a Maryland corporation (the “Company”) and ________________ (“Grantee”).

1.Grant of PSUs. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the same may be amended from time to time (the “Plan”), the Company hereby grants to Grantee an award for a target number of ______ Performance Share Units (the “Target PSUs”). Each Performance Share Unit (“PSU”) represents the right to receive one share of the Company’s common stock, par value six and two-thirds cents ($0.06 2/3) per share (“Stock”), subject to the terms and conditions, restrictions and other provisions set forth in this Agreement and in the Plan. The number of PSUs that Grantee actually earns (the “Earned PSUs”) will depend on the extent to which the performance criteria for the award (as set forth in Section 3 hereof) have been satisfied during the Performance Period (as defined in Section 2 hereof), and may be more or less than the Target PSUs based on the level of performance achieved. Any Target PSUs in excess of the Earned PSUs shall be forfeited as of the last day of the Performance Period. Any capitalized terms used in this Agreement and not defined herein shall have the meanings set forth in the Plan. This grant of PSUs is subject to Grantee’s execution and delivery to the Company of a copy of this Agreement. Grantee is not required to pay any purchase price for the PSUs.

2.Performance Period. The performance period for this award is January 1, [insert year 1] through December 31, [insert year 3] (the “Performance Period”).

3.Performance Criteria. _____________ shares of the Target PSUs are granted with respect to the Company’s EBITDA growth performance (as recorded by the Company) for the Performance Period and ____________ shares of the Target PSUs are granted with respect to the Company’s relative Total Shareholder Return (TSR) as compared to the TSR of the constituents of the Russell 2000 market index for the Performance Period. Additional detail regarding the vesting criteria is set forth as Exhibit A to this Agreement. The Committee shall have absolute discretion to determine the manner of making the calculations called for under this Section 3 and the extent to which the performance criteria set forth in this Section 3 have been attained, and its determination shall be final, conclusive and binding on Grantee. In addition, the Committee shall retain absolute discretion to reduce the number of Earned PSUs that will be treated as earned by Grantee based on such factors as the Committee may deem appropriate in its sole discretion.

4.Time-Vesting Requirement. The PSUs are subject to forfeiture until they vest. Unless they vest on an earlier date as provided in Section 5 hereof, the Earned PSUs will vest on the date that the Committee determines the number of Earned PSUs under Section 3 hereof, provided that Grantee has remained in continuous employment with the Company and/or the other members of the Group through such vesting date. Except in circumstances where a different treatment is provided in Section 5 hereof, in the event of Grantee’s termination of employment with the Company and/or the other members of the Group (whether by Grantee or by his or her employer) all of Grantee’s PSUs (whether or not Earned PSUs) which have not vested prior to such termination of employment will be forfeited.

5.Acceleration of Vesting. Notwithstanding the vesting date set forth in Section 4 hereof, the PSUs shall vest upon the following events, and shall be deemed Earned PSUs to the extent set forth below.

    - 1 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

(a)    Death or Disability. In the event of Grantee’s death while employed by the Company or any other member of the Group, or if the Grantee ceases to be employed by the Company and all other members of the Group by reason of his or her Disability (as such term is defined below), the number of PSUs that shall vest (and be deemed to be Earned PSUs) at the end of the Performance Period shall be the number of whole PSUs equal to the product of (A) 1/36th of the total number of Earned PSUs determined by the Committee under Section 3 hereof at the end of the Performance Period and (B) the number of full months of Grantee’s continuous employment with the Company and/or the other members of the Group from the beginning of the Performance Period to the date of Grantee’s death or Disability, as the case may be. To the extent vested, such PSUs shall be settled in accordance with Section 7 hereof, and all PSUs not so vested shall be forfeited. For the purposes of this Agreement, the term “Disability” shall mean “permanent and total disability” as defined in Section 22(e)(3) of the Code or successor statute.

(b)    Retirement. In the event of Grantee’s Retirement (as such term is defined below) from the Company or any other member of the Group on or following the first anniversary of the date of grant of the PSUs, the number of PSUs that shall vest (and be deemed to be Earned PSUs) at the end of the Performance Period shall be the number of whole PSUs equal to the product of (A) 1/36th of the total number of Earned PSUs determined by the Committee under Section 3 hereof at the end of the Performance Period and (B) the number of full months of Grantee’s continuous employment with the Company and/or the other members of the Group from the beginning of the Performance Period to the date of Grantee’s Retirement. To the extent vested, such PSUs shall be settled in accordance with Section 7 hereof, and all PSUs not so vested shall be forfeited. For the avoidance of doubt, in the event of Grantee’s Retirement from the Company or any other member of the Group prior to the first anniversary of the date of grant of the PSUs, all of Grantee’s PSUs will be forfeited. For purposes of this Agreement, the term “Retirement” shall mean termination of employment, with no less than one (1) year’s prior notice to the Company (unless otherwise agreed to by the Company), at a time when the sum of Grantee’s age and years of service is at least seventy (70), provided that Grantee has at least ten (10) years of service.

(c)    Change in Control. The treatment of the PSUs in the event of a Change in Control (as defined in the Plan) shall be governed by the terms of the Plan.

(d)    Committee Discretion. The Committee shall have absolute discretion to determine the date and circumstances of Grantee’s termination of employment or of the occurrence of Disability or a Change in Control, and its determination shall be final, conclusive and binding.

6.Voting and Dividends Equivalents.

(a)    Voting; Rights as Stockholder. Grantee shall have no voting rights or other rights as a stockholder with respect to the PSUs or the shares of Stock underlying the PSUs.

(b)    Dividend Equivalents. Grantee shall have the right to receive dividend equivalents with respect to the PSUs (to the extent they are Earned PSUs) equal to the cash dividends paid on the Company’s Stock. If the Company declares a cash dividend on its Stock, Grantee will be entitled to be credited with dividend equivalent units equal to (i) the amount of such dividend declared and paid with respect to one share of Stock, multiplied by (ii) the number of Target PSUs subject to this Agreement plus the number of dividend equivalent units previously credited with respect to such Target PSUs, that are outstanding on the applicable dividend payment date, divided by (iii) the Fair Market Value of a share of Stock on the dividend payment date. Dividend equivalent units will not be credited with interest. Each dividend equivalent unit represents one share of Stock, and will be paid in shares of Stock at the same time and to the same extent to which the Company issues the shares of Stock underlying the PSUs with respect to which they were credited. (In other words, if the PSUs are earned at the Target level, 100% of the dividend equivalent units will be paid; if the PSUs are earned at Threshold level, 50% of the dividend equivalent units will be paid; and if the PSUs are earned at
    - 2 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Maximum level, 200% of the dividend equivalent units will be paid.) Subject to the restrictions contained in the Plan, the Committee may prospectively change the method of crediting dividend equivalent units as it, in its sole discretion, determines appropriate from time to time.

7.Settlement of PSUs. Grantee’s PSUs that vest under this Agreement will be settled on the date the Committee determines the number of Earned PSUs under Section 3 hereof, but in no event later than the March 15 of the calendar year after the calendar year in which the Performance Period ends. On (or as soon as practicable after) the settlement date of a PSU, the Company will deliver to Grantee (or record Grantee as the owner on the Company’s books) one share of Stock for each of Grantee’s PSUs and dividend equivalent units being settled on such date. The Stock delivered upon the settlement of Grantee’s PSUs and dividend equivalent units will be fully transferable (subject to any applicable securities law restrictions) and not subject to forfeiture. The shares of Stock delivered upon such settlement will have full voting and dividend rights and will entitle the holder to all other rights of a stockholder of the Company.

8.Restrictions on Transfer of PSUs. Grantee may not sell, transfer, assign, or pledge Grantee’s PSUs or any rights under this Agreement. Notwithstanding the foregoing, Grantee may designate one or more members of Grantee’s immediate family or a trust whose beneficiaries are exclusively one or more members of Grantee’s immediate family to receive Grantee’s PSUs upon Grantee’s death. For purposes of this Agreement, the term “immediate family” shall mean the spouse, lineal descendant, father, mother, brother or sister of Grantee. In the absence of any such designation, shares of Stock that Grantee is entitled to receive upon his/her death shall instead be delivered to the legal representative of Grantee’s estate.

9.Adjustments for Stock Splits, Stock Dividends, etc. In the event of any stock split-up, stock dividend, stock distribution or other reclassification of Stock, the number of Grantee’s Target PSUs shall be appropriately adjusted to prevent enhancement or dilution of benefits, and Grantee’s Earned PSUs shall be determined with respect to such adjusted number. In addition, the Committee has the authority, in its discretion, to make changes to the PSUs to reflect a corporate transaction, such as a merger of the Company into another corporation, any consolidation of the Company with another company, any separation of the Company, any reorganization of the Company or any partial or complete liquidation of the Company.

10.Withholding. Grantee shall be required to remit to the Company, and the Company shall have the right to deduct from any compensation payable to Grantee, the amount sufficient to satisfy any federal, state or local withholding tax liability in respect of the PSUs and to take all such other action as the Committee deems necessary to satisfy all obligations for payment of such withholding taxes. To the extent permitted by the Committee, and subject to any terms and conditions imposed by the Committee, Grantee may elect to have the Company’s withholding obligation for federal, state and local taxes, including payroll taxes, with respect to the PSUs satisfied (i) by having the Company withhold from the shares otherwise deliverable to Grantee shares of Stock having a value equal to the amount of such withholding obligation with respect to the Stock or (ii) by delivering to the Company shares of unrestricted Stock. Alternatively, the Committee may require that a portion of shares of Stock otherwise deliverable be withheld and applied to satisfy the statutory withholding obligation with respect to the PSUs.

11.Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.

12.Amendment. No provision of this Agreement shall be amended, either generally or in any particular instance, except in a writing signed by the Company and Grantee.

    - 3 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

13.Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and Grantee and their respective heirs, executors, administrators, legal representatives, and permitted transferees.

14.No Rights to Employment. Nothing contained in this Agreement or the Plan shall be construed as giving Grantee any right to be retained, in any position, as an employee of or consultant or advisor to the Company.

15.Notices. All notices required or permitted hereunder shall be in writing and deemed effectively given upon personal delivery, delivery by Federal Express or other recognized overnight delivery service or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, return receipt requested, if to the Company at its executive offices and if to Grantee at the address shown beneath his or her signature to this Agreement, or in either case at such other address or addresses as either party shall designate to the other in accordance with this Section.

16.Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa.

17.Entire Agreement. This Agreement and the documents and agreements referenced herein constitute the entire agreement between the parties, and supersede all prior agreements and understandings, relating to the subject matter of this Agreement.

18.Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles. The Company and Grantee hereby (a) agree that any action, suit or other proceeding arising out of or based upon this Agreement shall be brought in the courts of the State of Maryland or any federal court located in such state, and (b) irrevocably consent and submit to the exclusive jurisdiction of such courts for the purpose of any such action, suit or proceeding.

19.Terms of Plan Control. The PSUs are issued pursuant to the Plan, a copy of which has been furnished to Grantee, and are subject to the Plan in all respects. Nothing contained in this Agreement shall in any way be deemed to alter or modify the provisions of the Plan and no act of the Company or its directors, officers or employees shall be deemed to be a waiver or modification of any provision of the Plan. The provisions of the Plan shall in all respects govern this Agreement. The Committee shall have authority in its discretion, but subject to the express provisions of the Plan, to interpret the Plan and this Agreement; to prescribe, amend and rescind rules and regulations relating to the Plan and this Agreement; and to make all other determinations deemed necessary or advisable for the administration of the Plan or this Agreement. The Committee’s determination on the foregoing matters shall be conclusive.

20.Section 409A Compliance. This Agreement is intended to comply with, or be exempt from, the requirements of Section 409A of the Code and the regulations issued thereunder. To the extent of any inconsistencies with the requirements of Section 409A, this Agreement shall be interpreted and amended in order to meet such Section 409A requirements. Notwithstanding anything contained in this Agreement or in any amendments hereto to the contrary, it is the intent of the Company to have the Plan interpreted and construed to comply with, or be exempt from, any and all provisions of Section 409A including any subsequent amendments, rulings or interpretations from appropriate governmental agencies. Without limiting the foregoing, notwithstanding the provisions of Section 7 hereof, if Grantee is a “specified employee” within the meaning of Section 409A of the Code, as determined by the Committee in accordance with Section 409A, any shares to be delivered in settlement of Grantee’s PSUs and dividend equivalent units that constitute “deferred compensation” within the meaning of Section 409A and that are otherwise payable or deliverable upon Grantee’s termination from employment (other than any payments that are permitted under Section 409A to be paid within six months following
    - 4 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

termination of employment of a specified employee) shall be suspended until the six-month anniversary of Grantee’s termination of employment (or date of death, if earlier), at which time all share deliveries that were suspended shall be paid to Grantee in a lump sum. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the settlement of PSUs upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A.
21.Data Privacy.

(a) Data Collection and Usage. The Company may collect, process and use certain personal information about Grantee, including, but not limited to, Grantee’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all Restricted Shares granted under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Grantee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The Company, with its address at 5 Paragon Drive, Montvale, New Jersey 07645, acts as the data controller in respect of such Data and may be contacted at DataPrivacy@balchem.com.

For Grantees in the European Union / European Economic Area / Switzerland / United Kingdom (“EEA+”), the legal basis for the processing of Data is that it is necessary for the performance of the Company's contractual obligation to deliver shares (if the conditions of the Plan and the Award Agreement are satisfied) and, generally, for the Company’s legitimate interests to manage and administer Grantee's participation in the Plan.

(b)    Data Disclosures. The Company transfers Data to service providers which assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select different service providers and share Data with such other providers serving in a similar manner. Grantee may be asked to acknowledge or (where applicable) agree to separate terms and data processing practices with the service providers, with such agreement (where applicable) being a condition to the ability to participate in the Plan. The Company may also share Data: with its affiliates: with other businesses in connection with a substantial corporate transaction (such as a sale, merger, consolidation, initial public offering, or in the unlikely event of bankruptcy); in response to a subpoena, court order, legal process, law enforcement request, legal claim or government inquiry; to protect and defend the rights, interests, safety, and security of the Company, Grantee, or others; or for any other purposes disclosed to the Grantee at the time the Company collects the Data. The Company does not sell Data or share Data for cross-context behavioral / targeted advertising purposes.

(c)    International Data Transfers. The Company and its service providers are based in the United States, and Data may be transferred to the United States to administer the Plan as a result. Grantee’s country or jurisdiction may have different data privacy laws and protections than the United States, and the Company complies with applicable laws that may place certain restrictions on such transfers.

For Grantees in the EEA+, the Company implements appropriate safeguards in accordance with applicable law to ensure the protection of Data outside of the EEA+, including by implementing standard contractual clauses, for which Grantees based in the EEA+ may request a copy.

(d)    Data Retention. The Company will hold and use Data only as long as is necessary to implement, administer and manage Grantee’s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and for archiving, back-up and deletion processes. This may extend beyond Grantee’s period of employment with the Company or the Employer.

    - 5 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

(e)    Data Subject Rights. Depending on where Grantee is based, and subject to applicable exceptions or exemptions, Grantee may have rights to access, correct, delete, restrict processing, or port their Data and lodge complaints with competent authorities in Grantee’s jurisdiction. Grantee or Grantee’s authorized agent may contact the Company at DataPrivacy@balchem.com to exercise such rights where applicable.

22.Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to the PSUs or other equity awards granted by the Company, whether under the Plan or otherwise, or any other Company securities by electronic means. By accepting this grant of PSUs, whether electronically or otherwise, Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company, including but not limited to the use of electronic signatures or click-through electronic acceptance of terms and conditions.

23.Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

24.Compensation Recovery. The PSUs shall be subject to the provisions of any applicable compensation recovery policy contained in the Plan or implemented by the Company, including without limitation any compensation recovery policy adopted to comply with the requirements of applicable law, to the extent set forth in such compensation recovery policy.

25.Parachute Payments.

(a)    Grantee shall bear all expense of, and be solely responsible for, any excise tax imposed by Section 4999 of the Code (the “Excise Tax”); provided, however, that any payment or benefit received or to be received by Grantee (whether payable under the terms of this Agreement or any other plan, arrangement or agreement with the Company or any of its affiliates) (collectively, the “Payments”) that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax but only if, by reason of such reduction, the net after-tax benefit received by Grantee exceeds the net after-tax benefit that would be received by Grantee if no such reduction was made. If a reduction in payments or benefits constituting “parachute payments” is necessary under the preceding sentence, the reduction shall be made in the manner that results in the greatest economic benefit for Grantee.

(b)    The “net after-tax benefit” shall mean (i) the Payments that Grantee receives or is then entitled to receive from the Company that would constitute “parachute payments” within the meaning of Section 280G of the Code, less (ii) the amount of all federal, state and local income and employment taxes payable by Grantee with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to Grantee (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in Section 25(a) above.

(c)    The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such change in control, change of ownership or similar transaction, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.

    - 6 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

(d)    The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Grantee within thirty (30) calendar days after the date on which Grantee’s right to a Payment is triggered (if requested at that time by the Company or Grantee) or such other time as reasonably requested by the Company or Grantee. Any good faith determinations of the independent registered public accounting firm made hereunder shall be final, binding and conclusive upon the Company and Grantee.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

BALCHEM CORPORATION


By:                         
Theodore L. Harris
Chairman, President and CEO



GRANTEE:

                        
                        (Signature)

Print Name:    ____________________________________

Address:                            

                                    

                        



    - 7 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Exhibit A
Performance Metrics Table
EBITDA Metric (50% of Target PSU Award)
Below ThresholdThresholdTargetMaximum
EBITDA Growth [insert year 1 - year 3]
below
[•]%
[•]%
([•]% of Target)
[•]%
([•]% of Target)
[•]%
([•]% of Target)
Payout (Percentage of EBITDA-Based Target PSUs)0%[•]%[•]%[•]%
Note:     Awards for results between points above threshold will be interpolated on straight-line basis.
    

Relative TSR Metric (50% of Target PSU Award)
The PSUs based on TSR (“TSR PSUs”) that shall become earned and payable, if any, will be based on the Company’s TSR for the Performance Period relative to the TSRs of the Peer Companies (as defined below), as determined by the Compensation Committee. The TSR PSUs that shall become earned and payable, if any, following the end of the Performance Period shall be determined by multiplying the number of PSUs granted by the “Earned Percentage,” as determined below, provided that the maximum Earned Percentage for the Performance Period shall be 200% and subject to certain caps described below. Any PSUs that do not become earned at the end of the Performance Period will be forfeited. [TO BE INSERTED IF APPLICABLE: Further, except as provided under Section 5 of the Agreement, shares of the Company’s common stock earned as vested TSR PSUs shall be subject to a mandatory holding period of one year from the vesting date, during which period the Grantee may not sell, transfer, or otherwise dispose of the shares, other than to cover required withholding taxes due upon the settlement of the vested TSR PSUs.]  

(a)TSR” means, for the Company and each of the Peer Companies, such company’s total shareholder return, expressed as a percentage, which will be calculated by dividing (i) the Closing Average Share Value by (ii) the Opening Average Share Value and subtracting one from the quotient.

(b)Opening Average Share Value” means the average Share Value over the trading days in the Opening Average Period.

    - 8 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

(c)Opening Average Period” means the sixty (60) calendar days ending on the day immediately preceding the first day of the Performance Period.

(d)Accumulated Shares” means, for a given trading day, the sum of (i) one (1) share and (ii) the cumulative number of shares of a company’s common stock purchasable with dividends declared on such company’s common stock to that point during the Opening Average Period and the Performance Period, assuming same day reinvestment of such dividends at the closing price on the ex-dividend date.

(e)Closing Average Share Value” means the average Share Value over the trading days in the Closing Average Period.

(f)Closing Average Period” means the sixty (60) calendar days ending on the last day of the Performance Period.

(g)Share Value” means, with respect to a given trading day, the closing price of a company’s common stock multiplied by the Accumulated Shares for such trading day.

(h)Peer Companies” means the constituents of the Russell 2000 Index as of the first day of the Performance Period. The Peer Companies may be changed as follows:

(i)    In the event of a merger, acquisition or business combination transaction of a Peer Company with or by another Peer Company, the surviving entity shall remain a Peer Company.

(ii)     In the event of a merger of a Peer Company with an entity that is not a Peer Company, or the acquisition or business combination transaction by or with a Peer Company, or with an entity that is not a Peer Company, in each case where the Peer Company is the surviving entity and remains publicly traded, the surviving entity shall remain a Peer Company.

(iii)     In the event of a merger or acquisition or business combination transaction of a Peer Company by or with an entity that is not a Peer Company, a “going private” transaction involving a Peer Company or the liquidation of a Peer Company, where the Peer Company is not the surviving entity or is otherwise no longer publicly traded, the company shall no longer be a Peer Company.

(iv)     In the event a Peer Company files for bankruptcy, regardless of whether the Peer Company is still trading on a market where an independent price can be determined (i.e., an over-the-counter market), it will remain a Peer Company and its TSR for the entire Performance Period shall equal negative 100%.

(v)    In the event of a stock distribution from a Peer Company consisting of the shares of a new publicly-traded company (a “spin-off”), the Peer Company shall remain a Peer Company and the stock distribution shall be treated as a dividend from the Peer Company based on the closing price of the shares of the spun-off company on its first day of trading.  The performance of the shares of the spun-off company shall not thereafter be tracked for purposes of calculating TSR.

    - 9 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Each Peer Company’s “common stock” shall mean that series of common stock that is publicly traded on a registered U.S. exchange or, in the case of a non-U.S. company, an equivalent non-U.S. exchange.

(i)Relative Total Shareholder Return” means the Company’s TSR relative to the TSR of the Peer Companies. Relative Total Shareholder Return will be determined by ranking the Peer Companies (including the Company) from highest to lowest according to their respective TSRs. After this ranking, the percentile performance of each of the Peer Companies will be determined as follows:

P =
N – R
N – 1

where:    “P” represents the percentile performance.

“N” represents the number of Peer Companies as of the Vesting Date.

“R” represents the Peer Company’s ranking among the Peer Companies.

Example: If there are 1,674 Peer Companies, the Peer Company that ranked 345th would be at the 79.44th percentile: 0.7944 = ((1,674 – 345) / (1674 – 1)).

(j)Earned Percentage” means the percentage determined according to the following table:
Below ThresholdThresholdTargetMaximum
Relative TSR Percentile [insert year 1 – year 3]
below
25th
percentile
25th
percentile
50th
percentile
75th
percentile
Payout (Percentage of TSR-Based Target PSUs)0%50%100%200%

Interpolation: To the extent performance falls between two levels in the table above, linear interpolation shall apply in determining the percentage of the PSUs that are earned.

Example: If the Company’s TSR was at the 66.24th percentile, the Earned Percentage would equal 164.96%.

    - 10 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

image_0.jpg

Limitations on the Earned Percentage: Notwithstanding the criteria in the table above, in the event the Company’s TSR over the Performance Period is negative, the Earned Percentage shall not exceed 100%.

    - 11 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Appendix
to

Balchem Corporation
Performance Share Unit Grant Agreement

Country-Specific Terms and Conditions


This Appendix includes special terms and conditions applicable to Grantee if the Grantee is primarily employed in one of the countries listed below. These terms and conditions supplement or replace (as indicated) the terms and conditions set forth in the Award Agreement. If the Grantee is a citizen or resident of a country other than the one in which he or she is primarily currently working, or if the Grantee transfers employment or residency to another country after the PSUs are granted, the Company, in its discretion but subject to applicable laws, will determine the extent to which the terms and conditions set forth in this Appendix will apply to the Grantee.

This Appendix also includes information relating to exchange control, foreign asset / account reporting requirements and other issues of which the Grantee should be aware with respect to his or her participation in the Plan. Such laws are often complex and change frequently. As a result, the Company strongly recommends that the Grantee not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time the PSUs vest or the shares acquired under the Plan are sold.

In addition, the information is general in nature and may not apply to the Grantee’s particular situation. The Company is not in a position to assure the Grantee of any particular result. Accordingly, the Grantee should seek appropriate professional advice as to how the relevant laws in his or her country may apply to his or her situation. Finally, if Grantee is a citizen or resident of a country other than the one in which he or she is currently primarily working, or if Grantee transfers employment or residency to another country after the PSUs are granted, the information contained herein may not be applicable to Grantee.


France

PSUs Not Tax-Qualified. The PSUs are not intended to be French tax-qualified.

Language Consent. In accepting the Option, Grantee confirms having read and understood the documents relating to the Option (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Consentement Relatif à la Langue Utilisée. En acceptant cette Attribution, le Grantee confirme avoir lu et compris les documents relatifs à cette Attribution (le Plan, le Contrat d’Attribution incluant cette Annexe), qui ont été remis en langue anglaise. Le Grantee accepte les termes de ces documents en conséquence.

Foreign Asset/Account Reporting Information. Grantee is required to report any shares and foreign bank accounts, including accounts closed during the tax year, to the French tax authorities when filing his or her annual tax return.
    - 12 -


FORM OF AGREEMENT (AS OF FEBRUARY 2024)


Germany

Exchange Control Information. Grantee must report any cross-border payments in excess of €12,500 to the German Federal Bank (Bundesbank). The report must be filed electronically by the 5th day of the month following the month in which the payment occurred. The form of report (Allgemeine Meldeportal Statistik) can be accessed via the Bundesbank’s website (www.bundesbank.de). Grantee should consult his or her personal legal advisor to ensure compliance with applicable reporting obligations.

Sole Contractual Relationship. Grantee understands that the PSUs are offered solely by the Company and not by any other member of the Group or entity that may be employing Grantee from time to time. Only the terms and conditions of the Plan and this Agreement shall govern the Agreement as well as the PSUs as a contractual relationship solely between Company and Grantee.

Language Consent. In accepting the PSUs, Grantee confirms having read and understood the documents relating to the PSUs (the Plan and the Award Agreement including this Appendix), which were provided in English. Participant accepts the terms of those documents accordingly.

Einwilligung zur Sprache. Mit der Annahme der PSUs bestätigt der Teilnehmer, dass er die mit den PSUs zusammenhängenden Dokumente (den Plan und diese Zuteilungsvereinbarung einschließlich dieses Anhangs), die jeweils in englischer Sprache zur Verfügung gestellt wurden, gelesen und verstanden hat. Der Teilnehmer akzeptiert die Bedingungen dieser Dokumente entsprechend.


Netherlands

Language Consent. In accepting the PSUs, Grantee confirms having read and understood the documents relating to the PSUs (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Instemming taal. Met het accepteren van de prestatieaandelen (PSU’s), bevestigt de Deelnemer dat hij/zij de documenten met betrekking tot de prestatieaandelen (het Plan en de toekenningsovereenkomst inclusief deze Bijlage), die in het Engels zijn opgesteld, heeft gelezen en begrepen. De deelnemer aanvaardt de voorwaarden van deze documenten dienovereenkomstig.


Norway

Tax information: Grantees who acquire shares will be required to report certain information related to their holdings with their annual tax return. Grantee should consult with Grantee’s personal tax or legal advisor, as appropriate, regarding any reporting requirements with respect to any shares acquired upon settlement of their award.

Language Consent: In accepting the PSUs, Grantee confirms having read and understood the documents relating to the PSUs (the Plan and the Award Agreement including this Appendix), which were provided in English. Grantee accepts the terms of those documents accordingly.

Språksamtykke: Ved å akseptere PSU-ene bekrefter mottakeren å ha lest og forstått dokumentene knyttet til PSU-ene (planen og tildelingsavtalen, inkludert dette vedlegget), som ble gitt på engelsk. Mottakeren godtar vilkårene i disse dokumentene tilsvarende.

    - 13 -

EX-10.9 5 axex109xstockoptionsformag.htm EX-10.9 Document
FORM OF AGREEMENT (AS OF FEBRUARY 2024)

Exhibit 10.9

BALCHEM CORPORATION
STOCK OPTION GRANT AGREEMENT

2017 Omnibus Incentive Plan


This STOCK OPTION GRANT AGREEMENT (the “Grant”), dated as of ________, is between BALCHEM CORPORATION, a Maryland corporation (the “Company”) and
                 (“Optionee”).

W I T N E S S E T H:

1.Grant of Options. Pursuant to the provisions of the Company’s 2017 Omnibus Incentive Plan, as the same may be amended from time to time (the “Plan”), the Company has on the date set forth on Exhibit A hereto (such date, the “Grant Date”) granted to Optionee, subject to the terms and conditions of the Plan and subject further to the terms and conditions herein set forth, the right and option to purchase from the Company the number of shares of the Company’s common stock par value six and two-thirds cents ($0.06 2/3) per share (“Stock”) set forth in Exhibit A at the price per share set forth in Exhibit A (the stock options granted hereby being referred to as the “Option” or the “Options”). The Option is a non-qualified stock option. Any capitalized terms used in this Grant and not defined herein shall have the meanings set forth in the Plan. This grant of Options is subject to Optionee’s execution and delivery to the Company of a copy of this Grant.

2.Terms and Conditions. The term of the Option shall be for the period specified in Exhibit A. The Option shall vest and become exercisable on the date or dates set forth, or upon satisfaction of the conditions set forth, in Exhibit A, provided that (unless expressly provided otherwise in Section 4 hereof or in Exhibit A) Optionee is an employee of the Company or any other member of the Group on each such date. To the extent the Option has become exercisable, it may be exercised, prior to the end of the Option term, at any time in whole or in part and from time to time, subject to earlier termination as provided in Sections 3 and 4 of this Grant, unless otherwise expressly provided in Exhibit A. Unless otherwise provided in Exhibit A, the Option may not be exercised (a) as to fewer than 100 shares at any one time (or for the remaining shares then purchasable under the Option, if fewer than 100 shares), and (b) until fulfillment of any conditions precedent set forth in Section 7 hereof. The holder of any Option shall not have any rights as a stockholder with respect to the Stock issuable upon exercise of an Option until certificates for such Stock shall have been issued and delivered to him or her after the exercise of the Option.

3.Termination of Employment. In the event that the employment of Optionee with the Company or other member of the Group terminates (other than by reason of (i) death, (ii) Disability (as such term is defined in Section 4 hereof), (iii) Retirement (as such term is defined in Section 4 hereof) on or after the first anniversary of the Grant Date, or (iv) for Cause), the Option shall be exercisable (to the extent that Optionee shall have been entitled to do so at the termination of his or her employment) at any time prior to the expiration of the period of sixty (60) days after such termination, but in no event later than the specified expiration date of the Option, except as may be expressly provided in Exhibit A. Notwithstanding anything herein to the contrary, in the event that the employment of Optionee is terminated for Cause, all vested and unvested portions of the Option shall be immediately forfeited by Optionee without any consideration.

316819059.3



This Grant does not constitute an employment contract. Nothing in the Plan or in this Grant shall confer upon Optionee any right to continue to be employed by the Company or any other member of the Group for the length of any vesting schedule or for any portion thereof or for any other period of time, or interfere in any way with the right of the Company or any other member of the Group to terminate or otherwise modify the terms of Optionee’s employment; provided, that a change in Optionee’s duties or position shall not affect Optionee’s Option so long as Optionee is still an employee of the Company or any other member of the Group.

4.Death, Disability, or Retirement of Optionee or Change in Control.

(a)Death. If Optionee ceases to be employed by the Company and all other members of the Group by reason of his or her death, the vesting of the Option shall accelerate and the Option shall become fully exercisable upon such termination of employment and may be exercised by Optionee’s estate, personal representative or Beneficiary who has acquired the Option by will or by the laws of descent and distribution, at any time prior to the earlier of the specified expiration date of the Option or two (2) years after the date of Optionee’s death, except as may otherwise be provided in Exhibit A.

(b)Disability. If Optionee ceases to be employed by the Company and all other members of the Group by reason of his or her Disability, the Option shall continue to vest during the Optionee’s lifetime and become exercisable in accordance with the vesting schedule set forth in Exhibit A. Except as otherwise provided in Exhibit A, any unexercised portion of the Option may be exercised by Optionee (or in the event of death, by Optionee’s estate, personal representative or Beneficiary who has acquired the Option by will or by the laws of descent and distribution) prior to the later of (i) two (2) years after Optionee’s termination of employment or (ii) two (2) years after the vesting date of the Option, but in any case, not beyond the specified expiration date of the Option. For the purposes of the Grant, the term “Disability” shall mean “permanent and total disability” as defined in Section 22(e)(3) of the Code or successor statute.

(c)Retirement. If Optionee ceases to be employed by the Company and all members of the Group by reason of his or her Retirement on or after the first anniversary of the Grant Date, the Option shall continue to vest during the Optionee’s lifetime and become exercisable in accordance with the vesting schedule set forth in Exhibit A. Except as otherwise provided in Exhibit A, any unexercised portion of the Option may be exercised by Optionee (or in the event of death, by Optionee’s estate, personal representative or Beneficiary who has acquired the Option by will or by the laws of descent and distribution) prior to the later of (i) two (2) years after Optionee’s termination of employment or (ii) two (2) years after the vesting date of the Option, but in any case not beyond the specified expiration date of the Option. For the avoidance of doubt, if Optionee ceases to be employed by the Company and all members of the Group by reason of his or her Retirement prior to the first anniversary of the Grant Date, the Option shall immediately be forfeited by Optionee for no consideration. For purposes of this Agreement, the term “Retirement” shall mean termination of employment, with no less than one (1) year’s prior notice to the Company (unless otherwise agreed to by the Company), at a time when the sum of Grantee’s age and years of service is at least seventy (70), provided that Grantee has at least ten (10) years of service.

(d)Change in Control. The treatment of the Option in the event of a Change in Control (as defined in the Plan) shall be governed by the terms of the Plan.

5.Transferability of Option. The Option shall not be transferable otherwise than by will or the laws of descent and distribution, except as, and then only to the extent, if any, provided in Exhibit A hereto or as subsequently approved by the Board or the Committee.


~2~



6.Adjustments Upon Changes in Capitalization. In the event of changes in the outstanding stock of the Company by reason of stock dividends, stock splits, recapitalizations, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations or liquidations, the number and class of shares subject to the Option shall be correspondingly adjusted as provided in the Plan.

7.Conditions Precedent to Exercise of Option. In the event that the exercise of the Option or the issuance and delivery of the shares hereunder shall be subject to, or shall require, any prior exchange listing, prior approval of the stockholders of the Company, or other prior condition or act, pursuant to the applicable laws, regulations or policies of any stock exchange, federal or local government or its agencies or representatives, and/or pursuant to the Plan, then the Option shall not be deemed to be exercisable under this Grant until such condition is satisfied. The Company shall not be liable in any manner to Optionee or any other party for any failure or delay by the Company on its part to fulfill any such condition, and any such failure or delay shall not extend the term of the Option.

8.Methods of Exercising Option. Subject to the terms and conditions of this Grant, the Option may be exercised by delivering a signed, completed exercise notice in the form of Exhibit B hereto, as the same may be modified from time to time by determination of the Company in its discretion, to the Company, at its office at 5 Paragon Drive, Montvale, New Jersey 07645 or such other address as the Company may designate. Such notice shall (i) identify the Option to which it applies, (ii) state the election to exercise the Option, (iii) designate the number of shares in respect of which the Option is being exercised, and (iv) be signed by the person or persons so exercising the Option, and shall otherwise be in such form and substance as the Company may require. Such notice shall be accompanied by payment of the full purchase price of such shares. The Company shall deliver to Optionee, at such address as is provided in the notice, a certificate or certificates representing such shares as soon as practicable after the notice shall be received and all conditions to the exercise of the Option are fulfilled and satisfied. Payment of such purchase price shall be made (a) in United States dollars in cash or by check, or (b) through delivery of shares of Stock previously owned by Optionee for at least six months and having a Fair Market Value equal as of the date of the exercise to the cash exercise price of the Option, or (c) by any combination of the above. Notwithstanding the foregoing, Optionee may not pay any part of the exercise price hereof by transferring Stock to the Company if such Stock is not fully vested or is subject to a substantial risk of forfeiture within the meaning of Section 83 of the Code. The certificate or certificates for the shares as to which the Option shall have been so exercised shall be issued in the name of the person or persons so exercising the Option (or, if the Option shall be exercised by Optionee and if Optionee shall so request in the notice exercising the Option, the certificate shall be issued in the name of Optionee and another person jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. In the event the Option shall be exercised by any person or persons other than Optionee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise the Option. At the election of the Company, such certificate may bear such legends regarding the limited transferability of the shares under applicable securities laws as the Company may require. All shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and non-assessable.

9.Compliance with Law. The exercise of the Option and the issuance and transfer of shares of Stock shall be subject to compliance by the Company and Optionee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Company’s Stock may be listed. No share of Stock shall be issued pursuant to the Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company


~3~



and its counsel. Optionee understands that the Company is under no obligation to register the shares with the U.S. Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.

10.Capital Changes and Business Successions. The Plan contains provisions covering the treatment of the Option in a number of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment with respect to stock subject to options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. In general, Optionee should not assume that the Option necessarily would survive the acquisition of the Company.

11.Withholding Taxes. Optionee shall be required to remit to the Company, and the Company shall have the right to deduct from any compensation payable to Optionee, the amount sufficient to satisfy any federal, state or local withholding tax liability in respect of the Options and to take all such other action as the Committee deems necessary to satisfy all obligations for payment of such withholding taxes. To the extent permitted by the Committee, and subject to any terms and conditions imposed by the Committee, Optionee may elect to have the Company’s withholding obligation for federal, state and local taxes, including payroll taxes, with respect to the Options satisfied (i) by having the Company withhold from the shares otherwise deliverable to Optionee shares of Stock having a value equal to the amount of such withholding obligation with respect to the Stock or (ii) by delivering to the Company shares of unrestricted Stock. Alternatively, the Committee may require that a portion of shares of Stock otherwise deliverable be withheld and applied to satisfy the statutory withholding obligation with respect to the Options.

12.Terms of Plan Control. The Option granted hereunder is granted pursuant to the provisions of the Plan, a copy of which has been made available to Optionee, and are subject to the Plan in all respects. Nothing contained in this Grant shall in any way be deemed to alter or modify the provisions of the Plan and no act of the Company or its directors, officers or employees shall be deemed to be a waiver or modification of any provision of the Plan. The provisions of the Plan shall in all respects govern the Option. The Committee shall have authority in its discretion, but subject to the express provisions of the Plan, to interpret the Plan and this Grant; to prescribe, amend and rescind rules and regulations relating to the Plan and the Option; and to make all other determinations deemed necessary or advisable for the administration of the Plan or the Option. The Committee’s determination on the foregoing matters shall be conclusive.

13.Governing Law. This Grant shall be construed, interpreted and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles. The Company and the Optionee hereby (a) agree that any action, suit or other proceeding arising out of or based upon this Grant shall be brought in the courts of the State of Maryland or any federal court located in such state, and (b) irrevocably consent and submit to the exclusive jurisdiction of such courts for the purpose of any such action, suit or proceeding.

14.No Right as Shareholder. Optionee shall not have any rights as a shareholder with respect to any shares of Stock subject to the Option prior to the date of exercise of the Option.

15.Severability. The invalidity or unenforceability of any provision of this Grant shall not affect the validity or enforceability of any other provision of this Grant and each other provision of this Grant shall be severable and enforceable to the extent permitted by law.



~4~



16.Pronouns. Whenever the context may require, any pronouns used in this Grant shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa.

17.Entire Agreement. This Grant and the documents and agreements referenced herein constitute the entire agreement between the parties, and supersede all prior agreements and understandings, relating to the subject matter of this Grant.

18.Notices. All notices required or permitted hereunder shall be in writing and deemed effectively given upon personal delivery, delivery by Federal Express or other recognized overnight delivery service or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, return receipt requested, if to the Company at its executive offices and if to Optionee at the address shown beneath his or her signature to this Grant, or in either case at such other address or addresses as either party shall designate to the other in accordance with this Section.

19.Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to this Option, any future options or other equity awards granted by the Company, whether under the Plan or otherwise, or any other Company securities by electronic means. By accepting this Option, whether electronically or otherwise, Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company, including but not limited to the use of electronic signatures or click-through electronic acceptance of terms and conditions.

20.Counterparts. This Grant may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

21.Data Privacy.

(a) Data Collection and Usage. The Company may collect, process and use certain personal information about Optionee, including, but not limited to, Optionee’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all Restricted Shares granted under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Optionee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The Company, with its address at 5 Paragon Drive, Montvale, New Jersey 07645, acts as the data controller in respect of such Data and may be contacted at DataPrivacy@balchem.com.

For Optionees in the European Union / European Economic Area / Switzerland / United Kingdom (“EEA+”), the legal basis for the processing of Data is that it is necessary for the performance of the Company's contractual obligation to deliver shares (if the conditions of the Plan and the Award Agreement are satisfied) and, generally, for the Company’s legitimate interests to manage and administer Optionee's participation in the Plan.

(b)    Data Disclosures. The Company transfers Data to service providers which assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select different service providers and share Data with such other providers serving in a similar manner. Optionee may be asked to acknowledge or (where applicable) agree to separate terms and data processing practices with the service providers, with such agreement (where applicable) being a condition to the ability to participate in the Plan. The Company may also share Data: with its affiliates: with other businesses in connection with a


~5~



substantial corporate transaction (such as a sale, merger, consolidation, initial public offering, or in the unlikely event of bankruptcy); in response to a subpoena, court order, legal process, law enforcement request, legal claim or government inquiry; to protect and defend the rights, interests, safety, and security of the Company, Optionee, or others; or for any other purposes disclosed to the Optionee at the time the Company collects the Data. The Company does not sell Data or share Data for cross-context behavioral / targeted advertising purposes.

(c)    International Data Transfers. The Company and its service providers are based in the United States, and Data may be transferred to the United States to administer the Plan as a result. Optionee’s country or jurisdiction may have different data privacy laws and protections than the United States, and the Company complies with applicable laws that may place certain restrictions on such transfers.

For Optionees in the EEA+, the Company implements appropriate safeguards in accordance with applicable law to ensure the protection of Data outside of the EEA+, including by implementing standard contractual clauses, for which Optionees based in the EEA+ may request a copy.

(d)    Data Retention. The Company will hold and use Data only as long as is necessary to implement, administer and manage Optionee’s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and for archiving, back-up and deletion processes. This may extend beyond Optionee’s period of employment with the Company or the Employer.

(e)    Data Subject Rights. Depending on where Optionee is based, and subject to applicable exceptions or exemptions, Optionee may have rights to access, correct, delete, restrict processing, or port their Data and lodge complaints with competent authorities in Optionee’s jurisdiction. Optionee or Optionee’s authorized agent may contact the Company at DataPrivacy@balchem.com to exercise such rights where applicable.


22.Compensation Recovery. The Options shall be subject to the provisions of any applicable compensation recovery policy contained in the Plan or implemented by the Company, including without limitation any compensation recovery policy adopted to comply with the requirements of applicable law, to the extent set forth in such compensation recovery policy.

23.Parachute Payments.

(a)    Optionee shall bear all expense of, and be solely responsible for, any excise tax imposed by Section 4999 of the Code (the “Excise Tax”); provided, however, that any payment or benefit received or to be received by Optionee (whether payable under the terms of this Agreement or any other plan, arrangement or agreement with the Company or any of its affiliates) (collectively, the “Payments”) that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax but only if, by reason of such reduction, the net after-tax benefit received by Optionee exceeds the net after-tax benefit that would be received by Optionee if no such reduction was made. If a reduction in payments or benefits constituting “parachute payments” is necessary under the preceding sentence, the reduction shall be made in the manner that results in the greatest economic benefit for Optionee.

(b)    The “net after-tax benefit” shall mean (i) the Payments that Optionee receives or is then entitled to receive from the Company that would constitute “parachute payments” within the meaning of Section 280G of the Code, less (ii) the amount of all federal,


~6~



state and local income and employment taxes payable by Optionee with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to Optionee (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in Section 23(a) above.

(c)    The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such change in control, change of ownership or similar transaction, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.

(d)    The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Optionee within thirty (30) calendar days after the date on which Optionee’s right to a Payment is triggered (if requested at that time by the Company or Optionee) or such other time as reasonably requested by the Company or Optionee. Any good faith determinations of the independent registered public accounting firm made hereunder shall be final, binding and conclusive upon the Company and Optionee.

IN WITNESS WHEREOF, the Company has caused this Grant to be executed by its duly authorized officer and Optionee has executed this Grant as of the date first written above.


BALCHEM CORPORATION



By: ____________________________________
                             Theodore L. Harris
                             Chairman, President and CEO


AGREED AND ACCEPTED:


________________________________
OPTIONEE:

Address: ________________________
________________________

     ________________________



~7~



Exhibit A


Balchem Corporation
                                5 Paragon Drive
                                Montvale, NJ 07645

Notice of Grant of Stock Options             

[Employee Name]
Participant ID: XXX-XX-XXXX
Dear [●],
Effective [insert date], you have been granted a non-qualified stock option (“Option”) to buy shares of Balchem Corporation (the “Company”) common stock par value six and two-thirds cents ($0.06 2/3) per share with the following parameters:
Plan Name: Balchem Corporation 2017 Omnibus Incentive Plan
Award Number: [●]
Shares Subject to Option Granted: [●]
Award Type: Non-Qualified Stock Option
Award Date: [●]
Award Price per Share: [●]
Vesting Schedule:

Shares        Vest Type        Vest Date             
[●]        On Vest Date        [●]                
[●]        On Vest Date        [●]                
[●]        On Vest Date        [●]            
                                                    

By your signature and the Company’s signature below, you and the Company agree that these Options are granted under and governed by the terms and conditions of the Company’s 2017 Omnibus Incentive Plan, as the same may be amended from time to time, and the Stock Option Grant Agreement between you and the Company, which are attached and made a part of this Notice. This Notice may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document.





~8~



Appendix
to

Balchem Corporation
Stock Option Grant Agreement

Country-Specific Terms and Conditions


This Appendix includes special terms and conditions applicable to the Optionee if the Optionee primarily employed is in one of the countries listed below. These terms and conditions supplement or replace (as indicated) the terms and conditions set forth in the Stock Option Grant Agreement. If the Optionee is a citizen or resident of a country other than the one in which he or she is currently primarily working, or if the Optionee transfers primary employment or residency to another country after the Option is granted, the Company, in its discretion but subject to applicable laws, will determine the extent to which the terms and conditions set forth in this Appendix will apply to the Optionee.

This Appendix also includes information relating to exchange control, foreign asset / account reporting requirements and other issues of which the Optionee should be aware with respect to his or her participation in the Plan. Such laws are often complex and change frequently. As a result, the Optionee should not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time the Option is exercised or the shares acquired under the Plan are sold.

In addition, the information is general in nature and may not apply to the Optionee’s particular situation. The Company is not in a position to assure the Optionee of any particular result. Accordingly, the Optionee should seek appropriate professional advice as to how the relevant laws in his or her country may apply to his or her situation. Finally, if the Optionee is a citizen or resident of a country other than the one in which he or she is currently primarily working and/or residing, or if the Optionee transfers employment or residency to another country after the Option is granted, the information contained herein may not be applicable to the Optionee.


France

Option Not Tax-Qualified. The Option is not intended to be French tax-qualified.

Language Consent. In accepting the Option, the Optionee confirms having read and understood the documents relating to the Option (the Plan and the Award Agreement including this Appendix), which were provided in English. The Optionee accepts the terms of those documents accordingly.

Consentement Relatif à la Langue Utilisée. En acceptant cette Attribution, le Optionee confirme avoir lu et compris les documents relatifs à cette Attribution (le Plan, le Contrat d’Attribution incluant cette Annexe), qui ont été remis en langue anglaise. Le Optionee accepte les termes de ces documents en conséquence.

Foreign Asset/Account Reporting Information. The Opitonee is required to report any shares and foreign bank accounts, including accounts closed during the tax year, to the French tax


~9~



authorities when filing his or her annual tax return on form Cerfa number 3916. This also applies to foreign accounts holding the allocated shares.


Germany

Exchange Control Information. The Optionee must report any cross-border payments in excess of €12,500 to the German Federal Bank (Bundesbank). The report must be filed electronically by the 5th day of the month following the month in which the payment occurred. The form of report (Allgemeine Meldeportal Statistik) can be accessed via the Bundesbank’s website (www.bundesbank.de). Optionee should consult his or her personal legal advisor to ensure compliance with applicable reporting obligations.

Sole Contractual Relationship. Optionee agrees that the Option is offered solely by the Company and not by any other member of the Group or entity that may be employing Optionee from time to time. Only the terms and conditions of the Plan and this Grant shall govern the Grant as well as the Option as a contractual relationship solely between Company and Optionee.

Language Consent. In accepting the Option, Optionee confirms having read and understood the documents relating to the Option (the Plan and the Award Agreement including this Appendix), which were provided in English. Optionee accepts the terms of those documents accordingly.

Einwilligung zur Sprache. Mit der Annahme der Option bestätigt der Teilnehmer, dass er die mit der Option zusammenhängenden Dokumente (den Plan und diese Zuteilungsvereinbarung einschließlich dieses Anhangs), die jeweils in englischer Sprache zur Verfügung gestellt wurden, gelesen und verstanden hat. Der Teilnehmer akzeptiert die Bedingungen dieser Dokumente entsprechend.


The Netherlands

Language Consent. In accepting the Option, Optionee confirms having read and understood the documents relating to the Option (the Plan and the Award Agreement including this Appendix), which were provided in English. Optionee accepts the terms of those documents accordingly.

Instemming taal. Met het accepteren van de Optie, bevestigt de Deelnemer dat hij/zij de documenten met betrekking tot de Optie (het Plan en de toekenningsovereenkomst inclusief deze Bijlage), die in het Engels zijn opgesteld, heeft gelezen en begrepen. De deelnemer aanvaardt de voorwaarden van deze documenten dienovereenkomstig.


Norway

Tax information: Optionees who acquire shares will be required to report certain information related to their holdings with their annual tax return. Optionee should consult with Optionee’s personal tax or legal advisor, as appropriate, regarding any reporting requirements with respect to any shares acquired upon settlement of their award.

Language Consent: In accepting the Option, Optionee confirms having read and understood the documents relating to the Options (the Plan and the Award Agreement including this Appendix), which were provided in English. Optionee accepts the terms of those documents accordingly.



~10~



Språksamtykke: Ved å akseptere Opsjonen bekrefter Mottakeren å ha lest og forstått dokumentene knyttet til Opsjonen (planen og tildelingsavtalen, inkludert dette vedlegget), som er skrevet på engelsk. Mottakeren godtar vilkårene i disse dokumentene tilsvarende.




~11~

EX-10.10 6 axex1010xofficerretireepro.htm EX-10.10 Document

Exhibit 10.10
Balchem Corporation Officer Retiree Program

Balchem Corporation (the “Company”) sets forth the below Officer Retiree Program (the “Program”) with the intent to help attract and retain top talent at the executive level. For purposes of this Program, the term "Retirement" shall mean voluntary termination of employment at a time when the sum of the Officer’s age and years of service is at least 70, provided that the Officer has at least ten years of service and has served at least three consecutive years as an Officer. Further, “Officer” shall mean only those individuals approved by the Board of Directors to be either an Executive Officer and/or Section 16 Officer of the Company.

In order to be eligible for this program, the Officer must, in addition to meeting all eligibility requirements, cooperate in good faith to ensure a smooth transition in relation to his/her anticipated retirement, including providing no less than one (1) year’s prior notice to the Company (unless otherwise agreed to by the Company).

a)Officer Retiree Medical Program
1.Retirement — an Officer is entitled to receive medical benefits (see coverage below) if he or she meets the definition of Retirement, as described above and has executed an appropriate non-compete agreement (subject to local laws and regulations) with the Company.
2.Included dependents — the spouse and any eligible dependents, who, at the time of retiree’s departure, are eligible to be covered under the retiree’s medical plan, are eligible for coverage.
3.Coverage — eligible persons are covered from the date of retiree’s departure, at the same coverage available to an active employee for the retiree’s and spouse’s life, or until Medicare is available. Eligible dependents are covered until the dependent ceases to be eligible under the then current Company medical plan. In addition, the maximum years of coverage for any person eligible for coverage under this program is ten years.
4.Premiums — The Company charges the retiree (or his or her spouse) that portion of the coverage premiums that the Company would have paid if the retiree were an active employee.

b)Stock Options
Notwithstanding anything to the contrary in the 2017 Omnibus Incentive Plan (as amended from time to time) or in the Officer’s applicable stock option agreements, if an Officer ceases to be employed by the Company or its subsidiary companies, as may be applicable, by reason of Retirement, meets the definition of Retirement, as described above and has executed and is in compliance with their non-compete agreement with the Company, options granted shall continue to vest and become exercisable in accordance with their original vesting schedule. Except as otherwise provided, any unexercised portion of the option may be exercised prior to the later of (i) two years after optionee's termination of



employment or (ii) two years after the vesting date of the option, but in any case not beyond the specified expiration date of the option.

c)Restricted Stock – Performance and Time Based
Notwithstanding anything to the contrary in the 2017 Omnibus Incentive Plan (as amended from time to time) or in the Officer’s applicable restricted stock agreements, if an Officer ceases to be employed by the Company or its subsidiary companies, as may be applicable, by reason of Retirement, meets the definition of Retirement, as described above and has executed and is in compliance with their non-compete agreement with the Company, all Restricted Stock grants shall continue to vest in accordance with their original vesting schedule.

d)Performance Shares
Notwithstanding anything to the contrary in the 2017 Omnibus Incentive Plan (as amended from time to time) or in the Officer’s applicable performance share agreements, if an Officer ceases to be employed by the Company or its subsidiary companies, as may be applicable, by reason of Retirement, meets the definition of Retirement, as described above and has executed and is in compliance with their non-compete agreement with the Company, all Performance Share grants shall continue to vest in accordance with their original vesting schedule.



Last updated: February 7, 2024

EX-21.1 7 bcpc202310k-ex211.htm EX-21.1 Document

Exhibit 21.1

LIST OF SUBSIDIARIES 

Subsidiaries of the RegistrantJurisdiction of Organization
  
Aberco, Inc.Maryland
  
Albion Laboratories, Inc.Nevada
  
Balchem BVNetherlands
Balchem Italia SrlItaly
  
Balchem Ltd.Canada
  
Balchem NVBelgium
  
Balchem Pty Ltd.Australia
  
Balchem Sdn BhdMalaysia
  
BCP Ingredients, Inc.Delaware
Kappa Bioscience ASNorway
Kappa Bioscience Europe GmbHGermany
Kappa Solutions ASNorway
Kechu BidCo ASNorway
SensoryEffects, Inc.Delaware
SensoryEffects Cereal Systems, Inc.Delaware
Stereo Gas Philippines Inc.Philippines
 




EX-23.1 8 bcpc202310k-ex231.htm EX-23.1 Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statements (Nos. 333-272998, 333-219722 and 333-155655) on Form S-8 of Balchem Corporation of our report dated February 16, 2024, relating to the consolidated financial statements, the financial statement schedules and the effectiveness of internal control over financial reporting of Balchem Corporation and its subsidiaries, appearing in this Annual Report on Form 10-K of Balchem Corporation for the year ended December 31, 2023.

/s/ RSM US LLP 
New York, New York
February 16, 2024



EX-31.1 9 bcpc202310k-ex311.htm EX-31.1 Document

Exhibit 31.1 
CERTIFICATIONS 
I, Theodore L. Harris, certify that:

1.I have reviewed this annual report on Form 10-K of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 16, 2024/s/ Theodore L. Harris
 Theodore L. Harris
 Chairman, President and
Chief Executive Officer
 (Principal Executive Officer)
 


EX-31.2 10 bcpc202310k-ex312.htm EX-31.2 Document

Exhibit 31.2 

CERTIFICATIONS 

I, C. Martin Bengtsson, certify that:

1.I have reviewed this annual report on Form 10-K of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 16, 2024/s/ C. Martin Bengtsson
 C. Martin Bengtsson
 Executive Vice President and
Chief Financial Officer
 (Principal Financial Officer)
 


EX-32.1 11 bcpc202310k-ex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Balchem Corporation (the “Company”) on Form 10-K for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Theodore L. Harris, President, and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 /s/ Theodore L. Harris
 Theodore L. Harris
 Chairman, President and
 Chief Executive Officer
 (Principal Executive Officer)
 February 16, 2024

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.


EX-32.2 12 bcpc202310k-ex322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Balchem Corporation (the "Company") on Form 10-K for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, C. Martin Bengtsson, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 /s/ C. Martin Bengtsson
 C. Martin Bengtsson
 Executive Vice President and
Chief Financial Officer
 (Principal Financial Officer)
 February 16, 2024

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 


EX-97.1 13 axex971xbalchemclawbackpol.htm EX-97.1 Document

Exhibit 97.1

BALCHEM CORPORATION
INCENTIVE-BASED COMPENSATION RECOVERY POLICY

PURPOSE
The Board of Directors (the “Board”) of Balchem Corporation (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this clawback policy which provides for the recoupment of certain executive compensation in the event that the Company is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the federal securities laws (the “Policy”). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934 (the “Exchange Act”), the rules promulgated thereunder, and the listing standards of the Nasdaq Stock Market LLC and shall be construed and interpreted in accordance with such intent.
ADMINISTRATION
This Policy shall be administered by the Compensation Committee of the Board (the “Compensation Committee”). Any determinations made by the Compensation Committee shall be final and binding on all affected individuals.
COVERED EXECUTIVES
This Policy applies to the Company’s current and former executive officers as determined by the Board in accordance with Section 10D of the Exchange Act, the rules promulgated thereunder, and the listing standards of the Nasdaq Stock Market LLC (“Covered Executives”).
RECOUPMENT; ACCOUNTING RESTATEMENT
In the event the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (each an “Accounting Restatement”), the Compensation Committee will require reimbursement or forfeiture of the Overpayment (as defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years.






INCENTIVE-BASED COMPENSATION
For purposes of this Policy, “Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (as defined below), including, but not limited to: (i) non-equity incentive plan awards that are earned solely or in part by satisfying a financial reporting measure performance goal; (ii) bonuses paid from a bonus pool, where the size of the pool is determined solely or in part by satisfying a financial reporting measure performance goal; (iii) other cash awards based on satisfaction of a financial reporting measure performance goal; (iv) restricted stock, restricted stock units, stock options, stock appreciation rights, and performance share units that are granted or vest solely or in part on satisfying a financial reporting measure performance goal; and (v) proceeds from the sale of shares acquired through an incentive plan that were granted or vested solely or in part on satisfying a financial reporting measure performance goal. Compensation that would not be considered Incentive-Based Compensation include, but is not limited to: (a) salaries; (b) bonuses paid solely on satisfying subjective standards, such as demonstrating leadership, and/or completion of a specified employment period; (c) non-equity incentive plan awards earned solely on satisfying strategic or operational measures; (d) wholly time-based equity awards; and (e) discretionary bonuses or other compensation that is not paid from a bonus pool that is determined by satisfying a financial reporting measure performance goal.
A “Financial Reporting Measure” is: (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or any measure derived wholly or in part from such measure, such as revenues, EBITDA, or net income and (ii) stock price and total shareholder return. Financial reporting measures include, but are not limited to: revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); net assets or net asset value per share (e.g., for registered investment companies and business development companies that are subject to the rule); earnings before interest, taxes, depreciation and amortization; funds from operations and adjusted funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to an accounting restatement; revenue per user, or average revenue per user, where revenue is subject to an accounting restatement; cost per employee, where cost is subject to an accounting restatement; any of such financial reporting measures relative to a peer group, where the issuer’s financial reporting measure is subject to an accounting restatement; and tax basis income.

OVERPAYMENT: AMOUNT SUBJECT TO RECOVERY
The amount of erroneously awarded compensation to be recovered will be the amount of Incentive-Based Compensation received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts, and must be computed without regard to any taxes paid (the “Overpayment”). Incentive-Based Compensation is deemed received in the issuer’s fiscal period during which the financial reporting measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.
For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received; and the
    2    



Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the Nasdaq Stock Market LLC.
METHOD OF RECOUPMENT
The Compensation Committee will determine, in its sole discretion, the method for recouping Overpayment hereunder which may include, without limitation:
requiring reimbursement of cash Incentive-Based Compensation previously paid;
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;
offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;
cancelling outstanding vested or unvested equity awards; and/or
taking any other remedial and recovery action permitted by law, as determined by the Compensation Committee.

LIMITATION ON RECOVERY; NO ADDITIONAL PAYMENTS
The right to recovery will be limited to Overpayments paid or distributed during the three years prior to the date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years. In no event shall the Company be required to award Covered Executives an additional payment if the restated or accurate financial results would have resulted in a higher Incentive-Based Compensation payment.
NO INDEMNIFICATION
The Company is prohibited from indemnifying any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive for purchasing insurance to cover any such loss.
INTERPRETATION
The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and the applicable rules or standards adopted by the Securities and Exchange Commission or the listing standards of the Nasdaq Stock Market LLC.
EFFECTIVE DATE
This Policy shall be effective as of the date it is adopted by the Board (the “Effective Date”) and shall apply to Incentive-Based Compensation received on or after October 2, 2023 (including Incentive-Based Compensation granted pursuant to arrangements existing prior to the Effective Date).

    3    



AMENDMENT; TERMINATION
The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final rules or additional standards adopted by the Nasdaq Stock Market LLC. The Board may terminate this Policy at any time.
OTHER RECOUPMENT RIGHTS
The Board intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company recovers pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, the amount the relevant Covered Executive has already reimbursed the Company will be credited to the required recovery under this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any compensatory or incentive plan, employment agreement, equity award agreement, or similar plan or agreement and any other legal remedies available to the Company.
IMPRACTICABILITY
The Compensation Committee shall recover any Overpayment in accordance with this Policy except to the extent that the Compensation Committee determines such recovery would be impracticable because:
(A) The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before concluding that it would be impractical to recover any amount of erroneously awarded compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such erroneously awarded compensation, document such reasonable attempts to recover and provide that documentation to the Nasdaq Stock Market LLC;
(B) Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before concluding that it would be impractical to recover any amount of erroneously awarded compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to the Nasdaq Stock Market LLC, that recovery would result in such a violation, and much provide such opinion to the Nasdaq Stock Market LLC; or
(C) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.
INDEMNIFICATION OF BOARD AND COMPENSATION COMMMITTEE
    Any members of the Compensation Committee, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other
    4    



rights to indemnification of the members of the Board or Compensation Committee under applicable law or Company policy.
SUCCESSORS
This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

Adopted by the Board on September 13, 2023
    5    

EX-101.SCH 14 bcpc-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - SIGNIFICANT ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - EQUITY-METHOD INVESTMENT link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - REVOLVING LOAN link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - NET EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - SIGNIFICANT ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - NET EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SIGNIFICANT ACQUISITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - SIGNIFICANT ACQUISITIONS - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - SIGNIFICANT ACQUISITIONS - Schedule of Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - STOCKHOLDERS' EQUITY - Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - EQUITY-METHOD INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - REVOLVING LOAN (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - NET EARNINGS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - INCOME TAXES - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - INCOME TAXES - Income Tax Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - SEGMENT INFORMATION - Depreciation/Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive (Loss)/Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - LEASES - Right-of-Use Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - LEASES - Schedule of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - LEASES - Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 bcpc-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 16 bcpc-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 17 bcpc-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Additional Information Relating to Stock Options Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Accrued expenses Accrued Liabilities, Current Incurred an income tax expense Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Reserve for inventory Inventory Valuation Reserves Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development expenses Research and Development Expense Changes in assets and liabilities, net of acquired balances Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Expiration period of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Interest rate Line of Credit Facility, Interest Rate at Period End Net Sales [Abstract] Net Sales [Abstract] Net Sales Payment Payments to Acquire Businesses, Gross Estimated Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Other Information Pertaining to Stock Option Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value and Grant Date Intrinsic Value [Table Text Block] Tabular disclosure of the weighted-average grant-date fair value and intrinsic value of equity options granted during the year. Net change in postretirement benefit plan taxes Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax Deferred income taxes Deferred Income Tax Liabilities, Net Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Insider Trading Policies and Procedures [Line Items] Exercisable at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Derivative assets Derivative Asset, Current Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Lease liabilities Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] Dividend Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Kappa bank debt paid on acquisition date Payments To Acquire Businesses, Net Of Foreign Currency Translation Gain (Loss) Payments To Acquire Businesses, Net Of Foreign Currency Translation Gain (Loss) Schedule of Assumptions to Determine Benefit Obligation Defined Benefit Plan, Assumptions [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding Preferred Stock, Value, Issued Estimated share-based compensation expense for current fiscal year Estimated Share Based Compensation Expense, Current Fiscal Year Estimated Share Based Compensation Expense, Current Fiscal Year Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted net earnings per common share (in dollars per share) Net earnings per share - diluted (in dollars per share) Earnings Per Share, Diluted Accounts receivable, net of allowance for doubtful accounts of $908 and $1,226 at December 31, 2023 and 2022, respectively Receivables Accounts Receivable, after Allowance for Credit Loss, Current Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Derivative Interest Rate, Type [Axis] Derivative Interest Rate, Type [Axis] Derivative Interest Rate, Type Services Provided Services Provided [Member] Services provided to the customers. Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Trading Symbol Trading Symbol Capital contributions Payments to Acquire Equity Method Investments Chemogas Defined Pension Plan Chemogas Defined Pension Plan [Member] Chemogas Defined Pension Plan Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash acquired from acquisition Cash Acquired from Acquisition Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Other Other Intangible Assets [Member] Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Service cost with interest to end of year Defined Benefit Plan, Service Cost Executive Category: Executive Category [Axis] Number of defined contribution plans Number Of Defined Contribution Plans Number Of Defined Contribution Plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unrecognized prior service cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Plant and Equipment Estimated Useful Lives Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Shares available for future awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Corporate Trademark Corporate Trademark [Member] Corporate Trademark Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Small Reporting Company Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Total lease liabilities, non-current Operating and Finance Lease, Liability, Noncurrent Operating and Finance Lease, Liability, Noncurrent Retirement Plan Type [Domain] Retirement Plan Type [Domain] Schedule of Non-vested Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Lease Liabilities Non-contractual monies owed Non-contractual Monies Owed [Member] Non-contractual Monies Owed Depreciation expense Depreciation Stock Options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Trademarks Trademarks [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Business Combination, Post-Closing Payment Business Combination, Post-Closing Payment Business Combination, Post-Closing Payment Principal payment on acquired debt Repayments of Assumed Debt Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Shares Outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Grantee Status [Axis] Grantee Status [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Net Earnings [Abstract] Net Earnings [Abstract] Net Earnings Goodwill percent Goodwill, Acquired During Period, Percent Goodwill, Acquired During Period, Percent Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Dividends Dividends, Common Stock Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Property, plant and equipment Property, Plant and Equipment, Gross Goodwill [Line Items] Goodwill [Line Items] QUARTERLY FINANCIAL INFORMATION (UNAUDITED) Quarterly Financial Information [Text Block] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount LEASES Lessee, Finance Leases [Text Block] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Schedule of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] 2027 Operating And Finance Lease, Liability, To Be Paid, Year Four Operating And Finance Lease, Liability, To Be Paid, Year Four Operating lease liabilities - current Operating leases liabilities - current Operating Lease, Liability, Current $118.96 - $150.85 Exercise Price Range 3 [Member] Exercise price range for stock options outstanding. Interest on lease liabilities Finance Lease, Interest Expense Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible assets with finite lives, net Finite-Lived Intangible Assets, Net Shares repurchased, average cost (in dollars per share) Shares Acquired, Average Cost Per Share Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Benefit Obligatoins Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Gross margin Gross margin Gross Profit Schedule of Assumptions Used in the Valuation of Option Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Stock-based Compensation Share-Based Payment Arrangement [Policy Text Block] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Cliff vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock Options Employee Stock Option [Member] DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Maximum Maximum [Member] Unrecognized compensation cost related to non-vested shares Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Goodwill, acquired during period Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Currency swap Cross-currency swap Currency Swap [Member] Specialty Products Specialty Products [Member] A reportable segment of the company that provides specialty-packaged chemicals for use in healthcare and other industries. Inventories Inventory, Policy [Policy Text Block] Selling expenses Selling Expense Federal Current Federal Tax Expense (Benefit) Business Acquisition [Axis] Business Acquisition [Axis] Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Trademarks and trade names Trademarks and trade names Trademarks and Trade Names [Member] Derivative [Table] Derivative [Table] Contribution rate increase Multiemployer Plan, Contribution Rate Increase (Decrease) State Deferred State and Local Income Tax Expense (Benefit) Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Reasonably certain criterion renewal period Lessee, Operating Lease, Remaining Renewal Lease Term, Reasonable Threshold Period Lessee, Operating Lease, Remaining Renewal Lease Term, Reasonable Threshold Period Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Related Party [Domain] Related Party, Type [Domain] Total expected payments Expected Payments to Acquire Businesses Including Contingent Consideration, Gross Expected Payments to Acquire Businesses Including Contingent Consideration, Gross SIGNIFICANT ACQUISITIONS Business Combination Disclosure [Text Block] Identifiable intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Schedule of Multiemployer Plans [Table] Multiemployer Plan [Table] Operating Segments Operating Segments [Member] Non-vested balance as of beginning of year (in dollars per share) Non-vested balance as of end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Foreign currency and interest rate swaps Deferred Tax Liabilities, Derivatives And Unrealized Currency Transaction Gains Deferred Tax Liabilities, Derivatives And Unrealized Currency Transaction Gains Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fixed interest rate Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Postretirement Medical Plans Postretirement Health Coverage [Member] Entity Tax Identification Number Entity Tax Identification Number Impact due to change in foreign exchange rates Goodwill, Foreign Currency Translation Gain (Loss) Lessee, Operating Lease, Tranches [Axis] Lessee, Operating Lease, Tranches [Axis] Lessee, Operating Lease, Tranches [Axis] Interest on lease liabilities Lease, Cost Inventories Deferred Tax Assets, Inventory Eastman Chemical Company Eastman Chemical Company [Member] Refers to the entity with which the joint venture is formed. Range [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] REVOLVING LOAN Long-Term Debt [Text Block] Goodwill and Acquired Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition and Cost of Sales Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Derivative Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] Business Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Bank debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Customer relationships and lists Customer Lists [Member] Other Other Operating Activities, Cash Flow Statement State income taxes, net of Federal income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net interest income (expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest rate swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Kappa & Bergstrom actual results included in the Company's consolidated income statement Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount ANH Animal Nutrition and Health Animal Nutrition and Health [Member] A reportable segment of the company that provides the animal, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies. Unrealized gain/(loss) on cash flow hedge taxes Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Total liabilities Liabilities Cash flows from operating and finance leases Cash Payments for Operating and Finance Leases Cash Payments for Operating and Finance Leases Expected Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Total expected consideration Business Combination, Consideration Transferred, Including Adjustments Business Combination, Consideration Transferred, Including Adjustments Principal payments on revolving debt Repayments of outstanding balance Repayments of Long-Term Lines of Credit Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Research and development Deferred Tax Assets, in Process Research and Development United States North America [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Net Cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Two General and administrative expenses General and Administrative Expense Weighted Average Exercise Price of Options Outstanding (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Total current assets Assets, Current Total net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Contingent consideration liability Contingent consideration liability Business Combination, Contingent Consideration, Liability Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] 2024 Operating And Finance Lease, Liability, To Be Paid, Year One Operating And Finance Lease, Liability, To Be Paid, Year One Retirement Plan Name [Domain] Retirement Plan Name [Domain] Net Earnings Per Common Share Earnings Per Share, Policy [Policy Text Block] Proceeds from insurance Proceeds from Insurance Settlement, Investing Activities $85.40 - $118.60 Exercise Price Range 2 [Member] Exercise price range for stock options outstanding. Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Accumulated Other Comprehensive (Loss)/Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Accounts Receivable Accounts Receivable [Policy Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Forward Contracts Forward Contracts [Member] Aggregate intrinsic value for exercisable stock options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value EQUITY-METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Depreciation and amortization Depreciation, Depletion and Amortization Kappa Kechu BidCo AS and Its Subsidiary Companies (Kappa) [Member] Kechu BidCo AS and Its Subsidiary Companies (Kappa) Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Allowance for Doubtful Accounts SEC Schedule, 12-09, Allowance, Credit Loss [Member] Business Combination and Asset Acquisition [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Pro forma combined net sales Business Acquisition, Pro Forma Revenue Long-lived assets, excluding intangible assets Long-Lived Assets Schedule of Amounts Recognized in Consolidated Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Unrealized (gain) loss on foreign currency transactions and deferred compensation Unrealized Gain (Loss) on Foreign Currency Transactions and Deferred Compensation Unrealized Gain (Loss) on Foreign Currency Transactions and Deferred Compensation Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Cash flow hedge Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Deferred income taxes, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Retirement Plan Name [Axis] Retirement Plan Name [Axis] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Weighted Average Assumptions [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Auditor Information [Abstract] Auditor Information Emerging Growth Company Entity Emerging Growth Company Capitalized costs net of accumulated amortization Debt Issuance Costs, Net Total deferred tax assets Deferred Tax Assets, Gross Total finance lease Finance Lease, Cost Finance Lease, Cost Proceeds from settlement of net investment hedge Proceeds from settlement of net investment hedge Payments for (Proceeds from) Hedge, Investing Activities Net gain on foreign currency exchange forward contracts Net gain on foreign currency exchange forward contracts Business Combination, Separately Recognized Transactions, Net Gains and Losses Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Capital expenditures and intangible assets acquired Payments to Acquire Other Productive Assets Common Stock Common Stock [Member] Net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Royalty Revenue Royalty [Member] Income Statement Location [Domain] Income Statement Location [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Minimum Minimum [Member] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Assets Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Schedule of Fair Value of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] VALUATION AND QUALIFYING ACCOUNTS SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Other Deferred Tax Assets, Other Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Investment in affiliates Payments to Acquire Interest in Subsidiaries and Affiliates Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Weighted Average Exercise Price of Options Exercisable (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Other expenses: Nonoperating Income (Expense) [Abstract] Exchange rate changes Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Net of tax Cash flow hedge (interest rate swap), net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic net earnings per common share (in dollars per share) Earnings Per Share, Basic Net foreign currency translation adjustment tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Changes in Benefit Obligation Schedule of Changes in Projected Benefit Obligations [Table Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Total intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Income taxes Income Taxes Paid Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations") Liability, Defined Benefit Pension Plan, Noncurrent Principles of Consolidation Consolidation, Policy [Policy Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest Expense [Member] Number of financial instruments held for trading purposes Financial Instruments, Number of Financial Instruments Held for Trading Purposes Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Reconciliation of Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Entity Public Float Entity Public Float Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Unrealized (loss) gain on cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax All Trading Arrangements All Trading Arrangements [Member] Years 3 and 4 Lessee, Operating Lease, Tranche Two [Member] Lessee, Operating Lease, Tranche Two [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Compensation Amount Outstanding Recovery Compensation Amount Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Proceeds from stock options exercised Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Installment payments required Line of Credit Facility, Periodic Payment Contributions of Balchem Corporation Multiemployer Plan, Employer Contribution, Cost Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total minimum lease payments Operating And Finance Lease, Liability, To Be Paid Operating And Finance Lease, Liability, To Be Paid Accumulated postretirement benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Range of exercise prices, maximum (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Proceeds from sale of assets Proceeds from Sale of Property, Plant, and Equipment Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Finance lease liabilities - non-current Finance Lease, Liability, Noncurrent Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Income tax expense Total income tax provision Income Tax Expense (Benefit) Foreign Countries Non-US [Member] Derivative Interest Rate, Type [Domain] Derivative Interest Rate, Type [Domain] Derivative Interest Rate, Type Designated as hedge Designated as Hedging Instrument [Member] Deferred compensation liability Deferred Compensation Liability, Classified, Noncurrent Right of use assets - finance lease Finance Lease, Right-of-Use Asset, after Accumulated Amortization FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] INVENTORIES Inventory Disclosure [Text Block] Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Total consideration on acquisition date and working capital adjustment Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Number of lease tranches Lessee, Operating Lease, Number Of Tranches Lessee, Operating Lease, Number Of Tranches Discount rate Lessee, Operating Lease, Discount Rate Income Tax Reconciliation [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Money Market Funds Money Market Funds [Member] Amortization of loss (gain) Defined Benefit Plan, Amortization of Gain (Loss) St. Gabriel CC Company, LLC St. Gabriel CC Company, LLC [Member] A joint venture formed in 2013 by the Company and Eastman Chemical Company (formerly Taminco Corporation) to design, develop, and construct an expansion of the Company's St. Gabriel aqueous choline chloride plant. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash paid for acquisitions, net of cash acquired Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Number of savings plan Number of Savings Plans Number of Savings Plans Expected return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Pay-Fixed Interest Rate Pay-Fixed Interest Rate [Member] Pay-Fixed Interest Rate Bergstrom Cardinal Associates Inc. (Bergstrom) [Member] Cardinal Associates Inc. (Bergstrom) Estimated useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contracts Derivative, Number of Instruments Held Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Number of share-based compensation plans Number of Share Based Compensation Plans Number of Share Based Compensation Plans Other and Unallocated Industrial Products [Member] A reportable segment of the company that provides certain derivatives of industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells. REVENUE Revenue from Contract with Customer [Text Block] Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Loss relating to joint venture's expenses Income (Loss) from Equity Method Investments Cover [Abstract] Amortization expense pertaining to capitalized costs Amortization of Debt Issuance Costs Prepaid expenses Other Prepaid Expense, Current United States UNITED STATES Dividends paid Payments of Dividends Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Total operating expenses Operating Expenses Receive-Fixed Interest Rate Receive-Fixed Interest Rate [Member] Receive-Fixed Interest Rate Amortization of ROU asset Finance Lease, Right-of-Use Asset, Amortization SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Former Bank Former Bank [Member] Former Bank (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Equity Component [Domain] Equity Component [Domain] Finance lease liabilities - current Finance Lease, Liability, Current State State and Local Jurisdiction [Member] Work in progress Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other Deferred Tax Liabilities, Other Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Entity Current Reporting Status Entity Current Reporting Status Earnings from operations Operating Income (Loss) Acquisition of transaction costs Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Total deferred tax liabilities Deferred Tax Liabilities, Gross Participant contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Segments [Axis] Segments [Axis] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] Property, Plant and Equipment and Depreciation Property, Plant and Equipment, Policy [Policy Text Block] Product Trademarks Product Trademarks [Member] Product Trademarks Schedule of Non-vested Performance Share Activity Schedule of Nonvested Performance-Based Units Activity [Table Text Block] ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Outstanding balance Long-Term Line of Credit Customer relationships Customer Relationships [Member] Initial total shareholder return percentage Initial TSR The initial percentage of total shareholder return. Non-employee director Share-Based Payment Arrangement, Nonemployee [Member] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Range [Domain] Statistical Measurement [Domain] Notional amount of derivatives Derivative Liability, Notional Amount Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Number of votes Equity Method Investment, Number Of Votes Equity Method Investment, Number Of Votes Non-vested balance as of beginning of year (in shares) Non-vested balance as of end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Revolving loan Revolving Credit Facility [Member] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Years 5 through 9 Lessee, Operating Lease, Tranche Three [Member] Lessee, Operating Lease, Tranche Three [Member] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Shares Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Weighted average remaining contractual term for exercisable stock options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023 Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Total other expenses Interest and other expense Nonoperating Income (Expense) Commitments and contingencies (Note 16) Commitments and Contingencies Capital expenditures Segment, Expenditure, Addition to Long-Lived Assets Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] INCOME TAXES Income Tax Disclosure [Text Block] 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Goodwill [Roll Forward] Goodwill [Roll Forward] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year One Outstanding at beginning of year (in shares) Outstanding at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted-average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net earnings Net earnings Net earnings Net Earnings - Basic and Diluted Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Former Shareholders' Lenders And Creditors Former Shareholders' Lenders And Creditors [Member] Former Shareholders' Lenders And Creditors LEASES Lessee, Operating Leases [Text Block] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Former Shareholders Former Shareholders [Member] Former Shareholders Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period $54.87 - $85.33 Exercise Price Range 1 [Member] Exercise price range for stock options outstanding. Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price Range [Domain] Useful life of intangible assets acquired Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Lessee, Operating Lease, Tranches [Domain] Lessee, Operating Lease, Tranches [Domain] [Domain] for Lessee, Operating Lease, Tranches [Axis] Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill, beginning of period Goodwill, end of period Goodwill Increases for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Derivative assets Derivative Assets (Liabilities), at Fair Value, Net Underlying Securities Award Underlying Securities Amount 2018 Credit Agreement 2018 Credit Agreement [Member] 2018 Credit Agreement ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Other long-term obligations Other Long-Term Debt, Noncurrent Operating lease liabilities - non-current Operating Lease, Liability, Noncurrent Summary of Pension Fund Multiemployer Plan [Table Text Block] Multiemployer Plans [Line Items] Multiemployer Plan [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Net earnings Share-Based Payment Arrangement, Expense, after Tax Number of unfunded plans Defined Benefit Plan, Number of Benefit Plans Defined Benefit Plan, Number of Benefit Plans Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Foreign Countries Europe [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Right of use assets Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets Unremitted foreign earnings Undistributed Earnings of Foreign Subsidiaries Belgium earnings remitted Foreign Earnings Repatriated Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Schedule of Lease Cost Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Plan Name [Domain] Plan Name [Domain] Related rabbi trust assets Asset, Held-in-Trust, Noncurrent Number of shares authorized for grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Weighted average remaining contractual term for outstanding stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Decreases for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization of identifiable intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Income taxes Increase (Decrease) in Income Taxes Payable Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Operating lease cost Operating Lease, Cost Impairment of Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Unrecognized net loss (gain) Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Foreign currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Weighted-average period of recognition for unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Total lease liabilities, current Operating and Finance Lease, Liability, Current Operating and Finance Lease, Liability, Current Schedule of Estimated Future Employer Contributions and Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Entity Address, Address Line One Entity Address, Address Line One Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Income tax payable Taxes Payable, Current Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating loss carryforwards Operating Loss Carryforwards Other Other Intangible Assets Excluding Regulatory registration Costs and Patents & Trade Secrets [Member] Intangible assets classified as other excluding regulatory registration costs and patents & trade secrets. Intangible Assets Estimated Useful Lives Schedule of Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Transaction and integration costs (credits) Business Combination, Integration Related Costs (Credits) Business Combination, Integration Related Costs (Credits) Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Supplemental pro forma combined financial information Business Acquisition, Pro Forma Net Income (Loss) Shares and options issued under stock plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends payable Dividends Payable, Current Other current assets Other Assets, Current Income tax at Federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Carrying value of joint venture Equity Method Investments Inventories, net Total inventories Inventory, Net Revolving loan Long-Term Line of Credit, Noncurrent Land Land [Member] Right of use assets Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets Working capital adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Number of Options Exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Repurchases of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Restructuring-related impairment and asset disposal charges Restructuring Costs and Asset Impairment Charges Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Foreign Deferred Foreign Income Tax Expense (Benefit) Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Shares purchased under restricted stock purchase agreements, maximum (in shares) Shares Purchased Under Restricted Stock Purchase Agreements, Maximum The maximum number of shares purchased under restricted stock purchase agreements. Retained earnings Retained Earnings (Accumulated Deficit) Percentage of production offtake Percentage of Production Offtake Refers to the percentage of production offtake. Exercise Price Range [Axis] Exercise Price Range [Axis] Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Patents and trade secrets Patents & Trade Secrets [Member] The exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, and information generally known to only a limited number of the entity's employees, such as a formula, pattern, machine, technology, and production process that may give an entity a competitive advantage. Net foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Credit Agreement Revolving Credit Agreement [Member] Revolving Credit Agreement Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Total before tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Additions charged to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 401(k) contributions Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Postretirement benefit plan Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Right of use assets Assets and Liabilities, Lessee [Abstract] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Percentage of operating expenses to be absorbed Percentage of Operating Expenses to be Absorbed Refers to the percentage of operating expenses to be absorbed. Inventory Reserve SEC Schedule, 12-09, Reserve, Inventory [Member] Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,254,728 shares issued and outstanding at December 31, 2023 and 32,152,787 shares issued and outstanding at December 31, 2022, respectively Common Stock, Value, Issued Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Principal payments on finance lease Principal payments on finance lease Finance Lease, Principal Payments Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Finance Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Raw Materials Sold Raw Materials Sold [Member] Raw materials sold to the customers. Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Regulatory registration costs Regulatory registration Costs [Member] Costs associated with the required registration, with the U.S. Environmental Protection Agency, of certain products considered pesticides under the Federal Insecticide, Fungicide and Rodenticide Act. Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Business combination, contingent consideration, liability, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Aggregate number of shares repurchased since inception (in shares) Stock Repurchase Program, Aggregate Number of Shares Repurchased Since Inception Cumulative number of shares repurchased under the repurchase program since the inception of the program as of balance sheet date. Trade accounts payable Payables Accounts Payable, Trade, Current Schedule of Income Tax Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Balance at beginning of period Balance at end of period Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Years 2029-2033 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Buildings Building Building [Member] Summary of Goodwill Schedule of Goodwill [Table Text Block] 2025 Operating And Finance Lease, Liability, To Be Paid, Year Two Operating And Finance Lease, Liability, To Be Paid, Year Two Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Restricted stock and stock options Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Adjustments/deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Prior service loss (gain) arising during the period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Other and Unallocated Corporate, Non-Segment [Member] Asset impairment charge and (gain) loss on disposal of assets Gain (Loss) on Sale of Assets and Asset Impairment Charges Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Restricted Stock Restricted Stock [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Expected Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Hedging Designation [Domain] Hedging Designation [Domain] Operating expenses Operating Expense [Member] Schedule of Long-Lived Assets by Geographical Area Long-Lived Assets by Geographic Areas [Table Text Block] Amortization of prior service gain Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Repurchases of common stock (in shares) Treasury Stock, Shares, Retired Post-employment Benefits Postemployment Benefit Plans, Policy [Policy Text Block] Schedule of Income (Loss) on Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Employee Share-Based Payment Arrangement, Employee [Member] Document Fiscal Period Focus Document Fiscal Period Focus Useful life of intangible assets Amortization Period (In years) Finite-Lived Intangible Asset, Useful Life Dividends (in dollars per share) Dividends Payable, Amount Per Share Unused portion of revolving loan Line of Credit Facility, Remaining Borrowing Capacity Operating And Finance Lease, Liability, To Be Paid [Abstract] Operating And Finance Lease, Liability, To Be Paid [Abstract] Operating And Finance Lease, Liability, To Be Paid Schedule of Changes in Plan Assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Outstanding at beginning of year (in dollars per share) Outstanding at end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock compensation expense Share-Based Payment Arrangement, Noncash Expense Finance Leases - ROU Finance Lease, Right-of-Use Asset, before Accumulated Amortization City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] NET EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] St. Gabriel CC Company, LLC Corporate Joint Venture [Member] Ownership percentage in joint venture Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Operating lease term Lessee, Operating Lease, Term of Contract More than 10 years Lessee, Operating Lease, Tranche Four [Member] Lessee, Operating Lease, Tranche Four [Member] BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Range of exercise prices, minimum (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Net gains on forward contracts Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Derivative assets Derivative Liability [Abstract] Developed technology Developed Technology Rights [Member] Schedule of Compensation Cost on Net Earnings Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Shares purchased under restricted stock purchase agreements, minimum (in shares) Shares Purchased Under Restricted Stock Purchase Agreements, Minimum The minimum number of shares purchased under restricted stock purchase agreements. Right of use assets - operating leases Operating Lease - ROU Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Foreign Current Foreign Tax Expense (Benefit) Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Participant contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Cash Paid for Income Taxes and Interest [Abstract] Cash Paid for Income Taxes and Interest [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Thereafter Operating And Finance Lease, Liability, To Be Paid, After Year Five Operating And Finance Lease, Liability, To Be Paid, After Year Five Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] 2028 Operating And Finance Lease, Liability, To Be Paid, Year Five Operating And Finance Lease, Liability, To Be Paid, Year Five Related Party Transactions [Abstract] Related Party Transactions [Abstract] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Additional paid-in capital Additional Paid in Capital HNH Human Nutrition and Health Human Nutrition and Health [Member] A reportable segment of the company that provides the human, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies. SUPPLEMENTAL CASH FLOW INFORMATION Cash Flow, Supplemental Disclosures [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Related Party [Axis] Related Party, Type [Axis] Aggregate intrinsic value for outstanding stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Shares and options issued under stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of sales Cost of Sales [Member] Change in fair value of contingent consideration liability Net decrease to contingent consideration liability and other post-closing payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Auditor Name Auditor Name Proceeds from revolving loan Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] 2017 Plan Omnibus Incentive Plan 2017 [Member] A share-based compensation plan under which awards may be granted for officers, employees and directors of the Company and its subsidiaries. Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price 2026 Operating And Finance Lease, Liability, To Be Paid, Year Three Operating And Finance Lease, Liability, To Be Paid, Year Three Total right-of-use assets Operating and Finance Lease, Right-of-Use Asset Operating and Finance Lease, Right-of-Use Asset Entity Central Index Key Entity Central Index Key Losses and gains recognized in accumulated other comprehensive income (loss) Derivative, Gain (Loss) on Derivative, Net Stock-based compensation cost Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Finished goods Inventory, Finished Goods, Net of Reserves Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Number of multiemployer benefit pension plans Multiemployer Plan, Pension, Number Of Plans Multiemployer Plan, Pension, Number Of Plans Income Tax Authority [Domain] Income Tax Authority [Domain] Years 1 and 2 Lessee, Operating Lease, Tranche One [Member] Lessee, Operating Lease, Tranche One [Member] Accrued compensation and other benefits Employee-related Liabilities, Current Cash paid for financing costs Payments of Financing Costs Name Trading Arrangement, Individual Name Other comprehensive income (loss), net of tax Other comprehensive (loss) income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Disaggregation of Revenue by Source and Geography Disaggregation of Revenue [Table Text Block] Amortization of loss (gain) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Net sales Payments for services Revenue from Contract with Customer, Excluding Assessed Tax Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] Identifiable intangible assets [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Amortization Deferred Tax Liability, Customer list and goodwill amortization The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of customer lists and goodwill and the basis of customer lists and goodwill computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses. Interest expense, net Interest Income (Expense), Net Weighted-average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Net deferred tax liability Deferred Tax Liabilities, Net Product Sales Revenue Product Sales [Member] Revenues generated from product sales. Weighted average common shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Grantee Status [Domain] Grantee Status [Domain] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Increase in amount approved (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Weighted Average Remaining Contractual  Term Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Lease Cost Lease, Cost [Abstract] 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equipment Equipment Equipment [Member] Transaction and integration related costs Business Combination, Transaction and Integration Related Costs This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs could include legal, accounting and other professional fees. This element also includes costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs and systems integration and conversion costs. Interest and other expense Segment Reconciling Items [Member] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Repurchases of common stock Repurchases of common stock Treasury Stock, Retired, Par Value Method, Amount Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Services and raw materials Related Party Transaction, Purchases from Related Party Construction in progress Construction in Progress [Member] Net change in postretirement benefit plan (see Note 15 for further information) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] Pension Plan Pension Plan [Member] Central States, Southeast and Southwest Areas Pension Fund Central States, Southeast and Southwest Areas Pension Fund [Member] A multiemployer defined benefit plan, in which the Company participates under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona facility. Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Earnings before income tax expense Earnings before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Weighted average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Debt Instrument [Line Items] Debt Instrument [Line Items] Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Cost of sales Cost of Revenue Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Foreign-derived intangible income (FDII) Effective Income Tax Rate Reconciliation, FDII, Amount Number of shares authorized to be repurchased (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) Treasury Stock Shares Acquired And Reissued Number of shares that have been repurchased and reissued during the period. EX-101.PRE 18 bcpc-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 19 bcpc-20231231_g1.jpg begin 644 bcpc-20231231_g1.jpg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�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end GRAPHIC 20 image_0.jpg begin 644 image_0.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Feb. 02, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-13648    
Entity Registrant Name Balchem Corp    
Entity Incorporation, State or Country Code MD    
Entity Tax Identification Number 13-2578432    
Entity Address, Address Line One 5 Paragon Drive    
Entity Address, City or Town Montvale    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07645    
City Area Code 845    
Local Phone Number 326-5600    
Title of 12(b) Security Common Stock, par value $.06-2/3 per share    
Trading Symbol BCPC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Small Reporting Company false    
Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 4,321
Entity Common Stock, Shares Outstanding   32,266,941  
Documents Incorporated by Reference
Selected portions of the Registrant’s proxy statement for its 2024 Annual Meeting of Shareholders (the “2024 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2023 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein.
   
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Central Index Key 0000009326    
XML 22 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
12 Months Ended
Dec. 31, 2023
Auditor Information [Abstract]  
Auditor Name RSM US LLP
Auditor Firm ID 49
Auditor Location New York, New York
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 64,447 $ 66,560
Accounts receivable, net of allowance for doubtful accounts of $908 and $1,226 at December 31, 2023 and 2022, respectively 125,284 131,578
Inventories, net 109,521 119,668
Prepaid expenses 7,798 4,903
Derivative assets 0 5,993
Other current assets 7,192 7,101
Total current assets 314,242 335,803
Property, plant and equipment, net 276,039 271,355
Goodwill 778,907 769,509
Intangible assets with finite lives, net 191,212 213,295
Right of use assets - operating leases 17,763 17,094
Right of use assets - finance lease 2,101 2,338
Other non-current assets 16,947 15,118
Total assets 1,597,211 1,624,512
Current liabilities:    
Trade accounts payable 55,503 57,322
Accrued expenses 40,855 36,745
Accrued compensation and other benefits 17,228 16,544
Dividends payable 25,717 23,129
Income tax payable 4,967 2,280
Operating lease liabilities - current 3,949 3,796
Finance lease liabilities - current 272 226
Total current liabilities 148,491 140,042
Revolving loan 309,569 440,569
Deferred income taxes 52,046 62,784
Operating lease liabilities - non-current 14,601 13,806
Finance lease liabilities - non-current 1,943 2,213
Other long-term obligations 16,577 26,814
Total liabilities 543,227 686,228
Commitments and contingencies (Note 16)
Stockholders’ equity:    
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding 0 0
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,254,728 shares issued and outstanding at December 31, 2023 and 32,152,787 shares issued and outstanding at December 31, 2022, respectively 2,152 2,145
Additional paid-in capital 145,653 128,806
Retained earnings 897,488 814,487
Accumulated other comprehensive income (loss) 8,691 (7,154)
Total stockholders’ equity 1,053,984 938,284
Total liabilities and stockholders’ equity $ 1,597,211 $ 1,624,512
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 908 $ 1,226
Stockholders’ equity:    
Preferred stock, par value (in dollars per share) $ 25 $ 25
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0667 $ 0.0667
Common stock, shares authorized (in shares) 120,000,000 120,000,000
Common stock, shares issued (in shares) 32,254,728 32,152,787
Common stock, shares outstanding (in shares) 32,254,728 32,152,787
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Earnings - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net sales $ 922,439 $ 942,358 $ 799,023
Cost of sales 620,383 661,907 555,849
Gross margin 302,056 280,451 243,174
Operating expenses:      
Selling expenses 74,397 67,409 60,413
Research and development expenses 15,049 12,191 13,524
General and administrative expenses 53,417 55,665 41,735
Total operating expenses 142,863 135,265 115,672
Earnings from operations 159,193 145,186 127,502
Other expenses:      
Interest expense, net 22,613 10,268 2,456
Other (income) expense, net (681) 1,169 (187)
Total other expenses 21,932 11,437 2,269
Earnings before income tax expense 137,261 133,749 125,233
Income tax expense 28,718 28,382 29,129
Net earnings $ 108,543 $ 105,367 $ 96,104
Basic net earnings per common share (in dollars per share) $ 3.38 $ 3.29 $ 2.98
Diluted net earnings per common share (in dollars per share) $ 3.35 $ 3.25 $ 2.94
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net earnings $ 108,543 $ 105,367 $ 96,104
Other comprehensive income (loss), net of tax:      
Net foreign currency translation adjustment 16,809 (4,799) (11,255)
Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively (1,065) 2,696 2,053
Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively 101 (58) 36
Other comprehensive income (loss), net of tax 15,845 (2,161) (9,166)
Comprehensive income $ 124,388 $ 103,206 $ 86,938
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Other comprehensive income (loss), net of tax:      
Unrealized gain/(loss) on cash flow hedge taxes $ (341) $ 868 $ 654
Net change in postretirement benefit plan taxes $ 39 $ 24 $ 13
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Common Stock
Additional Paid-in Capital
Beginning balance at Dec. 31, 2020 $ 828,233 $ 656,740 $ 4,173 $ 2,160 $ 165,160
Beginning balance (in shares) at Dec. 31, 2020       32,372,621  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings 96,104 96,104      
Other comprehensive (loss) income (9,166)   (9,166)    
Dividends (20,706) (20,706)      
Repurchases of common stock (35,239)     $ (17) (35,222)
Repurchases of common stock (in shares)       (249,848)  
Shares and options issued under stock plans 17,789     $ 11 17,778
Shares and options issued under stock plans (in shares)       164,377  
Ending balance at Dec. 31, 2021 877,015 732,138 (4,993) $ 2,154 147,716
Ending balance (in shares) at Dec. 31, 2021       32,287,150  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings 105,367 105,367      
Other comprehensive (loss) income (2,161)   (2,161)    
Dividends (23,018) (23,018)      
Repurchases of common stock (35,423)     $ (16) (35,407)
Repurchases of common stock (in shares)       (252,304)  
Shares and options issued under stock plans 16,504     $ 7 16,497
Shares and options issued under stock plans (in shares)       117,941  
Ending balance at Dec. 31, 2022 $ 938,284 814,487 (7,154) $ 2,145 128,806
Ending balance (in shares) at Dec. 31, 2022 32,152,787     32,152,787  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings $ 108,543 108,543      
Other comprehensive (loss) income 15,845   15,845    
Dividends (25,542) (25,542)      
Repurchases of common stock [1] (4,514)     $ (2) (4,512)
Repurchases of common stock (in shares) [1]       (32,558)  
Shares and options issued under stock plans 21,368     $ 9 21,359
Shares and options issued under stock plans (in shares)       134,499  
Ending balance at Dec. 31, 2023 $ 1,053,984 $ 897,488 $ 8,691 $ 2,152 $ 145,653
Ending balance (in shares) at Dec. 31, 2023 32,254,728     32,254,728  
[1]  * On August 16, 2022, the U.S. government enacted the Inflation Reduction Act (the "IRA") into law. The IRA imposes a 1% excise tax on share repurchases, which is effective for repurchases completed after December 31, 2022. The excise tax is recorded within equity as part of the repurchase of the common stock.
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]      
Dividends (in dollars per share) $ 0.79 $ 0.71 $ 0.64
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net earnings $ 108,543 $ 105,367 $ 96,104
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 54,935 51,848 48,879
Stock compensation expense 16,052 13,224 10,802
Deferred income taxes (10,814) (8,362) (5,944)
Provision for doubtful accounts 37 401 180
Unrealized (gain) loss on foreign currency transactions and deferred compensation (733) 914 (384)
Asset impairment charge and (gain) loss on disposal of assets 7,031 366 (53)
Change in fair value of contingent consideration liability (11,300) 0 0
Changes in assets and liabilities, net of acquired balances      
Accounts receivable 6,969 (3,618) (20,700)
Inventories 10,530 (7,804) (21,023)
Prepaid expenses and other current assets (3,540) 1,870 (881)
Accounts payable and accrued expenses 3,552 (15,543) 47,067
Income taxes 2,194 296 4,787
Other 305 (423) 1,680
Net cash provided by operating activities 183,761 138,536 160,514
Cash flows from investing activities:      
Cash paid for acquisitions, net of cash acquired (1,252) (365,780) 0
Capital expenditures and intangible assets acquired (37,892) (49,945) (37,363)
Proceeds from sale of assets 1,881 206 318
Proceeds from settlement of net investment hedge 2,740 0 0
Proceeds from insurance 0 0 1,831
Investment in affiliates (290) (495) (86)
Net cash used in investing activities (34,813) (416,014) (35,300)
Cash flows from financing activities:      
Proceeds from revolving loan 18,000 435,000 5,000
Principal payments on revolving debt (149,000) (103,000) (60,000)
Principal payment on acquired debt 0 (30,988) 0
Cash paid for financing costs 0 (1,232) 0
Principal payments on finance lease (222) (177) (159)
Proceeds from stock options exercised 5,242 3,212 6,943
Dividends paid (22,872) (20,713) (18,723)
Repurchases of common stock (4,469) (35,423) (35,239)
Net cash (used in) provided by financing activities (153,321) 246,679 (102,178)
Effect of exchange rate changes on cash 2,260 (5,880) (4,368)
(Decrease) increase in cash and cash equivalents (2,113) (36,679) 18,668
Cash and cash equivalents beginning of period 66,560 103,239 84,571
Cash and cash equivalents end of period $ 64,447 $ 66,560 $ 103,239
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Description
Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries.
Principles of Consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S. and other countries exceed the insurance limits of the Federal Deposit Insurance Corporation (“FDIC”) and other relevant insurance limits in other countries.
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Inventories
Inventories are valued at the lower of cost (first in, first out) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2023, 2022 and 2021, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired in accordance with ASC 805, "Business Combinations". Goodwill and intangible assets acquired in a business combination that have indefinite useful lives are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the assets might be impaired, in accordance with the provisions of ASC 350, "Intangibles-Goodwill and Other". The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the assets might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. In accordance with this update, a goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.
As of October 1, 2023 and 2022, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2023 and 2022. The Company may resume performing the qualitative assessment in subsequent periods.
The Company had goodwill in the amount of $778,907 and $769,509 as of December 31, 2023 and 2022, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2021$523,949 
Goodwill as a result of the Kappa acquisition216,295 
Goodwill as a result of the Bergstrom acquisition31,209 
Impact due to change in foreign exchange rates(1,944)
Goodwill at December 31, 2022769,509 
Goodwill as a result of the Bergstrom acquisition341 
Impact due to change in foreign exchange rates9,057 
Goodwill at December 31, 2023$778,907 

 December 31, 2023December 31, 2022
HNH$673,207 $665,804 
ANH24,469 24,218 
Specialty Products81,175 79,429 
Other and Unallocated56 58 
Total$778,907 $769,509 
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks and trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents and trade secrets
15 - 17
Other
 2 - 18
Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2023, there were no triggering events which required intangible asset impairment reviews.
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also had derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which were included in derivative assets and derivative liabilities, in the consolidated balance sheets (see Note 20, Derivative Instruments and Hedging Activities). The fair values of these derivative instruments were determined based on Level 2 inputs, using significant inputs that were observable either directly or indirectly, including interest rate curves and implied volatilities. These derivatives were settled on their maturity date on June 27, 2023 and there were no other derivatives outstanding as of December 31, 2023.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
Research and Development
Research and development costs are associated directly with the Company's efforts to develop, design, and enhance its products, services, technologies, or processes. Such costs are expensed as incurred.
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3, Stockholders' Equity. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the statement of earnings as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets
Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows.

Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments was to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

The derivative instruments were with the above single counterparty and were subject to a contractual agreement that provided for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments were categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet as of December 31, 2022. The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2023.

On a quarterly basis through their maturity, we assessed the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. The hedging relationships were determined to be highly effective. As such, the net change in fair values of the interest rate swap, that qualified as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and subsequently reclassified into interest expense as interest payments were made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remain in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, Derivative Instruments and Hedging Activities, for detailed information about our derivative financial instruments.
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment in this Update should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have to the financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures." The ASU expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning December 15, 2024. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. The adoption of this guidance will not affect the Company's consolidated results of operations, financial position or cash flows. The Company is currently evaluating the effect the guidance will have on its disclosures.
In August 2023, the FASB issued ASU 2023-05, "Business Combinations - Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement." The new guidance applies to the formation of a joint venture and requires a joint venture to initially measure all contributions received upon its formation at fair value. The guidance is intended to reduce diversity in practice and is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. While ASU 2023-05 is not currently applicable to Balchem, the Company will apply this guidance in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", and in December 2022 subsequently issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” These ASU’s provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The Standards Updates provide optional expedients and exceptions for applying accounting principles generally accepted in the United States to contract modifications and hedging relationships that reference LIBOR or another reference rate that are expected to be discontinued. The Standards Updates were effective upon issuance and can generally be applied through December 31, 2024. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its interest rate swap and replaced LIBOR with 1-month CME Term SOFR. The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. The interest rate swap matured on June 27, 2023.
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACQUISITIONS
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
SIGNIFICANT ACQUISITIONS SIGNIFICANT ACQUISITIONS
Cardinal Associates Inc. ("Bergstrom")
On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc. ("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc. ("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom"). Bergstrom Nutrition is a leading science-based manufacturer of MSM, based in Vancouver, Washington. MSM is a widely used nutritional ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. The addition of OptiMSM®, Bergstrom Nutrition's MSM brand, to the Company's portfolio within the Human Nutrition and Health and Animal Nutrition and Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products.
The Company made payments of $72,143 for the acquisition, amounting to $71,937 to the former shareholders or on behalf of the former shareholders and $206 to pay off Bergstrom's bank debt. Net of cash acquired of $773, total payments made to the former shareholders or on behalf of the former shareholders of Bergstrom were $71,164. The acquisition was primarily financed through the 2022 Credit Agreement (see Note 8, Revolving Loan). In connection with this transaction, the former shareholders of Bergstrom had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. As of December 31, 2023, the earn-out periods concluded and the Company recorded a contingent consideration liability of $100 which was included in "Accrued expenses" on the consolidated balance sheets. The Company also made an additional post-closing payment of $910 in the third quarter of 2023 that was negotiated as a deduction of the cash consideration at closing. As a result, total payments related to the transaction are expected to be $72,243, comprised of the upfront cash
consideration of $70,892, a working capital adjustment of $341, an additional post-closing payment of $910, and the fair value of the earn-out payment of $100.
The goodwill of $31,550 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. 80% of the goodwill is assigned to the Human Nutrition and Health business segment and 20% of the goodwill is assigned to the Animal Nutrition and Health business segment. For tax purposes, a joint election under 338(h)(10) was made to treat the stock acquisition as a deemed asset acquisition, therefore generating tax amortizable goodwill.
The following table summarizes the fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$773 
Accounts receivable4,699 
Inventories3,972 
Property, plant and equipment2,243 
Right of use assets866 
Customer relationships29,900 
Developed technology4,600 
Trademarks2,300 
Other assets197 
Accounts payable(699)
Bank debt(206)
Lease liabilities(871)
Other liabilities(462)
Goodwill31,550 
Total consideration on acquisition date and working capital adjustment78,862 
Net decrease to contingent consideration liability and other post-closing payments(6,825)
Total expected consideration72,037 
To pay off bank debt206 
Total expected payments $72,243 
The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration.
Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.

Transaction and integration costs related to the Bergstrom acquisition are included in general and administrative expenses and were $(10,614) and $4,604 for the years ended December 31, 2023 and 2022, respectively. There were no such amounts related to this acquisition for the year ended December 31, 2021. These amounts included favorable adjustments to transaction costs of $11,300 for the year ended December 31, 2023 and an unfavorable adjustment to transaction costs of $3,565 for the year ended December 31, 2022.
Kechu BidCo AS and Its Subsidiary Companies ("Kappa")

On June 21, 2022, Balchem Corporation and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as “Kappa”). Kappa manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition and Health segment.

The Company made payments of approximately kr3,305,653 ("kr" indicates the Norwegian krone), amounting to approximately kr3,001,981 to the former shareholders and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments to the former shareholders were kr2,938,917. Net of gains on foreign currency forward contracts of $512 (see Note 20, Derivative Instruments and Hedging Activities), these payments translated to approximately $333,112, amounting to approximately $302,464 paid to the former shareholders and approximately $30,648 to Kappa's lenders. Net of cash acquired of $6,365, total payments made to the former shareholders of Kappa were approximately $296,099. The acquisition was primarily financed through the 2018 Credit Agreement (see Note 8, Revolving Loan). In connection with this transaction, the former shareholders of Kappa had an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics were met. There was no contingent consideration liability recorded as of December 31, 2023.
The goodwill of $216,383 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition and Health business segment and is not deductible for income tax purposes.
The following table summarizes the fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022.
Cash and cash equivalents$6,365 
Accounts receivable8,036 
Inventories17,600 
Property, plant and equipment9,854 
Right of use assets3,349 
Customer relationships88,813 
Developed technology15,643 
Trademarks5,046 
Other assets2,399 
Accounts payable(3,301)
Bank debt(30,648)
Lease liabilities(3,349)
Other liabilities(4,461)
Deferred income taxes, net(24,716)
Goodwill216,383 
Total consideration on acquisition date307,013 
Decrease to contingent consideration liability(4,037)
Net gain on foreign currency exchange forward contracts(512)
Total expected consideration302,464 
Kappa bank debt paid on acquisition date30,648 
Total expected payments$333,112 
The fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration.
Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
Transaction and integration costs related to the Kappa acquisition are included in general and administrative expenses and were $533 and $(2,306) for the years ended December 31, 2023 and 2022, respectively. There were no such amounts related to this acquisition for the year ended December 31, 2021. The amount included a favorable adjustment to transaction costs of $4,037 for the year ended December 31, 2022.
The following selected unaudited pro forma information presents the consolidated results of operations as if the business combinations in 2022 had occurred as of January 1, 2021.

Twelve Months ended December 31,
Net SalesNet Earnings
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023
$59,532 $5,487 
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2022
$22,158 $(5,359)
2023 Supplemental pro forma combined financial
$922,439 $116,317 
2022 Supplemental pro forma combined financial
$982,021 $110,181 
2021 Supplemental pro forma combined financial
$859,252 $90,672 

The above selected unaudited pro forma information includes the following acquisition-related adjustments: (1) additional amortization of intangible assets and depreciation of fixed assets; (2) adjustments related to the fair value of the acquired inventory, (3) adjustments to interest expense on borrowings at rates in effect during the related period, factoring in estimated payments based on free cash flow, and (4) other one-time adjustments.

The pro forma information presented does not purport to be indicative of the results that actually would have been attained if these acquisitions had occurred at the beginning of the periods presented and is not intended to be a projection of future results.
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY
12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Stock-Based Compensation

All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values.

The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest.
The Company’s results for the years ended December 31, 2023, 2022 and 2021 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended December 31,
 202320222021
Cost of sales$1,900 $1,302 $845 
Operating expenses14,152 11,922 9,957 
Net earnings(12,375)(10,214)(8,370)

On December 31, 2023, the Company had one share-based compensation plan under which awards may be granted, which is described below.

In June 2017, the Company’s shareholders approved the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired in April 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. On June 22, 2023, the Company’s shareholders approved an amendment and restatement of the 2017 Plan (the “Amended 2017 Plan”). The Amended 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The Amended 2017 Plan provides as follows: (i) for a termination date of June 22, 2033; (ii) the authorization of 2,400,000 shares for future grants (which represents an increase of 800,000 shares from the amount approved under the 2017 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided by the Compensation Committee or in an employment agreement as in effect on the effective date of the Amended 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vi) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for incentive compensation recovery if the Company is required to prepare an accounting restatement of its financial statements, in accordance with any compensation recovery policy adopted by the Company, applicable law, government regulations or national securities exchange requirements, or in the discretion of the Compensation Committee in the event of a restatement due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant.

The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2023, the Amended 2017 Plan had 1,034,260 shares available for future awards.

The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements.

The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) market condition where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents.
The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. For the years ended December 31, 2023, 2022, and 2021, the fair value of each option grant uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202320222021
Expected Volatility28.1 %30.3 %32.9 %
Expected Term (in years)4.87.34.9
Risk-Free Interest Rate3.9 %2.8 %0.5 %
Dividend Yield0.5 %0.5 %0.5 %
The value of the restricted shares is based on the fair value of the award at the date of grant.
Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 4.2%, 1.8%, and 0.2%; dividend yields of 0.5%, 0.5%, and 0.6%; volatilities of 32%, 32%, and 33%; and initial TSR’s of 4.2%, -15.7%, and 11.7% in each case for the years ended December 31, 2023, 2022, and 2021, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.
Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three to five years for stock options, three years for employee restricted stock awards, three years for employee performance share awards, and three years for non-employee director restricted stock awards.
A summary of stock option plan activity for 2023, 2022, and 2021 for all plans is as follows:
202320222021
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
Outstanding at beginning of year1,045 $99.82 867 $88.19 858 $80.58 
Granted109 138.09 239 139.04 129 119.12 
Exercised(64)81.98 (44)73.58 (109)63.42 
Forfeited(11)131.79 (17)124.89 (10)106.93 
Cancelled(1)138.07 — — (1)74.57 
Outstanding at end of year1,078 $104.38 1,045 $99.82 867 $88.19 
Exercisable at end of year720 $88.49 654 $81.95 538 $75.51 

The aggregate intrinsic value for outstanding stock options was $47,889, $27,221 and $69,711 at December 31, 2023, 2022 and 2021, respectively, with a weighted average remaining contractual term of 5.7 years at December 31, 2023. Exercisable stock options at December 31, 2023 had an aggregate intrinsic value of $43,364 with a weighted average remaining contractual term of 4.4 years.
Other information pertaining to option activity during the years ended December 31, 2023, 2022 and 2021 is as follows:

 Years Ended December 31,
 202320222021
Weighted-average fair value of options granted$40.91 $44.77 $33.11 
Total intrinsic value of stock options exercised ($000s)$3,241 $2,713 $7,866 

Additional information related to stock options outstanding under all plans at December 31, 2023 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices
Shares
Outstanding
(000s)
Weighted
Average
Remaining
Contractual
 Term
Weighted
Average
 Exercise
Price
Number
Exercisable
(000s)
Weighted
Average
Exercise
Price
$54.87 - $85.33
387 3.5$72.41 387 $72.41 
$85.40 - $118.60
250 4.9101.84 248 101.71 
$118.96 - $150.85
441 8.1133.93 85 123.47 
 1,078 5.7$104.38 720 $88.49 

Non-vested restricted stock activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:
202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 122 $124.42 166 $99.7 159 $90.71 
Granted40 137.20 46 137.17 42 123.58 
Vested(42)112.30 (82)82.15 (24)85.83 
Forfeited(4)128.06 (8)118.07 (11)90.49 
Non-vested balance at end of year 116 $133.06 122 $124.42 166 $99.7 

Non-vested performance share activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:

202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 70 $127.69 69 $110.72 71 $91.99 
Granted42 139.66 39 114.22 36 108.74 
Vested(36)98.84 (35)53.17 (24)70.64 
Forfeited— — (3)84.09 (14)81.03 
Non-vested balance at end of year 76 $135.25 70 $127.69 69 $110.72 

As of December 31, 2023, 2022 and 2021, there was $18,817, $20,791 and $13,980, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2023, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.6 years. We estimate that share-based compensation expense for the year ended December 31, 2024 will be approximately $14,800.
Repurchase of Common Stock
The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,103,106 shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. Open market repurchases of common stock could be made pursuant to trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit common stock to be repurchased at a time that the Company might otherwise be precluded from doing so under insider trading laws or self-imposed trading restrictions. The Company also repurchases (withholds) shares from employees in connection with the tax settlement of vested shares and/or exercised stock options under the Company's omnibus incentive plan. Such repurchases of shares from employees are funded with existing cash on hand. During 2023, 2022, and 2021, the Company purchased 32,558, 252,304, and 249,848 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $137.29, $140.40, and $141.04 per share, respectively.
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES
12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, net of reserves at December 31, 2023 and 2022 consisted of the following:
 20232022
Raw materials$39,517 $44,477 
Work in progress3,960 3,143 
Finished goods66,044 72,048 
Total inventories$109,521 $119,668 
On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $2,463 and $2,640 at December 31, 2023 and 2022, respectively.
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at December 31, 2023 and 2022 are summarized as follows:
 20232022
Land$11,787 $11,415 
Building104,363 90,644 
Equipment312,704 278,851 
Construction in progress59,981 79,928 
 488,835 460,838 
Less: Accumulated depreciation212,796 189,483 
Property, plant and equipment, net$276,039 $271,355 

Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20232022
United States$203,692 $211,588 
Foreign Countries72,347 59,767 
Total$276,039 $271,355 
Depreciation expense was $26,373, $24,033 and $23,295 for the years ended December 31, 2023, 2022 and 2021, respectively.
In accordance with Topic 360, the Company reviews long-lived assets for impairment on an annual basis and also whenever events indicate that the carrying amount of the assets may not be fully recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. Included in “General and administrative expenses” were restructuring-related impairment and asset disposal charges of $7,764 related to building, equipment, and construction in progress mainly in the Human Nutrition and Health and the Animal Nutrition and Health segments, for the year ended December 31, 2023. Such expenses for the year ended December 31, 2022 were not material.
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS INTANGIBLE ASSETS
The Company had goodwill in the amount of $778,907 and $769,509 as of December 31, 2023 and 2022, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is primarily due to foreign currency translation adjustments.

As of December 31, 2023 and 2022, the Company had identifiable intangible assets as follows:
20232022
 Amortization
Period
(In years)
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount

Accumulated
Amortization
Customer relationships and lists
10-20
$362,032 $209,651 $357,131 $190,576 
Trademarks and trade names
2-17
50,286 37,773 50,058 33,416 
Developed technology
5-12
41,184 17,516 40,473 16,171 
Other
2-18
25,733 23,083 25,041 19,245 
  $479,235 $288,023 $472,703 $259,408 

Amortization of identifiable intangible assets was $28,035, $27,271 and $25,092 for 2023, 2022 and 2021, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $18,971 in 2024, $15,509 in 2025, $15,308 in 2026, $14,784 in 2027, and $14,387 in 2028. At December 31, 2023 and 2022, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2023 and 2022.

The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included as other in the table above.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY-METHOD INVESTMENT
12 Months Ended
Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY-METHOD INVESTMENT EQUITY-METHOD INVESTMENT
In 2013, the Company and Eastman Chemical Company formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity ("VIE") because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $509, $559, and $557 for the years ended December 31, 2023, 2022, and 2021, respectively, relating to its portion of the joint venture’s expenses in other expense. The Company made capital contributions to the investment totaling $290, $355, and $85 for the years ended December 31, 2023, 2022, and 2021 respectively. The carrying value of the joint venture at December 31, 2023 and 2022 was $4,076 and $4,295, respectively, and is recorded in "Other non-current assets" on the consolidated balance sheets.
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVOLVING LOAN
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
REVOLVING LOAN REVOLVING LOAN
On June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "2018 Credit Agreement"), which provided for revolving loans up to $500,000, due on June 27, 2023. During the second quarter of 2022, the Company borrowed $345,000 under the 2018 Credit Agreement to fund the Kappa acquisition (see Note 2, Significant Acquisitions). On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement (the "2022 Credit Agreement") with certain lenders in the form of a senior secured revolving credit facility, due on July 27, 2027. The 2022 Credit Agreement allows for up to $550,000 of borrowing. The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The Company used initial proceeds from the 2022 Credit Agreement to repay the outstanding balance of $433,569 due in June 2023 under the 2018 Credit Agreement. During the third quarter of 2022, the Company borrowed another $70,000 to fund the Bergstrom acquisition (see Note 2, Significant Acquisitions). As of December 31, 2023 and 2022, the total balance outstanding on the 2022 Credit Agreement amounted to $309,569 and $440,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date.

Amounts outstanding under the 2022 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2022 Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2022 Credit Agreement, and the interest rate was 6.580% at December 31, 2023. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2022 Credit Agreement and ranges from 0.150% to 0.225% (0.175% at December 31, 2023). The unused portion of the revolving loan amounted to $240,431 at December 31, 2023. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the 2022 Credit Agreement. Capitalized costs net of accumulated amortization totaled $1,030 and $1,317 at December 31, 2023 and 2022, respectively, and are included in "Other non-current assets" on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $287, $335, and $282 for the years ended December 31, 2023, 2022, and 2021, respectively, and are included in "Interest expense" in the accompanying consolidated statements of earnings.

The 2022 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At December 31, 2023, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements is secured by assets of the Company.
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET EARNINGS PER COMMON SHARE
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
NET EARNINGS PER COMMON SHARE NET EARNINGS PER COMMON SHARE
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202320222021
Net Earnings - Basic and Diluted$108,543 $105,367 $96,104 
Share (000s)
Weighted Average Common Shares - Basic32,108 32,019 32,215 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares340 374 457 
Weighted Average Common Shares - Diluted32,448 32,393 32,672 
Net Earnings Per Share - Basic$3.38 $3.29 $2.98 
Net Earnings Per Share - Diluted$3.35 $3.25 $2.94 
The number of anti-dilutive shares were 354,619, 371,513, and 155,294 for 2023, 2022, and 2021. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company’s effective tax rate for 2023, 2022 and 2021 was 20.9%, 21.2%, and 23.3%, respectively. The decrease from 2022 to 2023 is primarily due to an increase in certain tax credits.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences.
The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs. However, due to prevailing economic conditions of increased interest rates and subsequent borrowing costs, the Company remitted approximately $18,000 from its Belgium subsidiary and has incurred an income tax expense of approximately $20. The remittance was used to pay down U.S. debt. The Company had unremitted foreign earnings of approximately $109,000 and $94,000 for the years ended December 31, 2023 and 2022, respectively. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to change its assertion on its remaining undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion.
Income tax expense consists of the following:
 202320222021
Current:   
Federal$27,306 $26,423 $25,019 
Foreign7,634 7,103 7,553 
State4,403 3,964 3,664 
Deferred:
Federal(7,737)(7,532)(3,709)
Foreign(2,285)(215)(3,038)
State(603)(1,361)(360)
Total income tax provision$28,718 $28,382 $29,129 
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2023, 2022, and 2021 to earnings before income tax expense due to the following:
 202320222021
Income tax at Federal statutory rate$28,825 $28,087 $26,299 
State income taxes, net of Federal income taxes2,513 1,862 2,406 
Stock Options(1,004)(676)(924)
Foreign-derived intangible income (FDII)(1,752)(1,778)(1,540)
Foreign rate differential946 2,066 1,188 
Other(810)(1,179)1,700 
Total income tax provision$28,718 $28,382 $29,129 
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022 were as follows:
 20232022
Deferred tax assets:  
Inventories$1,049 $1,038 
Restricted stock and stock options5,565 3,932 
Lease liabilities4,812 5,439 
Research and development12,653 4,134 
Other3,874 3,717 
Total deferred tax assets27,953 18,260 
Deferred tax liabilities:
Amortization$(42,351)$(46,688)
Depreciation(28,937)(25,097)
Prepaid expenses(421)(462)
Foreign currency and interest rate swaps(647)(1,456)
Right of use assets(4,574)(5,324)
Other(3,047)(1,995)
Total deferred tax liabilities(79,977)(81,022)
Valuation allowance(22)(22)
Net deferred tax liability$(52,046)$(62,784)

As of December 31, 2023, the Company has state income tax net operating loss (NOL) carryforwards of $348. The state NOL carryforwards will expire between 2026 and 2035. The Company believes that the benefit from the state NOL carryforwards will not be realized, therefore, a valuation allowance has been established in the amount of $22.
Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202320222021
Balance at beginning of period$5,815 $5,881 $5,335 
Increases for tax positions of prior years1,353 2,194 806 
Decreases for tax positions of prior years(2,518)(2,260)(260)
Balance at end of period$4,650 $5,815 $5,881 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2023 and 2022, these amounts were reduced by $322 and $371, respectively. During the year ended December 31, 2021, this amounted to $262. As of December 31, 2023 and 2022, accrued interest and penalties were $1,413 and $1,735, respectively.
Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2019 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months.
The European Union (“EU”) member states formally adopted the EU’s Pillar Two Directive, which was established by the Organization for Economic Co-operation and Development. Pillar Two generally provides for a 15 percent minimum effective tax rate for the jurisdictions where multinational enterprises operate. While the Company does not anticipate that this will have a
material impact on its tax provision or effective tax rate, the Company continues to monitor evolving tax legislation in the jurisdictions in which it operates.
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Balchem Corporation reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated."

Human Nutrition and Health

The Human Nutrition and Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products; proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also manufactures specialty vitamin K2, which plays a crucial role in the human body for bone health, heart health and immunity, and methylsulfonylmethane ("MSM"), which is a widely used nutritional ingredient that helps provide benefits for joint health, sports nutrition, skin and beauty, and healthy aging. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.

Animal Nutrition and Health

The Company’s Animal Nutrition and Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. This segment also manufactures MSM, which is a widely used nutritional ingredient that provides benefits for pet health.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.

Specialty Products

The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. Ethylene oxide is sold as a sterilant gas, primarily for use in the health
care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Contract sterilizers and medical device manufacturers are principal customers for this product. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage, to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes, and for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to.

The Company’s performance gases and chemicals are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. The Company also sells single use canisters for use in sterilizing re-usable devices typically processed in autoclave units in hospitals.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.

The segment information is summarized as follows:

Business Segment Assets
 20232022
Human Nutrition and Health$1,180,527 $1,170,238 
Animal Nutrition and Health166,994 175,972 
Specialty Products168,307 177,187 
Other and Unallocated (1)
81,383 101,115 
Total$1,597,211 $1,624,512 

Business Segment Net Sales
 202320222021
Human Nutrition and Health$550,751 $527,131 $442,733 
Animal Nutrition and Health238,326 262,297 226,776 
Specialty Products125,965 131,438 117,020 
Other and Unallocated (2)
7,397 21,492 12,494 
Total$922,439 $942,358 $799,023 

Business Segment Earnings Before Income Taxes
202320222021
Human Nutrition and Health$102,419 $82,125 $76,031 
Animal Nutrition and Health27,576 36,056 26,179 
Specialty Products34,579 32,789 30,020 
Other and Unallocated (2)
(5,381)(5,784)(4,728)
Interest and other expense(21,932)(11,437)(2,269)
Total$137,261 $133,749 $125,233 
Depreciation/Amortization
 202320222021
Human Nutrition and Health$38,568 $33,728 $30,012 
Animal Nutrition and Health7,876 6,685 7,414 
Specialty Products7,278 7,507 8,332 
Other and Unallocated (2)
1,213 3,928 3,121 
Total$54,935 $51,848 $48,879 

Capital Expenditures
 202320222021
Human Nutrition and Health$26,415 $33,668 $23,714 
Animal Nutrition and Health6,993 10,809 8,100 
Specialty Products3,535 4,004 3,804 
Other and Unallocated (2)
331 605 524 
Total$37,274 $49,086 $36,142 

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,617, $3,581 and $1,264 for years ended December 31, 2023, 2022 and 2021, respectively, and (ii) Unallocated amortization expense of $312, $2,951, and $2,510 for years ended December 31, 2023, 2022, and 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE
12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

 202320222021
Product Sales Revenue$919,951 $939,166 $794,518 
Royalty Revenue2,488 3,192 4,505 
Total Revenue$922,439 $942,358 $799,023 


The following table presents revenues disaggregated by geography, based on customers' delivery addresses:

 202320222021
United States$689,601 $682,238 $584,661 
Foreign Countries232,838 260,120 214,362 
Total$922,439 $942,358 $799,023 

Product Sales Revenues
The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue.
Royalty Revenues
Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities
The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.

The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions
The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION
12 Months Ended
Dec. 31, 2023
Supplemental Cash Flow Information [Abstract]  
SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the year for:
202320222021
Income taxes$35,725 $33,016 $25,355 
Interest$25,933 $11,879 $4,547 
Non-cash financing and investing activities:
202320222021
Dividends payable$25,717 $23,129 $20,886 
Contingent consideration liability$— $11,872 $— 
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME
12 Months Ended
Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202320222021
Net foreign currency translation adjustment$16,809 $(4,799)$(11,255)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized (loss) gain on cash flow hedge(1,406)3,564 2,707 
Tax341 (868)(654)
Net of tax(1,065)2,696 2,053 
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service loss (gain) arising during the period132 (41)(4)
Amortization of prior service gain— 74 
Amortization of loss (gain)(2)(21)
Total before tax140 (34)49 
Tax(39)(24)(13)
Net of tax101 (58)36 
Total other comprehensive income/(loss)$15,845 $(2,161)$(9,166)
Included in "Net foreign currency translation adjustment" was loss of $1,455 related to a net investment hedge, which was net of tax benefit of $471 for the year ended December 31, 2023, and gains of $3,851, and $4,766, related to a net investment hedge, net of tax expenses of $1,236, and $1,527, for the years ended December 31, 2022 and 2021, respectively. See Note 20, Derivative Instruments and Hedging Activities.

Accumulated other comprehensive loss at December 31, 2023 and 2022 consisted of the following:
 Foreign currency
translation
adjustment
Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2022$(8,401)$1,065 $182 $(7,154)
Other comprehensive income (loss)16,809 (1,065)101 15,845 
Balance December 31, 2023$8,408 $— $283 $8,691 
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS
12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
Defined Contribution Plans
The Company sponsors one 401(k) savings plan for eligible employees, which allows participants to make pretax or after tax contributions and the Company matches certain percentages of those contributions. The plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees. In addition, on August 30, 2022, the Company completed the acquisition of Bergstrom, which sponsored one defined contribution plan for its employees. The Bergstrom plan merged into the Company sponsored 401(k) savings plan on January 1, 2023. The Company provided for matching 401(k) savings plan contributions of $4,381, $4,363, and $4,142 in 2023, 2022 and 2021, respectively. Profit sharing contributions in 2023, 2022, and 2021 were not material.
Postretirement Medical Plans
The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for executive officers of the Company who meet eligibility requirements as set forth in the Company's Officer Retiree Program. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,465 $1,293 
Service cost with interest to end of year108 79 
Interest cost62 26 
Participant contributions23 27 
Benefits paid(30)(69)
Actuarial (gain) loss(233)109 
Benefit obligation at end of year$1,395 $1,465 
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$— $— 
Employer contributions42 
Participant contributions23 27 
Benefits paid(30)(69)
Fair value of plan assets at end of year$— $— 
Amounts recognized in consolidated balance sheet:
 20232022
Accumulated postretirement benefit obligation$(1,395)$(1,465)
Fair value of plan assets— — 
Funded status(1,395)(1,465)
Unrecognized prior service cost74 
Unrecognized net loss (gain)(2)(24)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations")$(1,395)$(1,465)
Accrued postretirement benefit cost (included in "Other long-term obligations")N/AN/A
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$108 $79 $87 
Interest cost62 26 23 
Amortization of prior service cost— 74 
Amortization of loss (gain)(2)(24)
Total net periodic benefit cost$178 $112 $160 
Estimated future employer contributions and benefit payments are as follows:
Year 
2024$131 
2025132 
202699 
2027101 
202885 
Years 2029-2033615 
Assumptions to determine benefit obligations:
 20232022
Discount rate4.15 %4.40 %
Assumptions to determine net cost:
 202320222021
Discount rate4.40 %2.10 %1.75 %
Defined Benefit Pension Plans
The Company contributes to one multi-employer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability.
The Company’s participation in this plan for the annual period ended December 31, 2023 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2023 and 2022 was affected by a 4.0% increase in the 2023 contribution rate. There have been no other significant changes that affect the comparability of 2023 and 2022 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
Pension
Fund
EIN/Pension
Plan
Number
Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented
Contributions of Balchem CorporationSurcharge
Imposed
Expiration Date of Collective-
Bargaining
Agreement
20232022202320222021
Central States,
Southeast and
Southwest Areas
Pension Fund
36-6044243Critical & Declining as of 1/1/23Critical & Declining as of 1/1/22Implemented$1,020$939$816No7/12/2025

The Company provides an unfunded defined benefit pension plan for employees working in Belgium. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees.
The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows:
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,589 $1,859 
Service cost with interest to end of year65 44 
Interest cost65 17 
Participant contributions— 27 
Benefits paid(188)(60)
Actuarial loss (gain)80 (194)
Exchange rate changes49 (104)
Benefit obligation at end of year$1,660 $1,589 
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$1,196 $1,175 
Actual return on plan assets56 26 
Employer contributions138 94 
Participant contributions— 27 
Benefits paid(188)(60)
Exchange rate changes38 (66)
Fair value of plan assets at end of year$1,240 $1,196 

Amounts recognized in consolidated balance sheet:
 20232022
Benefit obligation$(1,660)$(1,589)
Fair value of plan assets1,240 1,196 
Funded status(420)(393)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$(420)$(393)
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$65 $44 $67 
Interest cost65 17 14 
Expected return on plan assets(42)(37)(34)
Amortization of net loss— — 
Total net periodic benefit cost$88 $24 $50 
Estimated future benefit payments are as follows:
Year 
2024$
202552 
2026
2027
2028
Years 2029-20331,096 
Assumptions to determine benefit obligations:
 20232022
Discount rate3.45 %4.00 %


Assumptions to determine net cost:
 202320222021
Discount rate4.00 %1.00 %0.75 %
Expected return on assets3.25 %3.25 %3.25 %
Deferred Compensation Plan

The Company maintains an unfunded, non-qualified deferred compensation plan for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2023 and 2022 was $10,188 and $8,543, respectively, and was included in "Other long-term obligations" on the Company's balance sheet. The related rabbi trust assets were $10,188 and $8,547 as of December 31, 2023 and 2022, respectively, and were included in "Other non-current assets" on the Company's consolidated balance sheets.
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company is obligated to make rental payments under non-cancelable operating and finance leases. Aggregate future minimum rental payments required under these leases at December 31, 2023 are disclosed in Note 19, Leases.
The Company’s Verona, Missouri facility, while held by a prior owner, Syntex Agribusiness, Inc. (“Syntex”), was designated by the U.S. Environmental Protection Agency (the "EPA") as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by Syntex under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. One of the sellers, in turn, has the benefit of certain contractual indemnification by Syntex in relation to the implementation of the above-described Superfund remedy. In June 2023, in response to a Special Notice Letter received from the EPA in 2022, BCP Ingredients, Inc. ("BCP"), the Company's subsidiary that operates the site, Syntex, EPA, and the State of Missouri entered into an Administrative Settlement Agreement and Order on Consent (“ASAOC”) for a focused remedial investigation/feasibility study ("RI/FS") under which (a) BCP will conduct a source investigation of potential source(s) of releases of 1,4-dioxane and chlorobenzene at a portion of the site and (b) BCP and Syntex will complete a RI/FS to determine a potential remedy, if any is required. Activities under the ASAOC are underway and are expected to continue for some period of time.
Separately, in June 2022, the EPA conducted an inspection of BCP’s Verona, Missouri facility (“2022 EPA Inspection”) which was followed by BCP entering into an Administrative Order for Compliance on Consent (“AOC”) with the EPA in relation to its risk management program at the Verona facility. Further, in January 2023, BCP entered into an Amended AOC with the EPA
whereby the parties agreed to the extension of certain timelines. BCP timely completed all requirements under the Amended AOC. In November 2023, BCP received a notice from the Environment and Natural Resources Division of the U.S Department of Justice (“DOJ”) primarily related to the 2022 EPA Inspection, which extended the opportunity to discuss alleged violations of Sections 112(r)(7) of the Clean Air Act and regulations in 40 C.F.R. Part 68, commonly known as the Risk Management Plan Rule (“RMP Rule”). BCP intends to participate in such discussions in 2024. In connection with the 2022 EPA Inspection, the Company believes that a loss contingency in this matter is probable and reasonably estimable and has recorded a loss contingency in an amount that is not material to its financial performance or operations.
In addition to the above, from time to time, the Company is a party to various legal proceedings, litigation, claims and assessments. While it is not possible to predict the ultimate disposition of each of these matters, management believes that the ultimate outcome of such matters will not have a material effect on the Company's consolidated financial position, results of operations, liquidity or cash flows.
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE OF FINANCIAL INSTRUMENTS
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2023 and 2022 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2023 and 2022 included $959 and $934 in money market funds and other interest-bearing deposit accounts, respectively.
Non-current assets at December 31, 2023 and 2022 included $10,188 and $8,547, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”
The contingent consideration liabilities included on the balance sheet at of December 31, 2023 and 2022 amount to $100 and $11,400, respectively, and were valued using level three inputs, as defined by ASC 820, "Fair Value Measurement".
The Company also had derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which were included in "Derivative assets" in the Company's consolidated balance sheets. The fair values of these derivative instruments were determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The Company settled its cross-currency swap and interest rate swap on June 27, 2023 and had no other derivatives outstanding as of December 31, 2023. The derivative assets related to the cross-currency swap and the interest rate swap were $4,587 and $1,406 at December 31, 2022, respectively.
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties. As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings.
Payments for the services the Company provided amounted to $4,363, $4,213, and $3,637, respectively, for the years ended December 31, 2023, 2022, and 2021. The raw materials purchased and subsequently sold amounted to $34,219, $39,853, and $27,915, respectively, for the years ended December 31, 2023, 2022, and 2021. These services and raw materials are primarily recorded in cost of goods sold, net of the finished goods received from St. Gabriel CC Company, LLC of $28,099, $29,062, and $22,043, respectively, for the years ended December 31, 2023, 2022, and 2021. At December 31, 2023 and 2022, the Company had receivables of $8,314 and $8,820, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. At December 31, 2023 and 2022, the Company had payables of $6,050 and $5,224,
respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had payables in the amount of $329 and $296, respectively, related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of December 31, 2023 and 2022.
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES
12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
LEASES LEASES
The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2023. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2023: (1) 1-2 years, 5.45%-6.72% (2) 3-4 years, 6.04%-7.31% (3) 5-9 years, 6.38%-7.65% and (4) 10+ years, 7.10%-8.37%.

Right of use assets and lease liabilities at December 31, 2023 and 2022 are summarized as follows:

Right of use assets20232022
Operating leases$17,763 $17,094 
Finance lease2,101 2,338 
Total$19,864 $19,432 

Lease liabilities - current20232022
Operating leases$3,949 $3,796 
Finance lease272 226 
Total$4,221 $4,022 
Lease liabilities - non-current20232022
Operating leases$14,601 $13,806 
Finance lease1,943 2,213 
Total$16,544 $16,019 
For the years ended December 31, 2023, 2022, and 2021, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:
Year ended December 31,
202320222021
Lease Cost
Operating lease cost$5,307 $4,478 $3,143 
Finance Lease cost
Amortization of ROU asset242 210 210 
Interest on lease liabilities115 125 129 
Total finance lease357 335 339 
Total lease cost$5,664 $4,813 $3,482 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$4,757 $4,269 $3,097 
Operating cash flows from finance leases115 125 129 
Financing cash flows from finance leases222 177 159 
$5,094 $4,571 $3,385 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$6,365 $11,488 $3,804 
Weighted-average remaining lease term - operating leases9.33 years5.63 years4.21 years
Weighted-average remaining lease term - finance leases9.07 years9.95 years11.41 years
Weighted-average discount rate - operating leases7.4 %2.7 %3.5 %
Weighted-average discount rate - finance leases5.0 %5.0 %5.1 %

Rent expense charged to operations under operating lease agreements for 2023, 2022, and 2021 aggregated approximately $5,307, $4,478, and $3,143, respectively.
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2023 are as follows:
Year 
2024$5,407 
20254,219 
20263,638 
20272,736 
20282,219 
Thereafter7,717 
Total minimum lease payments$25,936 
LEASES LEASES
The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2023. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2023: (1) 1-2 years, 5.45%-6.72% (2) 3-4 years, 6.04%-7.31% (3) 5-9 years, 6.38%-7.65% and (4) 10+ years, 7.10%-8.37%.

Right of use assets and lease liabilities at December 31, 2023 and 2022 are summarized as follows:

Right of use assets20232022
Operating leases$17,763 $17,094 
Finance lease2,101 2,338 
Total$19,864 $19,432 

Lease liabilities - current20232022
Operating leases$3,949 $3,796 
Finance lease272 226 
Total$4,221 $4,022 
Lease liabilities - non-current20232022
Operating leases$14,601 $13,806 
Finance lease1,943 2,213 
Total$16,544 $16,019 
For the years ended December 31, 2023, 2022, and 2021, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:
Year ended December 31,
202320222021
Lease Cost
Operating lease cost$5,307 $4,478 $3,143 
Finance Lease cost
Amortization of ROU asset242 210 210 
Interest on lease liabilities115 125 129 
Total finance lease357 335 339 
Total lease cost$5,664 $4,813 $3,482 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$4,757 $4,269 $3,097 
Operating cash flows from finance leases115 125 129 
Financing cash flows from finance leases222 177 159 
$5,094 $4,571 $3,385 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$6,365 $11,488 $3,804 
Weighted-average remaining lease term - operating leases9.33 years5.63 years4.21 years
Weighted-average remaining lease term - finance leases9.07 years9.95 years11.41 years
Weighted-average discount rate - operating leases7.4 %2.7 %3.5 %
Weighted-average discount rate - finance leases5.0 %5.0 %5.1 %

Rent expense charged to operations under operating lease agreements for 2023, 2022, and 2021 aggregated approximately $5,307, $4,478, and $3,143, respectively.
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2023 are as follows:
Year 
2024$5,407 
20254,219 
20263,638 
20272,736 
20282,219 
Thereafter7,717 
Total minimum lease payments$25,936 
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023, which was designated as cash flow hedge. The net interest income related to the interest rate swap contract were $1,518 and $400 for the years ended December 31, 2023 and 2022, respectively. The net interest expense related to the interest rate swap contract was $2,144 for the year ended December 31, 2021. The net interest income and expense were recorded in the consolidated statements of earnings under "Interest expense, net."
On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas, which was designated as net investment hedge. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $1,119, $2,250, and $2,257 for the years ended December 31, 2023, 2022, and 2021, respectively. The interest income was recorded in the consolidated statements of earnings under "Interest expense, net."

The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2023. The proceeds from the settlement of the cross-currency swap in the amount of $2,740 were classified as investing activities in the Consolidated Statements of Cash Flows.

As of December 31, 2022, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative assetsDecember 31, 2022
Interest rate swap$1,406 
Cross-currency swap4,587 
Derivative assets$5,993 

Gains and losses on our hedging instruments were recognized in accumulated other comprehensive income (loss) and categorized as follows for the years ended December 31, 2023, 2022, and 2021:

Location within Statements of Comprehensive IncomeYear ended December 31,
202320222021
Cash flow hedge (interest rate swap), net of taxUnrealized (loss) gain on cash flow hedge, net$(1,065)$2,696 $2,053 
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment(1,455)3,851 4,766 
$(2,520)$6,547 $6,819 
In connection with the Kappa acquisition (see Note 2, Significant Acquisitions), the Company entered into four short-term foreign currency exchange forward contracts to manage fluctuations in foreign currency exchange rates. The Company did not designate these contracts as hedged transactions under the applicable sections of ASC Topic 815, "Derivatives and Hedging". For the year ended December 31, 2022, the net gains on these forward contracts of $512 were recorded in other income or loss in the consolidated statements of earnings. As of December 31, 2023, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts expired during 2022.
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
12 Months Ended
Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]  
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
(In thousands, except per share data)
 20232022
 First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Net sales$232,540 $231,252 $229,948 $228,699 $228,867 $236,693 $244,267 $232,531 
Gross margin73,170 77,349 76,544 74,993 71,506 71,876 68,430 68,639 
Earnings before income taxes29,119 38,400 36,475 33,267 37,630 39,258 31,085 25,776 
Net earnings22,710 30,110 29,075 26,648 28,930 29,782 25,249 21,406 
Basic net earnings per common share$0.71 $0.94 $0.91 $0.83 $0.90 $0.93 $0.79 $0.67 
Diluted net earnings per common share$0.70 $0.93 $0.90 $0.82 $0.89 $0.92 $0.78 $0.66 
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
VALUATION AND QUALIFYING ACCOUNTS
12 Months Ended
Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
VALUATION AND QUALIFYING ACCOUNTS
Allowance
for Doubtful Accounts
Inventory
Reserve
Balance - December 31, 2020$2,092 $2,782 
Additions charged to costs and expenses180 7,312 
Adjustments/deductions (a)
(1,344)(8,669)
Balance - December 31, 2021928 1,425 
Additions charged to costs and expenses401 6,786 
Adjustments/deductions (a)
(103)(5,571)
Balance - December 31, 20221,226 2,640 
Additions charged to costs and expenses37 2,450 
Adjustments/deductions (a)
(355)(2,627)
Balance - December 31, 2023$908 $2,463 
(a) Represents write-offs and other adjustments
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure                      
Net earnings $ 26,648 $ 29,075 $ 30,110 $ 22,710 $ 21,406 $ 25,249 $ 29,782 $ 28,930 $ 108,543 $ 105,367 $ 96,104
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.
Revenue Recognition and Cost of Sales
Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S. and other countries exceed the insurance limits of the Federal Deposit Insurance Corporation (“FDIC”) and other relevant insurance limits in other countries.
Accounts Receivable
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Inventories
Inventories
Inventories are valued at the lower of cost (first in, first out) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2023, 2022 and 2021, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired in accordance with ASC 805, "Business Combinations". Goodwill and intangible assets acquired in a business combination that have indefinite useful lives are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the assets might be impaired, in accordance with the provisions of ASC 350, "Intangibles-Goodwill and Other". The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the assets might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. In accordance with this update, a goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value.
As of October 1, 2023 and 2022, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2023 and 2022. The Company may resume performing the qualitative assessment in subsequent periods.
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks and trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents and trade secrets
15 - 17
Other
 2 - 18
Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2023, there were no triggering events which required intangible asset impairment reviews.
Income Taxes
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Use of Estimates
Management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also had derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which were included in derivative assets and derivative liabilities, in the consolidated balance sheets (see Note 20, Derivative Instruments and Hedging Activities). The fair values of these derivative instruments were determined based on Level 2 inputs, using significant inputs that were observable either directly or indirectly, including interest rate curves and implied volatilities. These derivatives were settled on their maturity date on June 27, 2023 and there were no other derivatives outstanding as of December 31, 2023.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
Research and Development
Research and Development
Research and development costs are associated directly with the Company's efforts to develop, design, and enhance its products, services, technologies, or processes. Such costs are expensed as incurred.
Net Earnings Per Common Share
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3, Stockholders' Equity. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the statement of earnings as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using either the Black-Scholes model or the Binomial model, whichever is deemed to be most appropriate. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets
Impairment of Long-lived Assets
Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows.
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments was to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

The derivative instruments were with the above single counterparty and were subject to a contractual agreement that provided for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments were categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet as of December 31, 2022. The Company settled its derivative instruments on their maturity date of June 27, 2023 and had no other derivatives outstanding as of December 31, 2023.

On a quarterly basis through their maturity, we assessed the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. The hedging relationships were determined to be highly effective. As such, the net change in fair values of the interest rate swap, that qualified as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and subsequently reclassified into interest expense as interest payments were made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remain in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, Derivative Instruments and Hedging Activities, for detailed information about our derivative financial instruments.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures by requiring disaggregated information about a reporting entity's effective tax rate reconciliation and information on income taxes paid. The amendment is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment in this Update should be applied on a prospective basis, with retrospective application permitted. The Company is in the process of evaluating the impact that the adoption of ASU 2023-09 will have to the financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures." The ASU expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning December 15, 2024. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. The adoption of this guidance will not affect the Company's consolidated results of operations, financial position or cash flows. The Company is currently evaluating the effect the guidance will have on its disclosures.
In August 2023, the FASB issued ASU 2023-05, "Business Combinations - Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement." The new guidance applies to the formation of a joint venture and requires a joint venture to initially measure all contributions received upon its formation at fair value. The guidance is intended to reduce diversity in practice and is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. While ASU 2023-05 is not currently applicable to Balchem, the Company will apply this guidance in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", and in December 2022 subsequently issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” These ASU’s provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The Standards Updates provide optional expedients and exceptions for applying accounting principles generally accepted in the United States to contract modifications and hedging relationships that reference LIBOR or another reference rate that are expected to be discontinued. The Standards Updates were effective upon issuance and can generally be applied through December 31, 2024. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its interest rate swap and replaced LIBOR with 1-month CME Term SOFR. The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. The interest rate swap matured on June 27, 2023.
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Plant and Equipment Estimated Useful Lives
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Property, plant and equipment at December 31, 2023 and 2022 are summarized as follows:
 20232022
Land$11,787 $11,415 
Building104,363 90,644 
Equipment312,704 278,851 
Construction in progress59,981 79,928 
 488,835 460,838 
Less: Accumulated depreciation212,796 189,483 
Property, plant and equipment, net$276,039 $271,355 
Summary of Goodwill
The Company had goodwill in the amount of $778,907 and $769,509 as of December 31, 2023 and 2022, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2021$523,949 
Goodwill as a result of the Kappa acquisition216,295 
Goodwill as a result of the Bergstrom acquisition31,209 
Impact due to change in foreign exchange rates(1,944)
Goodwill at December 31, 2022769,509 
Goodwill as a result of the Bergstrom acquisition341 
Impact due to change in foreign exchange rates9,057 
Goodwill at December 31, 2023$778,907 

 December 31, 2023December 31, 2022
HNH$673,207 $665,804 
ANH24,469 24,218 
Specialty Products81,175 79,429 
Other and Unallocated56 58 
Total$778,907 $769,509 
Intangible Assets Estimated Useful Lives
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks and trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents and trade secrets
15 - 17
Other
 2 - 18
As of December 31, 2023 and 2022, the Company had identifiable intangible assets as follows:
20232022
 Amortization
Period
(In years)
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount

Accumulated
Amortization
Customer relationships and lists
10-20
$362,032 $209,651 $357,131 $190,576 
Trademarks and trade names
2-17
50,286 37,773 50,058 33,416 
Developed technology
5-12
41,184 17,516 40,473 16,171 
Other
2-18
25,733 23,083 25,041 19,245 
  $479,235 $288,023 $472,703 $259,408 
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACQUISITIONS (Tables)
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Estimated Fair Values of Assets Acquired and Liabilities Assumed
The following table summarizes the fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$773 
Accounts receivable4,699 
Inventories3,972 
Property, plant and equipment2,243 
Right of use assets866 
Customer relationships29,900 
Developed technology4,600 
Trademarks2,300 
Other assets197 
Accounts payable(699)
Bank debt(206)
Lease liabilities(871)
Other liabilities(462)
Goodwill31,550 
Total consideration on acquisition date and working capital adjustment78,862 
Net decrease to contingent consideration liability and other post-closing payments(6,825)
Total expected consideration72,037 
To pay off bank debt206 
Total expected payments $72,243 
The following table summarizes the fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022.
Cash and cash equivalents$6,365 
Accounts receivable8,036 
Inventories17,600 
Property, plant and equipment9,854 
Right of use assets3,349 
Customer relationships88,813 
Developed technology15,643 
Trademarks5,046 
Other assets2,399 
Accounts payable(3,301)
Bank debt(30,648)
Lease liabilities(3,349)
Other liabilities(4,461)
Deferred income taxes, net(24,716)
Goodwill216,383 
Total consideration on acquisition date307,013 
Decrease to contingent consideration liability(4,037)
Net gain on foreign currency exchange forward contracts(512)
Total expected consideration302,464 
Kappa bank debt paid on acquisition date30,648 
Total expected payments$333,112 
Schedule of Pro Forma Information
The following selected unaudited pro forma information presents the consolidated results of operations as if the business combinations in 2022 had occurred as of January 1, 2021.

Twelve Months ended December 31,
Net SalesNet Earnings
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023
$59,532 $5,487 
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2022
$22,158 $(5,359)
2023 Supplemental pro forma combined financial
$922,439 $116,317 
2022 Supplemental pro forma combined financial
$982,021 $110,181 
2021 Supplemental pro forma combined financial
$859,252 $90,672 
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost on Net Earnings
The Company’s results for the years ended December 31, 2023, 2022 and 2021 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended December 31,
 202320222021
Cost of sales$1,900 $1,302 $845 
Operating expenses14,152 11,922 9,957 
Net earnings(12,375)(10,214)(8,370)
Schedule of Assumptions Used in the Valuation of Option Awards Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202320222021
Expected Volatility28.1 %30.3 %32.9 %
Expected Term (in years)4.87.34.9
Risk-Free Interest Rate3.9 %2.8 %0.5 %
Dividend Yield0.5 %0.5 %0.5 %
Summary of Stock Option Activity
A summary of stock option plan activity for 2023, 2022, and 2021 for all plans is as follows:
202320222021
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
# of
Shares
(000s)
Weighted Average
Exercise Price
Outstanding at beginning of year1,045 $99.82 867 $88.19 858 $80.58 
Granted109 138.09 239 139.04 129 119.12 
Exercised(64)81.98 (44)73.58 (109)63.42 
Forfeited(11)131.79 (17)124.89 (10)106.93 
Cancelled(1)138.07 — — (1)74.57 
Outstanding at end of year1,078 $104.38 1,045 $99.82 867 $88.19 
Exercisable at end of year720 $88.49 654 $81.95 538 $75.51 
Schedule of Other Information Pertaining to Stock Option Activity
Other information pertaining to option activity during the years ended December 31, 2023, 2022 and 2021 is as follows:

 Years Ended December 31,
 202320222021
Weighted-average fair value of options granted$40.91 $44.77 $33.11 
Total intrinsic value of stock options exercised ($000s)$3,241 $2,713 $7,866 
Schedule of Additional Information Relating to Stock Options Outstanding
Additional information related to stock options outstanding under all plans at December 31, 2023 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices
Shares
Outstanding
(000s)
Weighted
Average
Remaining
Contractual
 Term
Weighted
Average
 Exercise
Price
Number
Exercisable
(000s)
Weighted
Average
Exercise
Price
$54.87 - $85.33
387 3.5$72.41 387 $72.41 
$85.40 - $118.60
250 4.9101.84 248 101.71 
$118.96 - $150.85
441 8.1133.93 85 123.47 
 1,078 5.7$104.38 720 $88.49 
Schedule of Non-vested Restricted Stock Activity
Non-vested restricted stock activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:
202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 122 $124.42 166 $99.7 159 $90.71 
Granted40 137.20 46 137.17 42 123.58 
Vested(42)112.30 (82)82.15 (24)85.83 
Forfeited(4)128.06 (8)118.07 (11)90.49 
Non-vested balance at end of year 116 $133.06 122 $124.42 166 $99.7 
Schedule of Non-vested Performance Share Activity
Non-vested performance share activity for the years ended December 31, 2023, 2022 and 2021 is summarized below:

202320222021
 Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 70 $127.69 69 $110.72 71 $91.99 
Granted42 139.66 39 114.22 36 108.74 
Vested(36)98.84 (35)53.17 (24)70.64 
Forfeited— — (3)84.09 (14)81.03 
Non-vested balance at end of year 76 $135.25 70 $127.69 69 $110.72 
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Tables)
12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories, net of reserves at December 31, 2023 and 2022 consisted of the following:
 20232022
Raw materials$39,517 $44,477 
Work in progress3,960 3,143 
Finished goods66,044 72,048 
Total inventories$109,521 $119,668 
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Property, plant and equipment at December 31, 2023 and 2022 are summarized as follows:
 20232022
Land$11,787 $11,415 
Building104,363 90,644 
Equipment312,704 278,851 
Construction in progress59,981 79,928 
 488,835 460,838 
Less: Accumulated depreciation212,796 189,483 
Property, plant and equipment, net$276,039 $271,355 
Schedule of Long-Lived Assets by Geographical Area
Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20232022
United States$203,692 $211,588 
Foreign Countries72,347 59,767 
Total$276,039 $271,355 
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks and trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents and trade secrets
15 - 17
Other
 2 - 18
As of December 31, 2023 and 2022, the Company had identifiable intangible assets as follows:
20232022
 Amortization
Period
(In years)
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount

Accumulated
Amortization
Customer relationships and lists
10-20
$362,032 $209,651 $357,131 $190,576 
Trademarks and trade names
2-17
50,286 37,773 50,058 33,416 
Developed technology
5-12
41,184 17,516 40,473 16,171 
Other
2-18
25,733 23,083 25,041 19,245 
  $479,235 $288,023 $472,703 $259,408 
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET EARNINGS PER COMMON SHARE (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202320222021
Net Earnings - Basic and Diluted$108,543 $105,367 $96,104 
Share (000s)
Weighted Average Common Shares - Basic32,108 32,019 32,215 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares340 374 457 
Weighted Average Common Shares - Diluted32,448 32,393 32,672 
Net Earnings Per Share - Basic$3.38 $3.29 $2.98 
Net Earnings Per Share - Diluted$3.35 $3.25 $2.94 
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Expense
Income tax expense consists of the following:
 202320222021
Current:   
Federal$27,306 $26,423 $25,019 
Foreign7,634 7,103 7,553 
State4,403 3,964 3,664 
Deferred:
Federal(7,737)(7,532)(3,709)
Foreign(2,285)(215)(3,038)
State(603)(1,361)(360)
Total income tax provision$28,718 $28,382 $29,129 
Schedule of Income Tax Reconciliation
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2023, 2022, and 2021 to earnings before income tax expense due to the following:
 202320222021
Income tax at Federal statutory rate$28,825 $28,087 $26,299 
State income taxes, net of Federal income taxes2,513 1,862 2,406 
Stock Options(1,004)(676)(924)
Foreign-derived intangible income (FDII)(1,752)(1,778)(1,540)
Foreign rate differential946 2,066 1,188 
Other(810)(1,179)1,700 
Total income tax provision$28,718 $28,382 $29,129 
Schedule of Deferred Tax Assets and Liabilities
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022 were as follows:
 20232022
Deferred tax assets:  
Inventories$1,049 $1,038 
Restricted stock and stock options5,565 3,932 
Lease liabilities4,812 5,439 
Research and development12,653 4,134 
Other3,874 3,717 
Total deferred tax assets27,953 18,260 
Deferred tax liabilities:
Amortization$(42,351)$(46,688)
Depreciation(28,937)(25,097)
Prepaid expenses(421)(462)
Foreign currency and interest rate swaps(647)(1,456)
Right of use assets(4,574)(5,324)
Other(3,047)(1,995)
Total deferred tax liabilities(79,977)(81,022)
Valuation allowance(22)(22)
Net deferred tax liability$(52,046)$(62,784)
Schedule of Reconciliation of Unrecognized Tax Benefits A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202320222021
Balance at beginning of period$5,815 $5,881 $5,335 
Increases for tax positions of prior years1,353 2,194 806 
Decreases for tax positions of prior years(2,518)(2,260)(260)
Balance at end of period$4,650 $5,815 $5,881 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The segment information is summarized as follows:

Business Segment Assets
 20232022
Human Nutrition and Health$1,180,527 $1,170,238 
Animal Nutrition and Health166,994 175,972 
Specialty Products168,307 177,187 
Other and Unallocated (1)
81,383 101,115 
Total$1,597,211 $1,624,512 

Business Segment Net Sales
 202320222021
Human Nutrition and Health$550,751 $527,131 $442,733 
Animal Nutrition and Health238,326 262,297 226,776 
Specialty Products125,965 131,438 117,020 
Other and Unallocated (2)
7,397 21,492 12,494 
Total$922,439 $942,358 $799,023 

Business Segment Earnings Before Income Taxes
202320222021
Human Nutrition and Health$102,419 $82,125 $76,031 
Animal Nutrition and Health27,576 36,056 26,179 
Specialty Products34,579 32,789 30,020 
Other and Unallocated (2)
(5,381)(5,784)(4,728)
Interest and other expense(21,932)(11,437)(2,269)
Total$137,261 $133,749 $125,233 
Depreciation/Amortization
 202320222021
Human Nutrition and Health$38,568 $33,728 $30,012 
Animal Nutrition and Health7,876 6,685 7,414 
Specialty Products7,278 7,507 8,332 
Other and Unallocated (2)
1,213 3,928 3,121 
Total$54,935 $51,848 $48,879 

Capital Expenditures
 202320222021
Human Nutrition and Health$26,415 $33,668 $23,714 
Animal Nutrition and Health6,993 10,809 8,100 
Specialty Products3,535 4,004 3,804 
Other and Unallocated (2)
331 605 524 
Total$37,274 $49,086 $36,142 

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,617, $3,581 and $1,264 for years ended December 31, 2023, 2022 and 2021, respectively, and (ii) Unallocated amortization expense of $312, $2,951, and $2,510 for years ended December 31, 2023, 2022, and 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE (Tables)
12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Source and Geography
The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

 202320222021
Product Sales Revenue$919,951 $939,166 $794,518 
Royalty Revenue2,488 3,192 4,505 
Total Revenue$922,439 $942,358 $799,023 


The following table presents revenues disaggregated by geography, based on customers' delivery addresses:

 202320222021
United States$689,601 $682,238 $584,661 
Foreign Countries232,838 260,120 214,362 
Total$922,439 $942,358 $799,023 
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)
12 Months Ended
Dec. 31, 2023
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information
Cash paid during the year for:
202320222021
Income taxes$35,725 $33,016 $25,355 
Interest$25,933 $11,879 $4,547 
Non-cash financing and investing activities:
202320222021
Dividends payable$25,717 $23,129 $20,886 
Contingent consideration liability$— $11,872 $— 
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)
12 Months Ended
Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202320222021
Net foreign currency translation adjustment$16,809 $(4,799)$(11,255)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized (loss) gain on cash flow hedge(1,406)3,564 2,707 
Tax341 (868)(654)
Net of tax(1,065)2,696 2,053 
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service loss (gain) arising during the period132 (41)(4)
Amortization of prior service gain— 74 
Amortization of loss (gain)(2)(21)
Total before tax140 (34)49 
Tax(39)(24)(13)
Net of tax101 (58)36 
Total other comprehensive income/(loss)$15,845 $(2,161)$(9,166)
Components of Accumulated Other Comprehensive (Loss)/Income
Accumulated other comprehensive loss at December 31, 2023 and 2022 consisted of the following:
 Foreign currency
translation
adjustment
Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2022$(8,401)$1,065 $182 $(7,154)
Other comprehensive income (loss)16,809 (1,065)101 15,845 
Balance December 31, 2023$8,408 $— $283 $8,691 
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS (Tables)
12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Schedule of Changes in Benefit Obligation
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,465 $1,293 
Service cost with interest to end of year108 79 
Interest cost62 26 
Participant contributions23 27 
Benefits paid(30)(69)
Actuarial (gain) loss(233)109 
Benefit obligation at end of year$1,395 $1,465 
Change in benefit obligation:
 20232022
Benefit obligation at beginning of year$1,589 $1,859 
Service cost with interest to end of year65 44 
Interest cost65 17 
Participant contributions— 27 
Benefits paid(188)(60)
Actuarial loss (gain)80 (194)
Exchange rate changes49 (104)
Benefit obligation at end of year$1,660 $1,589 
Schedule of Changes in Plan Assets
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$— $— 
Employer contributions42 
Participant contributions23 27 
Benefits paid(30)(69)
Fair value of plan assets at end of year$— $— 
Change in plan assets:
 20232022
Fair value of plan assets at beginning of year$1,196 $1,175 
Actual return on plan assets56 26 
Employer contributions138 94 
Participant contributions— 27 
Benefits paid(188)(60)
Exchange rate changes38 (66)
Fair value of plan assets at end of year$1,240 $1,196 
Schedule of Amounts Recognized in Consolidated Balance Sheet
Amounts recognized in consolidated balance sheet:
 20232022
Accumulated postretirement benefit obligation$(1,395)$(1,465)
Fair value of plan assets— — 
Funded status(1,395)(1,465)
Unrecognized prior service cost74 
Unrecognized net loss (gain)(2)(24)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations")$(1,395)$(1,465)
Accrued postretirement benefit cost (included in "Other long-term obligations")N/AN/A
Amounts recognized in consolidated balance sheet:
 20232022
Benefit obligation$(1,660)$(1,589)
Fair value of plan assets1,240 1,196 
Funded status(420)(393)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$(420)$(393)
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Schedule of Components of Net Periodic Benefit Cost
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$108 $79 $87 
Interest cost62 26 23 
Amortization of prior service cost— 74 
Amortization of loss (gain)(2)(24)
Total net periodic benefit cost$178 $112 $160 
Components of net periodic benefit cost:
 202320222021
Service cost with interest to end of year$65 $44 $67 
Interest cost65 17 14 
Expected return on plan assets(42)(37)(34)
Amortization of net loss— — 
Total net periodic benefit cost$88 $24 $50 
Schedule of Estimated Future Employer Contributions and Benefit Payments
Estimated future employer contributions and benefit payments are as follows:
Year 
2024$131 
2025132 
202699 
2027101 
202885 
Years 2029-2033615 
Estimated future benefit payments are as follows:
Year 
2024$
202552 
2026
2027
2028
Years 2029-20331,096 
Schedule of Assumptions to Determine Benefit Obligation
Assumptions to determine benefit obligations:
 20232022
Discount rate4.15 %4.40 %
Assumptions to determine net cost:
 202320222021
Discount rate4.40 %2.10 %1.75 %
Assumptions to determine benefit obligations:
 20232022
Discount rate3.45 %4.00 %


Assumptions to determine net cost:
 202320222021
Discount rate4.00 %1.00 %0.75 %
Expected return on assets3.25 %3.25 %3.25 %
Summary of Pension Fund
The Company’s participation in this plan for the annual period ended December 31, 2023 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2023 and 2022 was affected by a 4.0% increase in the 2023 contribution rate. There have been no other significant changes that affect the comparability of 2023 and 2022 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
Pension
Fund
EIN/Pension
Plan
Number
Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented
Contributions of Balchem CorporationSurcharge
Imposed
Expiration Date of Collective-
Bargaining
Agreement
20232022202320222021
Central States,
Southeast and
Southwest Areas
Pension Fund
36-6044243Critical & Declining as of 1/1/23Critical & Declining as of 1/1/22Implemented$1,020$939$816No7/12/2025
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES (Tables)
12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Lease Cost
Right of use assets and lease liabilities at December 31, 2023 and 2022 are summarized as follows:

Right of use assets20232022
Operating leases$17,763 $17,094 
Finance lease2,101 2,338 
Total$19,864 $19,432 

Lease liabilities - current20232022
Operating leases$3,949 $3,796 
Finance lease272 226 
Total$4,221 $4,022 
Lease liabilities - non-current20232022
Operating leases$14,601 $13,806 
Finance lease1,943 2,213 
Total$16,544 $16,019 
For the years ended December 31, 2023, 2022, and 2021, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:
Year ended December 31,
202320222021
Lease Cost
Operating lease cost$5,307 $4,478 $3,143 
Finance Lease cost
Amortization of ROU asset242 210 210 
Interest on lease liabilities115 125 129 
Total finance lease357 335 339 
Total lease cost$5,664 $4,813 $3,482 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$4,757 $4,269 $3,097 
Operating cash flows from finance leases115 125 129 
Financing cash flows from finance leases222 177 159 
$5,094 $4,571 $3,385 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$6,365 $11,488 $3,804 
Weighted-average remaining lease term - operating leases9.33 years5.63 years4.21 years
Weighted-average remaining lease term - finance leases9.07 years9.95 years11.41 years
Weighted-average discount rate - operating leases7.4 %2.7 %3.5 %
Weighted-average discount rate - finance leases5.0 %5.0 %5.1 %
Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2023 are as follows:
Year 
2024$5,407 
20254,219 
20263,638 
20272,736 
20282,219 
Thereafter7,717 
Total minimum lease payments$25,936 
Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Finance Leases
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2023 are as follows:
Year 
2024$5,407 
20254,219 
20263,638 
20272,736 
20282,219 
Thereafter7,717 
Total minimum lease payments$25,936 
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)
12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments
As of December 31, 2022, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative assetsDecember 31, 2022
Interest rate swap$1,406 
Cross-currency swap4,587 
Derivative assets$5,993 
Schedule of Income (Loss) on Hedging Instruments
Gains and losses on our hedging instruments were recognized in accumulated other comprehensive income (loss) and categorized as follows for the years ended December 31, 2023, 2022, and 2021:

Location within Statements of Comprehensive IncomeYear ended December 31,
202320222021
Cash flow hedge (interest rate swap), net of taxUnrealized (loss) gain on cash flow hedge, net$(1,065)$2,696 $2,053 
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment(1,455)3,851 4,766 
$(2,520)$6,547 $6,819 
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)
12 Months Ended
Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
(In thousands, except per share data)
 20232022
 First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Net sales$232,540 $231,252 $229,948 $228,699 $228,867 $236,693 $244,267 $232,531 
Gross margin73,170 77,349 76,544 74,993 71,506 71,876 68,430 68,639 
Earnings before income taxes29,119 38,400 36,475 33,267 37,630 39,258 31,085 25,776 
Net earnings22,710 30,110 29,075 26,648 28,930 29,782 25,249 21,406 
Basic net earnings per common share$0.71 $0.94 $0.91 $0.83 $0.90 $0.93 $0.79 $0.67 
Diluted net earnings per common share$0.70 $0.93 $0.90 $0.82 $0.89 $0.92 $0.78 $0.66 
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details)
Dec. 31, 2023
Minimum | Buildings  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 15 years
Minimum | Equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 2 years
Maximum | Buildings  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 25 years
Maximum | Equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 28 years
XML 73 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Aug. 30, 2022
Jun. 21, 2022
Goodwill [Line Items]        
Goodwill $ 778,907 $ 769,509    
Goodwill [Roll Forward]        
Goodwill, beginning of period 769,509 523,949    
Impact due to change in foreign exchange rates 9,057 (1,944)    
Goodwill, end of period 778,907 769,509    
HNH        
Goodwill [Line Items]        
Goodwill 673,207 665,804    
Goodwill [Roll Forward]        
Goodwill, beginning of period 665,804      
Goodwill, end of period 673,207 665,804    
ANH        
Goodwill [Line Items]        
Goodwill 24,469 24,218    
Goodwill [Roll Forward]        
Goodwill, beginning of period 24,218      
Goodwill, end of period 24,469 24,218    
Specialty Products        
Goodwill [Line Items]        
Goodwill 81,175 79,429    
Goodwill [Roll Forward]        
Goodwill, beginning of period 79,429      
Goodwill, end of period 81,175 79,429    
Other and Unallocated        
Goodwill [Line Items]        
Goodwill 56 58    
Goodwill [Roll Forward]        
Goodwill, beginning of period 58      
Goodwill, end of period 56 58    
Kappa        
Goodwill [Line Items]        
Goodwill       $ 216,383
Goodwill [Roll Forward]        
Goodwill, acquired during period   216,295    
Bergstrom        
Goodwill [Line Items]        
Goodwill     $ 31,550  
Goodwill [Roll Forward]        
Goodwill, acquired during period $ 341 $ 31,209    
XML 74 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details)
Dec. 31, 2023
Minimum | Customer relationships and lists  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 10 years
Minimum | Trademarks and trade names  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 2 years
Minimum | Developed technology  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 5 years
Minimum | Regulatory registration costs  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 5 years
Minimum | Patents and trade secrets  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 15 years
Minimum | Other  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 2 years
Maximum | Customer relationships and lists  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 20 years
Maximum | Trademarks and trade names  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 17 years
Maximum | Developed technology  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 12 years
Maximum | Regulatory registration costs  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 10 years
Maximum | Patents and trade secrets  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 17 years
Maximum | Other  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 18 years
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACQUISITIONS - Narrative (Details)
kr in Thousands
3 Months Ended 12 Months Ended
Aug. 30, 2022
USD ($)
Jun. 21, 2022
USD ($)
Jun. 21, 2022
NOK (kr)
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]                
Cash paid for acquisitions, net of cash acquired           $ 1,252,000 $ 365,780,000 $ 0
Contingent consideration liability       $ 0   0 11,872,000 0
Goodwill       778,907,000   778,907,000 769,509,000 523,949,000
HNH                
Business Acquisition [Line Items]                
Goodwill       673,207,000   673,207,000 665,804,000  
Goodwill percent 80.00%              
ANH                
Business Acquisition [Line Items]                
Goodwill       24,469,000   24,469,000 24,218,000  
Goodwill percent 20.00%              
Bergstrom                
Business Acquisition [Line Items]                
Payment $ 72,143,000         70,892,000    
Total expected consideration 72,243,000              
Cash acquired from acquisition 773,000              
Cash paid for acquisitions, net of cash acquired 71,164,000              
Contingent consideration liability       100,000   100,000    
Business Combination, Post-Closing Payment         $ 910,000      
Total expected payments           72,243,000    
Working capital adjustment           341,000    
Goodwill 31,550,000              
Transaction and integration costs (credits)           (10,614,000) 4,604,000 0
Acquisition of transaction costs       11,300,000     3,565,000  
Bergstrom | Former Shareholders                
Business Acquisition [Line Items]                
Payment 71,937,000              
Total expected consideration $ 72,037,000              
Bergstrom | Customer relationships                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired 15 years              
Bergstrom | Corporate Trademark                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired 2 years              
Bergstrom | Product Trademarks                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired 10 years              
Bergstrom | Developed technology                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired 12 years              
Kappa                
Business Acquisition [Line Items]                
Payment | kr     kr 3,305,653          
Total expected consideration   $ 333,112,000            
Cash acquired from acquisition   6,365,000 63,064          
Cash paid for acquisitions, net of cash acquired | kr     2,938,917          
Contingent consideration liability             0  
Goodwill   216,383,000            
Transaction and integration costs (credits)           $ 533,000 $ (2,306,000) $ 0
Acquisition of transaction costs       $ 4,037,000        
Net gain on foreign currency exchange forward contracts   512,000            
Kappa bank debt paid on acquisition date   333,112,000            
Kappa | Former Shareholders                
Business Acquisition [Line Items]                
Payment | kr     3,001,981          
Total expected consideration   302,464,000            
Cash paid for acquisitions, net of cash acquired   296,099,000            
Kappa bank debt paid on acquisition date   302,464,000            
Kappa | Former Shareholders' Lenders And Creditors                
Business Acquisition [Line Items]                
Payment | kr     kr 303,672          
Total expected consideration   $ 30,648,000            
Kappa | Customer relationships                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired   15 years 15 years          
Kappa | Corporate Trademark                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired   2 years 2 years          
Kappa | Product Trademarks                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired   10 years 10 years          
Kappa | Developed technology                
Business Acquisition [Line Items]                
Useful life of intangible assets acquired   12 years 12 years          
XML 76 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACQUISITIONS - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
12 Months Ended
Aug. 30, 2022
Jun. 21, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Goodwill     $ 778,907 $ 769,509 $ 523,949
Net decrease to contingent consideration liability and other post-closing payments     $ (11,300) $ 0 $ 0
Bergstrom          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Cash and cash equivalents $ 773        
Accounts receivable 4,699        
Inventories 3,972        
Property, plant and equipment 2,243        
Right of use assets 866        
Other assets 197        
Accounts payable (699)        
Bank debt (206)        
Lease liabilities (871)        
Other liabilities (462)        
Goodwill 31,550        
Total consideration on acquisition date and working capital adjustment 78,862        
Net decrease to contingent consideration liability and other post-closing payments (6,825)        
Total expected consideration 72,243        
Bergstrom | Former Shareholders          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Total expected consideration 72,037        
Bergstrom | Former Bank          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Total expected consideration 206        
Bergstrom | Customer relationships          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets 29,900        
Bergstrom | Developed technology          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets 4,600        
Bergstrom | Trademarks          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets $ 2,300        
Kappa          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Cash and cash equivalents   $ 6,365      
Accounts receivable   8,036      
Inventories   17,600      
Property, plant and equipment   9,854      
Right of use assets   3,349      
Other assets   2,399      
Accounts payable   (3,301)      
Bank debt   (30,648)      
Lease liabilities   (3,349)      
Other liabilities   (4,461)      
Deferred income taxes, net   (24,716)      
Goodwill   216,383      
Total consideration on acquisition date and working capital adjustment   307,013      
Net decrease to contingent consideration liability and other post-closing payments   (4,037)      
Net gain on foreign currency exchange forward contracts   (512)      
Total expected consideration   333,112      
Kappa | Former Shareholders          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Total expected consideration   302,464      
Kappa | Former Shareholders' Lenders And Creditors          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Total expected consideration   30,648      
Kappa | Customer relationships          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets   88,813      
Kappa | Developed technology          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets   15,643      
Kappa | Trademarks          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]          
Intangible assets   $ 5,046      
XML 77 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACQUISITIONS - Schedule of Pro Forma Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Net Sales [Abstract]      
Kappa & Bergstrom actual results included in the Company's consolidated income statement $ 59,532 $ 22,158  
Pro forma combined net sales 922,439 982,021 $ 859,252
Net Earnings [Abstract]      
Kappa & Bergstrom actual results included in the Company's consolidated income statement in 2023 5,487 (5,359)  
Supplemental pro forma combined financial information $ 116,317 $ 110,181 $ 90,672
XML 78 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Net earnings $ (12,375) $ (10,214) $ (8,370)
Cost of sales      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation cost 1,900 1,302 845
Operating expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation cost $ 14,152 $ 11,922 $ 9,957
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Stock-based Compensation (Details)
12 Months Ended
Jun. 22, 2023
shares
Dec. 31, 2023
plan
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of share-based compensation plans | plan   1
2017 Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized for grants (in shares)   2,400,000
Increase in amount approved (in shares) 800,000  
Expiration period of options granted   10 years
2017 Plan | Non-employee director    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares purchased under restricted stock purchase agreements, minimum (in shares)   70
Shares purchased under restricted stock purchase agreements, maximum (in shares)   54,000
2017 Plan | Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares available for future awards (in shares)   1,034,260
XML 80 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stock Options      
Weighted Average Assumptions [Abstract]      
Expected Volatility 28.10% 30.30% 32.90%
Expected Term (in years) 4 years 9 months 18 days 7 years 3 months 18 days 4 years 10 months 24 days
Risk-Free Interest Rate 3.90% 2.80% 0.50%
Dividend Yield 0.50% 0.50% 0.50%
Stock Options | Minimum      
Weighted Average Assumptions [Abstract]      
Vesting period 3 years    
Stock Options | Maximum      
Weighted Average Assumptions [Abstract]      
Vesting period 5 years    
Performance Shares | Employee      
Weighted Average Assumptions [Abstract]      
Expected Volatility 32.00% 32.00% 33.00%
Risk-Free Interest Rate 4.20% 1.80% 0.20%
Dividend Yield 0.50% 0.50% 0.60%
Initial total shareholder return percentage 4.20% (15.70%) 11.70%
Cliff vesting percentage 100.00%    
Vesting period 3 years    
Restricted Stock | Employee      
Weighted Average Assumptions [Abstract]      
Vesting period 3 years    
Restricted Stock | Non-employee director      
Weighted Average Assumptions [Abstract]      
Vesting period 3 years    
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding at beginning of year (in shares) 1,045 867 858
Granted (in shares) 109 239 129
Exercised (in shares) (64) (44) (109)
Forfeited (in shares) (11) (17) (10)
Cancelled (in shares) (1) 0 (1)
Outstanding at end of year (in shares) 1,078 1,045 867
Exercisable at end of year (in shares) 720 654 538
Weighted Average Exercise Price [Abstract]      
Outstanding at beginning of year (in dollars per share) $ 99.82 $ 88.19 $ 80.58
Granted (in dollars per share) 138.09 139.04 119.12
Exercised (in dollars per share) 81.98 73.58 63.42
Forfeited (in dollars per share) 131.79 124.89 106.93
Cancelled (in dollars per share) 138.07 0 74.57
Outstanding at end of year (in dollars per share) 104.38 99.82 88.19
Exercisable at end of period (in dollars per share) $ 88.49 $ 81.95 $ 75.51
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Aggregate intrinsic value for outstanding stock options $ 47,889 $ 27,221 $ 69,711
Weighted average remaining contractual term for outstanding stock options 5 years 8 months 12 days    
Aggregate intrinsic value for exercisable stock options outstanding $ 43,364    
Weighted average remaining contractual term for exercisable stock options outstanding 4 years 4 months 24 days    
Weighted-average fair value of options granted (in dollars per share) $ 40.91 $ 44.77 $ 33.11
Total intrinsic value of stock options exercised $ 3,241 $ 2,713 $ 7,866
XML 82 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details)
shares in Thousands
12 Months Ended
Dec. 31, 2023
$ / shares
shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Shares Outstanding (in shares) | shares 1,078
Weighted Average Remaining Contractual  Term 5 years 8 months 12 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 104.38
Number of Options Exercisable (in shares) | shares 720
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 88.49
$54.87 - $85.33  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 54.87
Range of exercise prices, maximum (in dollars per share) $ 85.33
Shares Outstanding (in shares) | shares 387
Weighted Average Remaining Contractual  Term 3 years 6 months
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 72.41
Number of Options Exercisable (in shares) | shares 387
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 72.41
$85.40 - $118.60  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 85.40
Range of exercise prices, maximum (in dollars per share) $ 118.60
Shares Outstanding (in shares) | shares 250
Weighted Average Remaining Contractual  Term 4 years 10 months 24 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 101.84
Number of Options Exercisable (in shares) | shares 248
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 101.71
$118.96 - $150.85  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 118.96
Range of exercise prices, maximum (in dollars per share) $ 150.85
Shares Outstanding (in shares) | shares 441
Weighted Average Remaining Contractual  Term 8 years 1 month 6 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 133.93
Number of Options Exercisable (in shares) | shares 85
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 123.47
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Unrecognized compensation cost related to non-vested shares $ 18,817 $ 20,791 $ 13,980
Weighted-average period of recognition for unrecognized compensation cost 1 year 7 months 6 days    
Estimated share-based compensation expense for current fiscal year $ 14,800    
Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested balance as of beginning of year (in shares) 122 166 159
Granted (in shares) 40 46 42
Vested (in shares) (42) (82) (24)
Forfeited (in shares) (4) (8) (11)
Non-vested balance as of end of year (in shares) 116 122 166
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Non-vested balance as of beginning of year (in dollars per share) $ 124.42 $ 99.7 $ 90.71
Granted (in dollars per share) 137.20 137.17 123.58
Vested (in dollars per share) 112.30 82.15 85.83
Forfeited (in dollars per share) 128.06 118.07 90.49
Non-vested balance as of end of year (in dollars per share) $ 133.06 $ 124.42 $ 99.7
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested balance as of beginning of year (in shares) 70 69 71
Granted (in shares) 42 39 36
Vested (in shares) (36) (35) (24)
Forfeited (in shares) 0 (3) (14)
Non-vested balance as of end of year (in shares) 76 70 69
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Non-vested balance as of beginning of year (in dollars per share) $ 127.69 $ 110.72 $ 91.99
Granted (in dollars per share) 139.66 114.22 108.74
Vested (in dollars per share) 98.84 53.17 70.64
Forfeited (in dollars per share) 0 84.09 81.03
Non-vested balance as of end of year (in dollars per share) $ 135.25 $ 127.69 $ 110.72
XML 84 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stockholders' Equity Note [Abstract]      
Number of shares authorized to be repurchased (in shares) 3,763,038    
Aggregate number of shares repurchased since inception (in shares) 3,103,106    
Repurchases of common stock $ 4,514 [1] $ 35,423 $ 35,239
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) 32,558 252,304 249,848
Shares repurchased, average cost (in dollars per share) $ 137.29 $ 140.40 $ 141.04
[1]  * On August 16, 2022, the U.S. government enacted the Inflation Reduction Act (the "IRA") into law. The IRA imposes a 1% excise tax on share repurchases, which is effective for repurchases completed after December 31, 2022. The excise tax is recorded within equity as part of the repurchase of the common stock.
XML 85 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 39,517 $ 44,477
Work in progress 3,960 3,143
Finished goods 66,044 72,048
Total inventories 109,521 119,668
Reserve for inventory $ 2,463 $ 2,640
XML 86 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 488,835 $ 460,838
Less: Accumulated depreciation 212,796 189,483
Property, plant and equipment, net 276,039 271,355
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 11,787 11,415
Building    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 104,363 90,644
Equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 312,704 278,851
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 59,981 $ 79,928
XML 87 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets $ 276,039 $ 271,355
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets 203,692 211,588
Foreign Countries    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets $ 72,347 $ 59,767
XML 88 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 26,373 $ 24,033 $ 23,295
Restructuring-related impairment and asset disposal charges $ 7,764 $ 0  
XML 89 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 778,907,000 $ 769,509,000 $ 523,949,000
Amortization of identifiable intangible assets 28,035,000 27,271,000 $ 25,092,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
2024 18,971,000    
2025 15,509,000    
2026 15,308,000    
2027 14,784,000    
2028 14,387,000    
Identifiable intangible assets $ 0 $ 0  
XML 90 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Identifiable intangible assets [Abstract]    
Gross Carrying Amount $ 479,235 $ 472,703
Accumulated Amortization 288,023 259,408
Customer relationships and lists    
Identifiable intangible assets [Abstract]    
Gross Carrying Amount 362,032 357,131
Accumulated Amortization $ 209,651 190,576
Customer relationships and lists | Minimum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 10 years  
Customer relationships and lists | Maximum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 20 years  
Trademarks and trade names    
Identifiable intangible assets [Abstract]    
Gross Carrying Amount $ 50,286 50,058
Accumulated Amortization $ 37,773 33,416
Trademarks and trade names | Minimum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 2 years  
Trademarks and trade names | Maximum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 17 years  
Developed technology    
Identifiable intangible assets [Abstract]    
Gross Carrying Amount $ 41,184 40,473
Accumulated Amortization $ 17,516 16,171
Developed technology | Minimum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 5 years  
Developed technology | Maximum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 12 years  
Other    
Identifiable intangible assets [Abstract]    
Gross Carrying Amount $ 25,733 25,041
Accumulated Amortization $ 23,083 $ 19,245
Other | Minimum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 2 years  
Other | Maximum    
Identifiable intangible assets [Abstract]    
Amortization Period (In years) 18 years  
XML 91 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY-METHOD INVESTMENT (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
vote
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]        
Number of votes | vote 2      
Percentage of operating expenses to be absorbed 66.66%      
Percentage of production offtake 66.66%      
St. Gabriel CC Company, LLC        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage in joint venture       66.66%
Loss relating to joint venture's expenses $ 509 $ 559 $ 557  
Capital contributions 290 355 $ 85  
Carrying value of joint venture $ 4,076 $ 4,295    
St. Gabriel CC Company, LLC | Eastman Chemical Company        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage in joint venture       33.34%
XML 92 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVOLVING LOAN (Details) - USD ($)
3 Months Ended 12 Months Ended
Jul. 27, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 27, 2018
Debt Instrument [Line Items]              
Proceeds from revolving loan       $ 18,000,000 $ 435,000,000 $ 5,000,000  
Repayments of outstanding balance       149,000,000 103,000,000 60,000,000  
Capitalized costs net of accumulated amortization       1,030,000 1,317,000    
Amortization expense pertaining to capitalized costs       $ 287,000 335,000 $ 282,000  
Credit Agreement              
Debt Instrument [Line Items]              
Interest rate       6.58%      
Commitment fee percentage       0.175%      
Unused portion of revolving loan       $ 240,431,000      
Credit Agreement | Minimum              
Debt Instrument [Line Items]              
Commitment fee percentage       0.15%      
Credit Agreement | Maximum              
Debt Instrument [Line Items]              
Commitment fee percentage       0.225%      
Revolving loan | 2018 Credit Agreement              
Debt Instrument [Line Items]              
Maximum borrowing capacity $ 550,000,000           $ 500,000,000
Proceeds from revolving loan   $ 70,000,000 $ 345,000,000        
Repayments of outstanding balance $ 433,569,000            
Installment payments required       $ 0      
Outstanding balance       $ 309,569,000 $ 440,569,000    
XML 93 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET EARNINGS PER COMMON SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Earnings Per Share [Abstract]                      
Net Earnings - Basic and Diluted $ 26,648 $ 29,075 $ 30,110 $ 22,710 $ 21,406 $ 25,249 $ 29,782 $ 28,930 $ 108,543 $ 105,367 $ 96,104
Weighted average common shares - basic (in shares)                 32,108,000 32,019,000 32,215,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)                 340,000 374,000 457,000
Weighted average common shares - diluted (in shares)                 32,448,000 32,393,000 32,672,000
Basic net earnings per common share (in dollars per share) $ 0.83 $ 0.91 $ 0.94 $ 0.71 $ 0.67 $ 0.79 $ 0.93 $ 0.90 $ 3.38 $ 3.29 $ 2.98
Net earnings per share - diluted (in dollars per share) $ 0.82 $ 0.90 $ 0.93 $ 0.70 $ 0.66 $ 0.78 $ 0.92 $ 0.89 $ 3.35 $ 3.25 $ 2.94
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)                 354,619 371,513 155,294
XML 94 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]      
Effective tax rate 20.90% 21.20% 23.30%
Belgium earnings remitted $ 18,000    
Incurred an income tax expense 20    
Unremitted foreign earnings 109,000 $ 94,000  
Valuation allowance 22 22  
Interest and penalties (322) (371) $ 262
Accrued interest and penalties 1,413 $ 1,735  
State      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards $ 348    
XML 95 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Components of Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Current:      
Federal $ 27,306 $ 26,423 $ 25,019
Foreign 7,634 7,103 7,553
State 4,403 3,964 3,664
Deferred:      
Federal (7,737) (7,532) (3,709)
Foreign (2,285) (215) (3,038)
State (603) (1,361) (360)
Total income tax provision $ 28,718 $ 28,382 $ 29,129
XML 96 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Reconciliation [Abstract]      
Income tax at Federal statutory rate $ 28,825 $ 28,087 $ 26,299
State income taxes, net of Federal income taxes 2,513 1,862 2,406
Stock Options (1,004) (676) (924)
Foreign-derived intangible income (FDII) (1,752) (1,778) (1,540)
Foreign rate differential 946 2,066 1,188
Other (810) (1,179) 1,700
Total income tax provision $ 28,718 $ 28,382 $ 29,129
XML 97 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Inventories $ 1,049 $ 1,038
Restricted stock and stock options 5,565 3,932
Lease liabilities 4,812 5,439
Research and development 12,653 4,134
Other 3,874 3,717
Total deferred tax assets 27,953 18,260
Deferred tax liabilities:    
Amortization (42,351) (46,688)
Depreciation (28,937) (25,097)
Prepaid expenses (421) (462)
Foreign currency and interest rate swaps (647) (1,456)
Right of use assets (4,574) (5,324)
Other (3,047) (1,995)
Total deferred tax liabilities (79,977) (81,022)
Valuation allowance (22) (22)
Net deferred tax liability $ (52,046) $ (62,784)
XML 98 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Income Tax Uncertainties (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Balance at beginning of period $ 5,815 $ 5,881 $ 5,335
Increases for tax positions of prior years 1,353 2,194 806
Decreases for tax positions of prior years (2,518) (2,260) (260)
Balance at end of period $ 4,650 $ 5,815 $ 5,881
XML 99 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Narrative (Details)
12 Months Ended
Dec. 31, 2023
segment
Segment Reporting [Abstract]  
Number of reportable segments 3
XML 100 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]                      
Assets $ 1,597,211       $ 1,624,512       $ 1,597,211 $ 1,624,512  
Net sales 228,699 $ 229,948 $ 231,252 $ 232,540 232,531 $ 244,267 $ 236,693 $ 228,867 922,439 942,358 $ 799,023
Operating Segments | Human Nutrition and Health                      
Segment Reporting Information [Line Items]                      
Assets 1,180,527       1,170,238       1,180,527 1,170,238  
Net sales                 550,751 527,131 442,733
Operating Segments | Animal Nutrition and Health                      
Segment Reporting Information [Line Items]                      
Assets 166,994       175,972       166,994 175,972  
Net sales                 238,326 262,297 226,776
Operating Segments | Specialty Products                      
Segment Reporting Information [Line Items]                      
Assets 168,307       177,187       168,307 177,187  
Net sales                 125,965 131,438 117,020
Other and Unallocated                      
Segment Reporting Information [Line Items]                      
Assets $ 81,383       $ 101,115       81,383 101,115  
Net sales                 $ 7,397 $ 21,492 $ 12,494
XML 101 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]                      
Interest and other expense                 $ (21,932) $ (11,437) $ (2,269)
Earnings before income tax expense $ 33,267 $ 36,475 $ 38,400 $ 29,119 $ 25,776 $ 31,085 $ 39,258 $ 37,630 137,261 133,749 125,233
Other and Unallocated                      
Segment Reporting Information [Line Items]                      
Earnings before income tax expense                 (5,381) (5,784) (4,728)
Interest and other expense                      
Segment Reporting Information [Line Items]                      
Interest and other expense                 (21,932) (11,437) (2,269)
Human Nutrition and Health | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings before income tax expense                 102,419 82,125 76,031
Animal Nutrition and Health | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings before income tax expense                 27,576 36,056 26,179
Specialty Products | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings before income tax expense                 $ 34,579 $ 32,789 $ 30,020
XML 102 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Depreciation/Amortization (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Depreciation and amortization $ 54,935 $ 51,848 $ 48,879
Other and Unallocated      
Segment Reporting Information [Line Items]      
Depreciation and amortization 1,213 3,928 3,121
Human Nutrition and Health | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization 38,568 33,728 30,012
Animal Nutrition and Health | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization 7,876 6,685 7,414
Specialty Products | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization $ 7,278 $ 7,507 $ 8,332
XML 103 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Capital expenditures $ 37,274 $ 49,086 $ 36,142
Amortization of identifiable intangible assets 28,035 27,271 25,092
Other and Unallocated      
Segment Reporting Information [Line Items]      
Capital expenditures 331 605 524
Transaction and integration related costs 1,617 3,581 1,264
Amortization of identifiable intangible assets 312 2,951 2,510
Human Nutrition and Health | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures 26,415 33,668 23,714
Animal Nutrition and Health | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures 6,993 10,809 8,100
Specialty Products | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures $ 3,535 $ 4,004 $ 3,804
XML 104 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]                      
Net sales $ 228,699 $ 229,948 $ 231,252 $ 232,540 $ 232,531 $ 244,267 $ 236,693 $ 228,867 $ 922,439 $ 942,358 $ 799,023
United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 689,601 682,238 584,661
Foreign Countries                      
Disaggregation of Revenue [Line Items]                      
Net sales                 232,838 260,120 214,362
Product Sales Revenue                      
Disaggregation of Revenue [Line Items]                      
Net sales                 919,951 939,166 794,518
Royalty Revenue                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 2,488 $ 3,192 $ 4,505
XML 105 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash Paid for Income Taxes and Interest [Abstract]      
Income taxes $ 35,725 $ 33,016 $ 25,355
Interest 25,933 11,879 4,547
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]      
Dividends payable 25,717 23,129 20,886
Contingent consideration liability $ 0 $ 11,872 $ 0
XML 106 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]      
Net foreign currency translation adjustment $ 16,809 $ (4,799) $ (11,255)
Unrealized (loss) gain on cash flow hedge (1,406) 3,564 2,707
Tax 341 (868) (654)
Net of tax (1,065) 2,696 2,053
Net change in postretirement benefit plan (see Note 15 for further information)      
Prior service loss (gain) arising during the period 132 (41) (4)
Amortization of prior service gain 0 9 74
Amortization of loss (gain) 8 (2) (21)
Total before tax 140 (34) 49
Tax (39) (24) (13)
Net of tax 101 (58) 36
Other comprehensive income (loss), net of tax 15,845 (2,161) (9,166)
Currency swap      
Other Comprehensive Income (Loss), Net of Tax [Abstract]      
Net foreign currency translation adjustment (1,455) 3,851 4,766
Net change in postretirement benefit plan (see Note 15 for further information)      
Net foreign currency translation adjustment tax $ (471) $ 1,236 $ 1,527
XML 107 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 938,284 $ 877,015 $ 828,233
Other comprehensive income (loss) 15,845 (2,161) (9,166)
Ending balance 1,053,984 938,284 877,015
Total      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (7,154) (4,993) 4,173
Other comprehensive income (loss) 15,845 (2,161) (9,166)
Ending balance 8,691 (7,154) $ (4,993)
Foreign currency translation adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (8,401)    
Other comprehensive income (loss) 16,809    
Ending balance 8,408 (8,401)  
Cash flow hedge      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 1,065    
Other comprehensive income (loss) (1,065)    
Ending balance 0 1,065  
Postretirement benefit plan      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 182    
Other comprehensive income (loss) 101    
Ending balance $ 283 $ 182  
XML 108 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Narrative (Details)
$ in Thousands
12 Months Ended
Aug. 30, 2022
plan
Jun. 21, 2022
plan
Jan. 01, 2021
plan
Dec. 31, 2023
USD ($)
plan
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Defined Benefit Plan Disclosure [Line Items]            
Number of savings plan     1      
401(k) contributions | $       $ 4,381 $ 4,363 $ 4,142
Number of unfunded plans       2    
Number of multiemployer benefit pension plans       1    
Contribution rate increase       4.00% 4.00%  
Deferred compensation liability | $       $ 10,188 $ 8,543  
Kappa            
Defined Benefit Plan Disclosure [Line Items]            
Number of defined contribution plans   1        
Bergstrom            
Defined Benefit Plan Disclosure [Line Items]            
Number of defined contribution plans 1          
XML 109 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Postretirement Medical Plans      
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation at beginning of year $ 1,465 $ 1,293  
Service cost with interest to end of year 108 79 $ 87
Interest cost 62 26 23
Participant contributions 23 27  
Benefits paid (30) (69)  
Actuarial (gain) loss (233) 109  
Benefit obligation at end of year 1,395 1,465 1,293
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 0 0  
Employer contributions 7 42  
Participant contributions 23 27  
Benefits paid (30) (69)  
Fair value of plan assets at end of year 0 0 0
Pension Plan      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 1,196    
Fair value of plan assets at end of year 1,240 1,196  
Pension Plan | Chemogas Defined Pension Plan      
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation at beginning of year 1,589 1,859  
Service cost with interest to end of year 65 44 67
Interest cost 65 17 14
Participant contributions 0 27  
Benefits paid (188) (60)  
Actuarial (gain) loss 80 (194)  
Exchange rate changes 49 (104)  
Benefit obligation at end of year 1,660 1,589 1,859
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 1,196 1,175  
Actual return on plan assets 56 26  
Employer contributions 138 94  
Participant contributions 0 27  
Benefits paid (188) (60)  
Exchange rate changes 38 (66)  
Fair value of plan assets at end of year $ 1,240 $ 1,196 $ 1,175
XML 110 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Unrecognized prior service cost $ 9 $ 74  
Unrecognized net loss (gain) (2) (24)  
Postretirement Medical Plans      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated postretirement benefit obligation (1,395) (1,465)  
Fair value of plan assets 0 0 $ 0
Funded status (1,395) (1,465)  
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations") (1,395) (1,465)  
Pension Plan      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated postretirement benefit obligation (1,660) (1,589)  
Fair value of plan assets 1,240 1,196  
Funded status (420) (393)  
Net amount recognized in consolidated balance sheet (after ASC 715) (included in "Other long-term obligations") $ (420) $ (393)  
XML 111 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Postretirement Medical Plans      
Defined Benefit Plan Disclosure [Line Items]      
Service cost with interest to end of year $ 108 $ 79 $ 87
Interest cost 62 26 23
Amortization of prior service cost 0 9 74
Amortization of loss (gain) 8 (2) (24)
Total net periodic benefit cost 178 112 160
Pension Plan | Chemogas Defined Pension Plan      
Defined Benefit Plan Disclosure [Line Items]      
Service cost with interest to end of year 65 44 67
Interest cost 65 17 14
Expected return on plan assets (42) (37) (34)
Amortization of loss (gain) 0 0 3
Total net periodic benefit cost $ 88 $ 24 $ 50
XML 112 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Postretirement Medical Plans  
Defined Benefit Plan Disclosure [Line Items]  
2024 $ 131
2025 132
2026 99
2027 101
2028 85
Years 2029-2033 615
Pension Plan | Chemogas Defined Pension Plan  
Defined Benefit Plan Disclosure [Line Items]  
2024 1
2025 52
2026 1
2027 1
2028 1
Years 2029-2033 $ 1,096
XML 113 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Central States, Southeast and Southwest Areas Pension Fund      
Multiemployer Plans [Line Items]      
Contributions of Balchem Corporation $ 1,020 $ 939 $ 816
XML 114 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pension Plan | Chemogas Defined Pension Plan      
Benefit Obligatoins      
Discount rate 3.45% 4.00%  
Net Cost      
Discount rate 4.00% 1.00% 0.75%
Expected return on assets 3.25% 3.25% 3.25%
Postretirement Medical Plans      
Benefit Obligatoins      
Discount rate 4.15% 4.40%  
Net Cost      
Discount rate 4.40% 2.10% 1.75%
XML 115 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
financial_instrument
Dec. 31, 2022
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Number of financial instruments held for trading purposes | financial_instrument 0  
Business combination, contingent consideration, liability, noncurrent $ 100 $ 11,400
Derivative assets   5,993
Cross-currency swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative assets   4,587
Interest rate swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative assets   1,406
Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Related rabbi trust assets 10,188 8,547
Money Market Funds    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cash and cash equivalents $ 959 $ 934
XML 116 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]                      
Payments for services $ 228,699 $ 229,948 $ 231,252 $ 232,540 $ 232,531 $ 244,267 $ 236,693 $ 228,867 $ 922,439 $ 942,358 $ 799,023
Receivables 125,284       131,578       125,284 131,578  
Payables 55,503       57,322       55,503 57,322  
St. Gabriel CC Company, LLC                      
Related Party Transaction [Line Items]                      
Services and raw materials                 28,099 29,062 22,043
Receivables 8,314       8,820       8,314 8,820  
Payables 6,050       5,224       6,050 5,224  
St. Gabriel CC Company, LLC | Non-contractual monies owed                      
Related Party Transaction [Line Items]                      
Payables $ 329       $ 296       329 296  
St. Gabriel CC Company, LLC | Services Provided                      
Related Party Transaction [Line Items]                      
Payments for services                 4,363 4,213 3,637
St. Gabriel CC Company, LLC | Raw Materials Sold                      
Related Party Transaction [Line Items]                      
Payments for services                 $ 34,219 $ 39,853 $ 27,915
XML 117 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
tranche
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Lessee, Lease, Description [Line Items]      
Reasonably certain criterion renewal period 2 years    
Number of lease tranches | tranche 4    
Operating lease cost | $ $ 5,307 $ 4,478 $ 3,143
Years 1 and 2 | Minimum      
Lessee, Lease, Description [Line Items]      
Operating lease term 1 year    
Discount rate 5.45%    
Years 1 and 2 | Maximum      
Lessee, Lease, Description [Line Items]      
Operating lease term 2 years    
Discount rate 6.72%    
Years 3 and 4 | Minimum      
Lessee, Lease, Description [Line Items]      
Operating lease term 3 years    
Discount rate 6.04%    
Years 3 and 4 | Maximum      
Lessee, Lease, Description [Line Items]      
Operating lease term 4 years    
Discount rate 7.31%    
Years 5 through 9 | Minimum      
Lessee, Lease, Description [Line Items]      
Operating lease term 5 years    
Discount rate 6.38%    
Years 5 through 9 | Maximum      
Lessee, Lease, Description [Line Items]      
Operating lease term 9 years    
Discount rate 7.65%    
More than 10 years      
Lessee, Lease, Description [Line Items]      
Operating lease term 10 years    
More than 10 years | Minimum      
Lessee, Lease, Description [Line Items]      
Discount rate 7.10%    
More than 10 years | Maximum      
Lessee, Lease, Description [Line Items]      
Discount rate 8.37%    
XML 118 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Right of use assets    
Operating Lease - ROU $ 17,763 $ 17,094
Finance Leases - ROU 2,101 2,338
Total right-of-use assets 19,864 19,432
Operating leases liabilities - current 3,949 3,796
Finance lease liabilities - current 272 226
Total lease liabilities, current 4,221 4,022
Operating lease liabilities - non-current 14,601 13,806
Finance lease liabilities - non-current 1,943 2,213
Total lease liabilities, non-current $ 16,544 $ 16,019
XML 119 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Lease Costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Lease Cost      
Operating lease cost $ 5,307 $ 4,478 $ 3,143
Amortization of ROU asset 242 210 210
Interest on lease liabilities 115 125 129
Total finance lease 357 335 339
Interest on lease liabilities 5,664 4,813 3,482
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from operating leases 4,757 4,269 3,097
Operating cash flows from finance leases 115 125 129
Principal payments on finance lease 222 177 159
Cash flows from operating and finance leases 5,094 4,571 3,385
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals $ 6,365 $ 11,488 $ 3,804
Weighted-average remaining lease term - operating leases 9 years 3 months 29 days 5 years 7 months 17 days 4 years 2 months 15 days
Weighted-average remaining lease term - finance leases 9 years 25 days 9 years 11 months 12 days 11 years 4 months 28 days
Weighted-average discount rate - operating leases 7.40% 2.70% 3.50%
Weighted-average discount rate - finance leases 5.00% 5.00% 5.10%
XML 120 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Operating And Finance Lease, Liability, To Be Paid [Abstract]  
2024 $ 5,407
2025 4,219
2026 3,638
2027 2,736
2028 2,219
Thereafter 7,717
Total minimum lease payments $ 25,936
XML 121 R101.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
derivative
Dec. 31, 2022
USD ($)
derivative
Dec. 31, 2021
USD ($)
Jun. 21, 2022
derivative
May 28, 2019
USD ($)
Derivative [Line Items]          
Proceeds from settlement of net investment hedge $ 2,740 $ 0 $ 0    
Interest rate swap | Interest Expense          
Derivative [Line Items]          
Net interest income (expense) $ 1,518 $ 400 (2,144)    
Forward Contracts          
Derivative [Line Items]          
Contracts | derivative 0 4   4  
Net gains on forward contracts $ 512        
Designated as hedge | Interest rate swap          
Derivative [Line Items]          
Notional amount of derivatives         $ 108,569
Designated as hedge | Interest rate swap | Pay-Fixed Interest Rate          
Derivative [Line Items]          
Fixed interest rate         2.05%
Designated as hedge | Cross-currency swap          
Derivative [Line Items]          
Notional amount of derivatives         $ 108,569
Designated as hedge | Cross-currency swap | Pay-Fixed Interest Rate          
Derivative [Line Items]          
Fixed interest rate         0.00%
Designated as hedge | Cross-currency swap | Receive-Fixed Interest Rate          
Derivative [Line Items]          
Fixed interest rate         2.05%
Designated as hedge | Cross-currency swap | Interest Expense          
Derivative [Line Items]          
Net interest income (expense) $ 1,119 $ 2,250 $ 2,257    
XML 122 R102.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Derivative assets  
Derivative assets $ 5,993
Interest rate swap  
Derivative assets  
Derivative assets 1,406
Cross-currency swap  
Derivative assets  
Derivative assets $ 4,587
XML 123 R103.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedge (interest rate swap), net of tax $ (1,065) $ 2,696 $ 2,053
Net foreign currency translation adjustment 16,809 (4,799) (11,255)
Losses and gains recognized in accumulated other comprehensive income (loss) $ (2,520) $ 6,547 $ 6,819
Interest rate swap      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively Unrealized (loss) gain on cash flow hedge, net of taxes of $341, $868, and $654 at December 31, 2023, 2022, and 2021, respectively
Cash flow hedge (interest rate swap), net of tax $ (1,065) $ 2,696 $ 2,053
Cross-currency swap      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively Net change in postretirement benefit plan, net of taxes of $39, $24, and $13 at December 31, 2023, 2022 and 2021, respectively
Net foreign currency translation adjustment $ (1,455) $ 3,851 $ 4,766
XML 124 R104.htm IDEA: XBRL DOCUMENT v3.24.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]                      
Net sales $ 228,699 $ 229,948 $ 231,252 $ 232,540 $ 232,531 $ 244,267 $ 236,693 $ 228,867 $ 922,439 $ 942,358 $ 799,023
Gross margin 74,993 76,544 77,349 73,170 68,639 68,430 71,876 71,506 302,056 280,451 243,174
Earnings before income taxes 33,267 36,475 38,400 29,119 25,776 31,085 39,258 37,630 137,261 133,749 125,233
Net earnings $ 26,648 $ 29,075 $ 30,110 $ 22,710 $ 21,406 $ 25,249 $ 29,782 $ 28,930 $ 108,543 $ 105,367 $ 96,104
Basic net earnings per common share (in dollars per share) $ 0.83 $ 0.91 $ 0.94 $ 0.71 $ 0.67 $ 0.79 $ 0.93 $ 0.90 $ 3.38 $ 3.29 $ 2.98
Diluted net earnings per common share (in dollars per share) $ 0.82 $ 0.90 $ 0.93 $ 0.70 $ 0.66 $ 0.78 $ 0.92 $ 0.89 $ 3.35 $ 3.25 $ 2.94
XML 125 R105.htm IDEA: XBRL DOCUMENT v3.24.0.1
VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Allowance for Doubtful Accounts      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance $ 1,226 $ 928 $ 2,092
Additions charged to costs and expenses 37 401 180
Adjustments/deductions (355) (103) (1,344)
Ending balance 908 1,226 928
Inventory Reserve      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance 2,640 1,425 2,782
Additions charged to costs and expenses 2,450 6,786 7,312
Adjustments/deductions (2,627) (5,571) (8,669)
Ending balance $ 2,463 $ 2,640 $ 1,425
EXCEL 127 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $B+4%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !(BU!8&M&?PN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*''_'$SJ2T=/'0Q6V-C-V&IK%B?&UDCZ]G.\-F5L#["CI9\_ M?0(UV@O=!WP.O<= %N/#Z-HN"NTW[$SD!4#49W0JEBG1I>:Q#TY1>H83>*4_ MU F!5]4:')(RBA1,P,+/1"8;HX4.J*@/5[S1,]Y_AC;#C 9LT6%'$>JR!B:G MB?XRM@W< 1.,,+CX74 S$W/U3VSN +LFQVCGU# ,Y;#(N;1##6]/^Y>\;F&[ M2*K3F'Y%*^CB<<-NDU\7V\?#CDE>\651\:)>'S@7?"56R_?)]8??7=CUQA[M M/S:^"&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !(BU!8K:K#@!4( E,0 & 'AL+W=OQIE2BIS3)Q&5K+>7F8Z&C,@@@Z9LF?<237EZU!"T5T2?)$WK/'G^FV03VE M%[)$Z/_18W%N+VBA,!>2I=M@N(,TSHJ_Y&D+8B]@X#4$X&T ?A'@=QL"@FU M<&Q =QO0U62*IF@.$R+)\(*S1\35V:"F-C1,'0W-CS/UO<\EAT]CB)/#,7N@ M'+71[_,)>OOF'7J#X@S=QDD"7XJXZ$BXA#JQ$V[EK@HYW"#G8W3+,KD6Z#J+ M:%07Z,"]E3>(=S=XA:V*$QJ>HWA-W1QACRLP[N&\(D]_'.> MP=4]T]5KK0E*W('6"ZRX_QXMA.30Y?\Q$2X4NF8%-0]\%!L2TLL6#'1!^0-M M#7_\P>][GTQT7(I-'(G5R'5+-(K,:G5_+I'<=GE&4Y2= ]W3 N3:#L.I+G)KQC:]2IH!R)U4#U2U#]XT#- M*(]9I"8J!%.GL4\=4-I-38USDS7^5&B.Q&K0SDMHY]:FCG/.%;.;6(30N;Y1 MPJW@[&KMMH_;@6\B9@T\E9@CL1JQ04EL<.1\Q0ED23K):1Z3=JTE281Q4%K# M3J7E2*Q&ZT-)ZX.UA=>9C.4S=*^$HKL\75!NHF37\-M^T.\.3)RL@:=RUFN M?PRU:19":QDG:CB^1W,)TQ=B'!CDF>3/\#-?AD>H[4ZO2JK-^WIL8[ M>J,H G7Q?K>!OL!YZ-?,W.?LDCTT(YRLX N8<'#.1H1.DW]7:G6$5?KOVQ/X MEPC':@^&[E?VF!GQV>642WT@B9F;4U/@2JW.K;(%OCV??\FMG/-FG#W$66CN M>W;-N\]&;$XM@BNU.K;*)/CVW/XEMAD3$A+?O^)-\T/"KNB=][L](S>G+L&5 M6IU;Y1/\ T9!4^.4-&.R"PP:(#DU!J[4ZI J:^#;\_DO3)FHV9IEMFSW@$B M^^U>W_.,M)P: U=J=5J5-?#M>?W76((K8$ODX[>+=VA.PYQ#+S,BLRN-69K" M W,N6?C]/=J AX5'0$[1FS.OW\:= &TH1V)-N/FQX-1%N%*K+ZI6-@+;LW]P MI5&#8V+L CW("NR7)8E%-SV60VN9F:';%IB[FU >X4JM3JWP /LH'3#-)>?&R52W> MDAU&(S6[8A,UIS; E5J=6F4#\%$V0 ]'- ;GM&+?!1&:O+N@H!U!?H9BKI0B!?LTE3&N9\NM&6FX+A@JU_E[[ HS[_0_=JHU; M$J]A X+*!@3VI'TWBXF]MWJ05RW4N]$EA9S6O+1]0'6N*Q)!1VGI$HI\XE3)PQW(\J-=N5X=Q2JA,?4-'?YIHE$3@[ M]%9I*B7L?=+GS[18.0_KC_Q/[Y!D:$'1$K+%"#W&D!*HP.VZ1 R= _I%M3JA MND\L=$WF)NKVD>?I *JT4;J"*=Q=F;LKDX]FBNU>I>N/%IP9 W7?IG-#1PTFMH#8DTU M2?:PDXF]AC\+*G\6'%G,M26VK>EJ9F:7N_EF).;4D;E2JQ.K'%E@]U$CP!45 MR!I2Y ,"S9F*4R/F2JV.J3)BP0$CMGT> R@._6J:1?0)_4+-J9U=RM/_/@2X M;Z3FU(ZY4BNH=?;JRI4QU?7Y H6J6J8H,2^/EK\!&.G*]TYU>O$#@ENB?*U M"5U"J'=V#O,&+VKRBQW)-KI*?<&D9*G>7%,"STIU GR^9$SN=M0%RE]&#/\# M4$L#!!0 ( $B+4%C:!DCC,0( +$% 8 >&PO=V]R:W-H965T&ULC911;]HP$,>_BI5)>ZH(),!6ED2"LFI(I4*@;IJF/9CD(%9C M.[.=IOWV.SLA8Q)$?4GN[+N?_^?D+JJE>M8Y@"&OO! Z]G)CRIGOZS0'3O5 MEB!PYR 5IP9==?1UJ8!F+HD7?C <3GU.F?"2R*UM5!+)RA1,P$8177%.U=L" M"EG'WL@[+6S9,3=VP4^BDAYA!^:IW"CT_(Z2,0Y",RF(@D/LS4>SQ=3&NX#O M#&I]9A-;R5[*9^NLLM@;6D%00&HL@>+K!>Z@*"P(9?QIF5YWI$T\MT_T>U<[ MUK*G&NYD\8-E)H^]SQ[)X$"KPFQE_0W:>B:6E\I"NR>IF]@03TPK;21OD]'G M3#1O^MK>PUG"Z/9*0M F!$YW2>95Q@Q9B>;SXCU%OD&LW?33%K%H$,$5Q"@@:RE,KLE7D4'V/\!'/9VH MX"1J$?02EY .2#BZ(<$P"'MX85=DZ'AA7Y%2G9=)?LWWVBC\*7Y?JKCAC2_S M;*/,=$E3B#WL! WJ!;SDXX?1=/BE1^VX4SONHW=J'RF'2]KZL[>[-7G:D8>' M38^422=E\BXI]TQQLEI>4M,/&-_VJ)AV*J;O4O$@TZN_:#_A$:?#3YP.-^1D M79+EG[41!W5TPT*35%;"-!W5K7;S:-ZTX;_P9IBMJ3HRH4D!!TP=#C[A-:EF M0#2.D:5KRKTTV.+.S'&F@K(!N'^0TIP<>T WI9._4$L#!!0 ( $B+4%CC M4?D0A@< #$@ 8 >&PO=V]R:W-H965T&ULK5I=<]NV M$OTK&-7326=DBP#XF=B:2>SIO7UHZXG3>Y\A";(XH0B5@.3X_OJ[H&B1(A:P MT\F#;5):+,XN%WL.0%\_J>:KWDAIR+=M5>N;R<:8W?O93"\WS*_;S^Z;^;7:FZJLY7U#]'Z[%3Z9O*1 MOK^-(SN@M?A/*9_TX)K84!9*?;4WOZUN)I%%)"NY--:%@#\'>2NKRGH"'']W M3B>G.>W X?6+]U_;X"&8A=#R5E7_+5=F O74 [P;P-M CLC:L M.V'$_+I13Z2QUN#-7K2Y:4=#-&5M'^.#:>#;$L:9^:VJM:K*E3!R13Z)2M1+ M21ZL.TTNR5\/=^3=Q2_D@I0U^;)1>RWJE;Z>&9C9CI\MNUD^'6=AGEGNY/** M<#HE+&(<&7[[]N'L?/@,XCT%S4Y!L]8?]P6];QI9&R*TACC?8_$<'<2X [NV MWNN=6,J;"2P>+9N#G,Q__HFFT0$'AJ9&DOY-_[ M\B J"!Y]BD=72>O*-H##/(WC.+N>'8;A(%9IDD8GJS.<\0EG',3Y<;E4>X % MO6$I >.BDE-20Q]3:R(JZ#9M94+?(BNU7YCUOH(6T T!DXLBRMLP+^B4L90( M0Z!JY'8AFV,J7ZJO-;)U-(69]$ZV;:1ZQK)Q!)P.XJ0L87D\2@=BQFF2Y7@^ MDE,^DF ^?JL/\)144TK=Y@$#F+@S1T7"Z @@8D:+-/4 3$\ TR# ^T;N1+DB M\AM0BI9H/:7.S%E6Y"-XKE%<1!P'EYW 94%P=[*!&K*/MEOD&+K,F3@:07,M MDJ+P0,M/T/(@M#_-1C;0VH\"W- C[7TJMGLJJ0L%19+WD131NP)A=6B11X0'7\R(- M4A$T'2/JQQ)Z;_?<08V8#5F7=6DDJ6 Y^9M1Y_JLS124T7$](':,SH/N>9"&B?!+(U:R%W$[\6Q%'QJV2W-)DD3.^D3,,LY\ M3Z?G0QHF1)"FS5Z&E0YU:2Z.\@%==! 1-DRSV-/[6$^&+$R&+Q"7:FLQBN,6 M&1A1M>MT(6NY+O'R9R[3T8RQL4K#S-(D]C0_UO,A"_/A77DH5Q)VE:$"8"[A ML22CXPZ"F7'*/+3(!MO%UV@1\BJ)$=^"(%UBBXO4P8C0'\L]FR?6DQ\+D]^? MYS0W["3 )5V/1E&[I,:+>"R',*NL2#VH>^9C8>;[="_/>N3@>($9Q(HP6YW$Q)A;4+HIB3^=B/?6Q,/5]E@=5'=JJ4*)&(;J< MQF$/F3H%@.S2XFAH=PZQIS[VVDYM+2&9*U*>%IDGFXR$XU31ZMA9CR/?$7;$Q@+$UAHF;V&W"4L6L1CYD6L M&(AZ'#?O68V'6>TH,BM5/UX:V6R)6E3E8\MM^.D52E&9#FGY'&7/93S,9;=JNRV-W2/KX[&@JFU5 MRWIIZ^'='PHV>C3]!<7^#\XQ"28\?X"C\^@'AZ$\*+0?C%I^W:AJ)1O]\T\Y MH]F']M# /*-ZFP=)]WOU]H_R=AY[3[8\3+;WS4NKU38+4W+!$M S#3F(:B^O MR,>]V:BF_!\8L&D41?:'Z(T +!]LFY"DU-J*S%97[HTV< &E@R;.)=_QV5K0 MY#S$GIUYF)UM<8/P?8GO*DK3S!,B99$3)&=3EL33C.7=1YZ(7SE=!C<37-7,C"8=)QCS,JWV^"]K.!A6?%QM2IM%X9V9X^ +\N:+,6NA/:' M0D6VS7&2)F,2P>Q8[J4_WDL,'I88GZ41\!%LX$130][QQNSJAKS(XGR\#\+L M:!SGF0=E+S!X6&# %FZ_W5?MB[CCKLUNYAJYL>],#_)%'[VKE-9X>W;50YXZ M6A.QNLQHXF._7F/PMYP::V]_11$CXB)*>.&\8D$,"YXSGZJ+>X41AQ6&P]GM M&OV^*+HIAN_#\/,CS! ]/YH-WN?:E^F_B^:QK#7HMS6,C*XR<-$&PO=V]R:W-H965T&ULK5;;;MLX M$/T50BV*!,A&$FU+3FH+:!PLN@\+&/5V]YF6QA812E1)RF[WZW+EYG#JB>= ACR/1.YGCNI,<6]Z^HXA8SI6UE CC,;J3)FL*NV MKBX4L*1RRH1+/2]P,\9S)YI58TL5S61I!,]AJ8@NLXRI'P\@Y'[N^,[SP!>^ M38T=<*-9P;:P O.U6"KLN2U*PC/(-9'O>ZTB96R MEO+)=OY(YHYG&8& V%@(AI\=+$ (BX0\OC6@3KNF=>RVG]%_K\2CF#73L)#B M'YZ8=.Y,'9+ AI7"?)'[S] (FEB\6 I=_9-];1O<.20NM9%9XXP,,I[77_:] M"43'P1^_XD ;!WJNPZAQ&%5":V:5K$=F6#13,S$-?F-?%T]DJOWU^0] MX3GY*Y6E9GFB9ZY!)A;/C9M5'^I5Z2NK/D)\2T;^#:$>'0VX+\YWIWUW%_6W M0:!M$&B%-WHM"*6R0@G3&G7?#^FI <;# /:LW>N"Q3!W\#!I4#MPH@_O_,#[ M.*3NCMUM$Q].A3',LRQ^PJB('OV%K #6$"CW.5>KP82"++M=F4 L]8 M;3L4D'J52;6*O2MVT9TWG;F[KLZ7-CZE06O4XS]N^8^/YFIE9/R42I& TA_> M3:D??B3PK>3FQV#>QF^9MS<"Z^F>M+HG1_.VQ.L-<)LF1-L(W)""*;)CH@1R MA8$>G>&ZOAZ(Q>9$0.CG(V5&3'O.@91Y@+ 5$/Z2 *YU>9I\^(+4(>UC%CW"TY;P])<( MXS.N#=[8/-^>8CT]R?J818_U7O1][^=3ZET@X.)=WJ 'O>O2&]SH9YGV570* O]R%>=M]0:Y2VM$Z60.[8,;,O^Z#]02P,$% M @ 2(M06-N.WZ0:!0 ;Q4 !@ !X;"]W;W)K/"3SB5/.B&=\J4L7#/[V_)YG6>D)YO%/ MXW32CED:GEX?O7^NR .9%Z;XO%WJ&T0-\V8J=8D:C95,,,2C_393/: M73T:&1@-$_1%%'JCT*F/>%[]#MU0LX];ZK$W] MRK3LB?M%1(CG1K/I_C08%IA'7#\\A\5]6!!%52'N+03\EH _2N!>*%TNP$$2 MM3D]&982QPU=@X0%1G'D! :)/LSW_="+["1H2X*.DOA5"J6@4\EU6M@XT-ZH MKD,AR_+KEDFGH@8B_PD:KN+JQ40DN MN0POZ2R^D+.SX(5M\,+1 GB&O?PT=+;(A;VT!; 6C0*][Z-HX#G&DHTM*,?# M TLQ:DE$HR2>("Q,+C<(]CN0$WO02=NJ,8^QBGHSP;[CF2W&@B(X,@O;@G)] M,E#7V.EV?6=\=?("2CNK:+$$=$5:;C.E!!MEUG@]ZQ6NA\V$V6 ^I;[!S0(# M7ZX_0.Y$TN!1SJ/7Z1P\+G0>"LW!;]N,/J"":VL,O?[V2"CNE4,?AAU"3=%C M\^:=;-SG;#K1@\=53UT+[]-* E_]/Z>^;/E(0VQ2ZJ,PIN;68?.%PV" 4:> M\+@$:OK068U;J5C4"RQ68G+IPS#V7%/.V;P1.J#F<">%\*A8Z/K/"U\)R5&= M)Z39ZY&;E5I@:9L!U)[)S89S W/3C&TXXA-W8)O'G5C!XVKEX6UT^B*#A $. M338VF!L2DXP%%F$RE*I.L^!QT5)^ /$F75864>^S!3NA[_7Z@0WGN[17<7U< M1+$S(%)()U+(N$BY8RI=ENN_98-@VT.0J%P42&T8E"'T"Y2(+&.R?ED]O;*Q M;@8+3[\XKETS=584,_6-%MOJO.M%:"WRZG+#6<)E"8#W*R'T\:8&PO=V]R:W-H965T M&ULK5==;]LV%/TKA&8,+9!$W[*J M+!@\"")7547%RSV4?#.Q7&LW\*58YDH/V--Q39?P".JI?A#X9'=?]D500JHT!<7+&F90EIH) MU_'?EM3JYM2!^_<[]@^->!0SIQ)FO/RKR%0^L6*+9+"@JU)]X9O?8"LHU'PI M+V7S2S9;K&.1="45K[;!N(*J8.V5/F^-V MPHQ,!WC; ZP<$)P+\;8#_UH!@ M&Q TSK12&A\2JNAT+/B&"(U&-GW3F-E$H_R"Z7U_5 +_+3!.36><25X6&560 MD4>%%]Q4)0E?D!FO,)5RO<=K(!]9RBL@U^3I,2'O!N_)@!2,_)'SE:0LDV-; MX6HTIYUN9[YO9_9.S.QZY!-G*I?D5Y9!=DA@HXQ.B[?3T4\ MQ_,-"YJ]/=PSA"=O#W?/J/&[G?$;/O\$7[<9)_?B[[NY5 +?G'],[K?L@9E= MEY-;6=,4)A822Q!KL*8__^1&SB\FYRY)EER([,#5H',U.,<^_8RE%*A@!5L: M<[:-#IMH73/74]>)PP#3:;WOAPD6^M'P$)8,C4N29945 ECZ0O#]8K*D[1F5_8L%6;^2)E-;\F@_):+8&?42YQAU'0Q'/51B0+FN M%X;FQ!EV H=G!3XQ[ S*XG^L]&VBD"4V!@25I53F9($] ,DA6\)^ D%S%@S\ M "O;(([B*X+EG@RB,"!4$2QZ4,U!M)NPJ[UM"6V1NAI>88<@:VB.^/+%9-[0 M(-B)PIYYQR@O&D4][PP@?#7-SL6=<_&KJ9'FE"WUFT9JCF475"':\CP'!HM" MD;JDS.3<"(WS@JUOKO^:;3_@6GR<($? M]W9A9L(YON?T$]R BZ.1'_?TV'M-805BV337$O=DQ53;4W6C70-_U[2MO?%[ MW=@WS>9WFO:KX!,5RX))4L("*9V;(:Y)M(UV^Z!XW;2>GV]:-DQ\L=?>B+=3'/$0\ID<.55,^Z ##DI>1" MC[S"F&K@^SHIH*3Z6E8@\$\F54D-+E7NZTH!31VHY'[0Z?3]DC+AQ4.W-U7Q M4"X,9P*FBNA%65+UYPZX7(V\KK?>>&1Y8>R&'P\KFL,,S%,U5;CR6Y:4E2 T MDX(HR$;>;7C4=2R.B"FT>Y^@J-'N=@(KEV M7[)J;#L>21;:R+(!HP^@:]LV?X2>/)7>U)<,23;D >)#)K\EFDD&X3^"BKU1:LM=T%)QDGD%R3 ML'M)@DX0'G!H_'IX< ^>3V\>T)-V&8J='SA$;[O&'1%DJVDL"8I7&I]<4D$ ME@E,G*$O@T/QK_FCP_RVO@QT11,8>7B"!K4$+W[_KMOO?#H4N[3L+][_',ND7P>38$U*J"Y(AH61%)#F8.,*!R]V?4#/'6#K M[#*^"B/,^7(S8/M&-_V;;9O)ODV_%[4V6_)ZK;S>27G?\$XD!16YO2VDDMHH M?+O*/7,R!P$9,Z3B5!R7U]OS*ORX(V[?)(AVM.V;=,,=:?Y&'2M!Y:X?:+SS M"V'J9]_NMBWGUE7:G?T[;$5UY_A/4_>Q!ZIR)C3AD"%EY_H#.J3JWE OC*Q< MM9Q+@[7730MLIZ"L ?[/I#3KA3V@;=#Q/U!+ P04 " !(BU!8@"1]_$ ( M #?.@ & 'AL+W=OWM28HWI:"9[6Q[$&6Y/O_T=B1'PISWC\9#J,B3?&7R' Q#W,3Q-MNFU9!_%VM6H#N>R41>JPQ[8NA] M'O.,H;-?>%F^,<"'P_ 2+)-)5H7/8#W_1N<6BT0E:92B#U&R.)=!OHLV22=6 M4TGT@6UR8)M4X'8/^"U;);F*FDS?-,ICAB*![EE\@2A^BXA%+!./>TRGPE2O MMJ=KG_B$TLOITS%OW6:NXWJVU6X6=)O9V-.PPFXC@ET-:=YMA%WGN%DK1O00 M(SHR1F>2@W(=%:Q\)_)F9M2&8AP0)(L! 2; X$UF+?.;#O#.;R;[*68_WSQ)W3 M>81G+K9L[<5V4JM@L"=C&8 $FP.!M1AP#PRX@PSLY]>X-;^>I6IBE6FHIED3 M+6XGX.RI&>_\;JRI M0^A,HV30Y]B4@ 0+_4ZM=HX]K4XP#Y(0?Y>@8-=V(L3:!H88W66O#HM;9YF)YOSB%\)!-@J.A_ M*ZN&/8U-*U"T !0MK-%:9+@V]?07'Y37-K>-*("'58$@7PQ( MC((>F,S/<\ M"SMZ.G7;>91@JKU: D.[)[V-$U'"B_;48;=0!_3WD @^H#H&@!*%H(BC:' M0FL_!(U(@%^F$N"N ( MA[J>_K([K5TPW)W15(!J!5!H;2H:M0"_@ER #8MW M@EVLTP,J&)SF- 1U.H=":[/3B ;X!:H!-ND!U,*^3L-I[8+AOHS.$E#E JM MS4.C'6!0\0 ;%]8VT7_ &?8Z.D% ]0-L$A!@J_1D+ KZ8A#"./ MK@E 5010M!";= 1'IG:G/G\-(8$T0@)Y52&!&%;8KM/YT6"X$V.9 D4+25=( MT)>DQE':LYY,(HV.0+Z;CC#L:6QF@:(%H&@A,>@(V)O9NO@#Y;7-[=''!2_1 M$8B1P^Z"?D9]XG>RR: W8-OV]=+:T.[.K[_R[X==C\ZGDYR&H$[G4&AM=AJ-@+Q (R"FM;\CEZ(Z#:>U M"X;[,CI+0#4"*+0V#XU&0" U@MMOH/V!S9.98<%M.[A3O8$*"Z!H(3$("T0O M0,S#[/DP@32R GDM6>'V&\A]?(&*$:!H 2A:2 QB!)6O$/V;!BBO[4^-&RV" MOJH60;NK=(*IJTNNPYT8_1$QJ!9!NUJ$]DW&W#Q*9V9./]IH$?2[:1'#GD9_ M\PVJ18"BA=2@15#;GG5(>PTM@C9:!'V)%D&-'!KV$U@.G77$"$-#?^;9OOX+ MAJF=.]-_(3*T4LM@/9R&SMF.Z]">)#C:[0"E19B#9OREW[$]TGD)P>YD@-W* M<.HHYE!^VVPI+:)]I5F8TN&%J9SIT;_0[SFZV:ZVI4#8W0M';Y%<)J%/%X\7 M:,6?6)&K?5V(Y5&LMCVI>^_S91I5^P$?V&*[WQEX$PMTIFY.WC_<3-2"2G"4 M1KL+]%%9/-R@)-MP5:]$"/\#L:]Q4C(DHJ^(U\\-*IJBYBW:K9-X+=^JB"V7 MK-IUB):\.&Y3+>12ICH5+85\Z\I'CF6?Y<&S!+;W?>1*PA4LYL5"VNP2L9:/ M+-O++U&)-E$A5#&E!M&X>;YR7&)=F!B9'FVERUBQJG9)JDYN<['?0W2X>MB) M>5MM6-2O4_M=2&WC'4?>J38(3AL7^ZV?OT;%*I'33^SKQ'NE-Z8 L.2YE)69TL+:>L*8R0HHN1FH&BJ<62E=!A[%NK!N M@"5QS=>P /NSGFN,6*>2BQ(J(U1%-*RF]#Z8I)'#>\ O 7MSU"F2<7[D'++DUBK/=$.C6JNX\WT;$Q?5.[8%U;C MK$">36:J,DJ*G%O(R<)B@V=J#5$KC%2V*93,09OWY,O35M@74T^DK>$$5/@J(F9Q1TY79:UJS\TJX=G5D\A&Y H^$#"81CUT&>7T\,>>GHY M/3BE,[2Q\S+LO R]7G1&K[/OK'M_[I?&:KSK?_N\:M1'_>JN_B>FYAE,*1:X M ;T#FKQ[$XR'G_N<>TVQ])7$3ER-.E>C_ZDGJ=B)'*KCF MUEWW.=DHWGE%]_#MDN'@]E/,=L<.]8*"4U#:!QJ/.E"3$3NJ/_=8_N!Z+2I# M)*R0AJHWE.CF 6H"JVI?DDMEL)+;\\TDL>D@])W3P)^:-=,Z:"YTW=M+>SM5+;Z_F\ M+==L4[2?Q)8U^I>5D)M"Z:_R<=YN)2LJ6VA3SW$8QO--P9O9XL9>NY>+&[%3 M-6_8O0S:W693R)[WPC3^NE;DP7]QLBT?VP-3W[;W4W^:'*!7? ML*;EH@DD6]W./J/KG&)3P"K^X.RI/?H<&"M+(7Z8+U^KVUEHGHC5K%0F1*'_ M[=D=JVL323_'7WW0V>&>IN#QY]?HOUKSVLRR:-F=J/_DE5K?SM)94+%5L:O5 M-_'T;]8;BDR\4M2M_1L\]=IP%I2[5HE-7U@_P88WW?_BN:^(HP(HGBB ^P)X M7(!.%"!] ?+6 K0O0&W-=%9L/>2%*A8W4CP%TJAU-//!5J8MK>WSQK3[@Y+Z M5Z[+J<6=:%I1\ZI0K H>E/ZG&U6U@5@%=T6[#G[5B=$&5\'WASSX\-/'X*> M-\%_UV+7%DW5WLR5?@83:5[V]_O2W0]/W _AX#?1J'4;_-)4K#H-,-' /%\[<71QXWY- >Q,8C4^UA*GUE*WTE MQ2;0'5P6BC>/70_ABK/V&JKV+BR%PYK1X[K=%B6[G>GAH65RSV:+?_X#Q>&_ MH"J[9+#\0L%.JI,>JI/ZHB]^UR,G*V2C*Q!,UJYT9$N;(7*_0&$:49U'^^/Z M@&01B9-36>[*LAB%]* ZL1 =+$3>C/A<_4\/ UVO5$*/M:5H2EZSH#GR9GXQ MWTN3/ELI]EQWKF#Y\O;\B2Z9/Y<,EE\HV$GEQX?*C[WYDS,=M.1%-T- M]L0"53PSL*>GSMVO].W1Z"'O %E*XI'A'%!%&9WHZ-G!2N:U4IC7-! M)79+M=K5NM^68J<[/V0JBU\[W1'%KS MOW7;?'C4 /HQJ$6KP<+:TSC6:+S1+=>4+X&2AYRD(&Z'; M$@D9#]^ *ANW? Z%(NE$FZ(COD+>:OC@'M8J#C(A*&8\.N+AS;]4E. MS0ZXAL[PFC7;&K==D]F&?76D)]N?[;QL6K3\:\=-3B^+NFA*>)1"%\6XBT;+ M+Q7MM*8'DD-^E/O-'&=Q-LX65W5%8C2>@2$9#I-P M*FT&ID->:EE\;?:Z'PC))](@ N;*B#@Y[\JNDC1T1C9 AI%=+8$N!CA"?CJZ METP/:]4K0'2Y+]2:R7YL5[YQS,6;*Q)1QZ,K0VGB=&T@6)JB"8,#*R$_+!UR M;EN\F(3K$+ LY8X-KD%S+NR0R.$F0'6%(F?YD0,ZFH1'RX]3>P,[(3\\?3W# M3,CE'(RR,3)!JLR9:EP13=(I!P,R(3\S_<^]BWK4>S%JO?.A!>-EE\JVFF=#H"%SP"6S1HS\)J%@N6*EEMX/L"&3:Q7 MX@"K%\(J[(Q0D(S$49*.!V! .-5#!K;"7J+0/K=<:1RV VW%U4[V4PQOE*8N M;@?D'KI\5@G@(4DSQRN@HUE&H[%5,!Z))Z93/! .]A..7@"6C%5]3]$+ >9? M"6"73M#QI-?;]R3H M\_W4NN$V.KIU&]ANG/]IHC=Q5;*M =L#>$: ;X@X0A 0P" MPCB Y^CB%O MZ-^E:&$:("Z6.'X WO9%.[0QL0\ZQ#92&G2T6U*R SQ\(M &#Q^0& MJ5 R/IT#5='$<0H9((>\"W+L\8K8=GO9[)G)DK6G-(AW2X*2L#XA _ MXGQCVYTLUX79IK*;T9N-3D#;7* OB%^HLX\(R4CD[B' .DRFLF]@'?)&UOG0 MP\['D_T$B M N]#Q6$0('J\F "&F<9QD8\/@>1M&R<2B@@SH0_Q;/K^L5JRT M2PCV7'9'#5*S:E#V._&Z54V%@"[=G1R,8V>4!':%HM19\4(R2N()?W3 $.K' MD \Y*Z49#S^:,TW[R3!LMZ+7BU_[@>G);:\7B!/G@A0XR\+(X5A(1H#&!'0H MC2>M#FQ"_6QR-^4I6+)'WI@W&TP[;YGD AQ]J(L4<1PY+0K(-*$<][[>IZM+ M:91,+*_H "CT#1LVH$]F-LR]#KO(Q^^4Q)32\2DO)',K(@=DHXKH',Z/7BC; M,/EH7\QK [L9WKV9=;AZ>/GOLWWE;73]"[K.NU?XAC#=&X6_%5(W<:NG_I4. M&7Y*]$/)[B6][HL26_O:VE(H)3;VXYH5%9-&H']?":%>OY@;'%Z57/P?4$L# M!!0 ( $B+4%A677_.&PO=V]R:W-H965TNHFB)DBS9>:F29#M1+GXIRT[JZNH^@,20 MG!@$& P@F?OKKY_NGA> I.S-[GZZJ]K:B"0PT]/3KT_WC+^[KYM/;FE,FWU> ME97[_F#9MNOG3YZXV=*LNUZ:B7^9UL\I;^M@LGKAU8_*"7UJ53R9'1T^? MK');'?SP'7_WKOGAN[IK2UN9=TWFNM4J;S97IJSOOS\X/O!?O+>+98LOGOSP MW3I?F%O3?ER_:^C3DS!*85>F;. M7-?E;[9HE]\?7!QDA9GG7=F^K^]_,KJ>,XPWJTO'_Y_=R[-/Z>%9Y]IZI2\3 M!2M;R7_SS\J'Y(6+HSTO3/2%"=,M$S&5+_(V_^&[IK[/&CQ-H^$/7BJ_3<39 M"IMRVS;TJZ7WVA^N/M[>O'EY>YN]>'E[_?[FW8>;MV^RRSY)2X1@N"3 MDP?&.PEL.>'Q3O:,=SF;U5W5VFJ1O:M+.[/&9?]].75M0V+T/[M6+..=[AX/ MJO79YLX<_/#7OQP_/?KV 6I/ [6G#XW^[]K$?_NDV57G:%3G MLA?&S1J[9D6]RDN8GNRZ;M9UD_-WC_[ZEXO)Y.A;_8T_'7^;U4W6+DVF/U[7 MJW5>;?3'QZ/,5K.R*V@31UE7E9@'3\](],SG-JOI0W-OG2'C\D=G:5OHC=9E M]\NZ+#>']7UE"C)64V<+FS>6?ZYF2A3]9"L>[K:E3UD]SUZ342OSBG\X?O;T MG!YWF:D69-O"PX6Y(SNX)JO6CDB-JVY.\M0U)L-[9!4_&98Y&LVMS5L59(6P_''VKB$&V#5Q M$A1>UY4CW2CDN0_"6?V&5CRW%9%L>4#Z8L4TRXX8(777 S0N?M.M9+JP)^DV MC+/+DMZQB\K.B>"JI5&)Y)F^,LU+L$KX0_I:N9P=@,N6^9W)IL94F2DMV5*_ MB[-T(>/LVC0M>3.2BEF9.\>3# =8Y5A$3?RWQ'C:(5L76;Z"S7#XGH;$GI$Q M;YJ<[TDNJL[0?VB9Q9*)<=B,= ?Z<5WB\-K[%MR+OH&"0W*Y+\(EN0O/ +S*FY(2H++*#N M&G4_IF'!)W;J FF O(5#AF<-*D7;8U19[TUF/I/XMAB((@62)4@N?3E;YM7" MJ+#6I'D\_9B%QV]Y8TC!(-[*S:DM2Z$IT$//E+QY]*5;VO4:.H/MIN&+DC_@ M&6&?:"2+G2-"G4AAQPL%(;L'8+%P+6MB7K+0*3W$64.!A+S<5?RZ@?8T6%T! M>Y*30E=UFVY"0M"THU]R&!_P;L-/X\FFD.?\,LE8K&MG5=/QE"Y#A%8%JK0Y M<8@D!C3>0%])FUC^03H1)R+! EN+K)/FB 'R%#T@+]N2(=(L)/*,^0RTLWEB M<4]\)]G&JL@;DK#KN@B*E#TZN+R]/GBE78A.D^DKRWHFXR76 M IH-)O*"(:G[WZ?-(=\%HYF+0-$O;J[#T";D>]X5L7?*(J;C7@QYDU@!&L!O M4UV5&]D=TC"V13*5A=SLF82H;^INL8R[&!BWQQK J2) H>5C]7FRV=?RVDB\ MF75!V.#+-J0"N7@YD%'AI^@8?IG2 M;L]MRR_0;T,*!SPD9P49P[[!1A$Y/".11FL@?:)-(KM/!+9!=J!41@(/8BU3 M2=/=D]$)+$O9E>]G5GT'C::,)0M"L!'V[MX9$)BM:\L.3%[TFY63X]XX&]SA MO(9P\,ZII#W/'MG'_)NN<$F6(_=>)6N0C##_\XWH^B.KSP?S@C=*LR#_2P.4 MAA_9]"$O<,C/$!19"J4L*4M=]<8.+E.YDI$,MW4C M889_%O%52ZDD"3A[5=V"1 MRM^0W^(^7%#K>D8> D4U)]"[10;%IHL62Z"DM M/0TQO3.N%XDM!S,0A0.B!I[C^<0 MOI'=RJW5^3Z74?O[W3G']<(\MF1 M?R1'_J8>\]N'QR>C[.!5D";B?=MT(NB'GB6_L!G)'GVHUW:6G4R>/GZ>O38Y M\9ES $XM>D_2"G8.>3 BDVTI,/;YFTBXF'%-:ZCPWR3#3ND>1AW\+DXJ0<#A2_$X_AUF[M6R$A7#E MCE*S*:E5($3?3^R.+(VF"FZK"/Z!G"H +R&71AS8LY%^[6-$'=Q6 N*Q >>8 MDFP&?44NP[#,SCO.1=EC.[C[4L$S339E%O7>B3PVDE3;JJL[1ZLB:V")#H0E ME08VHOL(;HJZF[;SKHQVB1,<,CNK/-D2HHJR4T@=SR;;XNW\GDPHDD0ZM,H_ MA*"((B#&7OAZTB=>=H!XSC!)W,8?1RD:A80-QVLL+98ABH2'DK]9 M8I=MO)*)C"2Q&G/,,XH(+@K%$-(M%&45*8PTY874CG#4> TQ:NOYQULDUP+!)C []$9'@(,(_B=4IM"HU; M$4D&5:!8'!I:4IX;_"J'80X)JD2C[GEVU=D2\)K+CL\.)V?9QN0DB7&UD\/) MA?\2$D+RU#7&YSB01:>\!()3\2ZQ,5GFS4(2.94L8#ZMX@O^G=^QB^![WI5J M^LUG&D;" Z6]P29"Y01SFN7K?*861!FGRVKX1]LR6D'[^!ORK.3'QK1L2#!I M XINZ0@ ]_.1PJ$N';(,"7(*PV9O6ZE.U.D>RFSK&K&%KS-"T8RF@_H-"A? M *1"> @G95T/'2">5[PQ/!!$3%@WCI K)7,S@QQ(>/JJ%P)ZI\U<==WT=T9S MDE 3<(QX%<3X$NW2TI/0>QYI;V)8M!4L)K&PF L?&(NAKA@]1<"*59$N4/[D MELB^*) V$&,Q]F2I%FSRD'$D$5DR]5U7XS!3'DD#NB/BD 23OE MDCD4%V7O3!:@6ZW59K&;,)9C%9)AM%WC%,QB.$9>6E0VRQ M9FII_((,%64T:PI2>\N,Q J#-98@Z8)EA9\#A3#;0I;N*ZG=S*X5%KN!Z6B[ M7LQ%:Y_/H33>,CJ3SMNWOG$1@\TA[I5%] B(1HW\O1O)O+W.SH_/1FF!B>21 MR3Q\']871'[DZU+W1JVY1I^,@RO RI2" 4B3Q:'@#_\1[KYS C5M*0/6%_DJ MS'M4*Y2,#<]6"/A$&^E+// 8HN>%@?V%]3$?_ >):2B_8-9H8SA]#KE";PF" MXVNZGDO&'VG7#!>.'W]+(L/[HZ_5Y *;D,R@<-.8)13]CG,OLD[C[,>Z+AB% MP^27,V7D#<7ME>CII;C7\%QC%/P2&,I'>B0-'9!Y0+A-A.D05E/\H0$D/05# MYSVVG\WN%HF+(Q*)@\21KJ8H)D$.#P:$VTCOKL%CTC^+@PA+.9ZU%8N ;4T_ M)/,%AAQZQ: ]B@I2(I!,-H#AL'E)W)]75<<.3AQQ P]&4DH_ >29:^HA7L4V M%*GX:H*'5H6Z)+Y9,=1(4;_,@E1G!]\49KZSCLT$,1RZ] MA60?])UJ!#:D,H+E9&0-L7L8]NVLK:>TP\=C/X/8KCY&L+TO3*5$P/BVQVY: M7.2TEQ].Y)$$HJUD7^PL_L&F^2V]9 L0S:+G/."-A'Y[N_XU.R(0#R4L,/R3 MH^/S'2C/[4>/XIP?'IT&DW=+8Y#WWO@,X@,X#2+#1MT$:KWU\]@:QM3Q8DU> MK 'EEHTBN&H3--C"3G+23U,L_!0)0RBI\\5;0:3,.ILD=0PH_4Y;SJA-Q["5 MKR,,QV8IXB^G*8 VW;")RAO/@[[AR!5?PJ]=Q;4#FD[0UZ9AQDG 2 +92\$E MR\GZ6>?:/O%'!T>>L]2+E0F9+?/?P!-(::>4$I!PTG./WD?%0@;8MPT[ MX?YBP'U>B,1-% M4]^3@&D(J*D=K9/RJ85%)+05)0;3(SAB,#V\9Q[S\X%G;$1)8M#A\I)]%R84 MO#EJA@8[M"V7'L>7'050V1=IE[3N!!&1I*[!=Z4@G%%Z]LQR3VR#F_2U&#@- M-8E#;S%0@[[\ =9"WKTR.X1YES*0 T3'BCA6[?G8JM44B?17J;837=^J8TOZ#D:P6B3[:5-WHD\"ADO/5#_E>M]<->>.R->_RI MW:+D./LF.Z.L\]GIL^0YQR82J(7?I_\D1;[_":I. MC_]1DIZ-CL[.'R3HA-CKY6+[MVWR?WKS$[WQ]/R$.'2.OYZ>C2Z.3K-+^GYR M.CI]^@S_F1Q?9+>AV>R=;RB[.!X=GY]EY\]&IY-G(@,L#1\K;9@@'3I[FIU= M9!\8*(BD?1/X]J%7NMX3^#^12FE0XOWX\B^3\T:6G78D=+"YS@^"@[).9G'YJ< M,F0RHZ$-K:"(/5_1$B?TQ#$VD#L!V2K/EE5=UHM-=H;?)ME[LP! B,IT8Q;6 M>>Q)L A^Z"A[1S3[P%#&=\AE0<293"&;QO-=I)G3@]S?%XFB[\2 >QJ/ DJ) M6>"7(M-AS(*XR:>DL*ZPTAH!T1P"++WW'T+-1PF74OC2E%)?ZN#*:6]74D,4 MX-^';"Z!TQZ@ 4ASE(,JB0FVG7= 4H0.[4>2>9-^A9LOS^HC-_:(8?JM&4># MVHT&COVN+3_Y5P2,*3[=BQ[[@6UX9A1KD;)8Y(\A@MH5/ZFO"PHU-[KNH0W MF&&D(61&LI^SOX\LER:A2-JW$5I7;8PUW,%,Z&6J!"L)4 C%4MTZ2M:WC+!S M3PQ<:5#"N@GM0DC<$C_* @X!YL*O[V-*%QTYS2$]BA15+G!E9>YI-*Y*M0IS MIB^$Z%V:= 9$\/A0X;ICA!ZZUPHT[)0M9C[G#DW4"KG:Y692OH1IJBA/AXZ8 M-N+(VJ3E0T&4M^J&N:(U%=@L#)<6;$Q:V4D1KWK*0*N ,?U"9Z)-L=+!3-*I M;!,@5BMN5-L8^IQ)>,T*E]BF+QBDAV02;31BVX!EM(H:JMNW%3?S$)]\T3;U M$Z*:3,&@B:^OPJC9C+-7FN4Q4F880MORZQSIHF?',.9#IMXN%H9S45UMKP=B M&W)*IQ7CS@DR)T0?\L]=+ P)]A!/1%=F:U9HZ6DVB@\;J5$W M9FBEU;,8[=AKVQ*PR*\AS4LKW(WI59JXX[(R0!8P$0.AJ# #GMU:LH;:(34? M$.&KBS>QWH/J<=>KPRNM_/6..1A?([$OI;K)Z/D(D+-/<[CC++_+;[9K0:TCV>U9$_F.'L+&<21JTUHA988@ ]Y M&$T(R.7DI=@4YVI4T+5*G-#=9Z]U7K6:0C 5BGM73E(Z.,*ZT@H()#U=L_?V MX^RC1!\O@T2\CI"-[3L_[J4))>S5 M6\>S.C%H"WVUOL\2P7\A1Y@$%*#DACPEJYHS#Q"N7CFB+J9((]P]]A\%7C+F MY/TX6I!E@ER3=&(,7PH@4J%53BW*?X$]"JL#,W.A EH!8. ME]S+CN1Q-(8!:/$!4A)QX4F7O,=5X5IK'D7FV_J1(V@W(*AX\$P R M#@W59FO<(H[1QUEUNJL4@2#B_]5'_+L;-_NH%=2EZCA$Z54+DZX1M!E4/*"" M_8UF:^S0*55E?G<-6F?4JB?93\Q!?)]%;.U*%J]&S!,F1CDZO=!=$EH>93^! M )-J0)(2C)=C&*3@V@2FIYDP4/ 6J8*S5212UHWQV"MFH]W,I0>/<_M>4Y4@ MP6%Q+#,C5> $TDPT3FM\?G^E"YOC6/AOGRGX,V<^L(W]YQ*TAM-7>6@'56H] M_J0- #Y)#/D?=_8QPSXK2>G>.)]EB5'F#H0TF=-)O&9LM6JF\H^\HLD%";-U M#R>-)8R=_4EL-N\M&NAI7DRW6^"3U)]&6#.EAB>48Q0"#>V 224K'> MPYJD=_W MHB0H?8@=9TG? D'Q:;RZVQDSY-T3!- 2N0O^Z8QR[V*6RD/CY!53.6.R-W6+=OH1945AH-2D8HZ? M3+' 8BX!UXNK>RS[LET_0:MA'"E5 %Y0:A:]_OW"&S4)VR3;US\UBU_$-B92[&MB,/Z#X8; 678 F9%EH MD0_:(C[?'U X3PH>_;18H(MTX)H6A_,*>AQT5^%$^WWIIUMN<;M.3WS*,8K0 MS\A=*E9Z/6FQ]Z$I6);KNC76*X:M6T5'GQ[REM8DX.NL-O=&2@K]5F)N,1[U M(!;]JM,A=Q++ MBU>F9%/1M\K78 A2C:2QW?%]_]AM.,*>GO E?27V+VN16AU-BFV;@D ?YC@G.Q!.)B9EB!?(NF+GUI?X"&O$ M8,UM'*=G2?NEK)_2!]JOO#(D&\,%*TO>DXW)F]E2N^W#C0O]'Y*K&/PL^ K*MV6U9+N:\!888*^,B?%,7>^YH/NQ5<(2"M M*["1MTA.(T7*.JY8^X-)X^P-N>R7OLG['3&&:"-_GMTN\[:7:KZ=4+6W88YA^A MC8-7$IE*CN+VL)KI5ZP4)8YU&T/D/[66OKWC=!1+83T3N!*FL:UGG] U(T7V M^#HN($%KN_1_M91C!"3^GAX65C$?Q $?;<"BUT9DD<:&PX18?#\7Y MIUVJ6\F;2Q[4-E&S'1^Z49*Z%7PWR]3X?L&NE/.@'.2-*C7BD)O9GWM%N>'U_L[L#EB7O+C0VX_7.! $29F3IM/.24])G@?*;; MVL51 B![E$L\>Z]M-DB?--M&FQG\]#2>'T2$DP1Y@U,#(0/<+LG)-2!R6CW' M@6I?%O'0""_"0^L2PW&30ID3RV]G2_A*;6E23(-+#1(Q/%]G& MFE(3D4XO=PBF8:\HC;/+7JBKC1:A6S_R6-)D'P@!(A-EWI6S;J'BXZ3Y$2SX MI:X6AR5?#J+=R/C%R5-P%UZ>U M&&B_TL=Z'D(P0:I/W MP/TV0$:-7+6@3.,U"&B0F,%>:T2^:(PX9K9?>@@M-E7SF39&'+SA1GP0+Q,* MM[#X^?WQ>@Y$/4V>?;[%X4['TBLAN:&E\2VWL0M@P^"9GXS;L>$11'H?8@T, M\J)N_&U2B(AQ4QM6PSZ)S ,T(VG&YM,P_FDL>@AVR0&H+:@KWINR%^?:@Z@, M^F8]K /+N&=I^Q"?^0[$!SCAGX=ZWF+S_NA(AE"IU7[ <#M2CP:NIO>:SB7$ MI\G2*V&6:@'[&;Z7LAT61\YJ;IN.Z4;=M@_S<U)D1 MVZEPXYE$_>%(M+]<9?M,V)-'Z)IYK%B5[ZXN-\E%?=[@!\H\[L"YLWX73I$R M5_S%:-)L,6UC5\Z.G1IMUURX. 5;N3&MOW\@S11"8M"8E53397!9,%;'UTR5 M"ISPI2&LP\[$&\2^BC\9*K]ED$Q-LN/Y:KAD4N="S@#B(J*070^R+M2A^7 G MVH#/#D_X?V>7H^S@1:)U:1!PR(!$/+[-/QC'QT'C\ $C MOE)W=.WY_#IO6QST/$3P$7NH#A!0HI!)V_LGX?61W#]BVMRR54IK@YRLB P\ M[.Q%K*AK=:4R]WP^7B H$7WN+D. K,B4H DD>;39QD-] MA9EQT5H;Z[RQ2[HATO(]FRUDV'HV.5\LT++9[N1M>DQ*KBP3&$WC'-__Q=I# M3"\3)#$=K-=) AL-\)!?<)I3/X3_##N&@+^W% MZ4C/ N9P$WFAZ?8:MI,D3D@)Y05 9GUSLE'%YCKV]VXA"R5*?_-%SG"6-MIHIBQU4"6+LX<:(+Y>"3(.[.F??TTX MHGZR:Y<1"52^5^BH]ZD\6!'\]9^^L\^?(CLN<] 03TQN174Q"U&HFAHB-9O!2H:%P M&W_[VZ!;Q++0 M$EYV"S#H2W9P[\T!9/]^YKM ?R6:H)ROO,^C4."VF[9L*2^.S@Z?'CU^WKLH M&IMU@[]I[=NM%KU@(-<2K[?WT:]"$W]G NZ4 +'[7C\&/W*0;?6R'&^/0AIM MIYT_PJ&7)7/[J=[!XN."MGY'4TAHC?S9JA6@YY.V 7TDL53/.X,\G1%P &*L)8JY72^S>?876 M4"RE]1WM%>DCOBS@@$-SKL&_!T/I(VX_5_=^<7I!$OLJ1U37]FXX>AG[)7>/ MT+OZ,<0-!]X"]L+K23\K[-,Y.<1=T^INOX):.?A3/*(CQHT'#OB$@]W>3K6N4-;'0:4>9<:B':6XAW="><(V5 M0;BHSO!NSCA_F!6!2_)O!TA9E-448[,4LM?YIYJ(I=%$KE9>)9=^^VN9=L$3 M_D)Y7=LO-U=OW[-&5OXVUMZR0]PUP/ 9P^9K*+V_V68*Y_Q15<0LD:2$>(*B MOA0?C_[.)ZY#:(D\Z8O8\1=I"((NRY$BKS])0^M'8!BB!PI'@TB-TKJYW-*K ML!5&V[ZD0;BL,-L>U(F,2)GC4D0AALW@\2%?,9Q=OWZ9?4"+XNW;5^]]9V!R M6[LO(@14M; %6SIVAWF_IZQW6&N/ ]^;9?1\ZH?=&!IC=!)O]1#"\:Y_1^5) M\@_CK$RSX'_^QPF>+/]&3O@V\__"T*7\PSKQ;TZM'X_.Q M;MGV'\A!\S^S,ZW;ME[QG^C%,@T>H-_G->FW?L $X=]=^N%_ 5!+ P04 M" !(BU!8O2HQO+0/ #;, &0 'AL+W=OVXSM:QHWR=TUOJ0?.OT D9#$F"(4@+3. M_?5]=@&^R)9=7R9-VVEF,F=*!!;[OL^ND%=[;6[L1JE2?-KFA7W=VY3E[L79 MF4TV:BOM4.]4@3S/K,[HV3*F[;Y630:3<^V,BMZ;U[Q=Q_,FU>Z M*O.L4!^,L-5V*\W=AM-R5]\\?'$QIO6\X(=,[6WG69 D2ZUOZ,-5^KHW(H94KI*2*$C\ MN567*L^)$-CXR=/L-4?2QNYS3?U+EAVR+*55ESK_:Y:6F]>]>4^D:B6KO/Q. M[[]27IX)T4MT;OE?L7=K)^.>2"I;ZJW?# ZV6>'^RD]>#YT-\]$C&R*_(6*^ MW4',Y5M9RC>OC-X+0ZM!C1Y85-X-YK*"C')=&KS-L*]\HIJWB^A)BF]5,A1Q&(AH%,5/T(L;66.F%S]"[Z*R^,9:<:FWRZR0SBV* M5)Q;"_<_3WZJ,IOQMW\[7]K2P&7^?DP1[ICQ\6,HC%[8G4S4ZQ[BQ"ISJWIO MOOA=.!V]?$*(<2/$^"GJGV6PGT=)7$J30CTYZ44GF2R5%5<%;-'O72BSAF+T MMC<0[PMQ7JWAHB(>L8VB0)0;1=K=R>+N#U;L-SK/[T[UOE IPGYILS1#Y(OS M?$E*_D8NM9&E-IFR07V">P?RJBB5P;ZL*+60XKK4R8WX4)ED@R 4YVNC%))# M&; %DUQ;K 516R4; =,55KJXWV?EYBF1ZE>] 4B)1)L=,44[D>IDD?T#="MX MM&'AVK?40XI[!;E=\%HFN!X=&=F848.?(S.!(VR521J%-* M7"GR1E&MH);*0!KP_>WUMX%PK[)"_""+1%>WR@0=@8:TR-%$8@(+HJ+E17T< MQ,!"B(5S2J=K8J@^NLQ662+4+;:"#1AG!^V6Q!D)OE2%6M$#BHOX49B]:EDE4)5;BE=T*N0<^YP4[5%(;B(RPDT]0I!<*^WY49 MR8)(G(U?BN"8\N"SM&0)]TD#LN"A/Q-/*YUGF@4%._3ZJPIJ[>B?^/B*>7"Y MI&<\6,49 MLSW*[A0")R?-MUZ5W)!;P5,-9(04:94 ([#NO=K@=*D2.WGG)(4A3F91$(YC M-CHI4+9Y%U;HYLMR*-[!B4 I00RT05A MZ7X!_G2'';%'XF/AP^G8.W*G-NTE.0R\RF0(QQ52"6R1@K+1U7K#)U R%I<4 ME66;*47?*B7>:>2L>2"^4[Q_]& MIE"XT!SL54$.!Q49E2AD,7I3QV6K27)K<#T6&32O3 DXZ47+:%''54MIUJIT M%M7D\6*K$%N)=6K#AR&R/#$$_*"V2RRH,81C7TE3G *?$M5,IY:D3O(*F(5I M=D*>6-:&7] B38Z@]E MC4NHRP(,/X@1HW(F[,.D6YSA0:R/Q+]?*DX/T1BV2B"UR:P+/MI8[59(3N4Q M5C@\1\%\$5$1IT: 5)'(74:&P60RQ;F2O8A +?D7'+7$@C_P)L.IVHF@DDV1)2Y3+W.U/;4^!4!1SHF9+JUM M$A_I$K&7J*&8CWY?R]U(1D7#VFQ=M/9]HB VJ,97/GX7/8_L4X7T/MVA^)** MB_Q$< RV9:D\PF@:0@?JXGC>WPSZX6C <=#D$%M _;YAX3J&TF=HP!4H#MVZ^BM:Y$!/>T]OVNP M)Y]K6S.1,NI,E"G67@7^7@!M6@=$.&H4EH,0A^6)0$%#UY-0Q;4^/?/QXV"Z M6* >W&(=HW,1!XM9)#X8#84=RQ+3EL!;?UQ"5P8LWE?#H5E]S+ M0N&<#: H(,R=%=$B6"!EOE6 MR#NG53G>GU';.#51P.30!LW6!S$^.(])WU/ M.ES,6A$0A,Q_'^P/ %U\21=]%/Z!^$91X]!54G\^"P>>WL'WXVDT$'^JG=%' M[D?.:O?R3O$P?$DK3V2@V3R83R-&&:E*##,%AWM&?6DKWK%T!;:GP3R:##RC M3<8X)(?L.@*D^MC"H ;Z",)']S8WQ$^$R\O.7P\3H2S6&>F=4631?GR>CU*P MNR8$["%U .32D5_\;AZ%LY=6*&#A+7=LG)AHTXX=B"$+6NP=0@5ZT)7I,M9N M\R%SA#,*"P\V'N,ZZ+#$\)1.8B-0!["V >L798\%Q"&I0GE/.;FEMYG59HC. M*J^<]H%.-@0Y -%S[BP]0D#]+1$9,O?IP8E "#GS48B@V^*4[-2A%E@HH81' M!8C8\)1Y2W(TU!SXP5>96HD5P32C[PC/=[GWE=D84E?046N _BHGBH ]X/ MR%;H+3J@/%LI+YO+LG5OSQ#$Y137"+F^I?WV*%^1(*: (,^N[<[I M77HLE5$].R071C6)5CY7;HRD%'I*XYK:--(V0-$[/P*S!)!KX%F-L1KIF]XZ MD46A2T)69'MXUQU8Q%;JVD@Q733FXE>M?:Y(M'T(WUJ8?U 3C3I NZ[TN1F' M3'%6QFTJX?\:_[I$R:T.RF\P#<<#UZ91WA\W/N6T3B&5/D3T'D#0Z*EK";8W M"#/U0OL&>%L7NHX\F3T0HWOH(V>&3-RJAEXC]DK>PKTX:IIT;QV8:'7L=,HP M,>1R]HPCG9B2(,NQ,QX_(@XFT\ES3HB&XFMX:R4NLO12B_-K/O$*9*[;L9UK M0[A ]KY&[$LW!/QS!4>-PGH$Z"<&6-U.TNI)UR,#P7;3Q?"'H4/^N6(;W]3>O@2V:(ICP[3H#OSH=P]EC/-69 $JBM'H M)0O#S^%+=.Y.M@[3]BC'@>], =[N",*B'>7NVNAJ,GIW-; (9PWU-2"D%:Z *+2MP&"(6G+$%06[813./RBYQ#Q!^6_'<=$H0$8V MZ+ZX0%X5<,;*,>/LEY+/HL_!:P>=!XSF;,=T'%Y-83O4WTD M1<%X.@;)+/T\^V!K,!W/CUCGB6GJ-(BGD\^?IZZ\A=D4]]B(%M-@M%C\S)%I M./_51Z9.E/_XN-2#)1H#/JL1;<>BQ^>L1Z9?40A[S^/_Y?'7@4R_P-PK(W67 M]:25()WK]R").IA=_9MG1(Y\QV6]:[0H#,YU+]$;5(-W[[_N#9K9:(V&>>MA M,OI^>#T4*=@G(-_O?7_]%OLJ6UON0TX M)\%H/#V<;45!O%@!M%,\&7#RHM!ZMK(V;/"RQ?=37?S$' MJZO=/;S@JM]Q4;C&/3X?\T7VMP'9;P.RWP9D_\<#,I=1?KGAV"1V\Y^3/OW^ M@6S\WST9\]1:@>71P=CC0RO._<\<6AT"(W?9D^]K22!#SL]&,_B6X,==867? MH'MY1=DZ3?/SN_L)FQDA2. BD=PK[EP@C&\]FO<2H=!C<-)W,\]"=!/ %>86ZNJQT0 M*"UUH-U;LH'Z;<=S(A8@,8X7> H)HX0S1_JS2,RC "9B$J,@G(=LL<\B,8?Z MH@E)M!CQP((#8HF$]GSG]-KTL+YQ[DXPGM:!VIDSOQ!]@+E.IUC_VEQ/V(Y7 M=Q1C0Y/">M4J^U3_JFU? @ .#F;9]S+=P_L0#93I5.5^/+@_$,_X;J86 "!U&K%=0FTLK4!:!FPE6_0-#,4_-;6NY!30>9-=!IA:[> M-0PKZ-05H_YXX&LZNII3[#T8WKL$\V0. >E4*]?*<<-F2G^1Q4_***LW-="^? +&N^5D_1CL3O[IXW MWS8W]\_=A?5VN;OV_RV:?)J=Y6J%K:/A;-(3QEVE=Q]*O>/KZTM= B#QXX9G MJ;0 [U=:E_4'.J#Y_QG>_!-02P,$% @ 2(M06'J@=%1)$ G2P !D M !X;"]W;W)K&ULW5I9<]M(DOXK%6IYAHJ (%PD M05\1DNV>\>Y.VRNYNZ-C8Q] H"C6& 0X.$2K?_U^F740("D?\[@O) A69>7Y MY0&\W-7-YW8M92>^;,JJ?76V[KKM\ZNK-E_+3=;Z]596^&=5-YNLP\_F_JK= M-C(K>-.FO(J"8':UR51U]OHEW_O8O'Y9]UVI*OFQ$6V_V63-XXTLZ]VKL_#, MWKA5]^N.;ER]?KG-[N6=['[=?FSPZ\I1*=1&5JVJ*]'(U:NSZ_#Y34+K><%O M2N[:P;4@299U_9E^O"]>G07$D"QEWA&%#%\/\HTL2R($-OYE:)ZY(VGC\-I2 M_YEEARS+K)5OZO)W573K5V?IF2CD*NO+[K;>_5T:>:9$+Z_+EC_%3J^-YV#.5614>ZZ!O\J[.M>WWWZ\.8___[AO]Z^N[W[JWCWW[^^__3'RZL.E.G_ MJ]Q0N=%4HB>HA)'X1UUUZU:\JPI9C E<@27'5V3YNHF^2O&MS'T1AYZ(@BC^ M"KW8R1DSO?@I.;LZ_[RNRT(V+>3\5Z^Z1_%+W4GQ/]?+MFO@'?][2FY--3E- ME2+F>;O-K?;9OOI_*7G](HG+\P MM 0KY?(&3EV(-_4&@=YF'"O792G:==;(RR7_N$8A=ZPE5Y65?J.I>W#<9 M[HAZ)5HB(^HM;<42;$.XYO5]I?[$7E6);BVQ*.LD$Z$M,FLJ$&E%AI];V>!8 MD)1?B 4)&OK8FK>J1JPR?#QD92];7WP"->(VJQ[%&OLW62%%5@G9=@IA*ID^ M*.4=2 "V5E)U?3.BJL#%6H'O1N59R:L;):M<@OL*++=. &(K'ZHFK]L.),I' M(@WVZE9J!1A5C19GNZPIVCTW72T>P.9(!F,3.K(%E+2&KA2/4!+V4D )A(/< M+&7C0H(_(^86%R'A8VG.P-9570)M3_-.6]H^7Y_X:YT=;I>K%:BVI+,*&<*: M[;EX7^7( :V\FH UOKIPC!-_FCUF[0UK#&Z2E;(5YR+T%D' WW$0X3M-IN+# MD0^(,/'":21"+ >EA;>8SL4O Q[$)(R\>#Z]P$7@16&"BQ0W@@OQH3JEL&[D M-^0'4&AX.6( 8[( MH78X!F#UME^VJE 98L/$G3L #@<5Y8;?<+%8:#31?Q*!#,%>Z("GG_#N/0)@ M3R,1#!.D+\[/#Q(!A1M+@HZ5;!H=+!DO%48Z/H7HGUU8Q<-;5*-!YGK;J)(8 M3'T NUCU#9UB[;93@#109[#0=G6,$TD=^ Q49!4Z-^O "]4UH)\]9*K,EJ5D MA;+U3U'1QS ZX*R^U5*TLNNP$R415% Q>!JNC!N=)$7\,+FJ[D -WBD';.QW M.)/XY/?:Y:(3/O\-MZ,3K<4.#6;]8V_]R< LUQN-44?.IUWFZ&^*EJQ +0, MEF2\Y:/CT\4??FQ4UTEIS[ZIH3'Z\?8)KWWJ-))/%9)3C08VP-=$Z=#(!%@ M*_K0PF2/@1+C^ 468S6=E/7 ^T;]J5=C8>0E0> %@#/C-41SU5.ZL?EQHAT5 MX4(%@HX&RJ*,F40C/:#0U!M]V*;NR1360"0F-4?9, /:7=#W#M6VUOLA?WG6 MK@5 G]L*@)G910(]7""L<[GM:*>QWC>=I"$(H"* $4X[\7TCM?N"#O[5N87(:BU>G?*?3R$']F]1F6AI0FI=HHG7]I9=5S3B.K:F_10,N.8I7* MP#5.4T39>$FA2)T5^!S\$!+U,,HK79V107<*SHFJC[&F9LWV%94NUKZ,SGG> M]))Y6-)J56CHP_E<8* KI21Q0BC7!89UAA$UDA%K$AX%S0IJ;PTKF6D,PSJF*!S"H7:1%J?_4H8 MF?7RP4B?C=11],Y2ASF%ZNZ&-%35%6F@5&.M[%4(I=>-T?2>VP&Z#02#+H ( MY%]D(A(8T=TOB]21#P9$9+M(9HU5F@G^8 MW$[N,@E.&%0S2P?_7' )HC'7E1[RBVQRU;HJHJQA,Z( !^S@XKK>SU:=483% M)0YBG=UL;<*%DFK;GO("X8VA[7!LB$L&^@?!9',*(SLUK84&$@J& JJD@W$& M^Z[(RM*11Q5XS0I^HKP^SKY4:(=>$"=>-',Y;EQ-F7RIX?.XO;O=)Q]=8?Z- MJZ]KB^[MW@W,MK^VY(;LF^$+6_(.JEV2U<*LJXA]\:MSP6\>Z;G]1J)]6&U@ M#;UIKV_7+>#[GDS"27X>#.PY309%@$=W"'D@QN7W"N!1N?Y/RG 4HX!>DXXM M\@YC9*SEK&QK5O4P'S,GKK'X>.=5UC\K.)PEQME2WP=5E!S."^))#. M'--'>>R4_@P8:?<824<%:'@AWMV\__3V>L3UNF^*4A)SJ"R=Z-R>;5T FH>+COJ?LM,=@JS9,QVVW?ME3I1>3""AQ^X46=ZOJ]M^UG.'H M!.)J@N#SE!@+MZN?+NQR& M@,-M -:E!? ;5=4;2DY\U[BV),VQTA$SA<'<#4]0"#[1;>(\7_S\_=,:SXUK M-%H^K1$K@M21E$$U&X/BZ ;W0[7]H*8C./7%.SMI>JC)AJ7.HQ3);O8UF'NY M18\'I>A8Y]I^^R$6.B:79PQ7T--P9'=$Y^2PC:6V\&5'DRZ3+24 5-6-CX[/ ME*F/2I;%@3C?.*T8[_7%K6H_7ZX:+G:H_80]X=R'2B*JBNH,Z4[5Q7Q']:U+ M7UCYJW\'_5 WUZ/.^U,VE#EW?L2 N]=P3<*DZ[U?/#^4S$?A3?#IC_4%J,S>'G^1+ MSNEUVMAWESH;''K3.% X(A@RT&B<*)0^#I#NCK.8F2D2W0T;BDKP)PXX15/T MI, _=8HXP!'9K>NB+NO[1]U3U$5/W2P_#Y&7;[*FK$6K-J:&-[AC1HH\C'#- M,;J9P;C/"'J+PZ"CA; ]ENA/O7"&A2.4PJJ8J/$'K8GC M9[KZ1]QT!,\F6W*,N\,OPZD_-SO"$)?;6#B8UK!H' M&OG-/@<=532',W]/:Y\!P'8LK>JHWVD>U#XIP$3;W4>--W/ <\ MX1S[LH'&:US2R,(@MWTPPK0?%%M^Q=-=<$'EA*KTXUW>#CHYVY?]C*,M[PBM MCF0LU6]MH4BLYKB/D3;H.5N0YB18&B1^G7]' N\&LX8#&/ KT MLF0A9M.$KB'J5$QCHCR?^M-0)XM[M+OW#!L5?!HU?VYR!#]3&C Y]N,=O.(\ MF7MINO#$>33WT-VP#YW/%MX\#(F?;SW.'..O9VNHG?61S/C(OJCBD:K!#%N@ M(B_8H/$O^3883/]$,^^(#]RU#7-[J MUI01R>&Q]$\1^\]T3M>1#>-EHOK6#C$LWJT3[?.A=)X"]" M^D[\.;EI'/MPA4_<'Y_0X]@<TYF'XDTYPH*\/ALXP9NV]H7O=\GP6@EF4L8G)P9Z[ M^$5G6??[? I F8M+<9Y._3@6,7X D$CDR(<*Z+>]IB5)0&O#,/5G@8BF =?O M88 :+1%1DO+E/-0K%C->.PW\= K3A((:A!"V 6KA3H@H2>8&=2B:'/(,0>27 MNKHTCP:.GR -D\J_XYPZ97$&Y.?J1XG&Z'&B_<)I[<=N#T189J5^'G4RY43T MP@)!/)) "']C[(6&I@NZ#$BQ-N' #F$\]Z&H9,97X5S0KHBSR6_ZM$D2(2.$ MD1\'8I+B.HW\<"HF$66@J9_&PU234'9!\IAA*>WB/,()"">/#3&08I0_0F*9 M# PB3PDS(',\$/Q_9M YOX@2S?T9DB'9, QAQ$A0@(@%\N)B;\^(BP;HB>+L&<]@C91B;1)/+Y!4R>QLSCE:GF1@SJ,"((;)$ZI/)J&N M/X+X.TPZUQ:=^M'T26F>G-D?)%U^+4,G\##U4GIOY3P*O/G")/ P]A9I<)B< MJ79F'.^K0;UZ_';1 (2KO5A/OH&3-30M-R/^XQV'+VV MII]]N SN$IUIT^CA&(T!O]@N)O1G-G?_/FBYN(=Z4L9A-V"#Z8E82MQSI/&Y MYV'BI4'@BUNY[9M\;=XJ&$[23[V*>#5X970CT3S1B[&MX,>@^NU1=]>]>WNM M7SG=+]&ULC55-;^,V$/TK [7H2; ^(R>I;2!.LF@. MNQLDZ>ZAZ(&6QA*Q%*DE*3O>7]\A)6M=('%[L1*1MLF9FI#B6M;)5NF:6IKB/3:625![4B2N.XB%K&9;!:^-BC M7BU4;P67^*C!]&W+]&&-0NV701(< T^\;JP+1*M%QVI\1OMG]ZAI%DTL%6]1 M&JXD:-PN@YOD>IV[?)_PA>/>G(S!5;)1ZIN;/%3+(':"4&!I'0.CSPYO40A' M1#*^CYS!M*4#GHZ/[!]\[53+AAF\5>(KKVRS#"X#J'#+>F&?U/X/'.NY<'RE M$L;_PG[(S=( RMY8U8Y@4M!R.7S9ZW@.)X#+^!U .@)2KWO8R*N\8Y:M%EKM M0;ML8G,#7ZI'DS@NW:4\6TVKG'!V]?#IR_VGE\]/#_?/B\@2H0M'Y0A>#^#T M'7"2PD9;S#<@99$D(:I]D9OFPJ+_-\V7OE MR1U*J_0![K@IA3*]1OCK9F.LIO?P]ULE#X3YVX2N1ZY-QTIO MU(O )71:U;2Q@2R\*F+Z3?(,/G#)Z)&R5785%)=*2"=]2R.BICG?F]MS2/3JY M9)TS>&FF-5_)3_B>T8&E85X,5TK#(H_/7WGHJ#KT_B@.L[?><73B,"WJVONH MH;?22SN8S12=K/IF<*B?Z8//?V2ZYM*=U9:@\6Q^$8 >O'.86-5YO]HH2^[G MAPW]W:!V";2^5)VZ#Z0]L]0]02P,$% @ 2(M06)OL<(QH P /0< M !D !X;"]W;W)K&ULI55M;^,V#/XKA%<,&^"K MWU^2)0&2-K<=D/9R?=DP#/N@V$PBG"WY)/G2[M>/LE-?AK4!AGVQ*)E\^) 4 MJ MZ/NI5S,NG-FD.UNKV42VIN("UPIT6]=,/2^PDH>I$S@O!W=\MS?VP)M-&K;# M>S2/S5K1SAM02EZCT%P*4+B=.O-@O(BM?J?P*\>#/I'!1K*1\K/=?"BGCF\) M886%L0B,EJ]XA55E@8C&ER.F,[BTAJ?R"_K[+G:*9<,T7LGJ-UZ:_=3)'2AQ MR]K*W,G#+WB,)[%XA:QT]X5#KQN3QZ+51M9'8]K77/0K>SKFX<0@]]\P"(\& M8<>[=]2QO&:&S29*'D!9;4*S0A=J9TWDN+!%N3>*_G*R,[/UWH/C>HK.K/OOPM2_Z*G=+*JE] $+A9GO5"'"2P:'E5%&W= M5LP0SQ*I: 5G'5!HO8Q2"/*1&^?1^7RX(&AX7A"EU/6C42<%;I0D\#,2&=;L M>0%SFIA@.Q3>P4J*W;L5#:,2YEJCT? #/A55VT7.A6%BQS<54NKLSQ]/\_8H MN"5[;XBSMI[\R$U'H94HA4F> \TJFD2"$M,*HSAI9:$;Q9E-2)9F\" -JUYE M>WV: 7RBL:\1#E2_BS!UHRQR28C)IJ_U11BYX2BAXBHP>X1G9$H#VJ[_]^UP MCU>COR-T2"5JL!O(U?/E:]WAG8RT&M6N&]P:"AM5/]V&T^%MF/&ULG59M;]LV$/XKA!H4+<#8>K6<5\!)DR[ V@5)NGT8]H&6 M:)NM)+HD96 MA\.A+1:R%G:@E[+!EYDVM7#8FOG0+HT4I5>JJV$"GF\E:Z+\MK@]UPBU*J6C96 MZ889.3L))M'A64KG_8%?E5S;G34C3Z9:?Z/-57D2A&20K&3A"$'@;R7/9541 M$,SXWF,&VRM)<7?]@'[I?8CU3[+W)R.\ M0E?6_[)U=S9+ E:TUNFZ5X8%M6JZ?W'?QV%'81S^0"'N%6)O=W>1M_*#<.+T MV.@U,W0::+3PKGIM&*<:(N76&7Q5T'.G5Y_O)I\_7IW]?,$FM[<7=[?'0P=8 M^C@L>HBS#B+^ 404LT^Z<0O++II2ED\!AK!G:U3\8-19_"+B!UD,6!)Q%H=Q M\@)>LG4R\7C)#_ ^:EVN554QT93LJG&BF:MI)=G$6NDL^Z!L46G;&LE^GTRM M,TB5/YZ+0W=+^OPM5#Z'=BD*>1*@/JPT*QFGH_Y09C[$.[EHP.>A0=, M6/H&NF0]E69+F3^$155&X[2GW[%CCGMX9=&KQ25MX>9W)ZS) LY M>_MF',?AT2-1=O\)@[] UPS\J>C(^Z": AW)TF+'!XL+%%J-JC:L;"7=BBZ& M.FU06<;(IM@PD-W82G0=HOR*@D/'09M#;KSFFOM;\%0)3353@E)+/6:9Z+(, ML9KI"DW0'G9(A,(FM39._=D9\-%H:]FD*-JZA4VR?$9R[GL"+#*R,]LNU-)Z MLRIE<4\4[L);2*#D*>Y2-V9T2)-H\GP$,X MVK)&U-*R>#_*&?B(QR.6Y#S/$]J%V9@E"4^C$8(#5O$\0$T6BT97>KYAV3[Z M01KQ:)RR*.<9SJ4A3Z$#A.:!>F$2SC<9K!Q#3' M*J%5/!YSBAC)8IZ'M(JS YZ&XZ9C*E!YXQU-:Q+)VD= M$I9H%KMNR7N\P93=(&F)HKGWAY#5>Q&*$@[@:AB9PJ,H\X79";).D"!,G6!$ M@I3GX*83Y+QS'L)DG/?",=QSKZ4^FN6:?N#_:R%7;@$QGDK5*"=9:^6LK9"M M*^FKPG^ R]/-_VT!5Z]4'LS$6T^# *[I:>HKER"B_ B$H9)TI4H?_:FH1%-( MYM]5RUH8;W8?CEW/>J^\.YPUT@VH)>V$ITL/^]#TGKA/>?$/V)TN^20-.G8> M>? 7L4L)XT0%\RRE9P$V.+ML 4E+?_A&^P#Y_:1PG+WKXWMY=7DSZ:/X'JG M%E)4\(F4K)A)MV'6"=O5LZIK[(:W8M-B8XYFA4"5'9!I,!\&=P.,$*LE-$-'89/UT:[?GR;S'V_ M?D.(5 -$EYXTDF#N$CH2ZIE,AAM/)S37T1H;9ML>BO-EWO]&IX M/:JVI*+#*=^=^AQQ/J'$5*_DX+DG?+@S=Z$ES_UT2:F$1[,;P;;2[0 [Z>:V MQ^/=]/M)F+F"/96<0342204 .8+ 9 >&PO=V]R:W-H M965TD M&89A'RCIVN8BD2I)V?%^_;(R]#J>#0BH=S4["VB<[ M.S&5SY6F3U:XJBBDW9Y3;C:GT2AJ%SZKY*UI@O* M5^=5I=!2)C!:RROUGLWE+33P3 MMI>:W(6GV-2RDVDDTLIY4S3*0% H7;_E?S6_>?GPC+C_HJ!T=/.R(&^F5*V5*IQ$ZQ9%=4S1[]M-H.GS]2!@' M71@'CUG_7RG[,4O@!IR/QCWA5R0N3%%*O0TDS24HDUI<8#:H5.;=)H\'RH04 M?P4:US6-XOETVI].GXJ!&(_[XX.GPFPT6;=2Y8N>N/9]\8M,K"+8N6A-]<3[ M]Q?P;-!<3BUU#^\UAD?9"PA2HY&7*O7X$W0/C3 ?S&(7Z[.?CN+1X6NWYT)^ MK4T5IS9J:2@,IBXH;1"3;8+IFI':_3UY"J2P@4)*5/,) MW04\>A$<58X"'&\\_%#= M*HC1*G?'9K3QF-R+A4H5X'%Z *M0/BCMX\;>0FFI4Q(*(2/ >O@JK]!8&X7V MJY"^+%--5*Y*C,V@PG37JBHLEZ6QB.ZL$\T1U]J YB6 8=XZ\3SF!=@EF:Y> M!'X9*BAG75;R =$WJIOB$";)U3(0R_LR<<8FG#J<%X"1&^=@U5@8<"E9@A M(0U<80&?:ZL!!# 6S1AE">5[A2.*4!<[D>=MX*"?L4(U!3(RX;LT&_:+6:# G&^#:6OI(=*Q@K(MT)J"QX>"+_0KB$$?0C64)*%7 M#088,Q(N-L"]GRQX,U#^.\PTK@7V]60R/.[A.3FNNQY?AX$>!K$E:6$YM#9. M+BH2(&]/K_",:RU\814%Q*6$6N":MI37246H#+#)X(,!=L.M*P %08C9=F4_ ME$)FH984-W8WV&#=M>6ANJ.P;G\&\B0^'B+6\632Q'HT^;%0]R*MD:72VBT[ M6SB!S^QW1K,Q8;5,Z3@][P<%J#.^C%QY-_DQJ&KPNIM P5-$4? T_: MZ)=I92U'+-'GWD6"QP!C R\X'[(PBQ*9AS$6[E>N_]#A/=BY>Q5DE^&&B4.& M>Z*^AG6KW27VK+Z[?1.O;\!7TBX5LI+3 JK#_N$DJJ=<^^--&6YRB?&X%X;/ M%2[B9%D ^PN#2=C\L(/N:C_[!U!+ P04 " !(BU!8D*JIVLT& !I$0 M&0 'AL+W=O+-ROI81MWX]"8U7 MLN)-M9D4>?YL4DMML^M+?O;.7U^Z-AIMU3LO0EO7TN]NE7';JVR:]0_>Z_4F MTH/)]64CU^J#BO]HWGG<3?96*ETK&[2SPJO5578S?7X[I_6\X*-6VS"X%N3) MTKE/=/.ZNLIR J2,*B-9D/ASIUXJ8\@08'SN;&;[(VGC\+JW_B?V';XL95 O MG?FGKN+F*KO(1*56LC7QO=O^177^+,A>Z4S@WV*;UA;GF2C;$%W=;0:"6MOT M5W[I>!ALN,B_L:'H-A2,.QW$*%_)**\OO=L*3ZMAC2[85=X-<-I24#Y$C[<: M^^+U^U\_OOWMX^LW?Q:_O;UYBR(O9 _9F>P]G;&_V37O+*%[I4!H76J_$ MOVZ6(7IDP[]/>9MLS4_;H@IY'AI9JJL,)1"4OU/9]4\_3)_E+QY .M\CG3]D M_1&Q^'_VB[=6_+6U2A3GQ.7T8B3B1HF7KFZDW0EI*R&1T/:3"#M;Z5)&)92- MRJM*:!L=WI:XUE'(M5<*A1C%$[*0D3'Q,KV[Z=]E3T=BN]'E1C3>W6GD@H!D MH&[OG+G3=BV,DS:(MA$P?;;(\U&.'U&U2K@CH,5L+%ZUGK;0:4&5#E _M](# MFW K6E(<^[)T'E3CQ+/9?$%V18MD]+SF)%C"L,(:7O$WV302\O"YU4&S5#P) M2HDW#H3@H ]Z;?4*_&#;S6%1$$_'B6*SZY'?@W7,IA4W.)IX(>K?JQ#!>/4U MM)[CHCC!,=0A;D2I?(3>"D/V?, !?"Y)-!$D09K5(!_\*)UOG*?<;%IT\G)K 83D/0ZY_^F' MBV)Z_B*("H7O%04L8>ICPW"T12BEH8PME:K@EG=UES6GG(>[7C4XFI:@PR&$ MJ!SXLI1&VE*1"V?SV6RT>/8+,ZO[S$96_Z^4XW([ =&L5]V^PX?M!OB1_K0"U.,88M(23T-V ]\%/&=P??4Y\7 M]'#7)P]>X7SI-5*_H;AJR@B(F#/PPM-U _ZYY. 4K:EU6],KC$324/FPBAIS MY'3R*S#0KKP("R8(Q#?N1(5L!K7=JN'.88:<9 P60[O\#R@125(T2TR(@DL$ MWB,0+-TKTY:QE9',\CL9:%A!QZC$Z1 >U&0USZ@6Q)5-/K8Y>WV/]LO+C( M?R0%^"I3CXL><*4)[I FH(K*&9W.U;6.3,!*[4/66I8)"!"7#4KAZZ3JN]Z> MBN\CXK$\, U>VK7JU"H?3Q=P'I[DXZ)8_"B>X,GYXC0=3Q,?C_'KN#P+5.1\ M-OU^CCG0A_3I5?\@^L1[P*H*0ZZF 8VJ'J-'%Y(P; IT3W8)M?3,AD]]H>N( M8\ )5((AN%(SY=PX.7]":'NQ/J$17&1=;])_=-T:7("J/U)TT5X!CZ;]GVD" MH[##:7?7E2Z\JGO;)T,(< /S)0.EA*#.799MW1H&W)TI.40LL33@3$?Y+$\J M.1W-INP 4WV!,@;TZC2@<#?C, 75.;IWI+C M'$VFRT2*MP7/![0@3LE$<\T M+'WE7#]I=3Y.'^7CZUXT.H197V1@/"4NCR1#1WD^2VT%D0$BT M .]7#F-5=T,'[/^[&PO=V]R:W-H965T'N(8=K=%L=@'6AI91"32):FX^_<[I"PE 1(7^R*2XIPS9X:%+'.@JO2C(!CZ%>/" MFT_=OXV:3V5M2BYPHT#75<74OTLLY6GFA5[[8\L/A;$__/GTR ZX0_/7<:-H MY76\77[*9%UA!6&)J+ .C MX0&OL2PM$>;T.I<6^'3>LG]TL5,L>Z;Q6I;?>6:*F3?V(,.G@#&KP&B,R!RNAM'3N4- M,VP^5?($REH3FYVX4!V:Q'%A#V5G%.URPIGY>O455HOM^LOZTPXVJRU MWJUA]WFQ74U]0RZLH9^>Z98-7?0*71C!K12FT+ 2&6;/"7S2U@F,6H'+Z"+C M#:9]B,,>1$$47^"+NX!CQQ>_PK=B2G!QT+!!!;N"*82_%WMM%-V/?UX*N*%+ M7J:S-7.ECRS%F4=%H5$]H#=_]R8(8^TOFDLJJ(W)%#BBV638"X/D?"7^"() _PG?75$39/& MBGH47#>"=DU4+7D<$71LAR"V&%:*VXX0=^]&4=A M^ %V1J;W<'>T2=0]V"+=1)Y:EVZGYX33577M5Z38NHZ3 .)1 LE@]'N5;>"D M+$F0MR/QVZ()C1$__1O'E ;IDZ<*&AQ)R@07\T\$ U3;E9 M&'ETC7 O#;55-RWH'4-E#6@_E]*T"^N@>QGG_P%02P,$% @ 2(M06&:B M\CSV"P 71T !D !X;"]W;W)K&ULG5EM;]PV M$OXKA.NV-J"L];9O3F+ L1,T0-L$3=(><+@/7(F[RT82MR*U:_?7WS-#29;< MM2^X+RNM1 Z',\\\,T.].ICZJ]TJY<1=653V];!T]N+AZM9,;]4FY+[N/-?Y=]%)R7:K*:E.)6JU?GUQ' MEV]2&L\#?M?J8 ?W@G:R,N8K_7F?OSX)22%5J,R1!(G+7MVHHB!!4..O5N9) MOR1-'-YWTM_QWK&7E;3JQA1_Z-QM7Y\L3D2NUK(IW&_F\)-J]S,E>9DI+/^* M@Q^;)"O:K-0=0T M&M+HAK?*LZ&1,_*_%691.11(&(PSAY1E[2[R]A M>+SULE;DRYD]7]#]\MXFC^T@JU M7BN. ^%@D5HZ)1#8;&PV>2QDE=--) [2XF:R_!XOHDG\O0C\NV22X!%VOO.2 MBOL)+Y6K#*Q@(; VI9?E#$L6VHI=K1'TNK@7>:/HA:R$KMH9NA*9JATHA-7" MTUR#:D3K/#Q35DCX36:9:2JG9JX;"VM!;\1>H56JYTH=V]*)7;FGPB M;M5:U9#(HGF@'8W4K>Q:9693Z;];X21VW3A""^MD*JO^:E25T7#G:KUJG%P5 MO)=?K2E:9EH6P#J8&ESF1R;J^U]5&R)*V8H59"W6GK>-G M3ZB'_Y"GZX'962OB(_\:+ UOD@Q O)W1F](OBET=9)W;;S=)">\T-*ZQ)%E5 MB)AV%D$'<+HC;>@1'+K;P;NXP6LVC/;>T]X6]TK6EOX.7M%JL UT-<5*O>P\X@6(/C\&W8%8TN1;66U\8KU.P%$!P#0 MU2/M85UMR G2T9NBR3&'7K!-V+$YY$R&00>!FZ:0=4%W>THG J@^JB8!KMUB M!U_2_&":(A?*$M"TW4+UO2P:Z=-9@7P*=$'%->3"2(56>]7J:!O8N!5>RGM1 M&3(F\R4#3X!2$K7:*W::K/O8GQZ/@V^BF M?#"RQ_16$C2RAD- ]G%&P4"X ,MRD(YE(P^QQ_W:C'I*3XWU!+$#PG-SJ 1[ M-5;"9>\&]+X=)GZG;59P3.9HH('3)JI'7,8 (\)\ MR '47XCDH:!"ZQ;PL* M\D2A-HAE.)9$87:3,:BZ<(3]=P7BC=99>Q,R;1IB ,ZWKQ+N@GMKOTM, C(_0(TB-M_#8%P%Q&0<$H9RD]M;A98=P8>:WCRB: MLEW'0$-%AM5$CS1F#NN3,"=L0ZP*/2Z],[F*X6KHA@!;N4OQ3A%1%N)4Q/,@ M"6=T,PM2#,;-- BCI7C7[FD>S)(4OU&8X'\VM%?1>!/-HX6^214PWRR"*EPS:AX$4 'I8DGE&MC[F MN0[CFH81Q=Y=W?NR@(D<[[O=43G4(,G<^Q(4UH^C[Q]5HL%#*0H4]%!?*8+, M,=IH$?^\'P<@ #,_H0\;8A%/_4VXF'LGQ\ME:^&A%0(@U=$6.F$C$\7!-$I$ M%"QF4 !^GT&"R;Z*#SO/RO!2&*;PTFP^P^\R3GL?OX XO?=D#4#K04UU]N[V M_7MV\7P:^^M\P==I&CZ A#?3I4U'=>@RG4&-<#:#2M%B(3[ 6K4X6T0ASX[F M@!B$@>W^?\ ,8Y/BZFB-QXEQ0W5LK2W[S4)CC?PG 2!,Z).68^(\7MH=I4NN M7MTSU"P.BNC/MC"Q0Y <*8TO 9H][&>X3#B%?<)TZ:_)0ORFB,RXG+'L6(:JIL$";?0T2),E"0/0J73CS2%SF!T7EU$L!)):8B*2G[,(D.CG\V7P7).XQ=P8PP-?S]269_1"_[Y%2'^1&Z&A:8(J73&QIK% MP7P!K:X9N__ X+B4HEK(/B(4SR;C;N[LUP\_GX^;.))^FJ0+7UAX(1CU:! G M4CA$ ^]=8PHU9FTH)--QG=3V$&UT^_6G&S%/PQ=1*#+T6'I]C\92,120 M14B14>G08@>OABC@BHZHS=BV2$97Q+T[MD]M$S:#8J(H%.H)G\U\;#6HQFHX M?R*N>1$T^84>574KM=$5USMD:A2+#RT_XWE8]'$G[PV-;.+[8VV[/I/M87AG MA:DV+ZB$% :VVG1-6#4$57_40[6-*32UI5!=%FQO/BBD(LL^P7^<)-^THZ4; M[ -:MR76*=AJ$4W]=1'Q-4FFE%NYO3AF6)J-R75;/:,V 2O%0;1,Q0))\59] M\]0S2JF4[&*B-+K2[T!E1<,PCPZY_[1/N<2=-CCPX&V M+?-+D,^X4==P0.:&SOCQZ(D;!'!_/I;R^.R@70_Q ><_<"7!"00K"Y_G+)J? MVG6H.Y:N)^*VJ;L"[%M[%XRUJC^BXGP)YFLR'P6G27M0>)K,H\>-SJ/5GE@L MHC4(A65[H(=P/8UGB/,GF'.@G,RRNADVL6.;L+:GR""1GX3;>3)]K&;K>+'6 M!1]6](:K%;Q2]6U%WP_A_QY$8YJ6LWT%TO4OOD_2BD\M>6(I_P1F_X0U;*XS M#^4#\>$H!7BF5[[O@3W\L4!1T)$-Q[NB+RBK/^F,B]JY8=DKNU;2DE.&Q-21 MFW=W6S+'U)N0SJ6LY,:?1N9&^=8159?.]([@26I1'UQ3P3@X*Z/2CK/J-] 8 MZ6HR9'LD!OC9SZ[4'39Q4 6"H>3/!A[S;YL:9I 5G:I0:4$4%H0X3#[ M0[V155?^D.7>=B/,>AE[U;Z15_6.RN;N=$U-Q!];78R1=2F@@'YS= M$EC;LH^+?JCW3ZW'Y0Q,!C4;?Q@ !VM'D_:FV#,A4-6$;&(+;\L6%./]]N?# MVO6A,3GV6>5B\,FK5/6&/^Q9'X;^ZU?_M/]V>.T_F3T,]Q\>?Y$U_1=02P,$ M% @ 2(M06)9&ULO5K;>FSK=EI?^'VIL29M:MVNL;/:G/I]Y71N=RT*R[3T6A^N=.V/'OU0O[[ M5+UZX9JZL*7Y5"G?[':Z.KPQA;M[>38^:__X;#?;FG]=5ORQN%QN_HOHCMT66EOWKKB7S:OMR_/EF1'UF7"]SA9=/=1>N3:_.5-;XVNWBS9!@9\OPK;]%.PQN6(X> MN"&--Z0B=]A(I/Q9U_K5B\K=J8I78S4>B*IR-X2S)9WRI:YPUN*^^M67=W^_ M?O?QJ_KP\9=?/U^__OKAUX\O+FLLS-.765SD35@D?6"1<:JN75EOO7I7YB8_ M7N 2$G5BI:U8;])'5_S99!=J,DY4.DHGCZPWZ=2^;I"4/S?*7W#:M/3JS%1GON]SLS+,V2"-]6M.7OUXP_C^>BG1V2= M=K).'UO]S[KD+R^BWNB".:W>N@I6T'7(*QK$JWI;&1-_Z55AE \6\\_5^V:G M2_6QJ2L;$JG,U7NCBWJ;J->EW>GB@9,\_K(WF<7/@_I4N;S)@"#JBRZ,E[/[ M\!]O=.OVEU< #V]SP_]<4YV22NYV]=943 J'S&P\+.!]2'/(PATJHVR9%0UB M$@?J[%>Y@;?^H]1%X3)=F_SB[!$-U=>M>>STT[/W']^?/6OEH@JWD-RKK=RS MJ334R+:.[E$E5^BDA]RF@NTT%8#8-L>%IJ!(O27@%M=LMOBVOML$4!S6ZJ39 M!FGT?E_83!P+,[^-V^+.RF1N4]I_8^G:J7VA#TJK&W-0E2MH(ZQO@&6WP.B] M;,%%D1Z0H:&,MJS-!OL=Z))5!:Q7&8!4[NMU> MEX>_^4=,RN5")(H1V@L]S.:3(W=D6*TPWV+X-!Y70X9*WP%U:U-A!2\.D,"2 MT@35@0([B] *7N]]T_KQ)Q[MJVB,VF3;TA5NPR#=:AAC94S)G5<00ER4H<#6 M!H(IU%M=VDSMX*FL"=[2E& G3ENY_* RS436N2U@)AA^9ZESFV@;X ^"@T+? MEV\8,"%."@L?*IS*[7IM*GC'!J!85VZG4,)-=9XY7XN=3&W%E]^%J\\8YW8- MN7-4I40"J& E;F!BVL)4=7!IJ'&F\G^C-!5]U.(!0RM7M[IHH,M;B&A^;[!L M<4A$]>AW^.5& O#6^#J TP4@J?' FI?N')S#A_NPIKW560T#;(,CG98NVS6 MFEF -7R'95B4,:;^)TW4W=9B*^840@:.:WC-46(%JXNG*,;*(2FW$2/Q7=5= M_D)=N]LU)3(M1J6IMX?"-Z!?Y:'@+V0;4.?ZR_79LW9ORXU!&PS<+P';.5A2 M=U.9G.Z +)I;%7O?XA0"KS1K6P?[_.;@IDXR'PI#MQ;^N;$!;E9&-ZV$X7+X MQ"+00S] ^AUD8M0AIG TC$,PY!2!QS MY7F-2.DE]T'(7&V@DQ^*Z*/8T7^Z'J0' ZJZ,?6QI%L C/G&E+ ^! VW8I70 MQ<';HU(YQ,T+]:]6-=@0P3TP!X7.]%ZO;!$2@) M^@L @L&C!N1 I. 0LVL* MCWQE[7%W.6R40"04 -^6&+W9%#2>#K& 8DRJIPJ[!\KZ@Z_-#O<4]O<&O]<% MW0-9"\ #3-&=_ZVQF9'U@HU(J&F]K0.1)>)U5_(ZHN N7*,"%$#@38#S(0)( M B"KSJ'?7GE7- '18I171]$UV/V$35&'3(Y(>IWG,8,"W RBNJOQ.YM5SI0P M,Q(T!$R_-WRM@\"A:AY#;2FY@%*YU6@M,H.;,A:N\J'DE05-B?2'71 JTH[Q M&$L/[UB3WJ[C1L-2G$#<;_(MT:2S&\G88[DDLX 0Z_/"K@&ZU_HW6*XUT_&E MJ(Y'&8!NJK(;!DB,*239OU'6\E 16K]&B4S(#=9EH[TK*8K$U/U42Y^F2@BNS"C03GAHR$(!^CGT''1*/#6":+CL-VI#;;%JZ"+!?J M%QJO05G40NFHS7&>=JK>DV=(>-&_^Z-Z""YS,^P35H<65A@RG3@#=X,2:STK08M0HPET7R\OP*EL-6]DED0#HZCIA-]R.-.V._0NR8F:][+J%<> MG5=@4[ 5P<$UD5;@AKX#ZAPDFX=?8L[ $'RL(G0QUFE"T0B7J+4A@PP5#7V4 MV/_.546.B/SX_@2KD9RG]2C#?:\RR$]YG_ON7.DV&I4'+"]NWG('\+CL53\'*2*%S5INC3BMN0:D:.C3 MR*DK 1'!)E,YEFI<W0D8^L@N(9?DQS"+X)!;^C 0Z\)LJ"*,!:+YA[07 M7/,_8II=)AR13#H_"-;V)Q!(^/@Y4 =+GL8%IO/6;K8%TW]/[A':%,>B7A0] MD42G6R+T,L^V[8Y-JO9#$$*;&$B1Q&71D@)>$=PL H&"XX2WL4D!,2KH%M2J M"F9P(9B.@O[^/*-3.@XQ]MWXXQJ\;B-0A8N0=8$=:V)8QBAH8Y5TU &'#^=. MDH[Q<"\](Q @WC,)I%,6.@7 PMP<%NSH1_02#3J3:T[H#+?V.S'NB-,X'>T M R=$'ZSMN-K"&PC2Q@A_R:M!M\C5S3KF6:P[KB);NR_5H-4,O><>J=:6 M)RQA9*)0'.*%L44>-JB@KBMX:F"MBQ.3J2/!*W,>2%),\-P2I%:-)#SB?K>" MI(3L 1?;=$R59YI+HY3U) )A"#J J7S5-D&.4D8 M$0PD.(?OH<":65 !>J0K(/K!TSPF< N=:%8M G;MNZH/^U@_"]0CYCY[/E:_ MDNU"" X+OV:RG12C8PH=YU]L.E9&0+75.I?1@TR*^S^K.,([,L!Q,RJ(!<,C MMO<<*_6])Q25?B+FP07C;W_/E5V![TJ>^'4->K6A6]E=V+Q'"@CH"C%\Z4W6 M31A!LWH.1"J-H&!_C=M#)0-QS<)4*]S!G;@:IQL! &345TDNLC,HHDP]C4<) M:*E\_Z??V^!"G6G'>4$I_LR=/!"0QLLD//"$ M[) )IP6T-KN / =4"*+H48N'4GS,%D/8-*40+_[RYKC8^JW=[P4!'B#"?X![ M7&,HNW!0P0]&4C"]E"IO-Z7)D_]$,PED[8$8)LQMK8@C Q^OUX8SJF&I,N6M M18&C5VCX&O\!>80IQ.>5.>%9:GOP!06HS(9L1&;0F[Y6'5MP6.+_E/TXKRQE MT0 _L']OE55CP3>IN3]2G6'!*68_TUJSO*UM4=#1B.TX[@G#=N/#TP9%&\M4 M@(V;W@LM[@>F)_ICCTQ'0<&BA0S!28,MX<\/@ZC%P]!)G4?_M>4 J!Q;KQX7 M6)F;VL&U$)MS3C'EUGF1Z8&>2W"L[Z(V:#C T^1Q03_*[AX !=&[1REQKN\' M6.\4G13U13 MM_[NK/#]PY9!.TPRX?O$0%N3W10='1##U$77T7=Z=$_* +X!8LG,@QG6ND(= MO60'ACLV['N"DGP (_[K!P [5PFMM\QUJ9J )%2(Z$C$/V>6N@)Z!_O[P4S; MRN#0Y;%B2YGU#9FN9!_*1!B!BKL4W17L'D*KY1$1!B1K*:^.D(0)9E=+9)T/);C>3I-9N/T>U4_HFD,S6*O+3[&CZL\ MFXV2Q8Q+0^UD/.'1=)HFB\GD4<5AF&22SE4Z3Y/T:J'2=)XL%O.3!DAAF_E, M8?%D"GN.QXMDE(X>,D3Z3"V2"9?$Y50.Z80%#N"W^=6S/LHFB+&YQ-ADDBRFU)6>2Q$( M/YO^H>/EZQW'Y_'ASU^Q(2)F-J>[N'XJ!] 4H?R8"1?)$A:<)_/E#,?3\?24 M_2#Y8HG/&=(,83E)'S'>&)DT49/D"A),X,IQ9X'9%":B9V?C9#FE?-,E=K]2 M;R,;>$=CYC9,?/Z*YO#\=#P+FL_%!"E, %T>TYS 0C!(EJ,K:#4>C4Z&3C*# MS--D-)KB>(G/AU6?(%SGHQDRO4\G>GTQI:Y(H>6<_R!,IZD TNFE=,!4(CVP MFN2@;7XR[;=)2YX$G NGB=>^D9++P02*20C-L$PR?"@="7U(TII)V@[5CFJ[ MXU#?<0P71&+-"BPIM[X$4$#2ZK&TMS;2\+.2WCN62%<^;O>8D5$7&&9^F MTRVGK1S-*^3KORA2G*F'EY],BQ^1+LA[&%Q?WL7H997G>-'2%_>T^&ZE/FZ> MJZ<6 3:Y'4_T _OT01A8L"\^_R)HXGP[.+H#&]H!OL59A/F^^2/#$(PBBI)FEP!8((8*4KYZ,^+D3PH2!69/#W!>00H MU,9*H\@@EP&%*\OXEF<,\_#DY' N#2=-')[PW;/TQ:FW]2X'+U."[&WDE5$? M6KWP7F7W;_=6ZNOP,F9_>7BE]1K,TI8>GEOCUM'%8G:FJO"::/A1N[V\FKER M=>UV<@CNB4:/%^ \Z&?=_N &W;NZK_X?4$L#!!0 ( $B+4%@26(0IX04 M $D- 9 >&PO=V]R:W-H965TO7MWI$]WQGYSE1">W=5*N[-1Y7US,IFXO!(U=V/3"(V9C;$U]WBUY<0U M5O B&-5JDDVGBTG-I1Z=GX:Q:WM^:EJOI!;7EKFVKKG=7PAE=F>C=-0/W,BR M\C0P.3]M>"ENA?_27%N\30:40M9".VDTLV)S-GJ;GES,:7U8\%6*G3MX9A3) MVIAO]/)[<3::DD-"B=P3 L?/5EP*I0@(;GSO,$?#EF1X^-RCOP^Q(Y8U=^+2 MJ#]EX:NST7+$"K'AK?(W9O=!=/$<$5YNE O?;!?7SH]'+&^=-W5G# ]JJ>,O MO^MX.#!83I\PR#J#+/@=-PI>ON.>GY]:LV.65@.-'D*HP1K.24U)N?46LQ)V M_OSFZNO5IR]7IQ,/,!J:Y)WA133,GC!,,_;1:%\Y=J4+43P$F,"+P96L=^4B M>Q;QGRHTL16Z%6QC3*'*-BN$IKE1!$$:#;,5X(UH$TZ3);& M%(Y)QT"4=AMA+0:]Z=0IK$N81'GA4YM6>QAS3_5*A><"%)"=+(3EP8F=8.*N MP22!H)$HN$ (XBZON"Z1,&-A9IR(6X_9YXH&%1J(U"7S?*W(/5"NL8'M8RJD MXV5I19JLD72SP=+R:)T?IDMV8/5=^/ZS. MDOERR69)NLH85DR/V&?CN3I$R[!FMJ*G>9;,CI8!;960+_^3CU*8TO*FVB-% 3#W2.A?H"/8W7I .CBT6*Z2Q30-3UF2S1"%E5B?S;)DB3798IJDV91EZ3R9+;(N].=#?I1T%YBX-'7# M]?[EBV66'K]Q8$+2^<)P<'6*DU&&-=?M!K7>6J*-=." 1GJOH$*T!1K:X8#0 MB!Z*!'>%!*=4"K1Y%/JNDGD5\+J-J9 $F"-I,6.A\R@@/I ;@#>MVDBE7*R/ ML&[\A/\Q5!?E:N_K!]0W1FK_6NK7'D=CG^OQS_IRPT!? P'"01Z(EB,P40>Q MA&XX:( *LD79^4>\PK9@!E7;(E=P$>0"_N>RY='KKK1L=*)W3_X[' /!L<-0 M E5]=[)4C-B"_/GPZ0-SHB2WQ_?=_ _)UU+) /WY84I@[6)/HX7J8&'L=MQ5 MK.'[R$.W(Z413EE6M*$E\6++=1XD@GC#%0BO) /J%$%%H>>Y3A419M/J@FKR MB?3&/9D7MG9L2TI%;5*(?M_$^)7)HW"Q[WUR:*9KS$&-F-T0B7$;@F-KX7<" MP4F]-3+O51[B[;=%+83@'-,&&D.%RHW,.;&*BF4YTHJKW,$FN,'A:)-YUSH' M39.WJ(B'A?"]E6@=PV9K <[$0Z^)HZ[5Q',DG! =ZAB%3A>U'"*[PB$1ZB]N M?'4GZH98>9CI4FB4N5+[<*AH=*VN<')3X_QRP2 P@*2UX>Q:BYSW,D?^K)<_ M(MW(L33@R[2J8!7?"BR%H=&"[06WQ 60XX'D2,?N7CI1K%1/8 ^W3M6SCU[T M37AZZQU\H M6&!%S@7Z=*]/YM>6J#;IKM8-S;B.I^.\UR,Q:R9)'/JCR7LG? M!K5W=1W:D2RE!IGQQ 6&$KK$')!_#BMX^TH^P"'D1QM>O#FX^[+U/9WA"F Z M*^G!8^R^EN['-!/%&?O%H I7R0;I'C]V=(?1X7_" MVW@]OE\>_V1\Y!9\.,2[@>ET?'PTBH[U+]XTX;*\-AZ"#(\X'-"L: 'F-\;X M_H4V&/X]G?\#4$L#!!0 ( $B+4%@\%<';R@( !H& 9 >&PO=V]R M:W-H965TW/5[\J- MR;B N2)ZD^=,[8:0R6W/"9S#QA-?I\9N>/UNP=:P /-2S!5J7HV2\!R$YE(0 M!:N>,P@ZPX:U+PV^<=CJ(YG83)92OEEEDO0TW9( BNVR*.-S/?.R"#GHOJRC_T]'#FT_4\/,ZZGL$XUMJ+]YC#"I-^@AE0,I7"I)K60WH6\1;B M*Q(&+J$^#<_@A77688D7?I;UIB@RP-HR+",CIE,RQNHD$U%5N2V7[X.E-@J+ MYL>I"ZC@&Z?A;2-U=,%BZ#G8*1K4.SC]RXN@Z=^<(=^HR3?.H?_GDYW%/,WX MWX&JNRL83TBR45RLB4F![( I@C?9*9_++M0N =YO+',@AGV )E](&+DM&EDA M=/V@B0*-W#"*T,X LC#5SG48HA $;KMUC4+#C1HM,I/B:VR#K[A@(K:AF4@( M%^_H5VJVW;GAH/^B<8L'"8A$(_,=6V90Q6D%+2N$;D!M'.J[[7:3C+"2$0]+ MA<029U$"JBJ0C+,ES[C9H>WE19L&].9 DQYMG7IP[ZA?;P2\ILJ M$#4\566M3IQ"Z\51KZ>R BNF#L4":_HR$[)BFE[EO*<6$EENC:JR%WA>TJL8 MKYWAL=V[D<-CL=0EK_%&@EI6%9//IUB*U8GC.^N-6SXOM-GH#8\7;(YWJ!\6 M-Y+>>AN4G%=8*RYJD#@[<4;^T6EDSML#7SFNU-8:3"13(;Z9EXO\Q/$,(2PQ MTP:!T>,1QUB6!HAH?&\QG8U+8[B]7J-_MK%3+%.F<"S*/WBNBQ,G=2#'&5N6 M^E:LSK&-)S9XF2B5_855ZTI*^<[/1P-!X_7#Y\&=U/SN#Z M_GQR"^/KRYO;R?GDZN[BZP0NKNA]Z M0 EC49&P"Z.X1X2+.A,50N>+4*KKPA4UB)C!/7N"OT93I27IZ>]=>6F\1KN] MFAX[4@N6X8E#OA3*1W2&'S_XB??IG9BB34S1>^C_HYKOXNYF_7O.X+Y R I6 MSU$!-VWXDG9ATYZ]2CMOTUZ:M,,*)0)3,!,EC0]U!'\BDZVF@!2!U900UJHP M/X'Y\6VY:&114];41E)BG3T#%:U6Y-J.@_P?ZBX:+QH.P$_MF8I*O+CS4 M-#!+_H-(MX'-:5X"T7B#Y[N1EW0A=.,D@L#M>WVKN3#RH9,F:1.N' M'*6-CA^^2IOO449C2FB8M##[Y=AKJT9*B=TTBHT^ M=/?*N4 :VH9#0PRJ71 M)<7B_ ?].; BA=L B=H!"2".Z?^N:1$M@$%-8+Q^Q%:O5BDNK J>%=:V?HEJ M75N#%/5]6U%3DV?J&\#=;>,"JW-;@X9!Z*:QWVP>4#\DB?L[=+9(X!/=&12N MXPG"I$7SW3CHNZ](J3VL FMA>MEX5PNT?]_E\R'<^!S"Z!?CQY:!Z1VSI:43D $=519@9L-HAA.Y.H+//Y=\ M_%-_W[S3BHT*3QFMJ2?>)H2DEM)TL**S/6^>J=WON[Z9"M>_'*CMI%O/#-,$ MK:3W^0T)W[A-Z;ENT0,(TF8_&?BPZX^KMW4EJ5#.[<5+$;5EK9O;R69W<[<; M-5>:E^/-Q?"2R;F19HDS,O4.^[$#LKEL-2]:+.P%9RHT79?LLJ#[*4IS@+[/ M!*FE?3$.-C?>X;]02P,$% @ 2(M06'#ER@@J#0 )R< !D !X;"]W M;W)K&ULO5I;<]LV%OXK&*_;E6=D72A9EG*;L1UG M-MTF\<1M=[H[^P"1D(0U2:@ :'*+)/V_EREYN[UP?B@^N&S7F\*^F'XYM56 MKM6U*G[<7ED\#6LHB M)Z\/1D202E5<$ 2)RZVZ4&E*@$#&+P'F08V2#C;O*^COF'?PLI1.79CT7SHI M-J\/Y@$5/Y5A;RS2MK[H2EW8!&-\PJGP9Q.B>E7!<6JQKGBC>7 M'ZZ^__3SY:4XO_QX^>[]#^+J^[./UZ^&!6#3CF$?@\<\1;\YRH1%]"9U0JE;D3/VP4?LZV,K\7;FMR M9ZP3)E=B.AKW;HZ$D[Z,$9%;(+P+GY:I05M!#W*#&"9DGHF@0 Q=$2'(B5K9 MM!%;96-H$Z$#]*VPU3C5!C%@9IA0F3HC-A)01:)=#.38@"@$.@Q,0;B-M&!+ M;(WUT0+(*X2!\39U=[K8\*D*>TWHMW^;1^/3EXZ>,X"Z+DQ\,Q!G:2ID9DH2 M0@T**H! BII*JQ!2ML9I6M$YUJ0H+,* 6)6@2"8( =I!7EA>WF,'=BO\@U'S M-@A_(#[EXKL2"HN\\T3]EAAC7%/%F/&KC'\I-= 1SV#CGW*[E97Z6MI/@L4T MI;"S 7*F6OT#\1ZL) E#[>.T."O7Q,-D]&R"SI5=PT5-]H H['XV560,-3R_ M*\-C)>EBW_"QU&7UP/&=S$LRGQ"?!BVW@4W=:D1!)H*MB$RK"U+;IL#OX;0_ MF0,H76>3/MLA[L?3"$0R*B]"7L -ML("MXJ36WH_$%=M>VXC:('HUS#$'0Q* MY*8@8I75,@4< S'M0N8'E>A8IATQ(C +AMHGEE60!5(2+140["EW1I0YF3,$ M].!,%K"0;-Q+UG"QD8703M!^Q HPE*:>6V1CNT8@(#;EVBH/@GB*S:V"V=:! MR6-(=K90>>Q/RB(*],4'[9PIK18K&>M4%_<,1C9BW!<5EXS4K%8Z)NAMIX=U M(K!1%>6Q>BA6P9@];X@\3CBL QPB1Q!*./UW)SYYN,*G*45Z7%N9M0VK=(HB M&%*CRI;8/!D#IW1E$%\"[=6&_Y1HO8?&L;&)S&/E@]G9]84X'9_T!06P:/22 MD*+ZDF0Z'-.BEQTYM,^[QR];PH"^ NL1,H10?^@E14;'ETA MBY)%*VO7#G;$_(@&0ZR;G@%$2T8"?D2&4DP')5O><$12IS5'H@>V5,N@&VB MQ$0H/4!@!4;(0Y.8C OAB]-0DX<8R"CGL IE(=JT!\7>*VGIW@8\[U5(0GL6N?L$6#P!#DB6]4GQZ.Y.%W %L,RGYA%(IJ)JUW-\""& M$7FGNQ)N*W4B>I/1D>C-%D?BK)9:CV+#D4B-F513F(%?RI1C!_<>37FE"-*>(OQUM.+Z&]Z)#YB MP5=O7RT3T?.5;8BK 3W3LO$GSOXQ)$K-?GZ&+NRADST0_9U0_)V0_%_+33XP$: M5@=;_U56Q5^'RBK%L^H>[F]J;K[3W0^F0#QXE"^B[I2H&Z.)Q?_92%RZ0F>L MT559(+L*U>V@E!OJ_"3O0YY_$&]_)@E 8%,"CHR-VQ/%L?1:#(1L_&).'.NS+8>+:2;*%(H$F2'3[6BTUMT.]YLJ3B8#@#J M&URF(UP>A4FRZE3Y0V@,)AJ,Z3(>G!+LJK6L(NU5F.#L5XZ[+HC14[7'&?RX MEO9>#4"AP%>"E%*)W% M[,K"X\ZRD$M"^HDB99F#H&.KN&_/BV=5ACXY6^UN M>&_=V[(-5!VW]C7*93(?9H++>RBU)X^J M.-C10';@1(=(0JU_S.0]1$E5))\*E?NN4B"O;0K"%U<-%D%-!0Q-?F]Y)#0) MOWL'HK+9-DBEM4:SZYO NGIIF&^E ]^A>9J7QI*MW_," E]0\*.TD6?V8J:O M5:5+YI(H>W VE(/[4FPWJW>F3,D>6_4M7-^7@E[3>94I:%Q(?6K@M*O.W4G# M*MA& $A4;GQ9GEAYA^A5UZVMAJ >-72;8=V^<&.=HV--0PBDZ Q4C4;"][%4 MN8?1;5)98B&IAUK2_-8C#_W!Y?N/PZ9SBX\EP:KZ 7ADF>6[]I! A3I'B?#S!_J3H >21Q_$K&6Y54KN=)'7N!]':A.J[J1QD9H4(D'CWVDU58 O: MSXV TD].JL5:@K[&S*GEFJ0DI@^2C2W*<>JK"$FBXM3; M)2^3RZ_A6U:FZ;U(E7.^44%1&697H7=X /]>D>OO8.Q.SD=[)PEOZS2%O'QW M&")*T2(6^V=;RGSW_FKX^4I<>XE#K0G8&+ZGR4S&(?*!6G5.[21%;H^.@'*6Z\2$M37W9:NLAQ,4F@QI7+_^'00+P#8U"ECPC> MD8X+U2(JF.OJ%&T$)KJE(J M'VH-N2@!LP"@XXVD:0A))S?!S(YGH^DTFD[$114,OI79]B5%UQ .)-,S'HZ'T=?MBD3#]<3AN#^* M1N)P,4']/!_/Q$%D1DWD(X.4\60N%M,_*,YN>0%R;S9[UKAEW(^FHYJ[/S)JZ= 1 MCPMF1"_?02]/T>9)\80\F*5,(YHD31:3WYZC5(.$O5&*-[DAFU^UZ4^?I)C' MAQPL!&;D,+#R[!G*D]#_R@D*3UBG-$28[0U0.%B,IY33?"71[2,0!:GTE/[! MPQ^.3^KAU\,IV^0K1BASFJ#PC..D8W[RO"&)'Y&M->K^#U4[@9YZG9BM/.M^HE-T*];]<+K5_:UU_+X -H=CF+CB\0J:8K]U- M/>$+-;&Z#;7'4N8WMMP6\3V1I2F*8"FN:_ @(U]4=,M@]UK(%V'[C7&K8C\< MC_I(#/[M[+Q_,IVT7\/ZMHQV?O4XMAH3[-X(MD)@&#LI/U9OR*XR'GZ%NT?7 MZ6_RTTDXP>J@G*PI+BU/L#S:#K(?#^-NT/5AS+#Q\1*_CJ=/M @,W,A_QU3_ M6G\%=N8_?MIM]Y^0?4!A3RZ0JA6.DK\=P'+XLRS_4)@M?PJU-$5A,K[=*)DH M2QNPOC+H-<(#(:B_C7OS?U!+ P04 " !(BU!8AO^RBQP( @$@ &0 M 'AL+W=ON KIV3.A\IB M,!X.WPU*J4UR?M0:*/F3OBZ+*7;WZC"[JZ24=(N+/1Z$VAA<'U9 MR;5:JO!+-7>X&W12M=O[H6I GJ;5/='.? M7R5#,D@5*@LD0>)OJZ:J*$@0S/BSD9ET*NG@\74K_1/[#E]2Z=74%K_I/&RN MDHM$Y&HEZR(L[.[?JO'G+Q..-H-:73!KO)I&*<-)649')YJG O7T\?9 M[/[K[.[AZU),'F[%]/'AZ_W#O^X>IO=WR\M!@ K:.,@:<3=1W/@;XD9C,;,F M;+RX,[G*7PH8P+;.P'%KX,WXNQ)O5=879Z.>& _'9]^1=]8Y?,;RSK[EL"U+ M'0"KX(4TN9C"7&W6RF1:>7&K?5987SLE?I^D/CB@YH_7PA"5G+^NA"KI@Z]D MIJX2E(I7;JN2ZQ]_&+T;?OR."^>="^??D_[_Y^P?B!-?-PHQ*BMI]D)[8=-" MKV50N0@6.'Q2J$P39"$JN8]!K9%X)XPU;S)I,E7(M% ").(DQ9ECOM*&'HE" MH9Y\7TS6:Z=(JEC5@6(/H.NR+O\FVZD_:^V@/"H)&\2VD2)D$,"**E,\:/$B M)(3E,:+\>C]1R]^5E" MAWU/[#8:[FQ4D8MT+Z2HG+9.V)U1KB>6>Q/4,]QQ.JT]PNQ]3]P; /B$9(^' M'^,.OAE]/(4XZ<$A7J\-QQ0BX9/XI;_LHX"V&F:4,01S!\,CD4T(K'MQ0CN3 MN_DD.160(L6R1I!7B(SP&DY2H*L"&,P%#M'F!TGG61B,UH$ _T7[0'$9_7QQ M)E*5R1H1M2L$S3YC.4-U2&2#3Y*)+5LA<(+-I>LNYK>JDHX+E;;!]MK!](6BI]E?,D?(U)!?&KW2 MASB"_ NH:E1K &@F]P#&<(2(>72\"J(VP(&0 *!B71E91T"E[3(#WN B.Q]M M_28V!#HDPA,@1,/00LN4UBG(4&8SS1G>Z;!A.2^SU1>/1G4QC6;W*"_PVO0$ M;.0GJ3)JI3D@F7)!-ADBEJJALPM!%E-Q"+ZF#EK$510NR=)E5;#+\M@]F<+_ M-X!D!@S#WH.9CG*\[P//XG,-8ZF^>E&PKX (18*!PDIEY#\*3:/$OZ@0$'N' MRD3W1>D[6W8YQV%(&??$S70.N !BW''B3VD9 M((ALB>M1[_P-E;DTD2RR36&=!<3^HVB%I#?5?ESLO/4DC<;0=8.PQBX"%6T2 M[ -!(L>]0UP5RVNMBF@"?E:BJ=^6V]$.:%*+E7,@#0XM\SFO[5#(I)T6U#,P MU[2DC-MYK3CXWI9* !W:YNP"ILD^L@I> 1**/:.WQ?*XU\'RP%[ A#:^:H@7 M(N#T_^X2'1Q(+$N\[X1TX(A9);)T.;MVLB04'$BO<[ O/M4.ZRY&4)J: MBC$20N?!<5U!)J9!01E\8C)C+Z_=24, MD%OMCTH&K?POG>PSAGH2VJ;I]O%SER9,$W@UTG"&$W0(PRM(ZC40X@B12]Q: M*RK9VA *J?8P^M3>4T#4&ENVVL:\,P$LHR O1J/QB3L]>7_:6CT%2R!MVE$M MLJ>8S^KV*#)P/A33_J?^HB_F<$V\N^A1^$MK8/J3P3@DFHZU(&#-#L":%Q"\ MJ(N#_XO9G!?:(,2< CKPRI,3#(Q,5\3>4.UK.-TXUIJ#\)QS.E&ZIJG6#FBO MQNZHI:"K%EIMN8$PZV%8] V1Q%&+(+$ED)H9KE ?*0^V,3;2HSQ2^$XD M7'8/J&T#3=;EC*;7Y"(:LK2U"5$Y1 -SI @4 & UY1D'9EJ@;DQOHUSSKIVK M$09V7^:Y/N[QW,U[#7Y1);R._Y?^:YH>*"TIH!0)JG!9Y%2\-:LR4U*)?9T M,Y:22&^$(4:*&'&H/N*FE^EZ(R9B.WU(>Z^*K5"HAH M!^3#C($L>5OHG&OP*/J-H3T:>J"5R^B0 XH06">GZD-R,NDW8@5N]_W7WOH& M1V_MI7)K_C9!JH&&^ +?K7:?/R;QK?^P/7X[F4FW1J-"SE8X.NR_?YN TOE[ M1+P)MN)O *D-P99\N5$2I$@;\'QET9F;&U+0?12Z_B]02P,$% @ 2(M0 M6%5X(:SV!0 T X !D !X;"]W;W)K&ULI5=- M<]LV$/TK&#:37A1+HF5;B6W-R'8\=2=V,W:2'CH]0,1*1 ,"# !*5G]]=P&2 MHA3)F;8'RR0^WNZ^?;L@+E;&?G4Y@&?/A=+N,LF]+]_U^R[+H>#NR)2@<69N M;,$]OMI%WY46N B;"M5/!X/3?L&E3B878>RCG5R8RBNIX:-EKBH*;M=7H,SJ M,ADFS<"C7.2>!OJ3BY(OX G\Y_*CQ;=^BR)D =I)HYF%^64R';Z[&M'ZL."+ MA)7K/#.*9&;,5WJY$Y?)@!P"!9DG!([_EG -2A$0NO&MQDQ:D[2Q^]R@WX;8 M,989=W!MU.]2^/PR&2=,P)Q7RC^:U2]0QW-">)E1+ORR55Q[?)JPK'+>%/5F M]*"0.O[GSS4/G0WCP8$-:;TA#7Y'0\'+&^[YY,*:%;.T&M'H(80:=J-S4E-2 MGKS%68G[_.1V>O?(ODP_?'[/?KMEMW@!TF+)[HWWNV'LM0&P#]-'#ULVT9Y(I)C;Q56*S>]9@V&FAZE1GL.C(LT<1^PQ8R8U'D M.!AALBQ&0P"9TK MGU#6P4Q#6>7(#E]RJ?A, 49FOV(KESKVZ]#XD 5>EM:4&#*&1T;B3 $^-\(H MLY"4BFOT5@JP >BO2BPH0B:1.636.6XE\F7A6R5MC%=J= O%[LF'VC+&RIDW MZ/(2.WX9G-WDE433!MHCUWJ!,4NJ4.O>SG+2#J6MZX#40F:<>CFA!<^U2]T\N6 M ML( ^,TOL(EUT2@A&_$8CE(".6Z]_&J?#LW.WK0Z%?%D\!@E%FJVZ:#<6,4H0NQFHD>JM:J8##F-S.8,G7]0BI),ML1;Y(/I-*>E1%KU/% M1(_$:60Y,\YOA!6YZ5(C\ ]%0%&[W%C_AO1+95=9Z==UXAQTXT#]D>\$NAO$ M#ZJ[CEVP5V]/WH;A5V^/1Y3O CO1NDG#O-+"A6F#QFV;MS'E+D2PG>#6A^Q!Z/?-/KASL&_<&PXZ W'X^C;N'CWV)30D"M1]Q 2 MH&+4NJ4NJZ"<8*CI.M.G:S9.!SU&=@2V(=>1(.=>F M;BX;II ^C-#CBG!2N[UZCEZ)W<3M=H!#+GY_#(6ID)=7H][)^*PN#*R+TWU- M*]WI=?N^6/N=6T8!=A'N4J0DK+]XX6A'V^O:--Y2-LOC7>^>VP4*"(MOCEL' M1V&ULK59=<^(V%/TK=VBF3QXP-A"2 C.$I.W.9+=,0MOI=/H@[ O61):\DAR6 M?]\KR2:P26AW9E]L6;KWZ)S[(6NR4_K)%(@6OI1"FFFGL+:Z[O5,5F#)3%=5 M*&EEHW3)+'WJ;<]4&EGNG4K12^)XU"L9EYW9Q,\M]6RB:BNXQ*4&4Y1X](E MY=%J6N7D9VP4L/:E./E[ZG M%@6SF,.2:;N'E6;2,%\=!OZ>KXW5]/7/6\(#[.!M6-ZF@E@6XU(76O!*GBT7?B%K35' 8M%BQ3!_?VBZ[ -OH!QF8DZ M1^K33-72JUEG!##D>0&G! MP(Y:WKWI(-,!2FW DK S[* 23-KNB7XFC")D(0QHMJ,FM*@Y3?Y/H:<^3"/4 MADJ12\^%@IO76@C;^AHTCC\R+:DH2-Z2[<.L"X27V!:??5WG.;#2%2(-2.W% M($I':>3>23\-!7>11J/T,G(AK=#_703I;['WM"])=B>:Z(M]R/X)O=3QNB)^Z54T'K8$D\OHJC_\?@R/ M^]4MO*[I2G/ZN7/BJ"G;.@\5GBEC72I".3OVD4]CTXA?E3MY(E'-8:-5>;;. MR/\B&4?QE5.>7$7Q*&F5)U$\2+^3\KE];=4N)]%)\10L;_BSM2M1QW \P.%F'O&@G2S=53$/M\*/3&\Y_9X%;L@U M[EX..Z##32M\6%7YV\U:6;HK^6%!EU/4SH#6-TK9]L-M<+CNSOX%4$L#!!0 M ( $B+4%AR @/BP@D "\K 9 >&PO=V]R:W-H965T7N;F. >>R:( --DAVNRB*/G DS@P12=12 M5,:SO[[?.90T%X^]0=''>?"8$GD.OW,_)'2[,?9KLU;*B8>RJ)K7%VOGZIOK MZR9;JU(VH:E5A9FEL:5T>+2KZZ:V2N9,5!;7\6@TN2ZEKB[N;OG=)WMW:UI7 MZ$I]LJ)IRU+:[1M5F,WKB^BB?_%9K]:.7ES?W=9RI;XH]VO]R>+I>N"2ZU)5 MC3:5L&KY^N(^NGDSIO6\X)]:;9J]L2!)%L9\I8N+$0%2AZ/>^X_LNR092$;]=84O^GX9<,DB7, M+WE*,@5C->+?]XO&61C_/Z>$]"S2TRPH(&Z:6F;J]04\OE'VF[JX^^M?HLGH M[\\ 3 > Z7/U$F]-60KD$$,E@.=9 XR%&3S75&DC_4*M 8[:6=M4)0&:QJH"\.6G2[G0 D(7.M"NV@@V5]_P85BB^M-EZ!ZZW @"6 ME-K B WGE%=0MR=9A!3IML+)!]590%=-:_>7>6@ 02+:?+>WI91&FFTAAVP: M2.DM:Z'TVE0YVP?JTX7&'INU\G0'2CPA#AM"O)2O8-$'TJ?%]%73(E(9EW\K M2]-6Y&"8?KEX!5,/MNHVX'S,YI 5..3J@=;";Z"P=ZT2SO">,H,7-YK2OZBD M:P$*,KF]4&''). &&G0:3@/_%LVV4G:EH: 6P@I2[XJ<$F/0,U>+[8G":=+N M/LM<(1)*]I[.&4B_LC$5)-B*#%:A2,NLQCIBF9FVR$5E(!6B$*HF"-YA*K4! MI)K6Y8@/M=)5Q7Z^,6*K$%IB:4TID$%5N5!VR**A^ #5Y+DFS(?P*#FL-E,V@+O"O6PL7@;U,31R@!^C8>C<_3@S@IYW(#8;$JI1?L2@S ME2EU)AI4<3;'HMT>DA/$QJ&;^!-X5M4%4EY^M#D[$M2SG\)0UHU5_V]K>/E\ M\#8DRK%RPD?)MS*4G'3>PGC?9 &'7+42D><4)](N%I ^JT9F)WCDVB/0.;G8 M0!;.*4;WDB!<7V<<97)AOAV)SEFQ4]RII A1NCS7 :)@J$QUY9\P!^?W MT;R?!1MFN,N0'*Q]9H3=&U/HG#$=I,E0?)05NCVVWK%5X'18=^P'$N:IH*6" MW\ND:J <>LH]NP^12\ _Z*E9QC!NV#)24;G6OTH3\THC#( M'Q1N"V0VLR'7AQHM+=.E+B1<'CA9U0WR\(%^05Z>E C>H@&^IA2,M.78_UNG M20R2R=C:4*KJDMAN:W[)P5\4@);)4ZZ!,E,@M:,FFM:R#Z%=YY+=Q>.0&CLO M ZRFSW.=US$%HH4O6@(^CR&A4?JFA/A(_Q57"G V];B;J,N5PW M&4< RQC07+$E?>SL;/O,0>R_TV('0/<5;G7S5?@.*1ALQZ4,&^LNW &S\%8Y MA,?>MAO_?0TC$:75[,PF5Z& MXO.CEL-[K==)WVM0389C/2IXO!2#V'<>?-#LVTJOC.;FY!9,S(0_'S>>+T0T M#::3Q ]&\U3\N-^&BCB(1A%^DV0F?C$.N14+Y\%LDOI!FL2^V3U ?S5$UK-; M)\$\G?/_Z7QRO/$T%G$\&39-@SB.^#\Q.[4E9?7OVC9*@\F(>$5),!L=;QP! M%&B#.$IV$D^"<9KZP2B:"QR9V05]>Z+HC/C87/P;![W5HN/$ZIAY7X<:V&D# M/]TS9H">4R, NWXX]V>'KG'<[]A1;1&K2XVW %:8AN3L/)W+!_=6OA'NJ#-9 M:]<5G5,-?S!TC9ELUF))>.!VOG/B?NQQ?;\1_X(^GE*'-P6\A\;!Y6 M!/0\#I+1E*V=3F?L(1&,TAOJI]W2^Q()2_\Q9-#//__:]?)QBMVB$?]]Z'/T MD'_V72>*QB**Z6_>6?S@*":2\50DR1A__?P1U@E'0QK,HH2QIK-8O"6UU5+G MOMAU:A],V1T82B[WOKKVN?( VTX_>W9@_3\Z0Q*"Z=AK+9[XN!K-I\^P.#QQ M'NC!J_H[B&(8-9I.132>LRXHA1""\31B!,ELO#,*_'-!K:A7@'I ^:I6:DC8 M1R+M*R+ G=H8&1]U'-9D.23()F,*3XC*-\[S&R4BM_XVDKE5Q(-#[H8! T= M)'<[<*&^>JS+>9@D772/PTD_3$,XKQ]^+^)+ MSF*+7K5G@8Z'.R-TI;IL2SI.4H .9W2KNG.LA\LU@D0O^*2]0__X N:)$GR0 MH;N,AYF4G3^%=?$PI@A$FF*-+FQFX\7,^-_\?KN6?ISM=SY^NY\_7<^7KN?#UWOIX[ M7\^=K^?.UW/GZ[GS]=SY>NY\/7>^GCM?SYVOY\[7<^?KN?/UW(GKN>N]CQA+ M'.SY4\U&L-G]]XS#V^%KT'O_$>1NN?^4]"/,K6'A0BU!.@JGXPM_6=(_.%/S M)Y&H1\Z4/%SCD*LL+<#\TAC7/] &PS>R=_\%4$L#!!0 ( $B+4%B'*18\ MGP4 *4. 9 >&PO=V]R:W-H965TW M+V#+VMUGGWU6+V<+(3^IC%(-3T7.U;F7:5V>=CHJR6A!5%N4E..7F9 %T?@J MYQU52DI2:U3DG2@(^IV",.Y=G-FQ]_+B3%0Z9YR^EZ"JHB!R>4ESL3CW0F\U M<,?FF38#G8NSDLSIE.H/Y7N);YVUEY05E"LF.$@Z._=&X>EES\RW$SXRNE"- M9S"9/ CQR;Q,TG,O,(!H3A-M/!#\>Z1CFN?&$<+X7/OTUB&-8?-YY?VUS1US M>2"*CD7^"TMU=NX-/4CIC%2YOA.+M[3.)S;^$I$K^PL+-[>/DY-*:5'4QHB@ M8-S]DZ>:AX;!,-AC$-4&D<7M EF45T23BS,I%B#-;/1F'FRJUAK!,6Z*,M42 MOS*TTQ=7UW>3CZ/[R<=KF-Q.[^\^W%S?WD]A='L%;Z^OWDQNW\!HC)\G]Y/K MZ5E'8TACV$EJ]Y?.?;3'?1C!C> Z4W#-4YIN.^@@UC7@: 7X,CKH\8HF;>B& M/D1!U#W@K[LFH&O]=??ZD^R1&&G A"LM*U2<5D!X"F]I.F=\#B.C'*8957#% M5)(+54D*OXT><#JJZO==M+B@O=U!3:>=JI(D]-S#5E)4/E+OXKMOPG[PPX&4 M>NN4>H>\__N:_H?NX6<.-V0)T=!4+#SQ06<4QJ(H"5\"4DTE38%Q+8! 29:O M9NP)!UI1.XB_/?:Q[Q.*M7DURP46"8O!K(G2((FFH!:DQ([1&5IS8?J8< M9Z&9@H2H#!#! C*4!&W#/>; <<5<@V$\$05%M+FUP6Q,FCNP)M@-1C2PP"^( MSX_#H45WU L"P$76&BXID0K9P98!%#PM'JAU?+D#%7W" MM5O]/5B8[E'DA[W>%I@]6,+]5!B0J_@V5ZRDD*DMMG6+(97(66J1*8U_KO.P M+!B08ZT55!A5@C=YEI!O(K:]P]HBN1('!!:T@V!+8$W=02*%4J^22DK*DZ7C M"#T4A.-.99C!U9XCG"0C' LUSC^%[5]#QB B9#D_\8MU8Q)VJ_Y)[9 M-'27;A:L#"<>U+V/90 ZFSF-K&6_3=K7](8+_06Y[R)M6UBA'YJ(*+ H#EQD M^SSX.N7[M>SK!@AW-A MH\@?] +7OTE.E&(SYO3IM&F1;';'VG[Z1>_8K*2O<255;1CM3"%R73PC M2-8CR2NZ KR'6:; ;J&\;IR9R(W[#995%VX5_8'DA"?(BSDXJ5-HG (P2QQZ MB0LF+Y?-(PC]7M"'\0XR>WX\'.QP? 2Q?W+2A3=X8G;G##Q0*&HU(BII6]UM M=)LDUPOHG+,_G8Y)DE1%Y?K/207ECDQDYL!L.;+R;QGGQS9,@G/G0EH'#:+^ M4>>=PD\"_9ESM=E]$<^S.F]AF3@LO^[?2+J.8N/::62SVT+KY7YU;-O0*H,\ MP0>.UY'/S71W@;LASA MQF@O1>Y%B])>1!Z$QFN-?&PO=V]R:W-H965TM*%I B"1*UDMJ&[#C>#/0N)F3=!B&?: EVA(JD2Y)U>F_ MWY&T/1=(C [[HGOAW7//B>1QN!?RBZH9T_#4JND85XW@(-EFY$VBZVEBXFW MYX;MU9D.II.U$%^,L:A&7F@(L9:5VB!0%-_8#6M; X0TOAXPO5-)DWBN']'G MMG?L94T5NQ'M'TVEZY&7>U"Q#>U;O1+[W]BAGX'!*T6K[!?V+G:0>%#V2HON MD(P,NH8[29\/_^$L(0]?22"'!&)YNT*6Y8QJ.AY*L0=IHA'-*+95FXWD&FXV MY4%+7&TP3X]_?YJL'F]7'_^$^6(Y6=XL)A]AL9Q_6MU-'A>?EO#N:3EYFBT> M;V?OAX'&@B8M* _@4P=.7@&/"-P)KFL%M[QBU8\ 3(]T25'NE-R$7'&RBN( M(Q](2.(+>/&I_=CBQ:^UWU.IF6R_P[SAE)<-;6'!W5DWAV;6J+(5JI<,_IJL ME99XBOY^Z4>X,LG+9>.WOT1I^.%"$\FIB>02^O_= MPXO@+U/_#Q7AW8*#KD6O**^4#^RY9#L-.X:3H:;X7RL\MN_M?IH/P8V02L,# M*P6OX+%N9 5ST4M=7UA9XO12M&4*W@")B3](0JM%/AD0HY'"+Y+<:KF?%L5! MR]/,QJ7HBXV6)#XY^! ECN!7*93""R>W#8<83XZ"^PC-^<^S = !GZ&)4S/[ A,B)]%&!@B5F@@0P0AV!8V MC7T6L75F.3'9!,F3",NE,*6J*8&?0YF=07H=GGZW06\@O,HB*XK$"6?EL;-" M)YR5%58@^5G3]II5/X/^ \(!+R=..+S"65GNT%-XZ=X$9W.P8W)KI[W">CW7 M;B2>O*<'9>+FZ+_A[C6ZLSNNH&4;3,7" P^DF_#.T&)GI^I::)S15JWQ4632 M!.#Z1@A]-$R!TS,[_@=02P,$% @ 2(M06,!MP*_T @ RP8 !D !X M;"]W;W)K&ULG55M;],P$/XKIX 02-F2.&G:CK92 MVC&H!'LK&T*(#VYR;0))7&QGW?X]9Z_Y9[GGCN?+Z.MD#]5CJCA MOBIK-79RK3<= M6+*BPEH5H@:)J[&3!"?3R-A;@]L"M^K1&DPD2R%^FLT\&SN^$80EIMHP<)KN M<(9E:8A(QJ\=IW-P:8"/UWOV,QL[Q;+D"F>B_%)D.A\[ P"<'IRFWR\23[/+\XA.3^%JYODX_SL MZ_S\/22SV<7-^>?%R-/DQAA[Z8YRVE*R9R@#!I]$K7,%[^H,L[\)/-)W$,GV M(J>LD_$4TV,( Q>8S\(.OO 0=&CYPF?X%N]FL*#RSIH270C8D3]TX9:7#6\K MI<[@JN%EL7HHZC4D:2J:6BOXEBR5EE1'WY]*2NLR>MJE>5LG:L-3'#OT>!3* M.W0FKUX$L?^V(Z#H$%#4Q?Y_M]A-F93T7GF=(LSK.ZRUD \PY:4].0*Z$:R6 M*/>WXL-+8*X_9';N#Q@D65:8;"I(33YQ7MJ*PH5! ,?^FX8 M&,0/JG=Z\%IY5#=-VL)?\S?P.G##**)YX,;Q\$V'D "&; "!&['>/TN(_ !B M$AUW2_!#&GMNKQ]T"6#DG+&8LA!'_C]+"/L$B'I^IX*PUZ.1B%F_2T%(=S#T M!_8FHCBTV&NT56>J>"L+C4=BM6HE")T3E/]Q^U0Y>H\:3(44AVFC%)-Y%VVO M.9P>.G72-J@_YFV;_T1I*"BB$E<$]8_[/0=DVSK;C18;VZZ60E/SL\N<_C8H MC0%]7PFA]QOCX/#_FOP&4$L#!!0 ( $B+4%@6NR32+@, /@- 9 M>&PO=V]R:W-H965T!5QV:#[O35QO$"&;DGR*PYYU-?:&@C1$FX2_D1V M8U3$XTJ_@"0L^P6[7.NZ&@@VC).T@,4(TACG3_A6?(<#P+P$6 5@G0+.!< N M +LNX!2 4Q=P"\"M"W@%X-4%6@70J@NT"Z!=%^@40.<4\"Y-G+&?.:-N'V8Y MV6>S?1'93[>9S;>>+ZQL50XAAWZ/DAV@4B_\9"%;VADO%F.,91(N.!5O8\%Q M?P[?P9:!.:)90N, @6',@H2P#47@*WA>#,&GJ\_@"L08_(C(AD$Z:-!LU:7;?I-FX2;-)DV;3)LT>FC2;-61V ME*Y.F:Y.E;O_71RK$:0XQBOE)IK3;D;+\_/6MSS/:??T[6':*50=H^4>JX;G M*MLP3>-8=:?PLEJGJI%"93J&=ZRZ5ZARCF<:3JG*IUP_.&VEB*ZR.P0# =E@GO]QEZWE M->4F.ZV=M _,[L14M$_%M2:_A?RUS^]$8NM;Q9B!!"U%5\9U2XR5YO>,O,+) M.COKO1 NSHY9,1)7,T2E0+Q?$L+W%=E!>=GS_P!02P,$% @ 2(M06&0Z MHFM# @ B@8 !D !X;"]W;W)K&ULG95;;YLP M%(#_BL6D/;7AELN6 5+2;EH>.D5IMST[< "KQF:V">V_KVT(RZ:$2GD!VYSS M^3M&'**6BV=9 BCT4E$F8Z=4JEZZKDQ+J+"<\!J8?I)S46&EIZ)P92T 9S:I MHF[@>7.WPH0Y2637MB*)>*,H8; 52#95A<7K&BAO8\=WC@L[4I3*++A)5.," M'D']K+="S]R!DI$*F"2<(0%Y[*S\Y7IAXFW +P*M/!DC4\F>\V"FGTEY1V\6&GQV4-E+QJD_6!A5AW1V_].=PDJ YYQ."/B&P MWMU&UO(>*YQ$@K=(F&A-,P-;JLW6",L *M MA,"L 'WL2D:NTCN8.#?M:>N.%ER@A>B!,U5*])5ED/V;[VJS02\XZJV#4> ] MI!,4^CX7<./0]N?D@-[_JU)Y Z*\(7W ;9[[GMAC<%EBGWO2'RH0A>V"$J6\8:IK%VVZSYTKW+CLL]<\"A G0SW/.U7%B-AA^/\D;4$L#!!0 ( $B+ M4%@3Q=)]J!X -9= 9 >&PO=V]R:W-H965T+LVH!F/9(\]<1(#<]C9">(#'CO!P\/[@1);$F.*5-CDC+5_ M_=9757U0HA3',1#$(Q[=U=5U?'4T?[BOFT]N:6UK/J_*ROUXM&S;]?-'C]QL M:5>9.ZG7MJ([\[I992W];!:/W+JQ65D@A?XB5\+>^^2OPV6,JWK3_AQD_]X= J*;&EG M+8;(Z)\[>V7+$B,1'7_HH$=A3KR8_NU'?\6+I\5,,V>OZO*W(F^7/QZ='YG< MSK.N;-_7]_^VNJ SC#>K2\?_-_?R[+/OCLRL)@E51R;_99V5$\L+Y MZ9X7)OH",^*13,147F=M]N*'IKXW#9ZFT? '+Y7?)N**"KMRVS9TMZ#WVA>7 M'V]OWKR\O377+V^OWM^\^W#S]HVY>'-M;C^^?GWQ_G_-VU?F]N:G-S>O;JXN MWGPP%U=7;S^^^7#SYB?S[NTO-U4V[P_PB!835C3Q*[J<'!SQVLY.S./QR$Q.)X\/C/Z#\V-_=+ M6YD9R6M#BJICK)MZ53BZN:CKG%\@R:C-:K)MW,@46*7)5A J M&B!K8=Q@I!P/1Z.[(K<-<]G<6V,_K^DF!B*K6Q(9&,%^GBVS:B$K:I>ULS+] MB?D0ET4OK.N&QI7):'E%60I-@1YZILQ:N>B6Q7H-.<T*L((HPU.ZC)RIPPIH M,\HB(PZ1Q(#&FXINN3:K9B+]($Y$8I7EUM25[-2BPL51H.B O.Q*!N^WDL@S M9C/0CCG)#;1+D]B>6R(ESQJ2L*LZ+^;%3 3DP='%[=710_/T].DHBCF))-25 M3923H:["C@=BCQ>V8D&CX6?A:7 G:B>==-P68R N&I.Y_GS9GUA2M;8I,!(KNN+D.0YN0 M[7E7Q-XIBYB.>\J;NELLXRX& MQNVQ!@9+( -/R\?JLV2SK^0U-@?MLG!!V$8D7QM2@:SB\40B-WA]S<23'K&\ M8U,@J;+9>=$ YH#Q]%)'3*[GPD_1,=R9TF[/BY9?H'O;%&[QL"#]H[W$OL%& M$3D\(Y%&:R!]HDTB.$($MD%VH%1V+79K:9E*FNZ>C$Y@6FP?%0[ZG*UR2 MY0!QY)QIP :XCOF?;437'Q3Z?# O>*.TBXP66K2EY4>&GEDOB909/4;6"!I& MM./9NX%'<0'FA56=R7"?G.[H/=L!6E!]3PH,R\0W'@R-0R:%]@2JO!2];OL^ M0E4=]KR$%_("!ZB;0W4)K!>D+'75&SNX3.6*(1ENZV;#A/AGRE@0+H&*@&)R[L9[2%QYIY" ?P;'X%4E-FT;J"$)$RV8D'32^1#2)D*D3AX MY5N:6 0?SQ\H^NN*-ED_<= MPH/?9*@>F<\"F<\.CJW^V0%LDI7-IJ4=(O!O#M(C[3R0=GYPU)L*SJ)NBF$, M_<4OF_1OZ"1QKX.7;%F_R):2H2&Q9(CW8%XT#C9X9.0ODL"'L.&5;16^8GDR MAJ)$\KU3:Q'BDQS2P-,-XV-8:=8^QNR?9VP_&A6X%@ ND*6Z09&^8G91BZ!? M(]%@GJ^O[%YC#XGL=X'AW_U)L%23=VHW(_.NA,'&;) V1HW\ZSHQ($-[\BW' M-_'Q=7C\<;P0! Q8=TA#1J?QF34Z4$9 MO_3Q-\%C\BFM#CZ85OJJD ]=MWT=XZT$W0$I\@HAO&7 MA'RT$0DLFD=.-L%^BR#5%86D]-PGV[*Y=#8%HRBA>ET;I MN8\H SSH(TC1#>=G0,C8NB3#($BR6W-ZQUC8_C!'"@>=8DI@']TCHBF/B2&= M0)"F#]*1Y>-:=H& M9NB]YI_V6QV&(2+OBKO:RY8 54&8(4&0YJI(<%PRAZ;0.-=&YK%;K=6@L]JD M9+$A;1N66(S_B734DIQ1)#J+\N:-'OP;V6*6!V2:+#%,$G)$!GY+4H&\3V4\ MO\0\"V/#LR1P,R2.3>?P^ MK"^(_(B?&W^/5(ZX.L()FF$+N3BF% R8=Z@S&$XXYN$GL%#G)"NQHPQ87^2K M,.]!K5E';+@AM]L6HHUT$0\\A.AY86!G6OC(&LZ5Q)3A%P](LT:3QWE*S@NP M?T^7("E?)Z$M.:P^[1KP A7A[WN2D:7LC[Y6$SYH0EZ$ VJ[A*+?<3J4C.5! M*S>)5FYRT#3]5-;/G9BF&!/3\E@3U*4,=J2EO*6G)T8GJ$%Y'> MH<%C$6(6!Y$-YV"IJ%A B];VT;3/E&?0>LX^(SLNN6[7(BT1LKJPR,4*,%EC MAZIC-""HI8&[)QVB6W2MF!M..XJUG!4-@4R?%OE\M].ZHCT T*P@&,IU8CB%;C=W#L&]G M;3VE'1Z?^!G$LJJE4/RWNR],I00ON-IC-RTNC1 M>)]>*G(0S:+G?.;VKK#WN]OU;7:$3>_/% W#+4U.Q\_$F+^ZN+TDS.\0XE_< M?C1OZA.^>WSZ)!CD6QJ#L,7&!W\?P&D0&3;J)E#K;?,#?1=CZGAZZ^%(;566 MYXVF(M5B*3+%3F(N3+'P4R0,F6Z (U:L*EPIL6LS21+R4/I!3\.)]VZ=$\-\ M0GQ[;)8BOCBUB9Q-)2.9-9X'?<.1:>D-=[N*D^ T'?O"K&F8<8*N22"K=#H) M4(U;LLN:_A9^2+&DIM0SAI.<>O8_4NPRP;QL& M\];Y%O=Y(8((TU4[L*MKR0'_Q\\I+L]D:Z(PFRU'&J<@U@B0CW[/D#6,^4N "+)2W"<6Q$ MR-O+2_9=F)#SYJ@9VMJA7;ET*K.RH_3PEDASY=RC7"\B$@$WN%9N1$R#].R9 MY9[8!C?IZ^QP&FH2M[W%EAKTY0]5.J1,5G9 F(>4@1P@A>9.'"O>*4*]/M:D M]O@@]??1T?=S=Z&J'3V2+1B?2LR-&E )F8#E8G&MY=96WD[O!3 4R!KV9,]1 MR,=\FG'D)85"LT1KD)1EL1:Y*@M$=>-3&GJ;(5+7%" M3XR?F6L2[[)>LY3.EE5=UHN-.<.]B7EO%\AUH>34V$7A?.)"(D=^Z-2\(YJ] MHY3Q'2(/$'$F4S"\^)&S,J'[/-PXOTOO&[T1\L_>'][ MN0P.8**35Q;[,$.2L$CK^H:#['.:.DRZ'20)10%9UX2LKJTR#ESQ%AL-SOY1 M-#AK@R>:DU4AR[$=#7-*.4K+#'&"/$)5Z6X/%F.PN*TK&DQ+JW4FVL+(+,1D6N1O.UT1[APG) MV;:):9=T+1?Y&FR(G642AJOQ5GLMGF$4GH!IT!3NR#]**V!ZQ"-JAJ#I)U-1TN:YW,9J7\23RL!C6\58 0W-*&'X>;W+E\$W""Y&DZW MXE(,&&A^$>#H3S7PUW)$K5Y36B&@(R7[$1]7@>#?$F1%S_CT5!$4+L3A)#G9 M)\O9G>2NI'Q0L91 /D)C36L..%SR+]52^T)KM1BDUQKD8%0O/: M"=U]]A;.JU:3"[ A5[?BU%W&(+NN-$D"24_7[$/'@VF+V#@Y/MSL^)&;9LQ+ M+U6#QONO#6%>1_C&C6$Q,;4BH8K)U/ "2WZB2'D7(HPU"ELQ.S\+W9CP!B%] M%+)*;BCBSF(_V3KV=DH;&"< ?+.()I,^ G;DZ#U3V'I!CIV0*6N\LP<(!Z;2 M(H0@,* 5T0[$1WO<$/=2N%E9.R[GR3)!KDT*:MLO!4"9:S[6MU$>9H^&V,#/ M+N1J*X2?"=,C>A3 =I)L[O:2)?>H,;L\CEX? %-?JA/_Z;033?,>\A[GKR/G MOVA[M2,*J"NT/X;.+._;@H,$6.;\KKH.S$R9>*Z*"4#"4(Q>^^,5Q*BDM9#R) M1!GD 1AK'X0V#V.@X$Y3T\-N@TA9(Z$M$2)F(SG+("^Y(.Y>U5[BU; XEN:1 MFI8D\$IL@68BO>2A3JJ)*0 <7\56'H40T3-$Q#)I=LY"AZY2Z[N?M8CB \60 M?LGMM!6&?5:2TKUQ&OZKU^(J3N%B^*^3>)W=[A'O:28Y:N(V80TVS+T(,29: M!DO.:0.7I %L;$T:#=4@DXOK;!/*S'2Q0;8NL8FCB*"(-T42**I8[V%-4@UV MA#C:8\@LVFBZ1EL;I+*3K$/R:GFN-0M2GV._66JO0Y,:2>6T("U"_RA*%]OU MO"27$,#U+*G],/03%O=*ZVS(=\9.6I5$P[!5A,PKD+_NF,< MF);7$A1AJ2='_?P3]F^9H7;:T/ZP9.^Q*0IC&<@C-SAK:N>4382FW'VVUBZ, M+:G$'9\=O;=;7>O)O(EG3*[V!&+(K4RSDJ$!GQYRYH&SUKRI:5YPX3H.E)I4 MS/%OFR^PF NDN<4)/]1$QDZ6![TL<:14 7A!J5GT^O<+;]0D;)-L7YH5DSMB M.7B8>HK.858)37R$9".'8OY7&E/U64V[<:<^G;/;1,I=C?R%/P_P86LMN@"- M6+7EE58?M$702&5^[DCD)L^29!((M/)Z56L[=SIP38M#&[:>OB!&7I,18,?E MSS4=],RQR7)\N#7RUI8XH3$R/PD"E+I:CF!-\BFT92\5%0VZZ&\WO-&'(PH; M[+7IV0,,YXNTVJ.:I0DI//\GR:B1IH70B5[[4P@Y^G0+QZ33A*O"N= =)KLE MEB?TQI[T5ICU5WAX063)FUI+6UMK0;V63,U,>ZK7\:B&:Q4;-\BQ,.B=XXC% M5H\R$Y,RQ/=27OLGO'>TUK8_Y>PN,BQ.%V>A1'R7@0&X+;AI'31F>2..7A01&- MC=;CPYW0MQCR6/!"VAPT*)U?-]1.Z.B2![71Q^ZB4S=* D=B_ZPIIM;W5'0E MQT$"L1Z/#,^]K$MR_>Y?W-Q,J&&KR.D!/Q_92$CHS;RG)>79^'RXAXHG[BTW MME Q]:$O OEJWEN=UK<"]FIQ35:)/^H)U2C)[_LD9*6]XDGC4U &:9>*7BX< ML FX4/!5 C&WVE!#_+E;CY,>!&^\E%H:Q>9IS(CEM_. MECCDHF5?K7U<%JB-DLOGJ[KOB 9A$W)K5R$!L^(*70S?TQP2XH'M--*4U!$; M/K?Y+M@#*]$] I0QF$PCKTV=*0&9C$9O')X1;OV&0"-OY25XOCDD\3[^\O M^Y8C]JF./<"3PXV[?RFN&ES#-QR_IT %2O!RZH 3U!QBCZ-1AS_^EPEUGU:6NX[:X' ?,$ MY;GIGI, 9"!@U1E7_$EN@+L18L&JOV1NU>?ZF[(R4(\[?>.7UU;:&IB+PL,_ MG3Q-:L*_K"V;![S0SW$>BN ##B:[A6/4R C",T:F\1HD6/9'$_@LM)X:1D8Z M6S167 )C'VU@CRU/W)[/D;973GBF>&8]'/;U\_M3J8S(/$V>?>J']#3UW'_$ M!3X!\TE#3#@%@9:GRH;)N%D*92J1WD.L02/>HF[\1PL #1UVAU;#UC!K&FA& MTBK%O:K^:2QZ.\DCS=,[*9YX/'=O?F=/)F&KJ\6G,Q"B[%G:ODS'?"#3@?S8 M5ZJ@7L9P.\E U8'#EV MLFLZIALM]7B\B\/D?+*;W73HPPR@)\/AWIDD;;VP"^N':=K.C@F46%(\0)P( M:]L21DB,6EM8X-V6JZ'T(FL<]RS)UP^X[!J:WD"=';&="A_6$+P9SIK)[@[U MDS]Z@"-D#_5XL^]]*L&[64F[)3.RL0J4^1P%![9Z+9Q 8:[X[V](%\:4V/A* M-W!@IT:[M08NRL!6;FSKCYZF TL:NI,RNQY16WCKRUPQ*3;+DOW=RE@N] M1<%J?!%_#&JQ99!,C3;C43&X9%+G7,X/$";/0YBYA?=1&>:#(E+8J/FNM8@]>J1V7O^2BBY*]$-?GP"4[2 M:EI+PG[2#!)&Z].6N9UQF5L;![TQ3MHXTH(_FU7$GGKN*EN0K5RHT&_O?=ID M+5_ND!R8X]%;:W(M:.)>)-[/8P#0R23SC<6Y1J(KF';27-V9]-/PGSDSO2D&9R=B.]1 MIMT+)PW8->HLC6V3.^IWAB9,<+_O)9!\(T?,L0F.'8=OY_"G"OPB^-!&D#AI M/V(#JS6] ZT7>E(YD36(]QO(Y)>(-^&,HUOY3!?9&2\(*N.3\T$9E^?8"_M7 M=V4=4Y 7RJ1"&5[03X(E!/L\B0R_+;MI%TOO0RZ[0X82@7QJAT=&=RO$)6!A M7R1=%G9NWH:0^MHKV.OL$W'-G[.X>GO]VA^P2+_;%0\99YSHT=8<;?Z4^J22 MQ=%-C8*$G@4_">SIGYY).*(X@[^"(YC6-Z8%!,(9"H!^_;"4@@Y>&Q'M*Z'$ M$T*O 88OR5Z'1SIGTZ,-D7YW> 'L.>7#.Z@H*O?31*8W60Q,><[:?]4*LSGR M-S/^@IE6O*6])Q'*K=R9GZ)/AJ9\4'1-!44P7MAP[=V6TTQZ<(Q/GR^\QG&&_Q-:]]M@>B!@4R_6N3M??2KT,3?F8 [ M)4#LOM>/K9L[PW M/@Q2E#;=6-# 1U6"6/4INLQ*?*2WGT:3@Y+TW&9+'[@W71+*6TV-3@EMM_B5 M8*F:\R#Z?I*W("6V-HBY'DP=WGU-_:'22NL[W2O2IWS4\(A#!SZ#_AX,I9_$ M8>_>SY^C1V"P8<,.1MX ]>#WI1ZU].B?'^.2B MNMLOH%;.863A8-)M5R&A];(2J+QK64' MW+5U+H2/S8'PSON;7:9P3B*JBI@EDI2 )PCU)6M-_)T/K+=37^1)KV,G7J0A M"+HL1ZJQ_@@0K1_ ,* '@J-!I$9I@9NL0I/[M!I&VSWB*5S6-.">K!@9D3+# M][J$&#:#X^,5ON5LKEZ_-!_0.GC[]M5[W[&7?+34=X"&K&]>Y&SIV!UF_5XO MB3PTO[G'@>^-,GH^]<-PCH]SB(*W>AG,P;S!H^13VRO;+/B#XD[RW?+5[7 U M?+3\0C[5'1^7+YZ_EL.9IK1S>O7TY-G9D7QLTO\@!\T?[I[6;5NO^$]\K,PV M>(#NSVO2;_V!"<*GW%_\%U!+ P04 " !(BU!84"3JKPP& !H#@ &0 M 'AL+W=OB"5VPF035E2>7S.2O$^JSG];8#=WRYTF9@,#RMZ9+- MF7ZH9Q)[@YV6G)>L4EQ4(-GBK#?R3LXC(V\%?N5LK?;:8"QY%.*SZ4SRLYYK M +&"9=IHH/A[8F-6%$81POBRT=G;;6D6[K>WVC]:V]&61ZK86!2_\5ROSGI) M#W*VH$VA[\3Z$]O8$QI]F2B4_<*ZE8WC'F2-TJ+<+$8$):_:/_VZX6%O0>*^ MLH!L%A"+N]W(HKR@F@Y/I5B#--*HS32LJ78U@N.5.92YECC+<9T>GC_,)]/+ M^1PN+N?CN\GL?G([A='T N8/-S>CN]_A]B/,)U?3R#2]A]%X?/LPO9], MKV!V>ST93R[G\.Z>/A9,O3\=:$1D] ZRS>[G[>[DE=T] C>BTBL%EU7.\F\5 M#-"4G3UD:\\YZ=1XP;)C\#T'B$O\#GW^CA_?ZO-?T3?*,M%4FE=+F(F"9YPI M^&/TJ+1$?_KSD,6MON"P/A-C)ZJF&3OK81 I)I]8;_CVC1>Y'SK0!CNT09?V MX:R@E09:Y7#YI>$U!H^&2Z4Y>B_+X4&Q15/ -8:!.H2\4_=AY!<,VQFG-L+$ M NH= +8#P!5DM,B:PH)HE.%2KQ@8#DW,],U.4#*]$CF()R;M+-O!;EK8A8%M M]C"S5"FF%?Y@(0I,+.H$SAM>Y*A;@1?V20C/C$JUQP/IDV0S.).8U*1^=@[B MI1K0BUCYB$BVGF1%L$& 2K;)8/QO!+>/P I:H6LC?@2>Y\1)W#8"+]Q!!,\- M'#_R(76=* CV0/H><6(W !(G3A)Z,!85TM2T&8Q74$NQ1/(5A*F3)A[$^$.S M@@3%_1""R,5_ M845S M6&[4&Q:M!Y4FKLW&1S&2G;JQ-?LHCE(G=%-SL#CWNB,X6))4S6Q1*9 YU3S^ MA3W0PJK'@WKBIG)9-:/Y&/S0=>#MFX00]\.DTK1:9;7"N/K93W M 5ZF?G1)#P\B)+Z3!NF>'(:$P84E:1LIO]"ZIEC\\#@5WYQ^Y) T[%QUSN02 M'4^4WZS$K0E2,T%6T=*\8<;:;(6F,$,K7A&P"%; OF[&)+J>@G<>@@S>=UI# M8,O[_T 5>/\54NJX8=P)R$=ZMW[QX]R/\#]-/^&**/:1(1/Q410Z"0;R",=) MX 11:G[$2V!>FS@L]+,)NQQ#6T'B.5XV^[7Y=,8DQ]HUMM?];MM/?Y5.>HWZ^ MX.;J=^#P#M?%;UB[D@(+V7Z1^G'D)RCM(Z%'X$<$JQ,QU0$4S1)(O!C)XY]TW,QYGP?BW?TRI'T\4 "#-\D0$Z=$.4" MUPEP,299+_:V+/>18Q(ZL8]$^(Z+-1=[+B8N+W5($"+$ *.?^*9%L)BW"2B( MS6W M C6^\!-#D;Y8._VCU0M[1L'[URFOK4/@=WH[ADU:E\/+^+M&^R&RB7' MDE6P!2YUCV,LO+)]U[0=+6K[EG@4&L_%-E?X%&32".#\0@B][9@-=H_+X3]0 M2P,$% @ 2(M06$@J0%KO!0 HPX !D !X;"]W;W)K&ULO5?+JE+H4V]A3'W< MZ^E\P2JJN[)F B,SJ2IJ\*KF/5TK1@NWJ"I[41"DO8IRX8U.W+=K-3J1C2FY M8->*Z*:JJ'H\9Z5F?A\7EBY[L)GSE;ZJUG8CV92GEG7\;%J1=80JQDN;$(%'_W[(*5I04" MC2\K3&]CTB[Q"EK_QPBQ.O:.-K%:+P:#BHOVG#ZLX;"W(@F<61*L%D>/=&G(L+ZFAHQ,E MET39V4"S#\Y5MQKDN+!)F1B%48YU9C09O[T:OQE?G%W=D+.+7V_'D_'-^./5 MA!S=T&G)=.>D9V#&3N[E*\CS%C)Z!C*,R .!T[O/@9O/-&XXO6Y$)64RYH6Q^B(&=:0P=G^9>& M:^Z^_GXVU4:A=O[8%XC63'^_&:NG8UW3G)UZ$(QFZIYYHY<_A&GPZH 3_8T3 M_4/HH]?:<%0E*\@;RA7Y3,N&:2)GK1.Z]4)AV#KVGM,I+^$2IF"\J;[.2^O/ M08O[_;E9,#*3)<3-Q9P86S0KA?._8,S88T#PW0 ,8&U+\A@$,/+7#;V5;&<8L,S2E%PX*3(%.Z6K%[W@M2;1 MT!\& ;ED]VAO-1PQ+%\(6W3 TI&MI38_Y:74U@:\KEQ"CU(_BY+.BBA[J-&X M$=%=N$'D!_$ <^PZY&F&GKR.$\+T]>(-^ N[TB;X/ZW7KH-'OQ":NEU'DR53 M##Y4=F?2*8U7#?'X3IEBRC$-'-XF_691P,_, %X;M4!VX03,<)=HY#FL5^ODPP MLJ3*B<[M>O M":-_T60<1/"_3][1NJ9;>JPI+YYQQ<;X@%;C./9#G",.;)/) M9IM,#FZ3$QQCBP:Y1KFA-HD[RZ%PV_,L*.W;!P]"?LL^V!X[X50C:%-PYQZ, M.Z.HCHUQX@"LTU:^-JRRY(53.P9PLG2*M8IJU6 ES-N6-%T?8O*G0XRV_<7* MFBPH0I^[!!=KW5/1X-Q-6N6'Z%5+5MZS]6&-V<.:K2Y635'?]KAE:V:"9J#= MTVNJ!'S3JSR_I%7]BIPS-</Q1[WJY M4HHV>',=HG4@1A$D0S^)(_O@][/!_V'5&HLB/TPR/!PE?IQ [H[-I*G1P.U4 M&'O*9!MZ ,Z0 )%S#+X@0T#TXR&>0BOQ<-!"?Q=$AFTN"AU$X(=9Z#+V71 9 MPAUL4!77?NKDJYAP% M6+(9E@;= 32DVBM1^V)D[:XA4VG0XMWC K=(INP$C,^D-.L7:V!S+QW]#5!+ M P04 " !(BU!8MAH:VF(' "%% &0 'AL+W=O?T\5Z$);C8O[_=A7A\9^Q7M]#:P_=E6;F3WL+[ MU=%PZ"8+O52.F96N\,W,V*7R^&CG0[>R6DW#H64YE)R/ADM55+W3X[#WT9X> MF[4OBTI_M.#6RZ6R]V]U:>Y.>J*WW;@JY@M/&\/3XY6:ZVOM/ZT^6GP:-E*F MQ5)7KC 56#T[Z9V)H[>"TX' \;G0=ZY% [DR-N8K/;R?GO0X6:1+/?$D0N%R MJ\]U69(DM./;1FBOT4D'V_16^B_!>71FK)P^-^4?Q=0O3GI9#Z9ZIM:EOS)W MO^J-0PG)FYC2A5^XJWG3J >3M?-FN3F,%BR+JE[5]TT@6@PW_.QLY;A,E_]_E=2XWW2Z7:.7(K-=$G/2P.I^VM[IW^_$J,^)L.F^/& MYKA+^NDUUN)T76HP,S@W2ZQ(IP*FSXWS@.L'+-\+9:NBFKM]QG>+OUGH(%95 M]S^_RJ1(WS@L.(>X=H!U#Q[?WVME'6A**F!*]'*L;9.6\"M!55,B!%4K51VR MTM&9*;'VT328M&V?D.UTQ*TGBSVO%NKQ<3V;H51'#E?HL-XX? 3OJPEV)*>' M?30M4(>-X61?;5XPK8[8#)Q"@,,!B$'.>5@C+G'-X@0N5]JB(:3Q.QF%C"(> MB$2"0':4E _R) U!W]H ?2$'49H<(L$'4L1(9+C!#SO2GS3I3UZ<_C.'_7-% M47+PR6&$BRJX^5F5ZSIXR'09&.#L3MGI7CQTZ[LJW-?7,ZLU"O<:D> !XX%1 M4%:'%CBE%)#68KDJ"WR\+W0Y==BOK-65+^]!W:JBI"9"G)_8-8,;RLO:WL.? MVAK,\'J%;PKT!N7>%7X!"F%#8X3BCEJ7H+^M50G>!$V4B8"HLIAI!E\P\'6+ M>8C&/T(7QMVS6\SA7+?C=?08"Q=;F9]-B;$KJ1/(C GX"2+.(EHDRW%I&&_( MKCZ&/)3#(<0L@Q0Y8V0+4?N%HO9^&[4KC!I$081$SI^ LP1_WQ6WQ11+";Y0 MV#:;K=\.R(P:R(RZ(5,/60)#:'@-)&@(HI_[0-$I<7^'.]M.\U!209&I%:U* MM1FY%%4JQEVC&.PZ!;U091G8'<(!E-L4_--TO2(E3Q+\([N7:^\\ZB:(*0]C M/2^J@#=DIHQB%^!8_P>0YRR3D(U2Z@B(B!RR)",:\Y/!/ZVJ2*S@.8@H8[C( MB,B<\1B$1%+D#$?AQ7=M)P752W^$'2$3+,^@'R.91B0(>T5^"*.(Q1+PCC'3 M!8GM"W&(P@1+JW(_Z6G?1TKUZH'M3 @WZIVL; MWOSH&'U4#E_"V3U-[U&=;&'_6FU@/U.%A5L<$"%R9C,]YAL4'T#,62YHC5E* M^8XB)@3<&(_M%R< &N^*R4Y N\[1EQW&#SCGV!11P$#&)% .4A$1 @;9:-2% M@*Q!0/;R23B=%F0"&MF&P94NZ]G]" 2N703[@-"I^9GVMS.AC09+)M#EQSR* ME6F5X1KSV.Y]6%)/D_H( 7L\:?;:Y7FEJGF(T;8!P?4"9[?;=<2&^+ .&IOG M@P1[30JOX2!+6!1!A _8JRB)DF%2Z7E+$TO,B5>(C(TXR(2'42BX8%D,,LX" MF8J:(Q\%WH2S+$&P":!9*Q!MV-!P1TALA.FF(24LW36E=G_I0%'>H"A_,8H^ MF.KU++-=*99"*!OJ2QFK L:L_/F$8F M3L01LM*I,!S#5$7-"*']7CP8BH),)FBBD.>@G9%O( M12<8NW7\3S2N6LI<4/9_!LG* MV!?UE9!'+P!D6N,Q83)YUIM]>!RVO@PMM9V'[U^._GY5OOY(U.PVW]C.ZB]+ M._;Z ]WORF)<'91ZAD=1(_Z)M/4WK_K!FU7XSC0VWIME(!=:X90C!GP_,\9O M'TA!\^7Q]"]02P,$% @ 2(M06$9>(FF9 @ CP4 !D !X;"]W;W)K M&UL?53+;MLP$/R5A5H4+6!$S]B.:PN(\T!R2!K8 M:7(H>J"EM42$(E62BI._[U*R51=P?!&7Y,YP5N3L=*/TBRD1+;Q50IJ95UI; M3WS?9"56S)RH&B7MK)6NF*6I+GQ3:V1Y"ZJ$'P7!T*\8EUXZ;=<>=#I5C15< MXH,&TU05T^]S%&HS\T)OM[#@16G=@I].:U;@$NW/^D'3S.]9 M>>?A9)ZX_#;AB>/&[,7@*EDI]>(FM_G,"YP@%)A9Q\!H>,4+%,(1D8P_6TZO M/](!]^,=^W5;.]6R8@8OE'CFN2UGWMB#'->L$7:A-C>XK>?4\65*F/8+FRXW MCCS(&F-5M063@HK+;F1OV_^P!Q@''P"B+2!J=7<'M2HOF67I5*L-:)=-;"YH M2VW1)(Y+=RE+JVF7$\ZFM_=/5_>//Q:W5TOX^LA6 LVWJ6^)V>W[V99EWK%$ M'["$$=PI:4L#5S+'_'\"GR3UNJ*=KGETE/$2LQ.(PP%$010?X8O[.N.6+_ZH M3OF*TBK]#I?<9$*91B/\.E\9J^EA_#Y48'"9T9IF8FF4X\\@-!O4K>NF7 M3^$P^'Y$;M++38ZQITLR7]X(!+6&G72.YI#,HT2'9>XQ#D"2\^F4[:8!9H%^ M/E8KU/T% ).Y"R+(%/G16,P=QI8(:R7(V%P6DRZSS5JP#3U2BYHS8> SQ&># MTW!$09(,DM$(GLFIP"746A5TL(%X<#8,Z!LF,5QSR>E!YU HE1L8#@=!DL H MHF$,C\HR0="^ "(- Z*/0A>%9X/A< R';L#?,TF%NFA;@:&"&FD[O_2K?;56RI*!V["DCHG:)=#^6BF[ MF[@#^AZ<_@502P,$% @ 2(M06!W!3=^? P -@@ !D !X;"]W;W)K M&ULC599;^,V$/XK W51[ )*=-MR:AMPCFT7<+9N MCA9%T0=:&MO$2J26I.*DO[Y#2E%:;@S.>[J7ZIG>(!I[K2NB9 MMS.FN0@"7>RP9OI<-BCHRT:JFADZJFV@&X6L=$IU%<1A. IJQH4WG[J[E9I/ M96LJ+G"E0+=US=3+)59R/_,B[_7BCF]WQEX$\VG#MGB/YK%9*3H% TK):Q2: M2P$*-S-O$5U<9E;>"?S.<:\/]F ]64OYS1Z^E#,OM(2PPL)8!$;+$UYA55D@ MHO&]Q_0&DU;Q;D')6Y86YD[N?\%>W\G2''\IH9-I\JN0=E MI0G-;IRK3IO(<6&36D9^:KNU]7-W/#VQ=H?XT#0S9LAI!T>->=KCQ.[A1#+=2F)V&&U%B^5^ @$@.3.-7II?Q M2<1K+,XAB7R(PS@Y@9<,GB<.+WG/5XQ88")$FZ^M[RADC/PUV*M MC:*:^?N8[QUR>AS9OJ,+W; "9QX]%(WJ";WYCS]$H_"G$[S3@7=Z"OTT[V-D M3\(=)WN-M"\X]QJX:2NHZ%%J:\-^95JCT;3 1E;4+_0%7+:\*@E;0Y2=Q1F\ M(%/Z(%'Q69SWEV^1.<:7&: 2PGI-3%[+R(G0)@:FL&],_!\B=\C "3JAI17_ M %'DC_-QMTFC;* (49CZR2B!2>B/TO2 9!+%_CA,(1[G?IY%<"4%A:GM&A,7 MT"BYI>!KR";^)(]@3 NYE>8DGF20CD):/@AJ^1^(TL@/DXG;17Z297"B1K.A1K.3-7I/LZ-L*[1Y74JQ/5M2 MEDM8=.E=O\#/2 ZS9L>IA&!!T^18X9ZT<;QPWW =*MB>"&='.'S$YZ)J7=:X M,$QL.36ZOOX^'>;\47 ;Z'M#\=8V2F'BCR:QW5'ZLSP'F@[4^P4EM15&<9(: MQWZ2CFTRQZ,Q/$A#3O[?2 <'O;Q&M743BYZ:!>_:^G [#,5%-PO>Q+N)>LO4 ME@L-%6Y(-3P?4T!5-Z6Z@Y&-FPQK:6C.N.V.!CLJ*T#?-U*:UX,U,/Q5F/\+ M4$L#!!0 ( $B+4%B 1ID&P@, ! ( 9 >&PO=V]R:W-H965TZN$:?M0]$'6AI; MQ%*DEZ3B3;]^AY3M=9#$Z$L\',Z<.7.H(3/>*?W9-(@6OK9"FDG06+N]BB)3 M-=@R1BWC,IB.O6^AIV/56<$E+C28 MKFV9?KY&H7:3( D.C@>^::QS1-/QEFUPB?;/[4+3*CJBU+Q%:;B2H'$]"6;) MU77NXGW 7QQWYL0&U\E*J<]N,:\G0>P(H<#*.@1&/T]X@T(X(*+Q98\9'$NZ MQ%/[@/Z;[YUZ63&#-TK\S6O;3()1 #6N62?L@]K]COM^"H=7*6'\7]CUL446 M0-49J]I],C%HN>Q_V=>]#B<)H_B=A'2?D'K>?2'/\I99-AUKM0/MH@G-&;Y5 MGTWDN'2'LK2:=CGEV>G\X^/LX_W\^H\[F"V7=X]+^/F1K02:7\:1)7P7%55[ MK.L>*WT'*TGA@Y*V,7 G:ZQ? D1$[,@N/;"[3L\BWF)U 5D20AJGV1F\[-AM MYO&R=_#NE:IW7 A@LH:YM$QN.#4+,V/0&KCEIA+*=!KAG]G*6$W?S+]OZ=!7 MR=^NXN;HRFQ9A9. !L6@?L)@^M,/R3#^]4P/^;&'_!SZ=$ES67=$6JUA7J.T M?,W=B;WNYRWF9['?9O[8(*R5H/'E<@/\>Q76J[;CMH$UE]PB"!HQ XP$-)99 MK(%9J)2Q7G#G9JW2EO]'.TAIJ,%-IAO.B@95^Q0:,FY ]5O@3L%-UL!Q/>P] M4:)]00N-Y:U/[PRN.]$SN8)97X_Y*V"!FJL:;OQ8$81&X3=,P[?&4Q3<4$=) M# /ZY.!1LYKN0+H?_:9U2Y"LI193BDA*N,4GNM>V5-9BU4@EU.89"K>7P@-N M.L)7^ID*;;AKQ+-P>I@^*(8%<9;V%-]@I9VL2=&7^.1E\O5&=+#NV&DLL%V1 M]S :/IV,-/2RW*AVR^0S-*P&?OJ)O#X\9O8BDE8>R:&\5.U>*V-@5E5=Z_JA M7E][_H>D Q+T1\B&:1AG*5EI?!D.B\3YBC),,F1)F(QRTC0L*"Z/PYR2DV&8E,E!Y0%IG!9A MF9$061B/,K>*\X28A6E>$,6\)"MS5CH:A4XQYTO#,G966ER&>3R"M^8\.KFE M2:J-?XL,?0Z=M/V%??0>G[M9?\M_#^_?R@],;[@T('!-J?%%602@^_>G7UBU M]7?^2EDZ%V\V]&2C=@&TOU;*'A:NP/&?@.DW4$L#!!0 ( $B+4%C2A 5I M.P, %T' 9 >&PO=V]R:W-H965TN> M<\]Q[.OA4:IGO4V,.=[ZOTST63+?E 06M;*4JF*&AVOGZH)!E M#E3D?A0$7;]@7'CCH9M;JO%0EB;G I<*=%D43/TSQ5P>1U[HG296?+<(9Y;HE(QL^:TVM26N!Y_\3^R7DG+QNF<2;S;SPS^Y'7 M]R##+2MSLY+'+UC[Z5B^5.;:?>%8QP8>I*4VLJC!I*#@HFK9KWH?_@\@J@&1 MTUTE%_2EKHVB5$\Z,%_,GF$]6BZ^+SVM8 MSE

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